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Carbo- and heterocyclic architectures occur in many bioactive natural products 
and synthetic drugs, and these structural units are also known to serve as important 
intermediates in organic synthesis. Although numerous methods exist to construct these 
skeletons, they often require elevated reaction temperatures and/or prolonged reaction 
times, stoichiometric or excess amounts of reaction promoters, and harsh reaction 
conditions. These limitations severely restrict their application and thus constitute a 
challenge in targeted syntheses. This thesis documents our recent progress in the 
development of novel In(OTf)3-catalyzed reactions to construct useful complex 
carbocycles and heterocycles, as well as their applications in the synthesis of natural 
products and related molecular analogs.   
Donor–acceptor cyclopropanes serve as synthetic building blocks for the 
construction of various carbo- and heterocyclic compounds due to their relative ease of 
ring-opening under milder conditions. Along these lines, we report the development of a 
new formal homo-Nazarov cyclization of alkenyl cyclopropyl ketones and heteroaryl 
cyclopropyl ketones, catalyzed by In(OTf)3. The reactions provided functionalized 
cyclohexenones/cyclohexenols and heteroaromatic ring-fused cyclohexanones in good to 
excellent yields. The studies showed that electron-rich, electron-neutral, and electron-
poor aromatics, heteroatoms, silylmethyl groups on the cyclopropyl are well tolerated.   
As an extension of the scope and applicability of donor-acceptor cyclopropyl 
based cyclizations, we explored the In(OTf)3-catalyzed tandem cyclopropane ring-
opening/Friedel-Crafts alkylation reaction of methyl 1-(1H-indolecarbonyl)-1-
 xxviii 
cyclopropanecarboxylates. The reaction found to be tolerant of electron-rich, electron-
neutral, and electron-poor aromatics, heteroaromatics, heteroatoms, and silylmethyl 
groups on the cyclopropanes. The protocol affords functionalized hydropyrido[1,2-
a]indole-6(7H)-ones in up to 99% yield from readily-available indoles and alkenes.  This 
skeleton appears in the core structures of an impressive number of naturally-occurring 
indole alkaloids and pharmaceutically relevant compounds.  
The functionalized pyrrolo[1,2-a]indoles and pyrrolo[3,2-1-ij]quinolines are 
unique structural features present in a wide range of heterocyclic compounds that play an 
important role in medicinal chemistry and organic synthesis. A simple and efficient 
approach to the synthesis of these useful skeletons is to utilize N-indolyl alkylidene 
malonate monoamides as cyclization precursors. An In(III)-catalyzed intramolecular 
Friedel-Crafts alkylation reaction of substituted methyl 2-(1H-indole-1-
carbonyl)acrylates was developed. The reaction occurs under mild conditions, affording 
the corresponding products in good to excellent yields (up to 98%) with high 
diastereoselectivities (up to >99:1 dr).  
Finally, the versatility of our cyclization method is demonstrated by its successful 
application in the diastereoselective synthesis of (±)-deethyleburnamonine. The key steps 
of the synthesis involve: (a) a tandem ring-opening/Friedel-Crafts alkylation to assemble 
the tetracyclic ABDE ring system with a cis D/E fused ring junction; (b) a TFA-promoted 
N-Boc deprotection/N-alkylation to generate the C-ring; and (3) a Krapcho 
decarbalkoxylation to generate the target. Using this protocol, (±)-deethyleburnamonine 














In 1861, German scientist Ferdinand Reich and Hieronymus Theoder Richter 
were the first to discover Indium, which was isolated from heating zinc ores in the flame 
of a Bunsen burner.
1
 This accidently discovered metal was named indium for the brilliant 
unique indigo lines seen in its atomic spectrum. Since then, indium has been primarily 
used in alloys for the electronics industry and as a medical diagnostic agent. Although it 
belongs to the same group as boron and aluminum which has a number of applications 
since their discoveries, indium remained largely unexplored in organic synthesis.
2
 One 
hundred and fourteen years later, Rieke and co-worker’s disclosure of an indium-
mediated Reformatsky-type reaction of ethyl bromoacetate with carbonyl compounds 
initiated a strong interest among synthetic chemists.
3
 In 1988, Butsugan et.al reported the 
allylation of carbonyl compounds using organoindium species under mild conditions.
4
 
However, indium metal emerged as a one of high potential in organic synthesis when 
Chan and coworkers reported an In-mediated allylation of aldehydes and ketones in 
aqueous media and demonstrated the use of organoindiums to achieve a Grignard-type 
reaction in the presence of water.
5
 Since then, the intriguing properties of this metal have 
led to an enormous development in indium catalysis chemistry, as evidenced by the large 




The intriguing property of indium that makes it unique in its application as 
reagent/catalyst is its first ionization potential (FIP). When compared to the elements of 
group 13 and the metal elements near it the periodic table, indium has the lowest first 
ionization potential. Surprisingly, the ionization potential of indium is not only much 
lower than that of boron, aluminum, tin, zinc, magnesium, copper, thallium, gallium but 






When oxidation potentials (E
o










were found to be relatively low (Table 1.2).
8
 These values become important as 
they directly relate to the reactions taking place in the solutions. Despite low FIP and E
o
 
values, indium metal is inert to boiling water or alkali and does not oxidize readily upon 
exposure to air. This is contrary to reactive alkali metals (Na, Li, and K). The 
organoindium compounds are known to be less reactive than alkyllithiums and Grignard 
reagents.
9
 These characteristic features makes metal indium-catalyzed reactions more 








1.2.CARBO- AND HETEROCYCLIC COMPOUND SYNTHESIS 
Carbo- and heterocyclic compounds occur in many bioactive natural products and 
synthetic drugs, and these structural units are also known to serve as important 
intermediates in organic synthesis. Numerous methods described in the literature utilize 
the unparalleled reactivity of organoindium species and In(III)-salts in Lewis acid-
promoted reactions to generate diversified carbo- and heterocyclic skeletons. The 
intention is to highlight some of the recent work rather than present an exhaustive review. 
More specifically, In(OTf)3 catalyzed reactions are covered in this dissertation. Therefore, 
it is recommended to the reader that the reviews of previous researchers be read for 
additional information. 
 
1.2.1. HYDROTHIOLATION OF ALKYNES 
In(III)-catalyzed substrate-selective hydrothiolation of terminal alkynes was 
developed recently by Prajapati and co-workers.
11
 When 2-mercaptobenzothiazole I-1 
was reacted with phenylacetylene I-2, Markovnikov’s hydrothiolation product I-3 was 
isolated in 90% yield (Figure 1.1). Prajapati also screened a wide variety of 
heteroaromatics, thiols and alkynes, and a smooth reaction was observed in all cases, 
providing product in excellent yields. However, when cyclohexyl thiol I-4 was reacted 
 4 
with phenylacetylene I-2 under identical reaction conditions, it furnished the anti-
Markovnikov hydrothiolation product I-5 in 85% yield. Various aliphatic and aromatic 
thiols under similar conditions afforded a mixture of E/Z-vinyl sulfides in excellent yield, 
however it was determined that these conditions were substrate-dependent. As 
anticipated, the thermodynamically stable E-isomer was predominantly favored over Z-
isomer in almost all the cases.  
 
 
1.2.2. MULTI-COMPONENT REACTION 
The isocyanide based Passerini three component reaction has been well studied 
due to its ability to synthesize compounds with structural diversity.
12
 This reaction 
generates α-acyloxyamides from the reaction of aldehydes, isocyanides, and carboxylic 
acids.
13
 In 2009, Taguchi et al. developed a Passerini three component reaction that forms 
α–alkoxyamides in good yields from the In(OTf)3-catalyzed reaction of aldehydes, 
isocyanides, and free aliphatic alcohols.
14
  In continuation of their efforts, Taguchi 
reported four component reactions of aldehydes I-6, isocyanides I-7, and trimethylsilyl 
azide I-8 in alcoholic solvents to give highly substituted 1H-tetrazoles I-9 in good yields 




1.2.3. CARBON NUCLEOPHILIC ADDITION REACTION 
Recently, Matsuo and co-workers reported an In(III)-catalyzed addition of carbon 
nucleophile to nitrones.
15
 While attempting to generate a seven-membered ring 
compounds I-14 by the nucleophilic addition of cyclobutanone I-11 to nitrones I-12 
followed by the ring cleavage of four-membered ring intermediate species, Matuso 
observed the unexpected formation of a γ-butyrolactone derivatives I-13 (Figure 1.3). 
Further investigation to expand the scope of the reaction various nitrones were employed 
to generate products in moderate to good yields and with very high diastereoselectivities. 




1.2.4. INTRAMOLECULAR PRINS CYCLIZATION 
The intermolecular Prins cyclization has emerged as a powerful synthetic strategy 
to generate highly functionalized tetrahydropyran scaffolds,
16
 whereas its intramolecular 
version is very useful in the stereoselective synthesis of angularly fused oxa-bicycles and 
tricycles.
17
 In continuation of their research on the Prins cyclization, the Yadav group 
recently reported the stereoselective synthesis of trans- and cis-fused hexahydro-2H-
furo[3,2-c]pyran and octahydropyrano[4,3-b]pyran scaffolds.
18
 When benzyl ether I-15 
was reacted with DDQ in the presence of In(OTf)3 it furnished products I-16 and I-17 in 
good yields and excellent stereoselectivity (Figure 1.4). This is reaction is proposed to 
proceed through oxidative cyclization with DDQ followed by a sequential C-H bond 




1.2.5. OXONIUM-ENE REACTION 
Oxonium-ene reactions are important in organic synthesis due to their ability to 
construct a wide variety of functionalized cyclic ethers namely, tetrahydropyrans, 




 The Saikia group recently reported the stereoselective synthesis of 
oxabicyclo[3.2.1]octene via a (3,5)-oxonium-ene-type reaction.
20
 Under In(OTf)3 
catalysis, oxabicycle I-21 or I-22 was generated by the reaction of (-)-terpinen-4-ol I-20 




1.2.6. ALLYLIC C-H OXIDATION 
Allylic C-H oxidation of olefins provides a very powerful synthetic tool to 
introduce wide variety of functionality into molecules.
21
 Recently, Shi used In(OTf)3 to 
successfully promote allylic C-H oxidation of aryl cycloalkanes I-23 with N-
propylthiosuccinimide II-24 in the presence of various nucleophiles to provide allylic 
ethers, esters, and sulfonamides I-25 in 49-83% yields (Figure 1.6).
22
 Shi proposed that 
the reaction proceeds through the formation of a thiiranium species to generate an allyl 
sulfide intermediate which then reacts with the requisite nucleophiles to form the desired 





1.2.7. FRIEDEL-CRAFTS/CONJUGATE ADDITION REACTION 
Friedel-Crafts alkylation is the most commonly used method for synthesis of 
elaborate heteroaromatic compounds.
23
 Along these lines, Trost and co-workers reported 
the tandem ruthenium/indium catalysis of propargylic alcohols.
24
 When propargylic 
alcohols I-26 were exposed to the mixture of ruthenium complex, indium triflate, and R-
camphorsulfonic acid (CSA), followed by addition to heteroarenes I-27, provided an 
atom-economical access to β-heteroarylated ketones I-28 (Figure 1.7). The reaction is 
proposed to go through a Ru-catalyzed redox isomerization of propargylic alcohols to 
enones (electrophile), followed by In(OTf)3
 
catalyzed Friedel-Crafts/conjugate addition 
reaction. Trost demonstrated that both electron-rich and neutral heteroarenes undergo this 
tandem reaction sequences smoothly to generate products in yields up to 97%.  
 
 9 
1.2.8. CONIA-ENE REACTION 
A large number of metal-catalyzed Conia-ene reactions have been described for 
the preparation of heterocycles such as 3-methylene pyrrolidines and tetrahydrofurans.
25
 
In 2008, Hatakeyama reported an indium-promoted Conia-ene-type reaction of nitrogen- 
and oxygen-tethered acetylenic malonic esters I-29 to form pyrrolidinones and other 
heterocyclic products I-30 (Figure 1.8).
26
 Further in their studies, Hatakeyama elegantly 
illustrated the power of this methodology towards the synthesis of (-)-salinosporamide A 




1.2.9. [2+2] CYCLOADDITION 
The [2+2] cycloaddition presents a straightforward and efficient method for the 
synthesis of cyclobutane and their derivatives.
27
 Cyclobutane fragments are a key motif 
found in a large number of biologically important natural products.
28
 The Loh group 
reported an indium(III)-catalyzed highly efficient intramolecular [2+2] cycloaddition 
reaction between the distal allenic double bond and unactivated alkene moieties of I-32.
29
 
The reaction is proposed to go through a [π2s+π2a ] concerted mechanism involving a 
vinylic cation species. Further investigation demonstrated that the reaction is highly 
 10 
chemo- and regioselective and also tolerates a variety of ene-allenones I-32 to furnish the 
strained bicyclo[n.2.0] skeletones I-33 in high yields and with excellent 




1.2.10. HETERO DIELS-ALDER REACTION 
The hetero Diels-Alder reaction is one of the most powerful tools used in 
generating highly substituted dihydropyranones, a key structural element present in many 
bioactive products and important pharmaceuticals.
30
 Feng and co-workers reported 
In(OTf)3 catalyzed hetero Diels-Alder reactions.
31
 The reaction of aldehydes I-35 with 
diene I-34 in the presence of 5 mol% of an aromatic amide derived N,N’-
dioxide/In(OTf)3 (1:1) complex in anisole formed hetero Diels-Alder products I-36 
(Figure 1.10). The Feng group also demonstrated the utility of this reaction through their 
gram-scale synthesis of a triketide. In a continuation of asymmetric indium-catalyzed 
hetero Diels-Alder work, the Feng group recently reported an efficient synthesis of β-
methoxy-γ-methyl α,β-unsaturated δ-lactones I-39.
32
 The hetero Diels-Alder reaction of 
the Brassard-type dienes I-37 and aldehydes I-38 furnished δ-lactones I-39 in good yields 
as well as dr and ee values. 
 11 
Additionally, Feng showed that these products can be easily transformed into the methyl-
protected epi-prelactones upon hydrogenation.  
 
 
1.2.11. NUCLEOPHILIC AROMATIC SUBSTITUTIONS 
Heteroaromatic compounds bearing heteroaryl-heteroaryl bonds are a privileged 
class of building blocks found in a wide variety of areas such as liquid crystals, 
optoelectronic materials, biological molecules, and ligands for asymmetric catalysis. 
Even though nucleophilic aromatic substitutions (SNAr) reactions have been known since 
the 1940, the majority of these compounds have recently been synthesized using a 
transition metal-catalyzed cross-coupling reaction.
33
 Within this context, the Tsuchimoto 
group reported indium-catalyzed heteroaryl-heteroaryl bond formation through 
nucleophilic aromatic substitution in 2011.
34
 Starting from 2- or 3-methoxythiophenes I-
41, the addition of 1.3 equiv. of substituted indoles I-40 in the presence of indium triflate 
 12 
underwent a SNAr reaction to afford heteroaryl products I-42 (Figure 1.11). The author 
also showed that quarter-heteroaryl compounds can easily be synthesized using this 




Allylation of aldehydes is one of the most commonly used strategies to generate 
homoallylic alcohols, which are versatile building blocks in organic synthesis.
35
 
Allylsilanes and allylstannanes have been used as potential reagents for allylation 
reactions due to their fascinating and excellent reactivity.
36
 Along these lines, Yoda and 
co-workers developed an efficient synthetic method for chiral α-methylene-γ-lactones I-
46.
37
 An In-catalyzed enantioselective allylation takes place when aldehydes I-44 was 
reacted with β-carbonyl allylstannanes I-43. The resulting products, upon subjecting to 
acidic hydrolysis, afforded γ-lactones in high yields (Figure 1.12).  
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1.2.13. C-S CROSS-COUPLING REACTIONS 
Aryl sulfides are a key motif found in numerous pharmaceutically active 
compounds as well as in a large number of drugs in therapeutic areas, such as immune, 
inflammatory, diabetes, Parkinson’s and Alzheimer’s diseases. In 2008, Rao and co-
workers developed indium-catalyzed C-S cross-coupling reaction.
38
 When aryl halides I-
47 were treated with alkane thiols I-48 in the presence of In(OTf)3, the reactions 
proceeded smoothly to afford the corresponding aryl sulfides I-49 in good to excellent 




1.3. SCOPE OF WORK 
Over the last two decades, indium triflate has emerged as a promising catalyst for 
various types of organic reactions involving carbon-carbon bond formation and other 
organic transformations to construct carbo- and heterocyclic molecules. Indium catalysis 
is of great interest to synthetic organic chemist primarily due to its stability in air and 
water, reactivities, selectivities, low toxicity, recyclability, and milder reaction 
conditions. Due to the unique advantages of indium over other commonly used metals, 
the France group decided to explore further utility of indium catalysis in organic 
synthesis. 
 14 
Chapter 2 in this thesis is focused on developing an In(III)-catalyzed efficient 
protocol for the formal homo-Nazarov cyclizations of alkenyl cyclopropyl ketones and 
heteroaryl cyclopropyl ketones. In this reaction, vinyl cyclopropyl ketones (or heteroaryl) 
cyclopropyl ketones are converted into cyclohexenones and heteroaryl ring-fused 
cyclohexanone derivatives.
39
 These viable approaches remained relatively underexplored. 
Previous approaches suffer from one or many of the following drawbacks: (a) narrow 
substrate scope; (b) longer reaction times; (c) poor yields; and (d) harsh reaction 
conditions- a large excess of acid and high temperatures.
40
 One reasonable approach to 
circumvent all these drawbacks is to utilize donor-acceptor cyclopropyl vinyl ketones I-
50 bearing a secondary electron acceptor group (such as an ester) in the α-position. The 
France group strongly believed that the secondary acceptor group would facilitate 
coordination with Lewis acids, thereby allowing milder reaction conditions for 
cyclopropane ring-opening A. An ester acceptor group would also serve to further 






The hydropyrido[1,2-a]indole skeleton and, more specifically, its C(6)-oxidized 
cogeners, are key structural motifs that appear in the core structures of an impressive 
number of naturally-occurring indole alkaloids and pharmaceutically relevant 
compounds.
41
 Despite several reported approaches to construct hydropyrido[1,2-a]indole-
based polycyclic skeletons, an efficient synthesis still remains a formidable goal for 
organic chemists.
42
 Chapter 3 in this thesis reports the synthesis of densely functionalized 
hydropyrido[1,2-a]indole-6(7H)-ones derivatives I-55 via In(OTf)3-catalyzed tandem 
cyclopropane ring-opening/Friedel–Crafts alkylation sequence of methyl 1-(1H-
indolecarbonyl)-1-cyclopropane carboxylates I-54, thereby potentially providing a 
method that is highly modular, operationally simple and amenable to a large variety of 




[a]-Annelated indoles such as the pyrrolo[1,2-a]-indoles are unique structural 
features present in a wide range of heterocyclic compounds that play important roles in 
medicinal chemistry and organic synthesis.
43
 Numerous routes to the pyrrolo[1,2-
a]indoles have been reported in recent years. However, these methods do not allow for a 
variety of functionality to be incorporated about the 1H-pyrrolo[1,2-a]indole skeleton.
44
 
In chapter 4, we report an In(OTf)3-mediated diastereoselective intramolecular Friedel-
Crafts cyclizations of substituted methyl 2-(1H-indole-1-carbonyl)acrylates I-56 to 
generate functionalized 1H-pyrrolo[1,2-a]indole derivatives I-57 (Figure 1.16).  
 
 
The tetrahydroquinoline (THQ) moiety is one of the most privileged class of 
nitrogen-containing compounds, being widespread in nature and found as a key structural 
unit in a large number of therapeutic agents.
45
 Within the THQ class of compounds, the 
 17 
4H-pyrrolo[3,2,1-ij]quinolines, as well as their reduced and oxidized derivatives have 
garnered considerable attention in the area of drug discovery and agrochemistry.
46
 
Chapter 5 includes our efforts to develop an effective strategy to access 4H-pyrrolo[3,2,1-
ij]quinoline derivatives I-59 using In(OTf)3-catalyzed diastereoselective intramolecular 
Friedel-Crafts cyclizations reaction of substituted methyl 2-(2-methyl-1H-indole-
carbonyl)acrylates I-58 (Figure 1.17). 
 
 
Chapter 6 discusses our efforts in the synthesis of (±)-deethyleburnamonine, using 
our catalytic tandem ring-opening/Friedel-Crafts alkylation protocol.  (±)-
Deethyleburnamonine is chosen because it represents the simplest example of both the 
eburnan-vinca and tacaman alkaloids, with interesting pharmacological activities.
47
 In 
comparison to the previously described synthetic routes to this natural product, our highly 
modular, operationally simple In(III)-catalyzed protocol allows for a large variety of 
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INDIUM(III)-CATALYZED FORMAL HOMO-NAZAROV 







2.1. INTRODUCTION AND BACKGROUND OF CYCLOPROPANES 
The smallest cycloalkane, the cyclopropane was first synthesized by W. H. 
Perkin
1
 through the attack of a diethyl malonate dianion upon 1,2-dibromoethane in 1984. 
Since then organic chemists have always been intrigued by the cyclopropane subunit.
2,3
 
Cylopropanes are the basic core of a wide range of natural products and compounds with 
interesting biological activities.
4
 Furthermore, several cyclopropane-containing unnatural 
products have been tested for their bonding features
2d,5
 and enzyme 
mechanism/inhibition.
6
 Additionally, these highly strained cycloalkanes have been used 
as versatile intermediates in the synthesis of several functionalized cycloalkanes and 
acyclic compounds.
2c,7
 The following section will provide a brief overview of the 
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2.1.1 BONDING IN CYCLOPROPANES 
Among cycloalkanes, the cyclopropane and its derivatives represent a unique 
class of compounds by virtue of their unusual structural, spectroscopic, and chemical 
properties.
5a
 In its simplest graphical representation, the cyclopropane can be viewed as a 
planar equilateral triangle with internal angles being 60
o
. However, these bond angles are 




-hybridized orbitals. This deviation 
imparts considerable angular (Bayer) strain. Additionally, cyclopropanes suffer from 
torsional (Pitzer) strain due to the rigid, coplanar arrangement of the three carbon atoms, 
thereby causing eclipsing of ring substituents (Figure 2.1). The release of the ring strain 
(27.5 kcal/mol) associated with ring-opening provides the rationalization for high 






The cyclopropanes have higher percentage of s character of the C-C bond forming 
orbitals, shortened interatomic bond distances, and weaker C-C bonds. They also have 
the ability to interact with neighboring π-electron systems and p-electron centers, form 
metal complexes, add reagents (strong acids, halogens, ozone), and undergo catalytic 
hydrogenation and cycloaddition reactions. To accommodate all of these, two alternative 
models have been presented: the Coulson-Moffit
9
 and Walsh models
10






Unactivated cyclopropanes have been directly employed for certain useful 
chemical transformations.
11
 However, the ring-opening reactions of monoactivated 
cyclopropanes are in general sluggish due to their low reactivities. Therefore, severe 
conditions are required. For example, cyclopropanes are either treated with strong 




 stronger Lewis acids (such as TiCl4),
13
 or assisted by the β-
stabilizing effect of the silicon atom of trimethylsilyl group.
14
 To facilitate ring-opening 
under mild reaction conditions, these strained cycloalkanes require further activation 
from electron-donating or accepting substituents. The facile cyclopropane ring-opening 
towards nucleophiles or electrophiles is often dictated by the electronics of the 
substituents on the ring
2c
. For example, cyclopropanes substituted with electron-donating 
groups are activated for C-C bond cleavage in the presence of electrophiles affording the 
cation equivalent for further reactions (Figure 2.3, Eq.1). Whereas, cyclopropane 
substituted with electron-accepting groups behave more like homo-Michael acceptors in 
the nucleophile initiated ring-opening to generate an anion equivalent for further 




The reactivity of cyclopropanes is further enhanced by substituting it with both 
donor and acceptor (D-A) groups, guaranteeing activation of the cyclopropanes and a 
high versatility of the products after ring-opening.
15
 This is achieved by placing D-A 
groups on the cyclopropane either geminally or vicinally. The use of geminal D-A 
substituted cyclopropanes in organic synthesis has been restricted due to the competing 
electronic effects of the two substituents that offer litter to no bond polarization. On the 
contrary, vicinal D-A cyclopropanes have been extensively studied over the past two 
decades.
2a,2c,16
 Such an arrangement of substituents with opposite electronic effects 
imparts reactivity to the cyclopropanes by a synergistic electron “push-pull” relationship. 
These results in an improved ability of vicinal D-A substituents on the cyclopropanes to 
stabilize the dipolar intermediate species formed upon heterolytic C-C α-bond cleavage. 
For this reason, under Lewis acidic conditions, vicinal D-A cyclopropanes undergo 
formal retro-aldol rearrangement to form 1,3-zwitterionic intermediates species that could 






2.2. VICINAL DONOR-ACCEPTOR CYCLOPROPANES IN ORGANIC 
SYNTHESIS 
The pioneering work of Cram and Danishefsky on vicinal D-A cyclopropanes 
provided better insight into the mechanistic understanding of the ring-opening reactions 
of D-A cyclopropanes.
16a,17
 Owing to the relative ease of ring-opening under a variety of 
mild Lewis-acid conditions, vicinal D-A cyclopropanes gained considerable attention as 
powerful synthetic building blocks towards the construction of highly functionalized 
carbo- and heterocyclic compounds. The chemistry of vicinal D-A cyclopropane is so 
extensive that a full discussion of all ring-opening and cyclization reactions is beyond the 
scope of this thesis. Therefore, only a short selection of relatively new methods for the 
synthesis of carbo- and heterocycles will be presented, with a focus on cycloadditions, 
cyclodimerizations, and formal homo-Nazarov chemistry.  
29 
 
2.2.1. CYCLOADDITIONS/ANNULATIONS OF CYCLOPROPANES 
2.2.1.1. [3+2] CYCLOADDITION 
In 2003, Kerr and co-workers reported the first homo [3+2] dipolar cycloaddition 
reaction of nitrones II-1 with cyclopropane diesters II-2 to generate tetrahydro-1,2-
oxazines II-3.
18
 In this seminal publication, Kerr elegantly utilized the reactivity of 1,1-
cyclopropanediesters as one-carbon homologues of electron-deficient olefins. 
Ytterbium(III) triflate was identified as an effective Lewis acid promoter for this reaction. 
The Kerr group was also able to screen a wide variety of nitrones and 1,1-
cyclopropanediesters. In every case examined, only the cis product was observed with 
yields ranging from 50-96%. The reaction is proposed to proceed through a step-wise 
mechanism, involving nucleophile-initiated cyclopropane ring-opening followed by a 
Mannich-type ring closure. Further in their studies, the utility of the reaction was 
demonstrated through the preparation of tricyclic precursor II-4 for antitumor antibiotic 






2.2.1.2. [3+3] CYCLOADDITION 
Charette and co-workers developed a Ni(ClO4)2–mediated  [3+3] cycloaddition 
reaction of aromatic azomethine imines II-5 with 1,1-cyclopropanediesters II-6 in 2008 
(Figure 2.5).
19
 The reaction afforded unique tricyclic pyridazino[1,6-a]quinolines based 
compounds II-7 in moderate to high yields and modest diastereoselectivities. The higher 
yields were obtained when electron rich aromatic substituted cyclopropanes were 
employed in the reaction. However, electron poor aromatics, vinyl, and unsubstituted 
cyclopropanes gave significantly lower yields. Further stereochemical studies showed 
that the reaction proceeded in a step-wise fashion which involves nucleophilic ring-




2.2.1.3. [3+4] CYCLOADDITION 
In 2008, the Ivanova group developed an analogue of the Diels-Alder reaction 
with a cyclopropane as the dienophile. This formal [3+4] cycloaddition between 
isobenzofuran II-8 with cyclopropanes II-09 proceeds in the presence of Yb(OTf)3 to 




The reaction is proposed to proceed through a concerted mechanism, providing the less 
stable exo isomer as the major product. This argument was confirmed when dimethyl 
methylenemalonate was formed as a decomposition product upon subjecting the major 
product to prolonged heating in the presence of catalyst. Ivanova observed a similar 
reaction when anthracene II-11 and aryl substituted cyclopropanes II-9 were reacted in 




2.2.1.4. [4+1] CYCLOADDITION 
 
Investigations by Zhang and co-workers into the reactivity of 2-substituted or 2,3-
disubstituted 1-(1-alkynyl)-cyclopropyl ketones II-13 revealed that carbon monoxide 
could act as a dipolarophile in a [4+1] cycloaddition reaction with D-A cyclopropanes to 
afford 1,3,5-tri- and 1,3,5,6-tetrasubstituted 5,6-dihydrocyclopenta[c]furan-4-ones II-14 
(Figure 2.7).
20
 In the presence of 5 mol% of Rh(I) catalyst, regio- and stereospecific 




Alkyl, electron-donating group (EDG) and electron-withdrawing group (EWG) 
substituted aryl, alkene, cyclopropyl, esters, and ketone groups are well tolerated in this 
highly modular, atom-economical reaction with cycloaddition yields varying from 38 % 
to 95%. The reaction is proposed to proceed through regioselective oxidative addition of 
Rh(I) across C1-C2 bonds of the cyclopropane forming a rhodacyclobutane which 
immediately isomerizes to a furano-fused rhodacyclopentane. Finally, insertion of carbon 
monoxide generates the furan-fused rhodacyclohexanone derivative, which on 




2.2.1.5. [4+2] CYCLOADDITION 
 
The [4+2] cycloaddition chemistry developed by Zhang et al. for the synthesis 
carbo- and heterocycles elegantly utilizes the reaction of Au-containing all-carbon 1,4-
dipoles generated from 1-(1-alkynylcyclopropyl) ketones II-15 (Figure 2.8).
21
 The 
reaction of D-A cyclopropane II-15 with indoles under IPrAuNTf2 promotion affords 
tetracyclic furan II-16 in good to high yields, however in low diastereoselectivities. 
Various substituents including cyclopropyl, cyclohexyl, phenyl, and alkyl ether groups 




However, a sterically demanding cyclohexyl group at the alkyne terminus 
lowered the yield. Further studies by Zhang showed that aldehydes/ketones can also work 




2.2.1.6. [4+3] CYCLOADDITION 
 
The synthesis of 5,7-fused heterobicyclic furo[3,4-d]-[1,2]oxazepines II-18 from 
the [4+3] cycloaddition of D-A cyclopropyl ketones II-17 and nitrones was described by 
Zhang in 2010 (Figure 2.9).
22
 The regioselectivity of the reaction was achieved by 
making subtle changes in the choice of Lewis acid. When 1-(1-alkynyl)cyclopropyl 
ketone II-17 was reacted with nitrones in the presence of 10 mol% Sc(OTf)3, the  reaction 
afforded tetrahydro-1,2-oxazines II-19 through 1,3-dipolar (formal [3+3]) cycloaddition 
reaction, whereas upon reacting in the presence of 2 mol % Ph3PAuOTf it fashioned 5,7-
fused products II-18. The reaction is effective with EDG- and EWG- substituted aryl, 
styryl, heteroaryl, and benzyl groups on the nitrones, and aryl, alkyl, biaryl, and 
cycloalkanes on the cyclopropanes furnishing products in good to excellent yields and 
moderate to high diastereoselectivities. The regioselectively-tunable cycloaddition was 
possible due to the difference in reactivity of the Lewis acids. The scandium catalyst 





2.2.2. CYCLODIMERIZATION OF CYCLOPROPANES 
2.2.2.1. [3+2] CYCLODIMERIZATION 
Recently, the Melnikov group reported a novel Lewis acid-catalyzed [3+2] 
cyclodimerization of cyclopropanes II-13.
23
 The cyclopropanes, upon subjecting to harsh 
reaction conditions involving Yb(OTf)3 or Sn(OTf)2 in refluxing chlorobenzene, afforded 
highly functionalized cyclopentanes II-14 (Figure 2.10). The proposed mechanism 
includes a Lewis acid catalyzed cyclopropane ring-opening with the formation of synthon 
I (umpolung) and its transformation into synthon II (normal reactivity), which provides 
only two-carbon units for the newly formed cyclopentane ring. The reaction worked well 
with aromatic, heteroaromatic, and diaryl-substituted cyclopropanes, providing products 






2.2.2.2. [3+3] CYCLODIMERIZATION 
 
In 2011, the Ivanova group demonstrated [3+3] cyclodimerization of 1,1-
cyclopropanediesters.
24
 Interestingly, this reaction process provides straight-forward one-
step access to three different types of six-membered cyclic compounds such as   cis-1,4-
diarylcyclohexanes II-16, 1-aryl-1,2,3,4-tetrahydronaphthalenes II-17 or 9,10-
dihydroanthracenes II-18 (Figure 2.11). The product outcome was completely dependent 
on the reaction conditions and substituent pattern in the parent cyclopropane. The 
cyclodimerization leading to 1,4-diarylcyclohexanes proceeded with excellent 
diastereoselectivity furnishing the cis-isomer exclusively, while the reaction leading to 1-
aryl-1,2,3,4-tetrahydronaphthalenes and 9,10-dihydroanthracenes proceeded with 







The D-A cyclopropanes were also known to undergo a different set of reactions 
when the nucleophile is intramolecularly located in the form of either an electron-rich 
double bond or aromatic group. One such reaction is referred to as the formal homo-
Nazarov cyclization reaction. In the next section, a brief survey of the history and current 
state of the formal homo-Nazarov cyclization will be outlined.  
 
2.3. FORMAL HOMO-NAZAROV CYCLIZATION REACTION 
 
2.3.1. BACKGROUND AND INTRODUCTION 
 
The abundance of useful compounds bearing functionalized cyclopentyl rings has 
led to the development of diverse methods for the construction of five-membered 
carbocycles.
 
Among these methods, the Nazarov cyclization has gained prominence as a 
one of the most powerful methods for the construction of unsaturated five-membered 
rings due to the stereoselectivity and controllable regioselectivity of the reaction.
25
 It is a 
4π-electron process involving the conversion of divinyl ketones II-19 to cyclopentenones 
by activation with protic or Lewis acids (Figure 2.12).
 
The individual mechanistic steps 
involved in the Nazarov cyclization are thought to proceed as follows: i) a divinyl ketone 
II-19 complexes to the acid to form a pentadienyl cation A; ii) a conrotatory ring closure 





iii) removal of proton from B (eliminative pathway) or trapping of the cation in the 
presence of a suitable nucleophile (interrupted pathway). Both pathways terminate the 






The Nazarov cyclization has gained recent attention in the literature due to several 
advances that have improved the synthetic utility of this transformation: (1) reactive 
substrates undergo cyclization using catalytic Lewis acids;
26
 (2) trapping of the 
intermediate cation was found to be efficient, allowing preservation of both stereocenters 
created during conrotatory electrocyclization;
27
 (3) chiral auxiliaries allow asymmetric 
cyclization;
28
 (4) axial to tetrahedral chirality transfer is possible;
29
 and (5) chiral Lewis 
acids afford enantioselectivity.
30
 The reaction has been featured as the key step of several 
syntheses of natural products and other bioactive molecules, further demonstrating the 
utility of the cyclization for application to complex molecule synthesis.
31
  
While the traditional Nazarov reaction (using divinyl ketones) has been very well-
studied, much less is known about the formal homo-Nazarov cyclization, a homologous 
variation. In contrast to the concerted Nazarov reaction, this reaction proceeds in a 
stepwise fashion. In this reaction, one double bond from divinyl ketones system is 
masked as a cyclopropyl group. Thus, the reaction of such cyclopropyl vinyl ketones II-
22 provides an access to larger ring systems, α,β-unsaturated cyclohexenones II-23 via a 






2.3.2. PREVIOUS METHODS OF ALKENYL FORMAL HOMO-NAZAROV 
CYCLIZATION 
The first example of a formal homo-Nazarov cyclization was reported by Murphy 
and Wattanasin in 1980.
32
 Murphy reported the synthesis of tetralones II-25 from 
activated aryl aroylcyclopropanes II-24 using a large excess of SnCl4. Studies showed 
cleavage of only the b bond, since product II-25b was not observed. Formation of 
carbocationic intermediates Int-a, and Int-b has been proposed (Figure 2.14). The 
products yields were obtained in the range of 14-80%. When the R
2 
group was incapable 
of stabilizing the benzyl cation Int-a, the reaction was slow and thus further supports the 
proposed cationic mechanism. Tetralone derivatives II-25a were obtained only when 
both ring substituents were suitably activated. This observation was bolstered when 
successful cyclization was observed only when the cyclopropane was substituted with an 






Tsuge and coworkers reported the first example of formal homo-Nazarov cyclization 
of alkenyl cyclopropyl ketones in 1888.
33
 In this seminal report, Tsuge reported the 
cyclization of several vinyl-cyclopropyl ketones in the presence of a large excess of 
polyphosphoric acid to generate cyclohexenones. In one representative example, cyclization 
of ketone II-26 proceeded successfully to provide cyclohexenones product II-27 in 63% 
yield (Figure 2.15). However, the reaction had three major drawbacks: (1) lack of 
generality - only five out of sixteen substrates provided the desired cyclohexenones; (2) 
poor product yields (15-63%); and (3) harsh reaction conditions -excess PPA in refluxing 
benzene for >24 h. All of these limitations resulted in sparse application of the alkenyl 






In 2009, the Waser group greatly expanded the scope of formal homo-Nazarov 
cyclization of alkenyl cyclopropyl ketones by utilizing cross-polarized substrates II-28.
34
  
Frontier and co-workers have demonstrated the benefit of cross-polarized substrates in 
the related classical Nazarov cyclization reaction.
35
 Various hetero-atom activated vinyl 
cyclopropyl ketones II-28 cyclized successfully to provide carbo- and heterocyclic 
products II-29 in high yields under catalytic amount of TsOH (Figure 2.16). The 
substitution of a heteroatom α- to the ketones by a silyl group was also tolerated. When 
unactivated vinyl ketone II-30 (cyclohexyl based) was subjected to the reaction 
conditions, none of the desired product formation was observed. The substrate either 
polymerized II-31 or gave alcohol II-32 product in 32% yield. This study has provided 
invaluable insight into the potential of the alkenyl reaction with two major limitations: i) 
simple alkenes did not work (an α-heteroatom was required to activate the alkenyl 
group); and ii) the necessity of having an electron-rich aromatic substituent on the 





The examples of heteroaromatic formal homo-Nazarov cyclization reaction 
involving the use of heteroaromatic rings as reactive π-system, to generate heteroaryl 
fused-cyclohexanones ring skeletons will be discussed separately in this chapter under 













2.4. INDIUM(III)-CATALYZED FORMAL HOMO-NAZAROV CYCLIZATION 
OF ALKENYL CYCLOPROPYL KETONES
†
 
As described in the previous section, only two reports on the cyclization of 
alkenyl (vinyl)-cyclopropyl ketones were mentioned in the literature. These 
methodologies suffer from one or more of these limitations: i) harsh reaction conditions-
use of a large excess of acid or heating at high temperatures; ii) lower product yields; iii) 
lack of generality; iv) use of a heteroatom in the -position on the vinyl group; and v) 
requires electron rich aryl group on the cyclopropane to promote cyclization. 
Unfortunately, these restrictions severely limit the scope and utility of the reaction in 
organic synthesis. Therefore, the development of an efficient and highly versatile 
protocol for the formal homo-Nazarov cyclization that can circumvent all these issues 
would be highly beneficial to the synthetic community. 
 
2.4.1. REACTION DESIGN 
To facilitate the formal homo-Nazarov cyclization of alkenyl cyclopropyl ketones 
and ultimately expand the scope and applicability of the reaction, the France lab 
envisioned that the introduction of a secondary electron-acceptor (an ester) in the α-
position of the cyclopropane II-33 would guarantee the activation of the cyclopropanes 
and circumvent the necessary reaction barrier by strongly coordinating with Lewis acids.  
Cyclopropanes bearing one donor and two geminal acceptors group (D-A-A) are known 
to undergo a rapid ring-opening due to increased polarization and elongation of the C-C 
bond (a-bond) between them. We also postulated that it would allow milder reaction 
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conditions for cyclopropane ring-opening. Substituting EWG- and EDG- groups 
strategically on the cyclopropane would serve to further polarize the resulting cyclic 
oxyallyl cation Int-d by localizing the charge density, which could favor the desired 
cyclization to furnish cyclohexenones II-34 (Figure 2.17). Frontier has similarly 





2.4.2. MODEL SUBSTRATE SYNTHESIS 
To test the rationale of using D-A-A cyclopropanes to promote catalysis, we set 
out to probe the reactivity of alkenyl cyclopropyl substrates. We chose to begin our 
investigation using a model substrate bearing an α-alkyl substituent and electron-rich aryl 
substituent on the cyclopropane. This substrate was chosen for initial examination due to 
the concerns about the stability of the resulting oxyallyl cation as compared to that of the 
benzylic cation (Figure 2.18). Thus, requisite alkenyl substrate II-33a was synthesized in 
three steps starting from the malonate derived Weinreb amide II-35.  The amide II-35 
was transformed into the diazo species, which upon subsequent Rh-catalyzed 
cyclopropanation with 4-methoxystyrene yielded cyclopropyl Weinreb amide II-36a. 
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Finally, the addition of a Grignard nucleophile afforded alkenyl cyclopropyl ketones in 




2.4.3. PROOF OF PRINCIPLE   
With model substrate in hand, the initial reaction with II-33a was conducted in 
dichloromethane at room temperature in the presence of 30 mol % Sc(OTf)3 as a Lewis 
acid promoter (Figure 2.19). The reaction progress was monitored by TLC and the 
reaction showed complete disappearance of starting material in less than 50 min. The 
crude 
1
H NMR was taken using an aliquot of the reaction mixture. As anticipated, the 
cyclization predominantly afforded the cyclohexenone II-34a based on a formal homo-
Nazarov-type eliminative pathway. Furthermore, we were intrigued to find another 
putative formal homo-Nazarov product, a cross-conjugated enol system with an exocyclic 
alkene II-37a. Beyond these two products, dihydrofuran II-38, which presumably arises 
from the enolate attack upon the acyclic benzylic cation, was observed (Figure 2.20). The 
reaction afforded II-37a and II-34a with a combined yield of 70%, accompanied by 





2.4.4. REACTION OPTIMIZATION 
With substrates in hand, it was imperative to identify conditions that allowed for 
the successful formal homo-Nazarov cyclization of the alkenyl cyclopropyl ketones II-
33. Based on preliminary results from the Sc(OTf)3 reaction, a thorough Lewis acid 
screening was performed using substoichiometric amounts of various metal catalyst, 
primarily focusing on readily available triflate salt. Each reaction was performed using 
II-33a with 30 mol% Lewis acid salt in dichloromethane at room temperature. The 
reaction progress was monitored by TLC. Each reaction was stirred from 1 h up to a 
maximum time of 105 h.  An aliquot of the reaction mixture was concentrated and a 
crude 
1
H NMR was for each reaction. Based on the crude 
1
H NMR spectra of the 
individual screening reactions, the ratios of formal homo-Nazarov products II-34a and 
II-37a were compared directly against those of II-33a and II-38a (Figure 2.21). To our 
satisfaction, In(OTf)3 emerged as the most efficient promoter (full conversion of II-33a 
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to II-34a and II-37a within 3 h), while Zn(OTf)2 and Cu(OTf)2 were the next best Lewis 
acids, although neither gave full conversion of II-33a even after 105 h. Pd(0) and Pd(II) 
complexes did not give any formal homo-Nazarov products.  
 
Next, the effect of solvent on product outcome was examined. These experiments 
showed that the reactivity of substrate II-33a is strongly dependent on the nature of the 
solvent.  Of the solvents screened, acetonitrile, THF, and nitromethane afforded relatively 
lower yields and thus were less promising. However, good yields were obtained in 
aromatic and halogenated solvents, indicating that the reaction progresses very smoothly 
in non-coordinating solvents. Of the solvents investigated, dichloromethane remained the 
47 
 
best choice and no observable changes in the product distribution were observed with any 




2.4.5. EXAMINING THE REACTION SCOPE AND LIMITATIONS  
Having identified that 30 mol% In(OTf)3 in dichloromethane at room temperature 
was the best overall catalyst system to promote the formal homo-Nazarov cyclization 
reaction of II-33, a diverse set of alkenyl cyclopropyl ketone substrates were screened to 
determine the reaction scope and applicability.  When α-alkyl substrates are subjected to 
the reaction conditions, mixtures of II-34 and II-37 are observed. Model substrate II-33a 
provided the cyclohexene derivative II-34a and cyclohexenol product II-37a in 75% 
yield as a 1.5:1 mixture (Table 2.2, entry 1). For II-37a, the methyl group and phenyl 
were found to be orienting in a trans relationship (5:1 trans/cis dr) as confirmed by NMR. 
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   Similarly, cyclohexenyl based ketone II-33b also proved to be a good substrate, 
affording products II-34b and II-37b in 1.5:1 mixture with a combined yield of 75% 
(Table 2.2, entry 2). With ketone II-33c, both products II-34c and II-37c were formed in 
a combined yield of 77% yield as a 1.5:1 mixture (Table 2.2, entry 3). Electron deficient 
aryl substituted cyclopropyl ketones proved to be more challenging than those that were 
electron rich. For example, cyclopropanes substituted with phenyl or 4-fluorophenyl 
(Table 2.2, entries 4 and 5), II-37d and II-37e were the only cyclized products observed 
in 46% (80% BRSM) and 56% yields (77% BRSM), respectively. The reactions did not 
go to completion even after 24 h, only offering starting material II-33. These 
observations can be rationalized based on the decreased cation stabilizing ability of the 
phenyl and 4-fluorophenyl groups in comparison to the strongly donating 4-
methoxyphenyl group. Inspired from the pioneering work of Denmark and coworkers on 
silicon-directed Nazarov reactions,
36
 a silyl group on the α-substituent of II-33f was 
installed to further stabilize the resulting oxyallyl cation. An allyl silane group to would 
also serve to enhance the nucleophilicity of the double bond and favor cyclization with a 
potentially altered product ratio. Gratifyingly, upon submitting silyl ketone II-33f to the 
optimized conditions, the reaction proceeded rapidly to form product II-37c in 92% yield 
within 0.5 h (Table 2.2, entry 6). The regioselectivity of the double bond formation in II-
37c was completely governed by the elimination of the silyl group. The formation of this 
product also agrees with the mechanistic hypothesis of carbocation formation due to the 
β-silyl effect. To further increase the versatility of our formal homo-Nazarov process, it 
was decided to test substrate derived from dihydropyran. This was chosen for two 
reasons: 1) reaction would furnish bicycylic pyran-fused cyclohexenones as a product; 2) 
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a pyranyl heteroatom ring would govern the regioselectivity of the double bond formation 
in the product. As anticipated, the cyclization of dihydropyran based ketone II-33g 
proceeded efficiently providing II-34d as the only observable product in 93% yield 
(Table 2.2, entry 7).  Finally, we inspected a substrate bearing a α-phenyl group (Table 
2.2, entry 8). We anticipated that the introduction of α-phenyl group would promote 
reactivity both by favoring the formation of the reactive pseudo s-trans conformation II-
33h(c) and further stabilizing the resulting cyclic oxyallyl cation (Figure 2.22). By 
avoiding any potential unfavorable steric interactions in the pseudo s-cis conformation II-
33h(a), α-phenyl substitution favors σ-bond rotation to populate the reactive conformer 
II-33h(c), which affords the correct geometry for cyclopropane ring-opening and 
subsequent ring-closure in the formal homo-Nazarov cyclization. Also, an electron-
withdrawing group (i.e. FG = ester) in this position has the potential to bind a Lewis acid 
in a bidentate fashion, further promoting the reactive pseudo s-trans conformation. When 
II-33h (bearing a α-phenyl substituent) was subjected to the reaction conditions, only 
30% yield (50% BRSM) of the expected cyclized product II-34e was observed after 35 h. 
Along with unreacted starting material, the major component was the dihydrofuran by-
product. This marks the only instance in which this by-product is observed when 
In(OTf)3 is used as the Lewis acid promoter. This can be rationalized if II-33h exists in 
the less reactive pseudo s-cis enone conformation. MMFF calculations revealed that the 
pseudo s-cis conformation II-33h(a)  is more stable than the pseudo s-trans conformation 
II-33h(c) by more than 6 kcal/mol due to the presence of stabilizing π-interactions 






Consequently, upon cyclopropane ring-opening, enolate trapping of the acyclic 
cation directly outpaces the formal homo-Nazarov cyclization pathway due to the 


















2.4.6. DERIVATIZATION OF PRODUCTS 
As a further illustration of the utility our formal homo-Nazarov cyclization of 
alkenyl cyclopropyl ketones, alkenyl products were used as synthetic building blocks by 
converting them into other useful compounds (Figure 2.23). For instance, when II-37c 
was treated with thiophenol, thioether II-39 was obtained in 58% yield as a 1:1 mixture 
of diastereomers. Similarly, II-34a was subjected to Krapcho decarbalkoxylation 






















2.5.1. INTRODUCTION AND BACKGROUND  
The acid-catalyzed ring closure of heteroaryl vinyl ketones to heteroaromatic 
ring-fused cyclopentanones is referred as the heteroaromatic Nazarov cyclization.
37
 
Analogous to this, an acid-catalyzed transformation of a cyclopropyl heteroaryl ketone 
into a heteroaromatic ring-fused cyclohexanone would constitute a homologous variation 
of above reaction and thus may be referred as the heteroaromatic formal homo-Nazarov 
cyclization (Figure 2.24). A viable approach to generate heteroaryl fused skeletons 







                                                 
‡
 This work was performed in collaboration with Lien H. Phun and Marchello A. Cavitt, fellow graduate 
students in the France research group. 
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In 2005, Otto and co-workers disclosed the first report on the homo-Nazarov 
cyclization of heteroaryl substituted cyclopropyl ketones to generate the [b]annelated 
cyclohexenones.
38
 When 2-furanyl- and 2-thienyl cyclopropyl ketones II-41 were reacted 
with SnCl4, and subsequent acidic work-up, ketones furnished the desired ring-fused 
cyclohexenone derivatives II-42 with yields of 94% and 54% respectively.  However, 
when the reactions were performed on an identical substrate but with subsequent work-up 




The scope of heteroaromatic formal homo-Nazarov cyclization was greatly 
expanded by Yadav and co-workers in 2008.
39
 The reaction of heteroaryl 2-silylmethyl 
substituted cyclopropanes in the presence of 4 equiv. SnCl4 in 1,2-dichloroethane at 80
o
C 
furnished 2,3-heteroaromatic ring-fused 4-silylmethyl substituted cyclohexanones. 
Several 2- or 3-substituted furanyl, thienyl, and indolyl ketones II-44a (or b) efficiently 
cyclized to provide corresponding products II-45a (or b) in good to high yields. Yadav 
elegantly utilized a bulky silyl group to stabilize the carbocationic intermediate formed 
upon ring-opening (Scheme 2.26). More importantly, this work also reported first 
example of an oxygen substituent derived from dihydrofuran as a donor group on 
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cyclopropane II-44c in formal homo-Nazarov chemistry to generate tricyclic product II-
45a. 
 
More recently, the Waser group reported a catalytic formal homo-Nazarov 
cyclization of activated vinyl cyclopropyl ketone using p-TsOH.
34
 In this report, Waser 
disclosed the successful cyclization of only one heteroaryl substrate II-46 derived from 2-
subsituted indole to generate tricyclic cyclohexanone product II-47 quantitative yield 




All of these reports suffer from one or more major limitations: 1) use of huge 
excess of Lewis acids; 2) harsh reaction conditions-use of elevated temperature; 3) 
generality of the reaction; and 4) tolerance to a wide range of functionality. Thus, a need 
remains for a general heteroaromatic formal homo-Nazarov cyclization protocol that will 
generate heteroaromatic ring-fused cyclohexanones more efficiently in high-yields and 
under mild conditions. In the following sections of this chapter, In(OTf)3-catalyzed 
cyclization of heteroaryl cyclopropyl ketones that allows for the synthesis of 
heteroaromatic ring-fused cyclohexanone compounds will be discussed. 
 
2.5.2. REACTION PROPOSAL 
In 2010, the France lab developed a In(OTf)3-catalyzed efficient formal homo-
Nazarov cyclizations of alkenyl cyclopropyl ketones to generate cyclohexenones and 
methylene cyclohexanols under mild conditions.
40
 More importantly, our report utilizes 
cyclopropane bearing a secondary electron acceptor (an ester group) for the first time in 
homo-Nazarov chemistry. The introduction of an acceptor group markedly changed the 
reactivity of the cyclopropyl ketone substrates allowing cyclopropyl ring-opening under 
catalytic amount of the Lewis acid promoter in DCM at room temperature. With this 
concept in mind, the France group began examining additional heteroaromatic structures 
that might be targeted using our donor-acceptor-acceptor (D-A-A) based formal homo-
Nazarov approach. The France and coworkers postulated that by replacing the 
unactivated vinyl group of the alkenyl cyclopropyl ketones previously used in the 
synthesis of cyclohexenones and methylene cyclohexanols with an electron-rich 
heteroaromatic group as reactive π-systems II-48 capable of attacking cationic 
57 
 
intermediate generated upon cyclopropane ring-opening, a synthesis of heteroaromatic 
ring-fused cyclohexanones II-49 could be achieved (Figure 2.28). If successful, this 
would open avenues to the convergent assembly of an even wider class of natural 




2.5.3. SUBSTRATE SYNTHESIS  
To begin our investigations, a variety of 2- and 3-heteroaryl substituted 
cyclopropyl ketone substrates were synthesized. Synthesis of the appropriate cyclopropyl 
ketones was achieved in three steps starting from readily available 2- or 3-substitued 
heteroaromatic acid chloride. Addition of in-situ prepared lithium 1-methoxyethenolate 
species to the appropriate 2- or 3-substituted heteroaromatic acid chloride generated β-
ketoesters II-50. Subsequent diazo transfer reaction then furnished α-diazoesters II-51. 
Finally, Rh(II)-catalyzed cyclopropanation in the presence of the requisite alkenes 
provided cyclopropyl ketones II-48 as the heteroaromatic formal homo-Nazarov 





2.5.4. INITIAL STUDIES 
Our initial investigations focused on cyclopropyl ketone substrate derived 
thiophene 2-carboxylic acid. This substrate was chosen for optimization of our protocol 
due to thiophene’s stability in the presence of Lewis acids and proven success as a 
promising substrate in the heteroaromatic Nazarov cyclization reaction.
37
 The initial work 
began by examining the conditions previously used in the France lab to promote alkenyl 
formal homo-Nazarov cyclization. The 2-thienyl substrate II-48a was treated with 30 
mol% In(OTf)3 in dichloromethane at room temperature. To our delight, this initial 
attempt produced the desired cyclohexanone II-49a in 88% yield, thereby confirming the 
feasibility of our D-A-A based heteroaromatic formal homo-Nazarov cyclization 
approach to heteroaryl ring-fused cyclohexanones (Table 2.3, entry 1). Next, the effect of 
lowering the amount of catalyst was examined. Treatment with 5 mol% and 1 mol% of 
In(OTf)3 promoted formation of the desired products in 86% and 77% respectively (Table 
2.3, entry 2 and 3). As anticipated, the reaction time gradually increased as the catalyst 
loading lowered. When the reaction was performed using 5 mol % of InCl3, cyclization 
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was observed which was comparable in time to In(OTf)3 with a significant decrease in 
yield (Table 2.3, entry 4). Influenced by successful use of LiClO4 as an additive in 
Sc(OTf)3- and In(OTf)3-catalyzed Friedel-Crafts acylations,
41
 and Nazarov 
cyclizations,
35,37
 LiClO4 salt was examined. When 1 equiv. of LiClO4 was used with 
either In
3+ 
salt, disappointingly both reactions resulted in poor conversions. Thus, 5 mol 




2.5.5. REACTION SCOPE EXAMINATION  
Having identified the optimal reaction conditions, the scope of this reaction was 
examined by subjecting a series of 2- or 3-substituted heteroaryl cyclopropyl ketones 
under identical conditions. The 3-thienyl substrate II-48c was found to produce the 
expected cyclohexanone product in 73% yield, lower than 2-thienyl cyclopropane II-48a 
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which afforded II-49a in 86% yield (Table 2.4, entry 1 and 3). When 3-furanyl substrate 
II-48d was reacted, it generated corresponding product II-49d in 73% yield (entry 4). 
However, its 2-furanyl counterpart II-48b readily cyclized at room temperature 
furnishing product II-49b in only 28% yield. The observed lower yields were attributed 
to the formation of several by-products. To attenuate this issue, II-48b was refluxed in 
1,2-DCE. Interestingly, subjecting to 1,2-DCE reflux, the reaction afforded its product II-
49b in 67%, and no side product formation was observed (entry 2). The higher 
temperature probably allows the 2-substituted furanyl substrate to achieve the requisite 
transition state that leads to the productive pathway. The success with the 2-substituted 
furanyl and thienyl substrates is indeed noteworthy, since the general observation of the 
literature examples clearly indicates that an electrophilic substitution at 3-position is less 
facile than an electrophilic substitution at 2-position in heteroaromatic compounds except 
the indoles.  The 2- and 3-substituted indolyl cyclopropanes II-48e and II-48g generated 
the desired products II-49e and II-49g in 63% and 61% yields, respectively (entries 5 and 
7). Similarly, the 2- and 3-substituted benzofuranyl precursor’s cleanly cyclized to give 
II-49f and II-49h in 91% and 71% yields respectively (entry 6 and 8). This result is 
notable because benzofuran derived substrates had been unsuccessful as a formal homo-
Nazarov substrate due to competing polymerization issues. The successful reaction of II-
48g/h demonstrates a remarkable ring-closing efficiency of the heteroaromatic formal 
homo-Nazarov protocol. 
To further expand the scope of this reaction in constructing other highly 
substituted heteroaryl ring-fused cyclohexanones, we examined a 3-substituted substrate 
with the 2-position blocked, as in the 2-bromo thienyl cyclopropane II-48i. With the 2-
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position unavailable, the only site for the electrophilic substitution would be the 4-
position. If successful, this would yield the 3,4-fused heteroaryl cyclohexanone II-49i. As 
envisaged, the reaction of II-48i generated the desired cyclization product II-49i in 56% 
yield (entry 9). This synthesis of 3,4-fused systems is reported for the first time in homo-
Nazarov chemistry as it mainly generates only 2,3-ring-fused heteroaromatics. Next, the 
effect of donor substituents about cyclopropane on reactivity was investigated (Table 
2.5). The phenyl derivatives II-48j and II-48k did not cyclize efficiently under optimized 
conditions. To alleviate this issue, the substrates were subjected to heating in 1,2-
dichloroethane at 80
o
C, to afford the desired ring-fused products II-49j and II-49k in 81 
and 83% yield respectively(entry 1 and 2). When the α-methyl styrene-derived 2-thienyl 
cyclopropane II-48l was treated with In(OTf)3 at room temperature, the reaction 
proceeded smoothly to generate product II-49l in 71% yield (entry 3), whereas the phenyl 
derivative II-48j did not cyclize at room temperature. Thus, with the introduction of a 
methyl group geminal to the phenyl a strong accelerating effect was observed. A 
plausible explanation would be a faster ring-opening of the cyclopropane ring due to 
release of steric strain and higher stability of the resulting tertiary benzylic carbocationic 
intermediate. Similarly, the indanyl substrate II-48m gave tetracycle II-49m in 87% 
yield (entry 4). Encouraged by Yadav’s recent work on the successful use of a 
silylmethyl group and oxygen substituent as a donor group on the cyclopropanes, silyl 
derivative II-48n and dihydropyran derivative II-48o was synthesized. The reaction with 
silylmethyl derivative afforded product II-49n in 72% yield (entry 5). Disappointingly, 
no cyclization occurred when dihydropyran derivative was subjected to the reaction 
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conditions. Even at higher catalyst loadings or elevated temperatures, only starting 
material was recovered (entry 6). 
This lack of reactivity can be rationalized if no chelation event was occurring at 
the two carbonyls (Figure 2.30). To support this postulation, MMFF calculations were 
performed for the lowest energy conformers of II-48o. In each of these conformers, the 
two carbonyl oxygens are found to be anti to one another, thus eliminating the two-point 
chelation to the Lewis acid. Without this activation, cyclopropane ring-opening does not 
occur. Additionally, this effect seems to arise from the stereoelectronic influence of the 
methyl ester on the conformation of the fused pyran ring. This effect can arguably be 
seen in the 
1
H NMR spectrum of II-48o where the hydrogen at the fused ring junction 
adjacent to the oxygen is located at 6.5 ppm, which represents a ∼3 ppm downfield shift 
from the analogous pyranyl derivative without the ester. This downfield shift suggests the 









This may explain why substrate II-48o failed to cyclize, even after extended 
reaction times and high catalyst loadings. To test confirm hypothesis, the acyclic ether 
derivative II-48p (derived from ethyl vinyl ether) was synthesized. When II-48p was 
subjected to the standard reaction conditions, the cyclization occurred to provide the 
substituted benzothiophene II-49p in 51% yield (entry 7). The resulting product 
seemingly arises from a rapid aromatization of the transient formal homo-Nazarov 
cyclization product through an In(III)-induced elimination of EtOH. This result further 
supported our hypothesis. 
 
2.5.6. ONE-POT PROCEDURE FOR FORMAL HOMO-NAZAROV REACTION 
Having confirmed that this D-A-A based heteroaromatic formal homo-Nazarov 
cyclization was capable of constructing several substituted heteroaryl ring-fused 
cyclohexanones, the development of a one-pot protocol that would occur in the presence 
of both the rhodium (for cyclopropanation) and indium (for cyclization) catalyst was 
examined. If successful, this route would enable a convergent approach to the assembly 
of functionalized derivatives, from readily available starting materials, and ultimately 
increasing the synthetic utility of this reaction. To verify the feasibility of this approach, 
two key control reactions were performed. First, the stability of α-diazoester II-51 in the 
presence of In(OTf)3 (5 mol %) was established by monitoring a stirring mixture of the 
two components. Next, the stability of the alkene (4-methoxy styrene) was tested in the 






To achieve an active indium catalyst loading of ∼20 mol%, 1 mol% of Rh2esp2 
and 0.2 mol% of In(OTf)3 in DCM at 0 
o
C were employed in the reaction. Gratifyingly, 
subjecting α-diazoester II-51 to these conditions afforded the desired product II-49d in 
56% yield, which is higher than the yield for the two-step procedure and equates to an 















In conclusion, an efficient protocol for the formal homo-Nazarov cyclization of 
alkenyl cyclopropyl ketones was developed. We also demonstrated that by utilizing the 
donor-acceptor-acceptor cyclopropanes (D-A-A), a high-yielding cyclization reaction 
could be developed. Alkenes bearing hydrogens on an α-substituent (or silyl groups) 
provided 1.5:1 mixtures of methylene cyclohexenols and cyclohexenones. When no α-
hydrogens (or silyl groups) are present, only cyclohexenone based products are observed. 
The products rapidly formed in good to high yields (up to 93%) under mild conditions 
and from readily available starting materials in only three steps. Finally, we have shown 
that homo-Nazarov cyclization products could be readily derivatized into useful building 
blocks. This method would find its application towards the natural product synthesis in 
the future.  
A general protocol for the heteroaromatic formal homo-Nazarov cyclization has 
also been reported. This methodology provides rapid access to functionalized 
heteroaromatic ring-fused rings to cyclohexanones. The products are formed in good to 
excellent yields (56-91%) yields. Expanding this scope of this result, we have 
demonstrated the potential of transforming this two-step process in one-pot method. 
Therefore, this methodology could be used for the synthesis of natural products 






2.7. EXPERIMENTAL SECTION FOR FORMAL HOMO-NAZAROV 
CYCLIZATION OF ALKENYL CYCLOPROPYL KETONES 
 
2.7.1. General Methods 
Infrared (IR) spectra were obtained using a Nicolet 4700 FTIR with an ATR 
attachment from SmartOrbit Thermoelectronic Corporations and and are reported as cm-1 
(w = weak, m = medium, s = strong, br = broad). Proton and carbon nuclear magnetic 
resonance spectra (
1
H NMR and 
13
C NMR) were recorded on a Varian Mercury Vx 300 
spectrometer with solvent resonance as the internal standard (
1
H NMR: CDCl3 at 7.26 
ppm; 
13
C NMR: CDCl3 at 77.0 ppm). 
1
H NMR data are reported as follows: chemical 
shift, multiplicity (s = singlet, bs = broad singlet, d = doublet, dd = doublet of doublets, dt 
= doublet of triplets, dq = doublet of quartets, ddd = doublet of doublet of doublets, ddt = 
doublet of doublet of triplets, dtd = doublet of triplet of doublets, t = triplet, bt = broad 
triplet, td = triplet of doublets, q = quartet, qd = quartet of doublets, qn = quintet, m = 
multiplet), coupling constants (Hz), and integration. Mass spectra were obtained using a 
VG-70SE instrument. Chromatographic purification was performed as flash 
chromatography using Dynamic Adsorbents silica gel (32-65µm), using the solvents 
indicated as eluent with 0.1-0.5 bar pressure. For quantitative flash chromatography 
technical grades solvents were used. Analytical thin-layer chromatography (TLC) was 
performed on EMD silica gel 60 F254 TLC glass plates. Visualization was accomplished 
with UV light, aqueous basic potassium permanganate (KMnO4) solution, iodine, 
aqueous acidic dinitrophenylhydrazine (DNP) solution, aqueous acidic p-anisaldehyde 
(PAA) solution, and ethanol solution of phosphomolybdic acid (PMA) followed by 
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heating. Yields refer to isolated yields of analytically pure material unless otherwise 
noted. All reactions were carried out in oven-dried glassware under an atmosphere of N2, 
unless stated otherwise. Tetrahydrofuran and Diethyl ether were distilled from a 
sodium/benzophenone ketyl under N2 and stored in a Schlenk flask. 1,2-dichloroethane 
and dichloromethane was purified by distillation from calcium hydride under N2 prior to 
use. Acetonitrile was dried by fractional distillation over CaH2. Benzene was purified by 
drying with CaH2. Nitromethane was distilled over CaH2 and stored under nitrogen under 
4Å molecular sieves. All other reagents were purchased from Acros, Sigma-Aldrich, 
Fluka, VWR, Merck, Alfa Aesar, TCI and Strem (for metal catalysts) and used without 
further purification unless otherwise noted.  
 
2.7.2. General Procedures 
2.7.2.1. Formation of Diazo Reagent II-52 
 
Diazo reagent II-52 was prepared using a modified version of Charette's 
protocol:
42
 A solution of N,O-dimethylhydroxylamine (3.35 g, 54.9 mmol) in dry DCM 
(10 mL) was added dropwise to a cold (0˚C) solution of methyl 3-chloro-3-
oxopropanoate (5.00 g, 36.6 mmol) in dry DCM (50 mL) under nitrogen atmosphere. The 
resulting reaction mixture was stirred for 2 h at room temperature. Upon completion (as 
monitored by TLC), the mixture was concentrated under reduced pressure. The resulting 
residue was dissolved in 50 mL acetonitrile. To this β-amide ester, tosyl azide (10.8 g, 
54.9 mmol, 1.5 equiv.) and triethylamine (7.41 gm, 73.2 mmol, 2.0 equiv.) were added. 
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The mixture was stirred at room temperature for 16 h then concentrated under reduced 
pressure. The resulting bright yellow/orange residue was purified by flash 
chromatography on silica gel using EtOAc/Hex (3:1) to give II-52 as yellow oil.  
  
2.7.2.2. Formation of Racemic Cyclopropanes II-36a-c 
A 100 mL flask was charged with Rh2(oct)4 (5 mol%) and a magnetic stir bar. The 
flask was purged with nitrogen.  CH2Cl2 and the corresponding styrene (5.0 equiv.) were 
then added and the reaction was stirred at room temperature. The diazo reagent (1.0 
equiv.) dissolved in CH2Cl2 was added to the reaction mixture over a period of 4 h using 
a syringe pump at 25˚C. After complete addition, the resulting mixture was stirred for an 
additional 30 h. The solvent was then removed under reduced pressure and the residue 
was purified by flash chromatography (100% hexane→15% EtOAc:hexane).  
 
Methyl 1-(methoxy(methyl)carbamoyl)-2-(4-methoxyphenyl) cyclopropane 
carboxylate(II-36a). To a solution of 4-methoxystyrene (9.82 mL, 73.86 mmol, 5 equiv.) 
and Rh2(oct)4 (0.575 g, 5 mol %), and CH2Cl2 (60 mL) was added solution of diazoamide 
II-52 (2.75 gm, 14.77 mmol, 1 equiv.) in CH2Cl2 (40 mL) over a period of 6 hours via 
syringe pump.  Reaction progress was monitored by TLC.  Reaction mixture was 
concentrated in vacuo after 30 hours, followed by purification via column 
chromatography (Hex→20% EtOAc/Hex) afforded cyclopropyl amide II-36a as an oil 
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(3.29 g, 76.0%).  
1
H NMR (CDCl3, 300 MHz) δ 715.-6.94 (d, 2H, J=12Hz), 6.74 (dd, 
J=5.70, 5.12 Hz, 2H), 4.04-3.39 (m, 6H), 3.39-2.60 (m, 6H), 2.37-1.86 (m, 1H), 1.33 (m, 
1H).  
13
C NMR (CDCl3, 75 MHz) δ 167.8, 158.7, 130.1, 127.0, 113.5, 77.8, 77.4, 76.9, 
61.4, 55.2, 52.1, 36.7, 17.6. IR: 3000.4(m), 2960.2(b), 2840.9(w), 2814.4(w), 1735.4(s), 
1654.1(s), 1611.3(s), 1514.9(s) cm
-1




To a solution of styrene (3.07 mL, 26.85 mmol, 5 equiv.), Rh2(oct)4 (214.8 mg, 4 mol %), 
and CH2Cl2 (20 mL) was added solution of amide II-52 (1.00 gm, 5.37 mmol, 1 equiv.) 
in CH2Cl2 (20 mL) over a period of 3 hours via syringe pump.  Reaction progress was 
monitored by TLC.  Reaction mixture was concentrated in vacuo after 30 hours, followed 
by purification via column chromatography (Hex→20% EtOAc/Hex) afforded 
cyclopropyl amide II-36b as an oil (862.5 mg, 62.0%).
  1
H NMR (CDCl3, 300 MHz) δ 
7.22 (m, 5H), 3.66 (s, 3H), 3.33 (s, 3H), 3.33-3.30 (m, 1H), 3.20 (s, 3H), 2.93-2.20 (dd, 
J=7.97, 4.94 Hz, 1H), 1.47 (dd, J=9.18, 4.94 Hz, 1H).
  13
C NMR (CDCl3, 75 MHz) δ 
167.4, 134.8, 128.8, 127.8, 126.8, 61.2, 51.8, 36.6, 32.9, 28.6, 17.2. All NMR shifts 






(II-36c). To a solution of 4-fluorostyrene (3.22 mL, 26.85 mmol, 5 equiv.) and Rh2(oct)4 
( 167.25 mg, 4 mol %), and CH2Cl2 (20 mL) was added solution of amide II-52 (1.00 gm, 
5.37 mmol, 1 equiv.) in CH2Cl2(20 mL) over a period of 3 hours via syringe pump.  
Reaction progress was monitored by TLC.  Reaction mixture was concentrated in vacuo 
after 30 hours, followed by purification via column chromatography (Hex→20 % 
EtOAc/Hex) afforded cyclopropyl amide II-36c as an oil (815.7 mg, 54.0%).
  1
H NMR 
(CDCl3, 300 MHz) δ 7.21-7.15(m, 2H), 6.96-6.85(t, 2H, J =6Hz, 6Hz), 3.65(s, 3H), 
3.33(s, 3H), 3.30-3.22(m, 1H), 3.20(s, 3H), 2.20-2.10(q, J =3Hz, 3Hz, 3Hz, 3Hz), 1.40-
1.50(q, J =3Hz, 3Hz, 3Hz, 3Hz). 
13
C NMR (CDCl3, 75 MHz) δ 167.5, 163.5, 120.3, 
130.7, 130.6, 130.5, 130.4, 115.0, 114.7, 61.3, 52.0, 36.6, 33.1, 27.9, 17.4. IR: 3725.3 
(m), 2949.8(m), 1733.9(s), 1652.9(s), 1604.1(m), 1558.1(s), 1511.6(s) cm
-1
.  
HRMS(ESI) M/Z+ Calc. 281.1063, Obs. 281.1074. 
 
2.7.2.3. Formation of Alkenyl Cyclopropyl Ketones II-33(a-h) 
General Method A: A solution of Grignard reagent (1.5 equiv.) was added slowly to a 
stirred solution of Weinreb amide II-36 in THF (10 mL) at -78˚C. The solution was 
stirred at this temperature for the indicated time, gradually warming to room temperature. 
The reaction was monitored by TLC. The solution was then quenched with saturated 
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aqueous NH4Cl (5 mL/mmol), extracted with Et2O (3x10 mL/mmol of amide) and 
washed with brine (2x5 mL/mmol of amide), dried over MgSO4 and concentrated under 
reduced pressure. 
General Method B: Adapted from a reported procedure,
34
 t-BuLi (1.7 M in pentane , 2.0 
equiv.) was added dropwise in a solution of bromoalkene
 
(2.2 equiv.) in THF (0.10 M) at 
-78˚C. The reaction mixture stirred at -78˚C for 30 min. The flask was then transferred to 
an ice bath (0˚C). After 30 min, the reaction was re-cooled to -78˚C and a solution of 
amide II-36 (331 mg, 1.12 mmol, 1.0 equiv.) in THF (0.20M) was added slowly 
dropwise. The reaction was stirred at -78˚C for another 1 h, gradually warming to room 
temperature. The solution was then quenched with saturated aqueous NH4Cl (5 
mL/mmol), extracted with Et2O (3x10 mL/mmol of amide) and washed with brine (2x5 
mL/mmol of amide), dried over MgSO4 and concentrated under reduced pressure.  
 
(E)-Methyl 2-(4-methoxyphenyl)-1-(2-methylbut-2-enoyl)cyclopropanecarboxylate 
(II-33a). Method A was followed using (E)-but-2-en-2-ylmagesium bromide (17.73 mL, 
8.86 mmol, 0.5M in THF, 1.3 equiv.) and amide II-36a (2.0 g, 6.81 mmol, 1.0 equiv.). 
The reaction was quenched after 2 h to give II-33a (1.25 g, 64% yield) after purification 
via flash chromatography (1:6 EtOAc/Hex) as a colorless oil. 
1
H NMR (CDCl3, 300 
MHz)  δ 7.14-7.06 (d, 2H, J =12Hz), 6.80-6.74 (d, 2H, J = 12 Hz), 5.64-5.56 (m, 1H), 
3.72 (s, 3H), 3.42-3.38 (t, 1H, J = 9Hz, 3 Hz), 3.32 (s, 3H), 2.28-2.20 (dd, 1H, J = 4.88, 




C NMR (CDCl3, 75 MHz)   δ 201.5, 195.7, 169.2, 168.5, 158.7, 158.5, 137.7, 137,6, 
137.1, 133.4, 129.9,129.7, 128.6, 128.0, 127.2, 126.9, 126.6, 113.9, 113.4, 113.3, 83.1, 
55.1, 55.0(2C), 52.0, 51.8, 50.8, 44.9, 41.3, 38.0, 33.8, 29.4, 22.0, 21.2, 20.3, 19.6, 15.3, 
15.2, 14.6, 11.7. IR: 3721(w), 2951(m), 2825(w), 1733(s), 1672(s), 1611(m), 1514(m) 
cm
-1





was followed using t-BuLi (2.24 mmol, 1.7 M in pentane, 2.0 equiv.), 
1-bromocyclohexene
 
(0.400 g, 2.48 mmol, 2.2 equiv.) and Weinreb amide II-36a (0.331 
g, 1.12 mmol, 1.0 equiv.).  Purification by column chromatography (1:9 EtOAc:Hex) 
afforded II-33b  (0.159 g, 45% yield) as a colorless oil. 
1
H NMR (CDCl3, 300 MHz) δ 
7.18-7.14 (d, 2H, J = 12Hz), 6.82-6.72 (d, 2H, J =12Hz), 3.76 (s, 3H), 3.38 (s, 3H), 3.34-
3.24 (t, 1H, J = 12Hz), 2.42-2.30 (m, 1H), 2.26-2.18 (m, 4H), 1.72-1.62 (m, 4H), 1.50-
1.44 (m, 1H). 
13
C NMR (CDCl3, 75 MHz) δ 195.4, 169.4, 158.5, 139.9, 138.8, 129.9, 
126.9, 113.4, 55.1, 52.1, 41.4, 29.3, 25.9, 23.6, 21.8, 21.5, 19.5. IR: 2956(m), 2872(w), 
1731(s) cm
-1






Methyl 1-methacryloyl-2-(4-methoxyphenyl)cyclopropanecarboxylate (II-33c). 
Method A was followed using prop-1-en-2-ylmagesium bromide (2.65 mL, 1.32 mmol, 
0.5M in THF, 1.3 equiv.) and amide II-36a (0.300 g, 1.02 mmol, 1.0 equiv.). The 
reaction was quenched after 2 h to give II-33c (0.196 g, 70% yield) after purification via 
flash chromatography (1:6 EtOAc/Hex) as a colorless oil. 
1
H NMR (CDCl3, 300 MHz)   
δ 7.18-7.10 (d, 2H, J = 12Hz), 6.80-6.74 (d, 2H, J = 12Hz), 5.88 (s, 1H), 5.60 (s, 1H), 
3.76 (s, 3H), 3.34(s, 3H), 2.30-2.22 (m, 1H), 1.94 (s, 3H), 1.52-1.46 (m, 1H). 
13
C NMR 
(CDCl3, 75 MHz)   δ 196.5, 169.1, 158.6, 144.4, 129.9, 128.7, 126.7, 123.7, 113.6, 113.4, 
55.1, 52.1, 41.7, 29.8, 20.1, 17.9. IR: 2951(m), 2837(m), 1734(s), 1673(s), 1558(s), 
1515(s) cm
-1
. HRMS(ESI) M/Z+ Calc. 274.1305, Obs. 274.1305. 
 
Methyl 1-methacryloyl-2-phenylcyclopropanecarboxylate (II-33d). Method A was 
followed using prop-1-en-2-ylmagesium bromide (8.69 mL, 4.34 mmol, 0.5M in THF, 
2.2 equiv.) and amide II-36b (0.520 g, 1.97 mmol, 1.0 equiv.). The reaction was 
quenched after 2.5 h to give II-33d (231.3 mg, 48% yield) after purification via flash 
chromatography (1:6 EtOAc/Hex) as colorless oil. 
1
H NMR (CDCl3, 300 MHz) δ  7.30 
(m, 5H), 5.90 (s, 1H), 5.70 (s, 1H), 3.42-3.36 (t, 1H, J = 9Hz, 9Hz), 2.36-2.28 (dd, 1H, J 
= 3 Hz, 6 Hz), 1.94 (s, 3H), 1.74-1.68 (dd, 1H, J = 3Hz, 6 Hz). 
13
C NMR (CDCl3, 75 Hz) 
δ 190.1, 168.8, 144.2, 134.8, 128.8, 127.9, 127.0, 123.7, 52.0, 41.7, 30.1, 19.7, 17.9. IR: 
3674(m), 2945(m), 2923(w), 2850(w), 1743(m), 1715(s), 1687(m), 1678(m) cm
-1
.  




Methyl 2-(4-fluorophenyl)-1-methacryloylcyclopropanecarboxylate (II-33e). Method 
A was followed using prop-1-en-2-ylmagesium bromide (6.3 mL, 3.128 mmol, 0.5M in 
THF, 2.2 equiv.) and amide II-36c (0.400 g, 1.42 mmol, 1.0 equiv.). The reaction was 
quenched after 3 h to give II-33e (0.149 mg, 40% yield) after purification via flash 
chromatography (1:6 EtOAc/Hex) as a colorless oil. 
1
H NMR (CDCl3, 300 MHz) δ  
7.22-7.16 (d, 2H, J = 18Hz), 6.98-6.90 (d, 2H, J = 18Hz),  5.90 (s, 1H), 5.70 (s, 1H), 3.36 
(s, 3H), 3.36-3.30 (t, 1H,  J = 12Hz, 6Hz), 2.28-2.22 (m, 1H), 1.94 (s, 3H), 1.56-1.44 (m, 
1H). 
13
C NMR (CDCl3, 75 Hz) δ 195.9, 168.7, 136.5, 160.3, 144.2, 130.5, 130.2, 115.1, 
114.7, 52.1, 41.6, 29.3, 21.6, 19.9, 17.8. IR: 2953(m), 1740(s), 1678(s), 1509(s), 1435(w) 
cm
-1
. HRMS(ESI) M/Z+ Calc. 262.1005, Obs. 262.0996. 
 
Methyl 2-(4-methoxyphenyl)-1-(2 ((trimethylsilyl)methyl)acryloyl) cyclopropane 
carboxylate(II-33f). A pre-cooled (-78
o
C) solution of 2-bromoallyltrimethylsilane (296 
mg, 1.53 mmol, 1.5 equiv.) in a solvent mixture of Et2O (5 mL) and THF (0.25 mL) was 
treated with t-BuLi (1.7 M in pentane, 1.80 mL, 3.0 equiv.) dropwise over 10 min. The 
light yellow reaction mixture was stirred at -78
o
C for 30 min. A solution of amide II-36a 
(300 mg, 1.02 mmol, 1.0 equiv.) was added dropwise over 10 min. The resulting mixture 
was stirred at -78
o
C for another 1 h and warmed up to room temperature. The reaction 
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was quenched after 1 hr with saturated solution of NH4Cl. After a usual workup and 
purification by column chromatography (1:10 EtOAc:Hex) afforded II-33f (0.128 g, 36% 
yield) as a yellowish oil. 
1
H NMR (CDCl3, 300 MHz)   δ  7.18-7.08 (d, 2H, J = 12Hz), 
6.80-6.74 (d, 2H, J = 16Hz), 5.82(s, 1H), 5.52(s, 1H), 3.70(s, 3H), 3.30(s, 3H), 3.35-3.25 
(t, 1H, J = 15Hz), 2.30-2.20 (m, 1H), 2.10 (s, 1H), 1.70 (s, 1H), 1.50-1.30 (m, 1H), 0.00 
(s, 9H). 
13
C NMR (CDCl3, 75 MHz)   δ 195.5, 169.1, 158.6, 150.4, 146.4, 129.9, 126.8, 
121.4, 113.4, 108.6, 55.0, 51.9, 41.5, 30.1, 26.3, 21.8, 20.6. IR: 2951(m), 1735(s), 1673 
(s), 1612 (m), 1515 (s) cm
-1
.  HRMS(ESI) M/Z+ Calc. 346.1600, Obs. 346.1629. 
 
Methyl1-(3,4-dihydro-2H-pyran-6-carbonyl)-2-(4-methoxyphenyl) cyclopropane 
carboxylate(II-33g). Method B was followed using dihydropyan (0.25 mL, 2.81 mmol, 
2.2 equiv.) and amide II-36a (0.375 g, 1.28 mmol, 1.0 equiv.). The deprotonation time 
was 30 min at 0
o
C and the reaction was quenched after 2 h to give II-33g
 
(0.222 g, 55% 
yield) after purification via flash chromatography (1:9 EtOAc/Hex) as a pale yellow oil. 
1
H NMR (CDCl3, 300 MHz)   δ  7.15-7.09 (d, 2H, J = 12Hz), 6.80-6.75(d, 2H, J = 
15Hz), 6.0-5.95 (t, 1H, J = 6 Hz, 9Hz), 4.15-4.05 (m, 1H), 4.0-3.9 (m, 1H), 3.75 (s, 3H), 
3.40 (s, 3H), 3.36-3.30 (t, 1H, J = 6Hz, 6Hz), 2.22-2.18 (m, 3H), 1.90-1.75 (m, 2H), 1.5-
1.4 (dd, 1H,  J = 3.9 Hz, 4.48 Hz, 4.8 Hz). 
13
C NMR (CDCl3, 75 MHz)   δ 190.7, 168.4, 
158.6, 150.6, 129.9, 126.8, 113.4, 109.9, 66.3, 55.1, 51. 9, 41.2, 29.9, 21.7, 20.6. IR:  
3622(m), 2951(br, m), 1737(s), 1726(m), 1665(w), 1611(m), 1540(s) cm
-1
. HRMS(ESI) 




Methyl 2-(4-methoxyphenyl)-1-(2-phenylacryloyl)cyclopropanecarboxylate (II-33h). 
The title compound was prepared following a previously reported procedure,
43
 t-BuLi 
(1.7M in pentane, 2.4 mL, 2.4 equiv.) was added dropwise in a solution of (1-
bromovinyl)benzene (375 mg, 1.2 equiv.) in Trap-mixture (THF/Et2O/Pentane 4:1:1, 
0.20M) at -120
o
C bath [ligroin(30-50), isopropanol, acetone (4:1:1)/liquid N2). The 




C for 1 hour, and then raised to -90
o
C. A 
solution of amide II-36a (500 mg, 1.0 equiv.) in THF (0.20M) was added slowly 
dropwise. The reaction was stirred at -90
o
C for 30 min. The reaction controlled via TLC. 
The solution was finally warmed upto room temperature (1 h), quenched with saturate 
solution of NH4Cl (5 mL/mmol), and followed up by usual workup. Purification by 
column chromatography (1:9 EtOAc:Hex) afforded II-33h (124 mg, 22% yield) as a 
white solid. 
1
H NMR (CDCl3, 300 MHz) δ 7.42-7.24 (m, 5H), 7.18-7.12 (d, 2H, J = 
12Hz), 6.82-6.76 (d, 2H, J = 12Hz), 5.98 (s, 1H), 5.84 (s, 1H) 3.76 (s, 3H), 3.58-3.40 (m, 
1H), 3.24 (s, 3H), 2.38-2.30 (ddd, 1H, J = 1.05Hz, 4.64Hz, 8.22 Hz), 1.88-1.70 (dd, 1H, J 
= 5.17Hz , 9.65Hz). 
13
C NMR (CDCl3, 75 MHz) δ 197.6, 168.4, 158.7, 149.7, 136.6, 
129.9, 129.0, 128.4, 128.0, 127.8, 126.5, 124.0,  121.5, 113.7, 83.3, 55.1, 52.0, 43.7, 32.2, 
22.2. IR: 3721(m), 3630 (m), 2951 (m), 2844(m), 1737 (m), 1729(s), 1687(s), 1678(w), 
1646(w), 1635(m) cm
-1





2.7.2.4. Lewis Acid Screening Method 
Alkenyl cyclopropyl ketone II-33a (0.36 mmol, 1.0 equiv.) was added to a 
solution of a Lewis acid (0.30 equiv.) in anhydrous dichloromethane (2 mL) at room 
temperature. Each reaction was stirred from 1 h up to a maximum time of 105 h. An 
aliquot of the reaction mixture was concentrated.  A crude 
1
H NMR was taken for each 






H NMR (CDCl3, 300 MHz)   δ 12.05 (s, 1H),  7.20-7.10 (d, 
2H, J = 9Hz), 6.90-6.80 (d, 2H, J = 15Hz), 6.02-5.88(d, 1H, J = 36Hz), 5.34-5.24 (d, 1H, 
J = 30Hz), 3.82 (s, 3H), 3.78 (s, 3H),  3.76 (s, 3H), 3.72 (s, 3H), 3.10-3.00 (s, 1H),  2.80-
2.40 (m, 4H),  1.00 (d, 3H, J = 12Hz). 
13
C NMR (CDCl3, 75 MHz)   δ 173.5, 164.1, 
163.6, 158.4, 144.7, 143.7, 137.0, 135.2, 128.9, 122.6, 114.2, 113.9, 98.9, 55.2, 52.2, 
46.4, 42.1, 41.3, 39.3. IR: 2928 (m), 1717(w), 1654(m), 1628(w), 1512(s) cm
-1
.
   
HRMS(ESI) M/Z+ Calc. 288.1362, Obs. 288.1360. 
Methyl 5-(4-methoxyphenyl)-3,4-dimethyl-2-oxocyclohex-3-enecarboxylate (II-34a). 
1
H NMR (CDCl3, 300 MHz)   δ  7.08-7.00 (d, 2H, J =6Hz), 6.88-6.81(d, 2H, J =10.5Hz), 
3.78(s, 3H), 3.68(s, 3H), 3.42-3.36(m, 1H), 2.76-2.64 (m, 1H), 2.38-2.30(m, 1H), 2.10-
2.02(m, 1H), 1.90(s, 3H), 1.80(s, 3H). 
13
C NMR (CDCl3, 75 MHz)   δ 193.6, 171.1, 
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158.7, 156.7, 155.9, 134.9, 132.3, 132.0, 129.2, 128.7, 122.2, 114.3, 114.2, 113.8,  55.3, 
55.2, 53.2, 52.2, 52.1, 49.1, 47.3, 45.5, 34.5, 33.7, 20.9, 20.4, 11.6, 11.2. IR: 2929(m), 
1717(w), 1654(s), 1627(w), 1586(m), 1512(m) cm
-1
.
   





H NMR (CDCl3, 300 MHz)  δ 7.30 (d, J = 8.39 Hz, 2H), 6.90 (d, J = 8.39 Hz, 
2H), 5.70-5.56 (m, 1H), 3.81 (s, 3H), 3.80-3.74 (m, H), 3.65(s, 3H), 3.38 (dd, J = 14.87, 
10.72 Hz, 1H), 3.02 (dd, J = 14.88, 8.64 Hz, 1H), 2.01-1.88 (m, 3H), 1.69-1.60 (m, 3H). 
13
C NMR (CDCl3, 75 MHz)   δ 166.6, 165.3, 159.5, 133.5, 128.7, 127.3, 126.9, 114.0, 
102.8, 83.2, 55.3, 50.9, 38.1, 21.4, 15.4. IR: 3648.6(w), 2947.0(m), 2847.6(m), 
1791.45(s), 1709.75(s), 1652.5(m), 1618.4(w), 1576.1(w) cm
-1
. HRMS(ESI) M/Z+ Calc. 






Determination of Product Ratios: The ratios of II-37a:II-34a:7II-38:II-33a were 
determined by examining the 5.0-6.5 ppm region of each NMR spectrum and comparing 
the relative integrations representing II-37a, II-38 and II-33a (Figure 2.32).  The amount 
of II-34a was extrapolated based on the 1.5:1 ratio of II-37a:II-34a, which is determined 
from isolated yields. The integral value for II-33a was set to 1 and the relative integrals 
for II-37a, and II-38, as well as the calculated integral for II-34a, were subjected to the 
following calculations: 
II-37a + II-34a + II-38 + II-33a = Total 
% II-37a: (II-37a /Total)*100 
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% II-34a: (II-34a / Total)*100 
% II-38: (II-38 / Total)*100 
% II-33a: (II-33a / Total)*100 
Final ratios are based on: (%II-37a +% II-34a):% II-38:% II-33a  
 
2.7.2.5. In(OTf)3-Catalyzed Cyclizations  
General Procedure: Alkenyl cyclopropyl ketone (0.36 mmol, 1.0 equiv.) was added to a 
solution of an In(OTf)3 (41 mg, 72 µmol, 0.30 equiv.) in anhydrous dichloromethane (2 
mL) at room temperature. The reaction was stirred during the indicated time. The 
reaction mixture was quenched with water (5 mL) and extracted with dichloromethane 
(3x10 mL). The combined organic layers were washed with brine (3x 10 mL), dried over 
MgSO4, and the solvent was removed under reduced pressure.  
 
 
II-33a (50 mg, 0.19 mmol) was added to a room-temperature solution of In(OTf)3 (30.8 
mg,  0.056 mmol, 0.3 equiv.).  After 3 hours, reaction was completed, and the standard 
work-up was performed.  Column chromatography afforded products II-37a (23.4 mg) 





II-33b (50 mg, 0.16 mmol) was added to a room-temperature solution of In(OTf)3 (61.5 
mg,  0.11 mmol, 0.3 equiv.) at room temperature. After 40 minutes, reaction was 
completed, and the standard work-up was performed.  Column chromatography afforded 
products II-37b (29 mg) and II-34b (9.6 mg) as a yellow oils (77% yield).  Rf  (20% 




H NMR (CDCl3, 300 MHz)   δ 12.1(s, 1H), 7.15-7.05 (d, 2H, J = 
15Hz), 6.9-6.8 (d, 2H J = 24Hz), 3.8 (s, 3H), 3.7 (s, 3H), 2.7-2.55 (m, 1H), 2.4 (s, 3H), 
2.3-2.1 (m, 2H),  1.75-1.65 (m, 1H), 1.5-1.35 (m, 2H), 1.00-0.85 (m, 1H). 
13
C NMR 
(CDCl3, 75 MHz) δ 173.2, 163.8, 158.1, 136.1, 132.6, 130.9, 128.4, 113.8, 97.6, 55.2, 
51.5, 46.5, 40.0, 31.9, 28.2, 26.1, 21.5. IR: 3654(b), 3445(m), 3021(w), 2924(m), 
2841(m), 1733(s), 1654(s), 1611(w), 1512(w) cm
-1
. HRMS(ESI) M/Z+ Calc. 314.1518, 
Obs. 314.1522. 
Methyl 4-(4-methoxyphenyl)-1-oxo-1,2,3,4,5,6,7,8-octahydronaphthalene-2  
carboxylate (II-34b). 
1
H NMR (CDCl3, 300 MHz)   δ 7.08-7.00 (d, 2H, J = 12Hz), 6.88-
6.82 (d, 2H, J = 9Hz), 3.78 (s, 3H), 3.7 (s, 3H), 3.5-3.36 (m, 1H), 2.8-2.64 (m, 1H), 2.50-
2.30 (m, 3H), 2.18-2.00 (m, 2H), 1.70-1.60 (m, 5H).  
13
C NMR (CDCl3, 75 MHz)  δ 
193.6, 171.1, 158.7, 158.6, 157.7, 134.4, 133.4, 132.2, 129.3, 128.9, 128.7, 114.2, 55.3, 
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53.4, 52.1, 49.4, 46.4, 44.2, 34.4, 30.7, 30.5, 22.8. IR: 2929(s), 2854 (m), 1740 (s), 1666 
(s), 1632(m), 1610(m) cm
-1
. HRMS(ESI) M/Z+ Calc. 314.1518, Obs. 384.1518. 
 
II-33c (100 mg, 0.36 mmol) was added to a room-temperature solution of In(OTf)3 (61.5 
mg,  0.11mmol, 0.3 equiv.).  After 40 minutes, reaction was completed, and the standard 
work-up was performed.  Column chromatography afforded products II-37c (45 mg) and 





H NMR (CDCl3, 300 MHz)   δ  12.00 (s, 1H), 7.20-7.15 (d, 2H, J = 12 Hz ), 6.90-
6.80 (d, 2H, J =15 Hz ), 5.85 (s, 1H), 5.20 (s, 1H), 3.80 (s, 3H), 3.65 (s, 3H), 2.85-2.80 
(m, 1H), 2.75-2.45 (m, 3H), 2.40-2.30 (m, 1H). 
13
C NMR (CDCl3, 75 MHz)   δ 173.1, 
163.8, 158.2, 138.5, 136.9, 127.6, 116.5, 113.9, 99.6, 55.3, 51.7, 39.3, 38.2, 31.7.  IR: 
3733 (m), 2951(m), 2850 (w), 1654, 1631, 1582 cm
-1
. HRMS(ESI) M/Z+ Calc. 
274.1205, Obs. 274.1214. 
Methyl 5-(4-methoxyphenyl)-3-methyl-2-oxocyclohex-3-enecarboxylate (II-34c). 
1
H 
NMR (CDCl3, 300 MHz)   δ 7.15-.7.08 (d, 2H, J = 12Hz), 6.80-6.72 (d, 2H, J = 9Hz), 
3.78 (s, 3H), 3.74 (s, 3H), 3.54-3.46 (m, 1H), 2.74- 2.62 (m, 1H),  2.42-2.36 (m, 1H),  
2.20-2.10 (m, 1H), 1.85 (s, 3H).  
13
C NMR (CDCl3, 75 MHz)   δ 194.4, 170.0, 158.6, 
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149.2, 148.0, 135.4, 133.9, 128.7, 122.2, 115.9, 114.7, 113.8, 55.3, 41.7, 39.2, 35.8, 16.2. 
IR: 2953, 2831, 1740, 1676, 1635, 1540 cm
-1
. HRMS(ESI) M/Z+ Calc. 274.1205, Obs. 
274.1204. 
 
Methyl 2-hydroxy-3-methylene-5-phenylcyclohex-1-enecarboxylate (II-37d). II-33d 
(70 mg, 0.28 mmol) was added to solution of indium triflate( 48.3 mg,  0.09 mmol, 0.3 
equiv.)  at room temperature.  After 30 hours, reaction was quenched, and the standard 
work-up was performed.  Column chromatography afforded products II-37d (32 mg) 
(45.7% yield).  Rf 0.6 (20% EtOAc/Hex) 
1
H NMR (CDCl3, 300 MHz)   δ 7.40-7.20(m, 
5H), 5.90 (s, 1H), 5.40 (s, 1H), 3.75 (s, 3H), 2.90-2.80 (m, 1H), 2.70-2.60 (m, 3H), 2.40-
2.30 (m, 1H). 
 13
C NMR (CDCl3, 75 MHz) δ 173.0, 163.7, 144.7, 138.4, 128.5, 126.7, 
126.5, 122.2, 116.6, 99.6, 51.8, 40.1, 37.9, 31.5, 14.5. IR: 3026(w), 2922(m), 2850(w), 











37e). II-33e (55 mg, 0.21 mmol) was added to solution of indium triflate( 35.3 mg,  0.06 
mmol, 0.3 equiv.) at room temperature. After 30 hours, reaction was quenched, and the 
standard work-up was performed.  Column chromatography afforded products II-37e (30 
mg) (54.5% yield).  Rf  0.6 (20% EtOAc/Hex) 
1
H NMR (CDCl3, 300 MHz)   δ  7.20-7.10 
(d, 2H, J =15Hz), 7.00-6.90 (d, 2H, J = 12Hz), 5.9 (s, 1H), 5.2 (s, 1H), 3.75 (s, 3H), 2.8-
2.7 (m, 1H), 2.70-2.50 (m, 3H), 2.4-2.3 (m, 1H). 
13
C NMR (CDCl3, 75 MHz)   δ 172.9, 
163.7, 163.1, 159.8, 140.4, 138.1, 128.1, 116.8, 115.3, 99.4, 51.8, 39.4, 38.1, 31.6. IR:  





M/Z+ Calc. 262.1005, Obs. 262.1014. 
 
II-33f (50 mg, 0.14 mmol) was added to solution of indium triflate (24.33 mg, 0.043 
mmol, 0.3 equiv.) at room temperature.  After 20 minutes, reaction was completed, and 
the standard work-up was performed.  Column chromatography afforded product II-37c 





carboxylate (II-34d). II-33g (90 mg, 0.28 mmol) was added to solution of indium triflate 
(31.9 mg, 0.09 mmol, 0.3 equiv.) at 0
o
C.  After 30 min, reaction was completed, and the 
standard work-up was performed. Column chromatography afforded products II-34d 
(27.8 mg) (92.6% yield).  Rf (25% EtOAc/Hex) = 0.2. 
1
H NMR (CDCl3, 300 MHz)   δ 
7.12-7.04 (d, 2H, J = 12Hz), 6.84-6.82 (d, 2H, J = 12Hz), 4.10-4.06 (t,1H,  J = 12Hz, 
6Hz), 3.72 (s, 3H), 3.70 (s, 3H), 3.60-3.42 (m, 2H), 2.74-2.62 (m, 1H), 2.42-2.28 (m, 
1H), 2.18-2.08 (m, 1H), 2.04-1.96 (m, 1H), 1.90-1.75 (m, 3H). 
13
C NMR (CDCl3, 75 
MHz) δ 187.6, 170.1, 158.7, 146.0, 133.7, 132.9, 132.5, 129.2, 128.9, 114.3, 66.0, 55.3, 
53.3, 52.4, 50.1, 44.7, 42.8, 34.2, 25.1, 21.8. IR: 2952 (m), 1738(s), 1681(s), 1610(s), 
1582(w) cm
-1
. HRMS(ESI) M/Z+ Calc. 316.1311, Obs. 316.1303. 
 
II-33h (23 mg, 0.07 mmol) was added to solution of indium triflate (11.54 mg, 0.02 
mmol, 0.3 equiv.) at room temperature.  After 12 hours, the reaction was stopped, and the 
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standard work-up was performed.  Column chromatography afforded the desired product 
II-34e (6.67 mg, 29% yield) as the minor component (Rf 0.6 (20% EtOAc/Hex). II-38b 
(9.4 mg, 41%) was isolated as the major component.  Starting material II-33h (7 mg) was 




H NMR (CDCl3, 300 MHz)   δ 12.2 (s, 1H), 7.4-7.2(m, 6H), 7.2-7.1 (d, 2H, J 
= 12Hz), 6.9-6.8 (d, 2H, J = 9Hz), 3.85 (s, 1H), 3.75 (s, 1H), 3.23-3.1 (t, 1H, J =  9Hz, 
12Hz), 2.9 (s,1H),  2.8-2.7 (m, 1H), 2.4-2.2 (m, 2H), 2.08-1.96 (m, 1H). 
13
C NMR 
(CDCl3, 75 MHz)   δ 172.9, 169.8, 158.1, 145.2, 136.6, 128.3, 127.4, 124.9, 114.4, 113.8, 
100.7, 55.3, 51.9, 47.4, 35.9, 31.7. IR: 2952(m), 2836(w), 1723(s), 1678(s), 1610(m), 
1510(m) cm
-1
. HRMS(ESI) M/Z+ Calc. 336.1362, Obs. 336.1361. 
 Methyl 5-(4-methoxyphenyl)-2-(1-phenylvinyl)-4,5-dihydrofuran-3-carboxylate (II-
38b). Rf 0.45 (20% EtOAc/Hex). 
1
H NMR (CDCl3, 300 MHz)   δ 7.57 (d, J = 8.11 Hz, 
2H), 7.45-7.28 (m, 5H), 6.92 (d, J = 8.2 Hz, 2H), 5.72-5.61 (m, 1H), 3.81 (s, 3H), 3.80 (s, 
3H), 3.42 (dt, J = 8.11, 8.11, 8.11 Hz, 1H), 3.07 (t, J = 8.93Hz, 16.18 Hz, 1H). 
13
C NMR 
(CDCl3, 75 MHz) δ 164.8, 159.8, 147.0, 132.6, 132.2, 128.4, 127.5, 126.3, 114.1, 114.0, 
111.4, 98.2, 84.1, 79.3, 55.3, 51.4, 37.7. IR: 2950.4(w), 2924.9(m), 2851.3(m), 1689.8(s), 
1614.0(s), 1514.4(m), 1439.0(m) cm
-1








2.7.2.6. Derivatization of Products  
 
Methyl 2-hydroxy-5-(4-methoxyphenyl)-3-(phenylthiomethyl)cyclohex-1-
enecarboxylate (II-39). Et3N (13.9 µL, 1.1 equiv.) was added dropwise at room 
temperature to a stirred solution of II-37c (25 mg, 0.09 mmol, 1.0 equiv.) and thiophenol 
(14 µL, 1.5 equiv.) in CHCl3 (1 mL). After 14 h, the reaction mixture was directly 
purified by flash chromatography using 1:11 EtOAc:Hex) to give the thioether II-39 
(20.3 mg, 58% yield). 
1
H NMR (CDCl3, 300 MHz)  δ 12.04(s, 1H), 7.40-7.10 (m, 7H), 
6.90-6.80 (d, 2H, J =12Hz), 3.80 (s, 1H), 3.70 (s, 3H), 3.0-2.90 (m, 2H), 2.70-2.60 (m, 
2H), 2.35-2.20 (m, 2H), 1.90-1.78 (m, 1H). 
13
C NMR (CDCl3, 75 MHz) δ 172.8, 171.6, 
158.1, 137.1, 129.01, 127.7, 127.6, 126.04, 113.8, 98.3, 55.3, 51.6, 38.3, 35.7, 34.4, 31.6, 
30.8. IR: 3625(w), 2926(m), 2850(w), 1716(m), 1654(s), 1611(m), 1512(s) 1438(s) cm
-1
.  







4-(4-Methoxyphenyl)-2,3-dimethylcyclohex-2-enone (II-40). A 10 mL flask open to air 
was charged with diester II-34a (50 mg, 0.17 mmol), NaCl (10.63 mg, 0.182 mmol), 
water (6.25 µL, 0.346 mmol) and DMSO (2 mL) at room temperature. The flask was 
fitted with a reflux condenser and heated to 150˚C with vigorous stirring. After heating 
for 12 h TLC analysis indicated consumption of starting material, and the reaction was 
cooled to 22˚C. The reaction was diluted with 7:3 hexane/Et2O (25 mL) and washed with 
water (3x 5 mL). The organic layer was dried over MgSO4, concentrated, and purified by 
silica gel chromatography (2:3 EtOAc/Hex) to afford II-40 (30 mg, 74% yield). 
1
H NMR 
(CDCl3, 300 MHz)  δ 7.10-7.00 (d, 2H, J = 12Hz), 6.86-6.82 (d, 2H, J =12Hz), 3.78 (s), 
3.60-3.50 (s, 1H), 2.40-2.24 (m, 3H), 1.84 (s, 3H), 1.76 (s, 3H). 
13
C NMR (CDCl3, 75 
MHz) δ 198.8, 158.6, 155.4, 133.5, 130.6, 129.2, 114.2, 55.3, 47.2, 33.9, 31.1, 20.6, 
17.45. IR: 2925(m), 2835(w), 1661(s), 1609(w), 1509(s), 1453(w) cm
-1
. HRMS(ESI) 













2.8. EXPERIMENTAL SECTION FOR FORMAL HOMO-NAZAROV 
CYCLIZATION OF HETEROARYL CYCLOPROPYL KETONES 
 
2.8.1. General Methods 
Infrared (IR) spectra were obtained using a Nicolet 4700 FTIR with an ATR 
attachment from SmartOrbit Thermoelectronic Corp. Proton and carbon nuclear magnetic 
resonance spectra (
1
H NMR and 
13
C NMR) were recorded on a Varian Mercury Vx 300 
spectrometer with solvent resonance as the internal standard (
1
H NMR: CDCl3 at 7.26 
ppm; 
13
C NMR: CDCl3 at 77.0 ppm). 
1
H NMR data are reported as follows: chemical 
shift, multiplicity (s = singlet, bs = broad singlet, d = doublet, dd = doublet of doublets, dt 
= doublet of triplets, dq = doublet of quartets, ddd = doublet of doublet of doublets, ddt = 
doublet of doublet of triplets, dtd = doublet of triplet of doublets, t = triplet, bt = broad 
triplet, td = triplet of doublets, q = quartet, qd = quartet of doublets, qn = quintet, m = 
multiplet), coupling constants (Hz), and integration. Mass spectra were obtained using a 
VG-70SE instrument. Chromatographic purification was performed as flash 
chromatography using Dynamic Adsorbents silica gel (32-65µm), using the solvents 
indicated as eluent with 0.1-0.5 bar pressure. For quantitative flash chromatography 
technical grades solvents were used. Analytical thin-layer chromatography (TLC) was 
performed on EMD silica gel 60 F254 TLC glass plates. Visualization was accomplished 
with UV light, aqueous basic potassium permanganate (KMnO4) solution, iodine, 
aqueous acidic dinitrophenylhydrazine (DNP) solution, aqueous acidic p-anisaldehyde 
(PAA) solution, and ethanol solution of phosphomolybdic acid (PMA) followed by 
heating. Yields refer to isolated yields of analytically pure material unless otherwise 
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noted. All reactions were carried out in oven-dried glassware under an atmosphere of N2, 
unless stated otherwise. Tetrahydrofuran and diethyl ether were distilled from a 
sodium/benzophenone ketyl under N2 and stored in a Schlenk flask. 1,2-dichloroethane 
and dichloromethane was purified by distillation from calcium hydride under N2 prior to 
use. Acetonitrile was dried by fractional distillation over CaH2. Benzene was purified by 
drying with CaH2. Lithium bis(trimethylsilyl)amide (LHMDS) was purchased from 
Sigma-Aldrich as a 1.0 M solution in THF. n-Butyllithium was purchased from Sigma-
Aldrich as a 2.5 M solution in hexanes. t-Butyllithium was purchased from Sigma-
Aldrich as a 1.7 M solution in hexanes. Nitromethane was distilled over CaH2 and stored 
under nitrogen under 4Å molecular sieves. All other reagents were purchased from 
Acros, Sigma-Aldrich, Fluka, VWR, Merck, Alfa Aesar, TCI and Strem (for metal 
catalysts) and used without further purification unless otherwise noted. Compounds II-
50a, II-50b, II-50c, II-50e, II-50f, II-50g were made via a modified Warner’s method.
44
  
Compound II-50d was prepared by a modified version of Frontier’s method.
37
  




2.8.2. General Procedures 
2.8.2.1. Formation of β-Keto ester II-50i 
 
Methyl 3-(2-bromothiophen-3-yl)-3-oxopropanoate(II-50i). 2-Bromo-3-thiophene 
carboxylic acid chloride was prepared from a solution of 2-bromo-3-thiophene carboxylic 
acid (0.50 g, 2.41 mmol) in DCM( 0.5M) and was added a catalytic amount of N,N’-
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dimethylformamide (0.2 mL).  The solution was cooled to 0°C, and to it was added 
oxallyl chloride (0.25 mL 2.9 mmol). LHMDS (5.1mL, 5.1 mmol) was added to a 
solution of methyl acetate (0.21 mL, 2.54 mmol) in THF at -78°C and allowed to stir for 
45 minutes. To the solution of the enolate was added the 2-bromo-3-thiophene acid 
chloride in 10 mL of THF. Reaction was allowed to stir for 30 minutes at -78°C, 
quenched with saturated ammonium chloride. Reaction was then allowed to warm up to 
rt, extracted with Et2O, washed with brine, and dried with anhydrous Na2SO4.  The 
solution was then concentrated and column chromatography (15% EtOAc/Hex, Rf 0.3) 
afforded II-50i as an oil (0.317g, 50.4%).  (4:1 mixture of ester and enol)   
1
H NMR 
(CDCl3, 300 MHz) δ 12.4 (s, 0.23, enol) 7.34 (d, J = 5.85 Hz, 1H), 7.24 (d, J = 5.84 Hz, 
1H), (5.80, s, 0.23, enol), 4.01-3.96 (s, 2H), 3.76-3.69 (s, 3H); 
13
C NMR (CDCl3, 75 
MHz) δ 186.489, 167.498, 128.921, 126.578, 119.415, 90.181, 52.485, 51.554. IR: 
3103(w), 2940(w), 2021(m), 1957(m), 1731(m), 1658(m), 1512(w), 1402(w), 1309(m), 
1213(m) cm 
-1
. HRMS(ESI) M/Z+ Calc. 261.9299, Obs. 261.9299. 
 
2.8.2.2. General procedure for the formation of α-diazo-esters (II-51a-m) 
In a flame dried flask containing a solution of the β-keto ester in acetonitrile (0.2 
M) was added Et3N (1.2 equiv.). After vigorous stirring for 5 minutes, tosyl azide (1.2 
equiv.) was added, and the reaction was allowed to stir for 3 hrs. After complete 
disappearance of starting material, mixture was concentrated in vacuo, followed by 







Methyl 2-diazo-3-oxo-3-(thiophen-2-yl)propanoate (II-51a).  According to the general 
procedure, to a solution of the β-keto ester II-50a (1.50 g, 8.14 mmol) in acetonitrile was 
added Et3N (1.4 mL, 9.77 mmol) and tosyl azide (1.93 g, 9.77 mmol). Column 
chromatography (10% EtOAc/Hex, Rf 0.25) furnished compound II-51a as a yellow oil 
(1.20 g, 69.5%). 
1
H NMR (CDCl3, 300 MHz) δ  8.06 (dd, J = 3.91, 1.12 Hz, 1H), 7.66 
(dd, J = 4.99, 1.12 Hz, 1H), 7.12 (dd, J = 4.98, 3.92 Hz, 1H), 3.92-3.82 (s, 3H) ppm;  
13
C 
NMR (CDCl3, 75 MHz) δ 176.3, 161.1, 141.2, 133.8, 127.6, 52.2. IR: 3100(m), 
2947(m), 2146(s, N2 stretch), 1721(s), 1712(s), 1692(s), 1617(s), 1604(s), 1433(m), 
1299(s) cm 
-1
. HRMS(ESI) M/Z+ Calc. 210.0099, Obs. 210.0095. 
 
Methyl 2-diazo-3-(furan-2-yl)-3-oxopropanoate (II-51b).   According to the general 
procedure, to a solution of the β-keto ester II-50b (0.75 g, 4.46 mmol) in acetonitrile was 
added Et3N (0.75 mL, 5.35 mmol) and tosyl azide (1.06 g, 5.35 mmol). Column 
chromatography (10% EtOAc/Hex, Rf 0.20) furnished II-51b as a bright yellow oil 
(0.614 g, 71.0%).  
1
H NMR (CDCl3, 300 MHz) δ 7.62-7.44 (m, 1H), 7.28-7.20 (m, 1H), 
6.72-6.19 (m, 1H), 3.90-3.82 (s, 3H); 
13
C NMR (CDCl3, 75 MHz) δ 170.7, 161.5, 150.4, 
146.0, 145.9, 119.4, 112.3, 52.5. IR: 3102(w), 2953(w), 2140(s,N2), 1717(s), 1584(s), 
1514(m), 1434(m), 1410(w) cm
-1




Methyl 2-diazo-3-oxo-3-(thiophen-3-yl)propanoate (II-51c). According to the general 
procedure, to a solution of the β-keto ester II-50c (1.50 g, 8.14 mmol) in acetonitrile was 
added Et3N (1.4 mL, 9.77 mmol) and tosyl azide (1.93 g, 9.77 mmol). Column 
chromatography (10% EtOAc/Hex, Rf 0.20) furnished II-51c as a yellow oil (1.10 g, 
64.7%). 
1
H NMR (CDCl3, 300 MHz) δ 8.17 (dd, J = 2.95, 1.26 Hz, 1H), 7.47 (dd, J = 
5.12, 1.15 Hz, 1H), 7.26 (dd, J = 5.11, 2.96 Hz, 1H), 3.84-3.77 (s, 3H). 
13
C NMR 
(CDCl3, 75 MHz) δ 179.0, 161.4, 138.9, 132.9, 127.9, 124.9, 52.3. IR: 3102 (w), 
2943(w), 2126 (br s, N2 stretch), 1721(s), 1212(s), 1604(m), 1498(m), 1435(m), 1299(s) 
cm 
-1
. HRMS(ESI) M/Z+ Calc. 210.0101, Obs. 210.0106. 
 
Methyl 2-diazo-3-(furan-3-yl)-3-oxopropanoate (II-51d). According to the general 
procedure, to a solution of the β-keto ester II-50d (1.50 g, 8.9 mmol) in acetonitrile was 
added Et3N (1.5 mL, 10.7 mmol) and tosyl azide (2.1 g, 10.7 mmol). Column 
chromatography (10% EtOAc/Hex, Rf 0.20) furnished II-51d as a bright yellow oil (1.17 
g, 68.0%). 
1
H NMR (CDCl3, 300 MHz) δ  8.45-8.35 (m, 1H), 7.52-7.28 (m, 1H), 6.88-
6.81 (m, 1H), 3.89-3.76 (s, 3H); 
13
C NMR (CDCl3, 75 MHz) δ  177.5, 161.2, 148.9, 
142.7, 124.9, 110.2, 52.2.  IR: 3143(w), 2957(w), 2133(s, N2 stretch), 1721(s), 1711(s), 
1604(s), 1509(m), 1369(m), 1323(s), 1284(s), 1178(m), 1119(s) cm 
-1
. HRMS(ESI) 




Methyl 3-(benzofuran-2-yl)-2-diazo-3-oxopropanoate (II-51f). According to the 
general procedure, to a solution of the β-keto ester II-50f (0.76 g, 3.50 mmol) in 
acetonitrile was added Et3N (0.60 mL, 4.22 mmol) and tosyl azide (0.81 g, 4.22 mmol).  
Column chromatography (10% EtOAc/Hex, Rf 0.20) furnished II-51f as a bright yellow 
oil (0.48 g, 57.0%). 
1
H NMR (CDCl3, 300 MHz) δ  7.77 (s, 1H), 7.65 (ddd, J = 4.15, 
2.91, 0.69 Hz, 1H), 7.65-7.45 (m, 2H), 7.42-7.28 (m, 1H), 3.93-3.80 (s, 3H). 
13
C NMR 
(CDCl3, 75 MHz) δ  172.1, 161.4, 155.0, 150.5, 128.3, 126.8, 123.9, 123.4, 115.1, 112.2, 
52.6.  IR:  3129(w), 2950(w), 1737(s), 1671(s), 1555(s), 1446(m), 1316(w), 1246(m), 
1123(s), 1088(m) cm
-1
.  HRMS(ESI) M/Z+ Calc. 244.0484, Obs. 244.0479. 
 
Methyl 3-(benzofuran-3-yl)-2-diazo-3-oxopropanoate (II-51h). According to the 
general procedure, to a solution of the β-keto ester 1II-50h (0.26 g, 1.18 mmol) in 
acetonitrile was added Et3N (0.2 mL, 1.41 mmol) and tosyl azide (0.28 g, 1.41 mmol).  
Column chromatography (10% EtOAc/Hex, Rf 0.25) furnished II-51h as a bright yellow 
oil (0.25 g, 86.3%). 
1
H NMR (CDCl3, 300 MHz) δ  8.80-8.71 (s, 1H), 8.24-8.07 (m, 1H), 
7.56-7.44 (m, 1H), 7.38-7.28 (m, 2H), 3.87-3.83 (s, 3H). 
13
C NMR (CDCl3, 75 MHz) δ  
177.8, 161.5, 154.6, 152.8, 130.2, 127.5, 125.5, 124.4, 122.8, 119.2, 111.4, 52.3. IR: 
2955(m), 2924(w), 2138(br s, N2 stretch), 1721(s), 1711(s), 1635(m), 1570(m), 1385(s), 
1168(s) cm
-1




Methyl 3-(2-bromothiophen-3-yl)-2-diazo-3-oxopropanoate (II-51i).   According to 
the general procedure, to a solution of the β-keto ester II-50i (0.317 g, 1.21 mmol) in 
acetonitrile was added Et3N (0.20 mL, 1.45 mmol) and tosyl azide (0.285 g, 1.45 mmol). 
Column chromatography (10% EtOAc/Hex, Rf 0.25) furnished II-51i as a yellow oil 
(0.213 g, 61.0%). 
1
H NMR (CDCl3, 300 MHz) δ  7.25 (d, J = 5.44 Hz, 1H), 7.01 (d, J = 
5.72 Hz, 1H), 3.79 (s, 3H). 
13
C NMR (CDCl3, 75 MHz) δ  180.8, 160.8, 138.1, 127.8, 
126.1, 114.9, 77.4, 77.0, 76.6, 52.5. IR: 3096(w), 2953(w), 2134(br s, N2 stretch), 
1735(s), 1726(s), 1629(s), 1625(m), 1620(m), 1435(m), 1407(m) cm 
-1
. HRMS(ESI) 
M/Z+ Calc. 287.9221, Obs. 287.9204. 
 




In a flame dried flask containing a solution of Rh2esp2 (0.1 mol %) in DCM 
(0.2M) at 0 °C was added the corresponding alkene (1.0 equiv.).  After stirring for 5 
minutes, a solution of the α-diazo ester (0.2M) was added in one shot, and allowed to stir 
for 10 minutes at 0 °C.  At this time, the ice bath was removed and the reaction was 
allowed to warm up to rt.  After two hours, the reaction was quenched with saturated aq. 
thiourea and allowed to stir for 30 minutes.  The mixture was transferred to a separatory 
funnel and extracted with CH2Cl2 (3x).  The organic layer was washed with brine, dried 
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with Na2SO4, concentrated, and column chromatography afforded the desired 
cyclopropyl heteroaryl ketones. 
 
Methyl 2-(4-methoxyphenyl)-1-(thiophene-2-carbonyl)cyclopropanecarboxylate (II-
48a).  According to the general procedure, to a solution of Rh2esp2 (3.8 mg, 5.12 µmol) 
in DCM was added 4-methoxy styrene (0.68 mL, 5.12 mmol), followed by a solution of 
α-diazo ester II-51a (1.4g, 6.66 mmol).  The reaction was quenched and column 
chromatography (10% EtOAc/Hex) afforded II-48a as a solid (1.32 g, 82%).  
1
H NMR 
(CDCl3, 300 MHz) δ 7.49 (dd, J = 4.92, 1.11 Hz, 1H), 7.47 (d, J = 1.15 Hz, 1H), 7.46 (d, 
J = 1.15 Hz, 1H), 7.00 (d, J = 8.70 Hz, 2H), 6.67 (d, J = 8.80 Hz, 2H), 3.81 (dd, J = 
10.96, 5.19 Hz, 3H), 3.71 (s, 3H), 3.41 (dd, J = 10.72, 6.55 Hz, 1H), 2.36 (dd, J = 8.01, 
5.16 Hz, 1H), 1.82 (dd, J = 9.26, 5.16 Hz, 1H). 
13
C NMR (CDCl3, 75 MHz) δ 186.4, 
168.7, 158.7, 143.1, 133.7, 132.4, 130.0, 128.0, 126.5, 113.5, 104.9, 55.1, 52.3, 42.4, 
30.0, 19.6. IR: 3002(w), 2951(m), 2923(w), 1721(s), 1682(s), 1661(s), 1558(w), 
1444(m), 1430(s), 1386(m) cm
-1




Methyl 1-(furan-2-carbonyl)-2-(4-methoxyphenyl)cyclopropanecarboxylate (II-48b).  
According to the general procedure, to a solution of Rh2esp2 (1.8 mg, 2.36 µmol) in DCM 
was added 4-methoxy styrene (0.32 g, 2.36 mmol), followed by a solution of the α-diazo 
ester II-51b (0.75g, 3.07 mmol). The reaction was quenched and column chromatography 
(10% EtOAc/Hex) afforded II-48b as a solid (0.467 g, 66 %). (1.5:1 trans/cis 
diastereomeric mixture)  
1
H NMR (CDCl3, 300 MHz) δ 7.67(m, 0.92), 7.58 (m, 0.59), 
7.33-7.21 (m, 2.98), 6.99 (dd, J = 17.71, 6.22 Hz, 1.02), 6.87 (d, J = 6.22 Hz, 2.10), 6.60 
(dd, J = 3.59, 1.70 Hz, 1.15), 6.35(m,0.80), 3.83 (s, 3.50), 3.70(m, 3.41), 3.51-3.42 (dd, J 
= 17.96, 8.88 Hz, 1.74), 3.40 (s, 3H), 2.40-2.34 (dd, J = 8.11, 4.94 Hz, 2.40), 1.67-1.55 
(dd, J = 9.20, 4.93 Hz, 2.62). 
13
C NMR (CDCl3, 75 MHz) δ 182.4, 168.5, 158.7, 146.4, 
130.0, 129.1, 117.9, 113.4, 112.1, 55.0, 52.4, 41.7, 33.0, 30.0, 20.1, 17.4.  IR: 3139 (w), 
2953(w), 2827(w), 1726(s), 1672(s), 1612(m), 1542 (m),  1513(s), 1436(w), 1309(s), 
1248( s), 1159(s) cm
-1
. HRMS(ESI) M/Z+ Calc. 300.1004, Obs. 300.0998. 
 
Methyl 2-(4-methoxyphenyl)-1-(thiophene-3-carbonyl)cyclopropanecarboxylate (II-
48c).  According to the general procedure, to a solution of Rh2esp2 (3.6 mg, 4.76 µmol) in 
DCM was added 4-methoxystyrene (0.49g, 3.65 mmol), followed by a solution of the α-
diazo ester II-51c (1.0 g, 4.76 mmol). The reaction was quenched and column 
chromatography (10% EtOAc/Hex) afforded II-48c as a solid (0.86 g, 75.0%). 
1
H NMR 
(CDCl3, 300 MHz) δ  8.14-8.02 (m, 1H), 7.52 (d, J = 3.87 Hz, 1H), 7.33 (d, J = 2.59 Hz, 
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1H), 7.21 (d, J = 8.22 Hz, 2H), 6.83 (d, J = 8.78 Hz, 2H), 3.78 (s, 3H), 3.33 (s, 3H), 3.44 
(t, J = 8.56, 8.56 Hz, 1H), 2.32 (dd, J = 8.04, 4.92 Hz, 1H), 1.63 (dd, J = 9.16, 4.91 Hz, 
1H). 
13
NMR (CDCl3, 75 MHz) δ  187.980, 169.036, 158.724, 141.255, 132.132, 130.010, 
128.928, 127.067, 126.639, 126.322, 113.529, 55.155, 52.312, 43.010, 29.854, 19.739.  
IR: 3113(w), 2947(w), 2831(w), 1726(s), 1671(s), 1665(m), 1608(w), 1552(m), 1513(s), 
1117(m), 1034(m)cm
-1
.  HRMS(ESI) M/Z+ Calc. 316.0762, Obs. 316.0769. 
 
Methyl 1-(furan-3-carbonyl)-2-(4-methoxyphenyl)cyclopropanecarboxylate (II-48d).  
According to the general procedure, to a solution of Rh2esp2 (3.0 mg, 3.96 µmol) in DCM 
was added the 4-methoxy styrene (0.53 g, 3.96 mmol), followed by a solution of the α-
diazo ester II-51d (1.0 g, 5.15 mmol). The reaction was quenched and column 
chromatography (10% EtOAc/Hex) afforded II-48d as a yellow solid (0.86 g, 72%). 
(2.12:1 tran/cis diastereomeric mixture)  
1
H NMR (CDCl3, 300 MHz) δ  8.02 (s, 0.71), 
7.80-7.75 (s, 0.72), 7.54-7.43 (s, 0.85), 7.20-7.05 (m, 1.81), 7.04-6.97 (m, 0.69), 6.87 (dd, 
J = 8.76, 2.83 Hz, 1.37), 6.77 (s, 0.86), 6.65-6.55(m, 0.65), 6.40(s, 0.32), 3.87-3.79 (s, 
2.45), 3.60 (t, J = 8.58, 8.58 Hz, 1.89), 3.43-3.39 (m, 3.34), 2.31 (ddd, J = 7.74, 7.33, 
4.87 Hz, 1.13), 1.75(m, 0.47), 1.65 (ddd, J = 8.94, 4.89, 3.13 Hz, 1.00). 
13
C NMR 
(CDCl3, 75 MHz) δ 188.1, 168.8, 158.7, 147.2, 143.9, 141.7, 140.8, 129.9, 128.9, 126.5, 
113.5, 109.1, 55.1, 52.3, 32.9, 29.9, 19.7. IR: 3139 (w), 2953(w), 2827(w), 1726(s), 
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1672(s), 1612(m), 1542 (m),  1513(s), 1436(w), 1309(s), 1248( s), 1159(s) cm
-1
. 
HRMS(ESI) M/Z+ Calc. 300.1004, Obs. 300.0998. 
 
Methyl 1-(benzofuran-2-carbonyl)-2-(4-methoxyphenyl)cyclopropanecarboxylate 
(II-48f). According to the general procedure, to a solution of Rh2esp2 (1.1 mg, 1.46 
µmol) in DCM was added the 4-methoxy styrene (0.2 g, 1.46 mmol), followed by a 
solution of the α-diazo ester II-51f (0.46 g, 1.9 mmol). The reaction was quenched and 
column chromatography (10% EtOAc/Hex) afforded II-48f as a solid ( 0.323 g, 66.0%). 
1
H NMR (CDCl3, 300 MHz) δ  7.71 (d, J = 8.51 Hz, 1H), 7.62-7.40 (m, 2H), 7.38-7.15 
(m, 2H), 7.02 (d, J = 8.84 Hz, 2H), 6.85 (d, J = 8.54 Hz, 1H), 6.59 (d, J = 8.59 Hz, 1H), 
3.80-3.77 (s, 3H), 3.55 (t, J = 8.59, 8.59 Hz, 1H), 3.40-3.38 (s 3H), 2.38 (dd, J = 8.23, 
5.16 Hz, 1H), 1.71 (dd, J = 9.37, 5.11 Hz, 1H). 
13
C NMR (CDCl3, 75 MHz) δ  184.5, 
183.6, 168.5, 158.8, 155.6, 152.1, 130.1, 129.2, 128.3, 128.0, 127.5, 126.4, 123.9, 123.3, 
113.4, 112.3, 55.1, 52.6, 42.1, 34.3, 30.2, 20.6. IR: 2940(w), 2831(w), 1721(s), 1658(s), 
1513(s), 1432(m), 1246(s), 1246(m), 1162(m) cm 
-1
. HRMS(ESI) M/Z+ Calc. 350.1154, 





(II-48h). According to the general procedure, to a solution of Rh2esp2 (2.2 mg, 2.9 µmol) 
in DCM was added the 4-methoxy styrene (0.4 g, 2.92 mmol), followed by a solution of 
the α-diazo ester II-51h (0.92 g, 3.8 mmol). The reaction was quenched and column 
chromatography (10% EtOAc/Hex) afforded II-48h (0.646 g, 66.0%). 
1
H NMR (CDCl3, 
300 MHz) δ  7.71 (d, J = 7.86 Hz, 1H), 7.65-7.38 (m, 2H), 7.38-7.14 (m, 2H), 7.02 (d, J 
= 8.86 Hz, 1H), 6.84 (d, J = 8.76 Hz, 2H), 6.71-6.45 (m, 1H), 3.81-3.77 (s, 3H), 3.58-
3.47 (m, 1H), 3.40-3.36 (s, 3H), 2.38 (dd, J = 8.19, 4.97 Hz, 1H), 1.70 (dd, J = 9.23, 4.97 
Hz, 1H); 
13
C NMR (CDCl3, 75 MHz) δ  184.5, 168.4, 158.8, 155.6, 151.9, 130.1, 129.3, 
128.3, 128.0, 123.9, 123.4, 113.6, 113.5, 112.4, 55.2, 55.0, 52.4, 42.0, 33.4, 30.3, 20.5.  
IR: 2940(w), 2840(w), 1729(s), 1737(s), 1672(s), 1553(m), 1514(s), 1442(m), 1305(m), 
1282(m), 1248(m) cm 
-1
.  HRMS(ESI) M/Z+ Calc. 350.1154, Obs. 350.1163. 
 
Methyl-1-(2-bromothiophene-3-carbonyl)-2-(4-methoxyphenyl)cyclopropane 
carboxylate(II-48i). According to the general procedure, to a solution of Rh2esp2 (0.51 
mg, 6.65 µmol) in DCM was added the 4-methoxy styrene (0.089 g, 0.665 mmol), 
followed by a solution of the α-diazo ester II-51i (0.25 g, 0.864 mmol). The reaction was 
quenched and column chromatography (10% EtOAc/Hex) afforded II-48i as a solid 
(0.15g, 57.0%).  
1
H NMR (CDCl3, 300 MHz) δ  7.28 (d, J = 8.77 Hz, 1H), 7.19-7.12 (m, 
2H), 7.03-6.94 (m, 1H), 6.82 (d, J = 8.77 Hz, 2H), 3.71 (s, 3H), 3.56 (s, 3H), 3.38 (dd, J 
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= 15.27, 10.72 Hz, 1H), 3.03 (dd, J = 15.27, 8.99 Hz, 1H), 2.36-2.25 (m, 1H), 1.64 (dd, J 
= 8.89, 5.15 Hz, 1H). 
13
C NMR (CDCl3, 75 MHz) δ 165.0, 159.6, 133.0, 130.1, 129.1, 
128.7, 128.0, 127.5, 126.3, 125.6, 125.5, 114.0, 55.3, 51.2, 38.5, 32.0, 21.5. IR: 3103(w), 
2933(m), 2827(w), 1688(m), 1602(w), 1512(s), 1429(m), 1245(s), 1167(m), 1110(m), 
1088(w), 1031(m) cm
-1
. HRMS(ESI) M/Z+ Calc. 393.9841, Obs. 393.9831. 
 
Methyl 2-phenyl-1-(thiophene-2-carbonyl)cyclopropanecarboxylate (II-48j). 
According to the general procedure, to a solution of Rh2esp2 (0.83 mg, 0.1 mol %) in 
DCM was added styrene (0.113 g, 1.09 mmol), followed by a solution of the α-diazo 
ester II-51a (0.30 g, 1.43 mmol). The reaction was quenched and column 
chromatography (10% EtOAc/Hex) afforded II-48j as a solid (0.198 g, 81.0 %). 
1
H 
NMR (CDCl3, 300 MHz) δ 7.72 (d, J = 1.13 Hz, 1H), 7.67-7.65 (d, J = 1.12 Hz, 1H), 
7.45-7.30 (d, J = 1.12 Hz, 5H), 7.05-7.00 (m,1H), 3.49 (dd, J = 8.98, 8.32 Hz, 1H), 3.37-
3.28 (s, 3H), 2.38 (dd, J = 8.10, 5.05 Hz, 1H), 1.67 (dd, J = 9.17, 5.04 Hz, 1H). 
13
C 
NMR (CDCl3, 75 MHz) δ 186.226, 168.651, 143.043, 134.674, 133.877, 132.471, 
128.982, 128.101, 127.530, 127.245, 52.345, 42.519, 30.402, 19.427. IR: 3036 (w), 
2947(w), 1745(s), 1656 (s), 1409(s), 1271(s), 1141(s), 1197(s), 1040(s), 957(s) cm
-1
. 




Methyl 1-(furan-3-carbonyl)-2-phenylcyclopropanecarboxylate(II-48k): According 
to the general procedure, to a solution of Rh2esp2 (1.1 mg, 1.19 µmol)  in DCM was 
added the styrene (0.154 g, 1.83 mmol), followed by a solution of the α-diazo ester II-
51d (0.30 g, 1.54 mmol).  The reaction was quenched and column chromatography (10% 
EtOAc/Hex) afforded II-48k as an oil (0.18 g, 43.0%). 
1
H NMR (CDCl3, 300 MHz) δ 
8.02 (dd, J = 1.46, 0.86 Hz, 1H), 7.43 (dd, J = 1.93, 1.47 Hz, 1H), 7.32-7.20 (m, 5H), 
6.76 (dd, J = 1.94, 0.85 Hz, 1H), 3.55-3.42 (m, 1H), 3.34 (s, 3H), 2.31 (dd, J = 8.05, 4.95 
Hz, 1H), 1.62 (dd, J = 9.15, 4.95 Hz, 1H) ). 
13
H NMR (CDCl3, 75 MHz) δ 187.9, 168.7, 
147.2 (2C), 143.9(2C), 134.6, 128.8, 128.1, 127.2, 126.7, 109.0, 52.2, 43.3, 30.2, 19.5. 
IR: 3121.1(m), 2990.4(w), 1844.1 (w), 1829(m), 1772.1(s), 1700.0(s), 1684.0(m), 
1665.8( m), 1635.8(w) cm
-1
.  HRMS (ESI) Calc. 270.0892, Obs. 270.0893. 
 
Methyl 2-methyl-2-phenyl-1-(thiophene-2-carbonyl)cyclopropanecarboxylate(II-
48l). According to the general procedure, to a solution of Rh2esp2 (0.83 mg, 1.09 µmol) 
in DCM was added the alpha methyl styrene (0.13 g, 1.09 mmol), followed by a solution 
of the α-diazo ester II-51a (0.30 g, 1.43 mmol).  The reaction was quenched and column 





(CDCl3, 300 MHz) δ  7.90 (dd, J = 3.81, 1.15 Hz, 1H), 7.69 (dd, J = 4.95, 1.15 Hz, 1H), 
7.43-7.38 (m, 5H), 7.19 (dd, J = 4.94, 3.82 Hz, 1H), 3.38-3.33 (s, 3H), 2.35 (d, J = 4.98 
Hz, 1H), 1.81 (d, J = 4.98 Hz, 1H), 1.43-1.40 (s, 3H). 
13
C NMR (CDCl3, 75 MHz) δ 
186.157, 169.698, 145.168, 141.387, 134.034, 133.560, 128.351(2C), 128.191(2C), 
128.106, 127.079, 52.259, 43.701, 37.888, 25.659, 25.165. IR: 3002 (w), 2951(w), 
2923(w), 1721(s), 1682(s), 1661(s), 1515(w), 1444(s) 1410(m) cm
-1
. HRMS(ESI) M/Z+ 
Calc. 300.0820, Obs. 300.0830.    
 
Methyl-1-(thiophene-2-carbonyl)-1,1a,6,6a-tetrahydrocyclopropa[a]indene-1-
carboxylate(II-48m).  According to the general procedure, to a solution of Rh2esp2 (1.08 
mg, 1.43 µmol) in DCM was added indene (0.128 g, 1.10 mmol), followed by the α-diazo 
ester II-51a (0.30 g, 1.43 mmol). The reaction was quenched and column 
chromatography (10% EtOAc/Hex) afforded II-48m as an oil (0.20 g, 62%).  
1
H NMR 
(CDCl3, 300 MHz) δ  7.90-7.75 (m, 1H), 7.70 (ddd, J = 4.98, 1.45, 0.84 Hz, 1H), 7.55-
7.33 (m, 1H), 7.30-7.19 (m, 3H), 7.19-7.07 (m, 1H), 3.69 (ddd, J = 18.20, 12.11, 0.73 
Hz, 1H), 3.48-3.30 (m, 1H), 3.30 (dd, J = 2.31, 1.77 Hz, 1H), 2.74 (dt, J = 6.54, 6.54, 
0.74 Hz, 1H). 
13
C NMR (CDCl3, 75 MHz) δ 186.0, 167.8, 143.6, 143.2, 139.3, 134.0, 
132.3, 128.2, 127.1, 126.6, 125.3, 124.4, 52.0, 44.6, 39.5, 33.6, 33.6. IR: 3060(w), 
2943(m), 1735(s), 1657(s), 1648(s), 1640(s), 1434(w), 1410(s), 1353(m), 1301(s), 
1264(s) cm
-1




Methyl 2-((tert-butyldiphenylsilyl)methyl)-1-(thiophene-2-carbonyl) cyclopropane 
carboxylate (II-48n).  According to the general procedure, to a solution of Rh2esp2 (1.4 
mg, 1.83 µmol) in DCM was added TBDPS allylsilane (0.513 g, 1.83 mmol), followed 
by a solution of the α-diazo ester II-51a (0.50 g, 2.40 mmol).  The reaction was quenched 
and column chromatography (10% EtOAc/Hex) afforded II-48n as an oil (0.375 g, 
44.3%). 
1
H NMR (CDCl3, 300 MHz) δ  7.66 (dd, J = 7.54, 1.90 Hz, 4H), 7.62-7.54 (m, 
3H), 7.45-7.30 (m, 4H), 7.06 (dd, J = 4.83, 3.95 Hz, 2H), 3.66 (s, 3H), 2.20-1.99 (m, 
1H), 1.62 (dd, J = 14.80, 3.19 Hz, 1H), 1.45-1.23 (m, 1H), 1.16 (dd, J = 9.13, 4.77 Hz, 
1H), 1.10 (s, 9H).  
13
H NMR (CDCl3, 75 MHz) δ 186.9, 170.2, 143.3, 135.9, 135.9, 
134.1, 133.8, 133.2, 131.9, 129.1, 129.1, 127.8, 127.6, 127.5, 52.3, 40.2, 27.7, 24.1, 23.4, 
18.0, 8.2. IR: 3013.6, 2928.5, 2855.8, 1725.4, 1657.7, 1457.5, 1426.9, 1310.2, 1275.3 
cm
-1
. HRMS (ESI) Calc. 462.1719, Obs. 462.1681.  
 
Methyl 7-(thiophene-2-carbonyl)-2-oxabicyclo[4.1.0]heptane-7-carboxylate(II-48o): 
According to the general procedure, to a solution of Rh2esp2 (1.4 mg, 1.83 µmol)  in 
DCM was added the dihydropyran (0.154 g, 1.83 mmol), followed by a solution of the α-
diazo ester II-51a (0.50 g, 2.37 mmol).  The reaction was quenched and column 





(CDCl3, 300 MHz) δ 7.77 (dd, J = 3.85, 1.13 Hz, 1H), 7.66 (dd, J = 4.95, 1.13 Hz, 1H), 
7.18-7.06 (m, 1H), 6.52 (s, 1H), 4.68 (s, 1H), 4.00-3.90 (m, 1H), 3.74 (s, 3H), 3.71-3.64 
(m, 1H), 2.43-2.19 (m, 1H), 2.14-1.94 (m, 1H), 1.96-1.72 (m, 1H). 
13
H NMR (CDCl3, 75 
MHz) δ 186.7, 169.3, 144.8, 142.4, 134.5, 132.9, 128.2, 106.9, 65.7, 58.7, 52.4, 22.0, 
21.4. IR: 3137.0(m), 2950.9(m), 1734.5(s), 1727.2(m), 1672.2(s), 1462.0(m) cm
-1
. 
HRMS (ESI) Calc.  266.0647, Obs. 266.0624.  
 
Methyl 2-ethoxy-1-(thiophene-2-carbonyl)cyclopropanecarboxylate (II-48p):  
According to the general procedure, to a solution of Rh2esp2 (1.8 mg, 2.37 µmol)  in 
DCM at 0 °C was added the ethyl vinyl ether (0.132 g, 1.83 mmol), followed by a 
solution of the α-diazo ester II-51a (0.50 g, 2.37 mmol). The reaction was quenched and 
column chromatography (10% EtOAc/Hex) afforded II-48p as an oil (0.43 g, 72 %).   
1
H 
NMR (CDCl3, 300 MHz) δ  8.20 (d, J = 3.82 Hz, 1H), 7.46 (dd, J = 5.05, 1.15 Hz, 1H), 
7.06 (dd, J = 5.05, 3.87 Hz, 1H), 5.57 (dd, J = 7.16, 2.58 Hz, 1H), 3.89 (qd, J = 9.57, 
7.08, 7.08, 7.07 Hz, 1H), 3.71 (s, 3H), 3.60 (qd, J = 9.57, 7.08, 7.08, 7.07 Hz, 2H), 3.20 
(dd, J = 16.75, 7.17 Hz, 1H), 2.92 (dd, J = 16.75, 2.56 Hz, 1H), 1.21 (t, J = 7.09, 7.09 
Hz, 3H).
 13
H NMR (CDCl3, 75 MHz) δ 165.1, 156.7, 132.1, 131.4, 130.1, 127.1, 104.0, 
99.8, 77.6, 77.2, 76.7, 64.1, 51.0, 38.2, 15.1. IR: 3138.1(w), 2950.9(w), 1736.7(s), 
1726.4(s), 1672.2(s), 1506.8(m), 1462.2(m) cm
-1






carboxylate (II-48e).  t-BuLi (1.3 mL, 1.70 mmol) was added over 15 minutes to a -
78°C solution of n-methyl indole (0.24 mL, 1.87 mmol) in THF (8.52 mL).  After stirring 
for 45 minutes at -78 °C, a solution of the Weinreb amide cyclopropane (0.250 g, 0.852 
mmol) in 2 mL THF was added slowly to the reaction and allow to warm up to rt.  After 
3 hours, the reaction was quenched with saturated aqueous NH4Cl, extract 3x with Et2O, 
dried with Na2SO4, and column chromatography (10 % EtOAc/Hex, Rf 0.25) afforded 
cyclopropane II-48e (0.21 g, 68%). 
1
H NMR (CDCl3, 300 MHz) δ  7.69 (ddd, J = 11.39, 
5.62, 4.54 Hz, 1H), 7.46-7.27 (m, 3H), 7.12 (d, J = 9.50 Hz, 2H), 6.83 (d, J = 8.76 Hz, 
1H), 6.71 (d, J = 8.75 Hz, 2H), 4.07 (s, 3H), 3.81 (s, 3H), 3.71 (s, 3H), 3.51-3.37 (m, 
1H), 3.18-3.02 (m, 1H), 2.77 (dd, J = 16.96, 8.66 Hz, 1H), 2.39 (dd, J = 8.03, 5.07 Hz, 
1H), 1.99 (dd, J = 12.26, 5.65 Hz, 1H). 
13
C NMR (CDCl3, 75 MHz) δ 186.9, 169.2, 
158.6, 139.9, 138.7, 130.0, 126.8, 123.0, 122.3, 121.0, 119.8, 113.5, 111.6, 110.3, 103.5, 
55.1, 52.4, 43.2, 32.0, 32.0, 29.1, 19.8. IR: 2924.2, 1728.3, 1699.8, 1684.1, 1656.3, 
1363.5, 1248.3 cm
-1








solution of the  -ketoester II-50g (0.75 g, 3.24 mmol), p-anisaldehyde (0.56 g, 4.09 
mmol), glacial acetic acid (80 µL, 1.49 mmol), piperidine (32 µL, 0.324 mmol) was 
refluxed in benzene (30 mL) using a Dean-Stark apparatus for 16 hours. The residual 
dark red brown mixture was dissolved in de-ionized water and extracted with ethyl 
acetate (3x). The combined organic layers were then washed with 1N hydrochloric acid 
followed by a subsequent wash with saturated sodium bicarbonate solution. The mixture 
was concentrated under high vacuum after drying with magnesium sulfate. Column 
chromatography (25% EtOAc/Hex) furnished the desired alkenyl substrate as an orange 
oil (0.724 g, 63%). 
1
H NMR (CDCl3, 300 MHz) δ  7.91-7.79 (m, 1H), 7.59-7.50 (m, 
1H), 7.45 (d, J = 8.95 Hz, 2H), 7.40-7.27 (m, 4H), 6.71 (d, J = 8.89 Hz, 2H), 3.74 (s, 
3H), 3.70 (s, 3H), 3.70 (s, 3H). 
13
C NMR (CDCl3, 75 MHz) δ 189.2, 166.5, 161.1, 141.0, 
138.0, 137.8, 132.4, 129.7, 126.2, 125.7, 123.7, 122.9, 122.6 (2C), 116.3, 114.2, 109.8, 
55.2, 52.4, 33.6. IR: 3051.8, 2949.5, 2182.9, 2055.7, 1709.6, 1599.3, 1511.5, 1250.3, 
1173.6 cm
-1





 Following a Waser’s protocol, n-BuLi (0.858 mmol) was added 
dropwise to a solution of trimethylsulfoxonium iodide (0.193 g, 0.944 mmol) in 
anhydrous THF (0.75 M) at 0 °C. The solution was allowed to warm to rt and stirring was 





ylide (1.74 mL, 0.943 mmol) was added dropwise to a solution of the alkene (0.300g, 
0.858 mmol) in anhydrous THF (0.10 M) at rt and stirred for 3 hours. The reaction was 
quenched with NaHCO3 and extracted with Et2O (3x). The combined organic layers were 
washed with brine (2x), dried over MgSO4, and the solvent was removed under reduced 
pressure. Column chromatography (10% EtOAc/Hex, Rf 0.15) afforded the indolyl 
cyclopropane II-48g (0.168 g, 54.0%).  
1
H NMR (CDCl3, 300 MHz) δ  8.94 (s, 1H), 8.16 
(ddd, J = 7.74, 1.39, 0.75 Hz, 1H), 6.84 (d, J = 8.76 Hz, 2H), 7.40-7.24 (m, 3H), 7.22 (d, 
J = 8.74 Hz, 2H), 4.88 (dd, J = 9.75, 8.95 Hz, 1H), 4.51 (dd, J = 8.92, 3.86 Hz, 1H), 4.43 
(dd, J = 9.77, 3.83 Hz, 1H), 3.87 (s, 3H), 3.79 (s, 3H), 3.60 (s, 3H), 1.84(m,1H). 
13
C 
NMR (CDCl3, 75 MHz) δ 187.5, 169.9, 158.5, 137.3, 135.5, 129.9, 127.3, 126.6, 123.5, 
122.8, 122.5, 115.4, 113.4, 109.6, 55.1, 52.3, 43.1, 33.6, 28.6, 18.7.  IR: 2924.2, 1728.3, 
1699.8, 1684.1, 1656.3, 1363.5, 1248.3 cm
-1




2.8.2.4. Procedure for Catalyst Screening 
To a flame dried flask containing the indium catalyst with the appropriate loading 
(1, 5, or 30 mol%) in anhydrous CH2Cl2 (0.2 M) was added cyclopropane II-48a.  The 
reaction was monitored via TLC, and upon complete disappearance of the starting 
material, the reaction was quenched with H2O.  The mixture was extracted with CH2Cl2, 





2.8.2.5. General Procedure for the Lewis-Acid catalyzed cyclization of heteroaryl 
cyclopropyl ketones (II-48a to II-48n) 
To a flame dried flask containing In(OTf)3 (5 mol %) in anhydrous CH2Cl2 
(0.2M) was added the corresponding cyclopropane.  The reaction was monitored via 
TLC, and upon complete disappearance of the starting material, the reaction was 
quenched with H2O.  The mixture was extracted with CH2Cl2, dried with Na2SO4, and 
column chromatography provided the fused heteroaromatic cyclohexanones. 
 
Methyl-4-(4-methoxyphenyl)-7-oxo-4,5,6,7-tetrahydrobenzo[b]thiophene-6 
carboxylate (II-49a).  According to the general procedure, a solution of In(OTf)3 (4.42 
mg, 8.33 µmol) in DCM was added cyclopropane II-48a (0.050 g, 0.17 mmol).  The 
reaction was quenched after 4.5 h, and column chromatography (15% EtOAc/Hex, Rf 
0.25) provided II-49a as a solid (0.043 g, 86.4%).  (Diastereomeric ratio 1.5:1)  
1
H 
NMR (CDCl3, 300 MHz) δ  7.64 (d, J = 4.94 Hz, 0.90), 7.59 (d, J = 4.93 Hz, 1.13), 7.13 
(d, J = 8.48 Hz, 2.82), 7.03 (d, J = 8.55 Hz, 2.02), 6.88 (dd, J = 10.85, 8.57 Hz, 4.46), 
6.71 (d, J = 5.00 Hz, 0.90), 6.58 (d, J = 5.01 Hz, 1.14), 4.38 (dd, J = 7.49, 4.81 Hz, 
1.00), 4.10 (dd, J = 11.85, 4.48 Hz, 1.52), 3.82-3.73 (m, 15.44), 3.68 (dd, J = 7.19, 4.84 
Hz, 1H), 2.92-2.62 (m, 2.72), 2.58-2.32 (m, 2.32). 
13
C NMR (CDCl3, 75 MHz) δ 165.3, 
159.8, 133.0, 130.1, 129.1, 127.5(2C), 125.4, 114.0(2C), 113.5, 104.9, 83.7, 55.3, 55.1, 
51.2, 38.5. IR: 3086(w), 2950(m), 2827(w), 1736(s), 1664(s), 1602(w), 1510(m), 
112 
 
1413(s), 1244(s), 1175(s), 1151(s), 1014(m) cm
-1
. HRMS (ESI) M/Z+ Calc. 316.0769, 
Obs. 316.0771. 
 
 Methyl 4-(4-methoxyphenyl)-7-oxo-4,5,6,7-tetrahydrobenzofuran-6-carboxylate (II-
49b).  A solution of In(OTf)3 (8.15 mg, 0.015 mmol) in DCE was added cyclopropane II-
48b (0.088 g, 0.29 mmol) and the reaction was heated to reflux.  After 6 h, the reaction 
was cooled to room temperature, followed by the general work up. Column 
chromatography (15% EtOAc/Hex, Rf 0.25) provided II-49b as a solid (0.059 g, 67.0 %).  
(Diastereomeric ratio 1.1:1) 
1
H NMR (CDCl3, 300 MHz) δ   7.38-7.30 (m, 1.91), 7.14-
7.08 (d, J = 0.58 Hz, 1.98), 7.04-7.01 (d, J = 0.58 Hz, 2.24), 6.92-6.86 (m, 4.29), 6.76-
6.72 (m, 2.02), 4.53-4.39 (m, 1.00), 4.30-4.19 (m, 0.95), 3.82-3.78 (m, 6.23), 3.76-
3.70(m, 6.28), 3.68-3.58(m, 2.56), 2.91-2.83 (m, 1.23), 1.30-1.18 (m, 2.27), 2.40-2.30(m, 
1.22). 
13
C NMR (CDCl3, 75 MHz) δ 187.7, 170.9, 166.8, 159.1, 151.0, 129.8, 128.8, 
114.3, 113.9, 110.9, 106.9, 104.8, 55.3, 54.4, 52.4, 51.6, 51.3, 40.2, 35.5, 29.7, 22.7.  IR: 
3116 (w), 2947(w), 2824(w), 1735(m), 1685(s), 1602(m), 1525(m), 1439(m), 1247(br s) 
cm 
-1





carboxylate (II-49c). According to the general procedure, a solution containing In(OTf)3 
(8.9 mg, 0.158 mmol) was added cyclopropane II-48c (0.10 g, 0.316 mmol).  The 
reaction was quenched after 5 h, and column chromatography (15% EtOAc/Hex, Rf 0.25) 
provided II-49c as a solid (0.073 g, 73.0%). (Diastereomeric ratio 1.7:1)  
1
H NMR 
(CDCl3, 300 MHz) δ 7.45-7.36 (m, 1.96), 7.21-7.11 (m, 2.65), 7.10-7.00 (m, 2.67), 6.99-
6.80 (m, 3.59), 4.55 (dd, J = 8.04, 4.66 Hz, 0.58), 4.29 (dd, J = 11.87, 4.30 Hz, 1.00), 
3.80-3.56 (m, 13.8), 2.93-2.67 (m, 2.11), 2.62-2.39 (m, 2.04). 
13
C NMR (CDCl3, 75 
MHz) δ 187.6, 170.4, 161.6, 159.2, 135.9, 134.4, 129.1, 128.9, 124.9, 114.2, 55.3, 52.5, 
42.4, 42.6, 39.6, 37.0. IR: 3086(w), 2950(m), 2827(w), 1736(s), 1664(s), 1602(w), 
1510(m), 1413(s), 1244(s), 1175(s), 1151(s), 1014(m) cm
-1
. HRMS (ESI) M/Z+ Calc. 






49d). According to the general procedure, to a solution containing In(OTf)3 (9.36 mg, 
0.017 mmol ) was added cyclopropane II-48d (0.100 g, 0.33 mmol).  The reaction was 
quenched after 6 h, and column chromatography (15% EtOAc/Hex, Rf 0.25) provided II-
49d as a solid (0.073 g, 73.0%).  (Diastereomeric ratio 1.1:1)  
1
H NMR (CDCl3, 300 
MHz) δ 7.36 (d, J = 2.05 Hz, 1.03), 7.32 (dd, J = 1.45, 0.60 Hz, 1.12), 7.17-7.07 (m, 
2.32), 7.06-6.98 (m, 2.21), 6.96-6.84 (m, 4.31), 6.74-6.70 (m, 2.20), 4.46 (dd, J = 3.76, 
3.07 Hz, 1.00), 4.24 (dd, J = 10.49, 5.79 Hz, 1.09), 3.84-3.72 (m, 12.77), 3.72-3.54 (m, 
3.25), 2.87 (s, 1.29), 2.75-2.46 (m, 2.61), 2.46-2.26 (m, 1.44). 
13
C NMR (CDCl3, 75 
MHz) δ 188.7, 170.0, 167.2, 159.2, 144.1, 131.0, 129.1, 128.6, 121.1, 114.5, 106.8, 55.3, 
54.5, 52.6, 52.4, 51.6, 40.5, 37.9, 36.0, 35.5. IR: 3060(w), 2947(w), 2834(w), 1745(m), 
1687(s), 1679(m), 1442(m), 1264(s), 1249(s), 1180(w), 1117(w), 1027(w) cm 
-1
. HRMS 
(ESI) M/Z+ Calc. 300.0998, Obs. 300.0998. 
 
Methyl-4-(4-methoxyphenyl)-9-methyl-1-oxo-2,3,4,9-tetrahydro-1H-carbazole-2-
carboxylate (II-49e). According to the general procedure, to a solution containing 
In(OTf)3 (3.85 mg, 6.85 µmol) was added cyclopropane II-48e (0.049 g, 0.137 mmol).  
The reaction was quenched after 5.5 h, and column chromatography (20% EtOAc/Hex, Rf 
0.20) provided II-49e as a solid (0.031 g, 63.0 %).  (Diastereomeric ratio 1.2:1)  
1
H 
NMR (CDCl3, 300 MHz) δ  7.41-7.33 (m, 3.96), 7.33-7.28 (m, 2.23), 7.16 (d, J = 8.63 
115 
 
Hz, 2.81), 7.12-7.01 (m, 1.29), 6.96-6.81 (dd, J = 7.89, 4.16 Hz, 4.52), 6.69 (td, J = 8.18, 
0.95, 0.95 Hz, 1.06), 4.62 (t, J = 5.63, 5.63 Hz, 1.00), 4.37 (dd, J = 11.21, 4.71 Hz, 1.21), 
4.09 (d, J = 9.30 Hz, 4.97), 3.80-3.60 (m, 12.85), 2.99-2.84 (m, 1.39), 2.60-2.48 (m, 
2.52), 2.40 (m, 1.63). 
13
C NMR (CDCl3, 75 MHz) δ 186.9, 170.7, 158.6, 140.4, 135.2, 
134.2, 131.1, 130.3, 127.0, 124.3, 122.9, 120.1, 114.0, 110.3, 55.6, 52.4, 40.4, 38.5, 37.4, 
31.6. IR: 3030.6, 2924.2, 2850.4, 1791.7, 1771.8, 1737.9, 1657.6, 1623.3 1518.8, 1540.0, 
1511.3, 1246.4, 1246.4 cm 
-1
.  HRMS (ESI) Calc. 363.1471 Obs. 363.1478. 
 
Methyl 1-(4-methoxyphenyl)-4-oxo-1,2,3,4-tetrahydrodibenzo[b,d]furan-3-
carboxylate (II-49ff). According to the general procedure, a solution containing In(OTf)3 
(6.55 mg, 0.017 mmol) was added the cyclopropane II-48f (0.078 g, 0.233 mmol). The 
reaction was quenched after 5 h, and column chromatography (15% EtOAc/Hex, Rf 0.25) 
provided II-49f as a solid (0.071 g, 91.0%). (Diastereomeric ratio 1.4:1)  
1
H NMR 
(CDCl3, 300 MHz) δ 7.57 (dd, J = 8.45, 3.57 Hz, 2.41), 7.47-7.40 (m, 2.73), 7.22-7.01 
(m,5.41), 6.90-6.70 (dd, J = 14.89, 6.23 Hz, 4.67), 4.60 (dd, J = 8.46, 4.96 Hz, 1.00), 
4.38 (dd, J = 10.88, 4.98 Hz, 0.73), 3.90-3.80 (m, 12.35), 3.77-3.74 (m, 3H), 2.91 (m, 
1.19), 2.69-2.56 (m, 1.94), 2.56-2.41 (m, 1.37). 
13
C NMR (CDCl3, 75 MHz) δ 224.963, 
158.994, 156.447, 133.151, 132.548, 129.394, 128.978, 125.526, 123.590, 123.286, 
114.303, 112.833, 55.294, 52.639, 52.351, 39.608, 37.871. IR: 2942(w), 2831(w), 
116 
 
1731(s), 1677(s), 1608(s), 1511(s), 1426(m), 1245(s) cm
-1
. HRMS (ESI) M/Z+ Calc. 
350.1154, Obs. 350.1163. 
 
Methyl-1-(4-methoxyphenyl)-9-methyl-4-oxo-2,3,4,9-tetrahydro-1H-carbazole-3-
carboxylate (II-49g). According to the general procedure, to a solution containing 
In(OTf)3 (2.86 mg, 5.0 µmol) was added cyclopropane II-48g (0.037 g, 0.102 mmol).  
The reaction was quenched after 6 h, and column chromatography (20% EtOAc/Hex, Rf 
0.25) provided II-49g as a solid (0.022 g, 61.0%).  (Diastereomeric ratio 1.2:1)  
1
H 
NMR (CDCl3, 300 MHz) δ  7.36-7.30 (d, J = 3.34 Hz, 3.70), 7.18-7.10 (d, J = 8.60 Hz, 
3.50), 7.07-7.00 (m, J = 8.64 Hz, 2.68), 6.98 (dd, J = 8.02, 3.98 Hz, 0.92), 6.93-6.78 (m, 
4.05), 4.64 (t, J = 5.61, 5.61 Hz, 1.00), 4.38 (dd, J = 10.76, 5.06 Hz, 0.87), 4.12 (m, 
4.68), 3.82-3.70 (m, 11.75), 2.93 (ddd, J = 13.51, 8.75, 5.04 Hz, 1.20), 2.49-2.36(m, 
3.14). 
13
C NMR (CDCl3, 75 MHz) δ 187.1, 171.0, 158.5, 135.2, 134.2, 130.3, 129.2, 
127.0, 122.9, 122.3, 120.3, 120.1, 114.0, 110.3, 55.6, 52.2, 40.3, 38.5, 37.4, 36.9, 31.6, 
29.6. IR: 3000.6, 2924.2, 2850.4, 1791.7, 1737.9, 1657.6, 1623.4, 1540.0, 1511.3, 
1246.4, 1218.7 cm 
-1





carboxylate (II-49h). According to the general procedure, to a solution containing 
In(OTf)3 (5.8 mg, 0.103 µmol) was added cyclopropane II-48h (0.075 g, 0.206 mmol).  
The reaction was quenched after 5.5 h, and column chromatography (15% EtOAc/Hex, Rf 
0.25) provided II-49h as a solid (0.053 g, 71.0%). (Diastereomeric ratio 1.2:1)  
1
H NMR 
(CDCl3, 300 MHz) δ  7.61-7.52 (m, 2.40), 7.50-7.42 (dd, J = 13.96, 7.11 Hz,2.73), 7.22-
7.00 (m, 6.82), 6.95-6.82 (m, 5.51), 6.77-6.69 (m, 1.16), 4.65-4.55(m, 1.00),  4.36 (dd, J 
= 10.80, 4.86 Hz, 1.21), 3.90-3.70 (m, 15.76), 2.96-2.84 (m, 1.15), 2.80-2.56 (m, 2.66), 
2.53-2.40 (m, 1.25). 
13
C NMR (CDCl3, 75 MHz) δ 182.8, 169.8, 169.6, 159.0, 158.9, 
156.4, 146.0, 136.9, 132.6, 129.4, 129.2, 125.6, 123.7, 123.6, 114.3, 112.8, 55.3, 54.5, 
52.3, 39.6, 38.0. IR: 2960(m), 2923(m), 2844(w), 1721(s), 1675(m), 1615(w), 1552(m), 
1505(w), 1459(m), 1426(m) cm 
-1






carboxylate (II-49i). According to the general procedure, to a solution containing 
In(OTf)3 (3.55 mg, 6.32 µmol ) was added cyclopropane II-48i (0.050 g, 0.126 mmol).  
The reaction was quenched after 8 h, and column chromatography (15% EtOAc/Hex, Rf 
0.25) provided II-49i as a solid (0.028 g, 56.0 %).  
1
H NMR (CDCl3, 300 MHz) δ  7.16 
(d, J = 8.80 Hz, 1H), 6.96-6.79 (m, 1H), 6.45-6.40 (m, 1H), 3.95-3.84 (m, 1H), 3.83-3.77 
(s, 3H), 3.79-3.73 (s, 3H), 2.91-2.76 (m, 1H), 2.70-2.55 (m, 1H). 
13
C NMR (CDCl3, 75 
MHz) δ 173.0, 163.1, 158.7, 146.7, 144.7, 133.8, 131.8, 130.0, 129.2, 122.7, 121.2, 
114.3, 57.4, 56.6, 55.3, 51.8, 43.0, 30.8. IR: 2920(m), 2840(m), 1735(m), 1598(m), 
1511(s), 1440(m), 1353(m), 1246(s), 1176(m) cm
-1
. HRMS (ESI) M/Z+ Calc. 393.9841, 
Obs. 393.9869.   
 
Methyl 7-oxo-4-phenyl-4,5,6,7-tetrahydrobenzo[b]thiophene-6-carboxylate (II-49j):  
A solution containing In(OTf)3 (5.2 mg, 9.24 µmol) in DCE  was added cyclopropane II-
48j (0.050 g, 0.19 mmol) and the reaction was heated to reflux.  The reaction was 
quenched after 6 h, followed by general work up, and column chromatography (15% 
EtOAc/Hex, Rf 0.25) provided II-49j as a solid (0.041 g, 81.0%).  (Diastereomeric ratio 
2.3:1)  
1
H NMR (CDCl3, 300 MHz) δ  7.72-7.50 (m, 1.26), 7.50-7.25 (m, 5.26), 7.25-
6.98 (m, 6.06), 4.71-4.48 (m, 0.42), 4.32 (dd, J = 11.93, 4.36 Hz, 1.00), 3.89-3.54 (m, 
13.78), 3.06-2.63 (m, 4.33), 2.63-2.31 (m, 4.05). 
13
C NMR (CDCl3, 75 MHz) δ 187.5, 
170.3, 160.7, 142.4, 136.4, 135.2, 134.9, 129.8, 128.9, 127.8, 125.0, 124.9, 54.9, 41.9, 
119 
 
40.7, 37.2. IR: 3030(w), 2957(w), 2840(w), 1737(s), 1671(m), 1409(m), 1399(s) cm 
-1
.  
HRMS (ESI) M/Z+ Calc. 286.0664, Obs. 286.0674. 
 
Methyl 4-oxo-7-phenyl-4,5,6,7-tetrahydrobenzofuran-5-carboxylate (II-49k). 
According to the general procedure, a solution containing In(OTf)3 (12.4 mg, 0.23 µmol, 
5 mol %) was added cyclopropane II-48k (0.12 g, 0.44 mmol). The reaction was 
quenched after 6 h, and column chromatography (20% EtOAc/Hex, Rf 0.25) provided II-
49k as a solid (0.099 g, 82.5%). (Diastereomeric ratio 1.2:1)  
1
H NMR (CDCl3, 300 
MHz) δ  7.35-7.20 (m, 5H), 7.11 (dd, J = 7.98, 1.57 Hz, 1H), 7.02 (dd, J = 7.78, 1.77 Hz, 
1H), 4.44 (dd, J = 6.35, 5.92 Hz, 1H), 4.21 (dd, J = 10.39, 5.78 Hz, 1H), 3.67 (s, 3H), 
3.66 (s, 3H), 3.64-3.49 (m, 1H), 2.84 (q, 1H), 2.65-2.47 (m, 1H), 2.41-2.23 (m, 1H) ).  
13
C NMR (CDCl3, 75 MHz) δ 188.4, 170.2, 166.7, 143.8, 139.1, 128.9, 127.7, 121.4, 
106.8, 54.4, 52.5, 51.5, 41.1, 38.7, 36.0, 35.3. IR: 3121.1 (w), 2937.3(w), 1772.0 (s), 
1729.7(s), 1684.0(m), 1605.2(w), 1583.6(m) cm
-1







(II-49l). According to the general procedure, to a solution containing In(OTf)3 (7.06 mg, 
0.125 µmol) was added cyclopropane II-48l (0.075 g, 0.25 mmol). The reaction was 
quenched after 4.5 h, and column chromatography (15% EtOAc/Hex, Rf 0.25) provided 
II-49l as a solid (0.053 g, 71.0 %). (Diastereomeric ratio 2:1)  
1
H NMR (CDCl3, 300 
MHz) δ 7.91 (dd, J = 3.86, 1.09 Hz, 1H), 7.84-7.75 (m, 1H), 7.73-7.67 (m, 1H), 7.44-
7.25 (m, 2H), 7.21-7.09 (m, 1H), 7.10-6.93 (m, 1H),  4.32 (dd, J = 9.84, 9.00 Hz, 1H), 
3.76-3.67 (s, 3H), 3.36-3.06 (m, 1H), 2.88-2.38 (m, 1H), 1.83-1.79 (s, 3H). 
13
C NMR 
(CDCl3, 75 MHz) δ 187.5, 170.4, 157.5, 144.6, 135.5, 128.6, 128.3, 127.7, 126.9, 126.8, 
126.3, 126.2, 125.0, 52.3, 51.8, 43.5, 42.1, 29.5. IR: 3002 (w), 2951(w), 2923(w), 
1721(s), 1682(s), 1661(s), 1515(w), 1444(s) 1410(m) cm
-1
. HRMS (ESI) M/Z+ Calc. 
300.0820, Obs. 300.0830.    
 
Methyl 4-oxo-5,5a,10,10a-tetrahydro-4H-fluoreno[2,1-b]thiophene-5-carboxylate 
(II-49m). According to the general procedure, a solution containing In(OTf)3 (4.71 mg, 
8.38 µmol) was added cyclopropane II-48m (0.050 g, 0.17 mmol). The reaction was 
quenched after 6 hours, and column chromatography (15% EtOAc/Hex, Rf 0.25) 
provided II-49m as a solid (0.043 g, 87.0 %). 
1
H NMR (CDCl3, 300 MHz) δ 7.80 (td, J 
= 3.86, 1.18, 1.18 Hz, 1H), 7.75-7.62 (m, 1H), 7.50 (td, J = 8.63, 3.74, 3.74 Hz, 1H), 
7.45-7.31 (m, 1H), 7.31-7.05 (m, 1H), 6.99-6.81 (m, 1H), 4.10 (s, 1H), 3.92-3.62 (m, 
1H), 3.62-3.41 (m, 1H). 
13
C NMR (CDCl3, 75 MHz) δ  185.6, 168.7, 143.9, 142.3, 139.8, 
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135.1, 133.3, 132.6, 128.4, 126.3, 125.0, 123.6, 121.1, 57.7, 52.8, 40.1. IR:  2930 (m), 
2847(w), 1737(s), 1664(s), 1959(s), 1595(w), 1413(m), 1254(s), 1207(s), 1147(s), 
1087(s) cm 
-1
. HRMS (ESI) M/Z+ Calc. 298.0670, Obs. 298.0697. 
 
Methyl 4-((tert-butyldiphenylsilyl)methyl)-7-oxo-4,5,6,7-tetrahydrobenzo[b] 
thiophene-6-carboxylate (II-49n). According to the general procedure, a solution 
containing In(OTf)3 (12.1 mg, 0.21 µmol, 30 mol %) was added cyclopropane II-48n 
(0.10 g, 0.429 mmol). The reaction was quenched after 6 h, and column chromatography 
(20% EtOAc/Hex, Rf 0.25) provided II-49n as a solid (0.071 g, 71.0 %).  
(Diastereomeric ratio 2.4:1)  
1
H NMR (CDCl3, 300 MHz) δ 7.76-7.62 (m, 8.34), 7.60-
7.53 (d, J = 5.05 Hz, 2.15), 7.48-7.29 (m, 14), 7.10-7.00 (dd, J = 8.49, 5.31 Hz, 1.69), 
6.79 (d, J = 5.02 Hz, 0.65), 3.70-3.66 (d, J = 4.46 Hz, 2.23), 3.64-3.58 (m,1.09), 3.60-
3.54(s, 2.46), 3.31-3.00 (m, 2.92), 2.39-1.98 (m, 1.39), 2.18-1.76(m, 4.81), 1.72-1.36 (m, 
5.62), 1.15-0.99 (m, 18.39). 
13
C NMR (CDCl3, 75 MHz) δ  187.7, 186.6, 169.9, 159.1, 
136.1, 136.0, 135.9, 135.9, 134.9, 129.6, 129.5, 129.4, 128.0, 127.9, 127.8, 127.7, 127.6, 
52.2, 51.1, 30.6, 27.8, 27.7, 18.3. IR: 2926.6, 2854.9, 1741.5, 1677.6, 1457.6, 1426.6, 
1274.9, 1260.1 cm
-1





Methyl 4-hydroxybenzofuran-5-carboxylate (II-49o). According to the general 
procedure, a solution containing In(OTf)3 (11.8 mg, 0.21 µmol) in CH2Cl2 was added 
cyclopropane II-48p  (0.10 g, 0.419 mmol). The reaction was quenched after 24 h, and 
column chromatography (15% EtOAc/Hex, Rf 0.25) provides the product II-49o as a 
white solid (0.081 g, 81.0%). All data matches literature. 
 
2.8.2.6.Tandem Cyclopropanation-Formal Homo-Nazarov Cyclization 
 
To a flame dried flask containing Rh2esp2 (6.00 mg, 7.93 µmol) and In(OTf)3 
(1.01 mg, 1.79 µmol) in DCM (2 mL) was added 4-methoxystyrene (0.106 g, 0.793 
mmol) at 0 °C.  After 5 minutes, a solution of α-diazo ester II-51d (0.200 g, 1.03 mmol) 
in DCM (2mL) was added to the flask.  The ice bath was removed after 10 minutes and 
the reaction was allowed to warm up to RT.  The reaction was quenched with water after 
12 hours, extracted with DCM (3x), dried with Na2SO4, and column chromatography 
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SYNTHESIS OF HYDROPYRIDO[1,2-a]INDOLE-6(7H)-ONES VIA 







3.1. HYDROPYRIDO[1,2-a]INDOLES IN NATURE 
A common motif present in an astonishing variety of natural products endowed 
with potent and multiform biological activities is an indole nucleus annulated to carbo- or 
heterocyclic ring(s).
1-6
 A large number of indole compounds are at the forefront as 
pharmacologically-active lead compounds for drug discovery and development 
processes. At present, more than 2000 indole alkaloid natural products have been 
characterized, which encompasses simple and more complex functionalized indole 
derivatives.
7
 Among [a]-annelated systems, the hydropyrido[1,2-a]indole skeleton (III-1) 
and, more specifically, its C(6)-oxidized cogeners (III-2) are key structural motifs that 
appear in the core structures of an impressive number of naturally-occurring indole 
alkaloids and pharmaceutically relevant compounds (Figure 3.1).  
 
 
                                                 
‡‡
This work was performed in collaboration with Marchello A. Cavitt, a fellow graduate student and Paul 
Grzybowski, an undergraduate student in the France research group. 
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In 1818, Pelletier and Caventou reported the first isolation of the bioactive 
pentacyclic alkaloid strychnine (III-3) from Strychnos ignatii.
8
 Vinca alkaloids comprise 
a large number of biologically active, naturally-occurring bases isolated from several 
plants of the Vinca species.
9
 For example, vincamine (III-4) possesses strong 




 exhibits strong 
cerebrovascular, antihypoxic, antiamnesic, antiischemic, and cytoprotective effects.
12,13
  
(-)-Eburnamonine (III-6)  and (±)-vindeburnol (III-7)  shows strong vasodilation 
activity.
14
 The structurally related tacaman alkaloids represented by tacamine (III-8), and 
tacamonine (III-9)  show potential hypotensive and cerebral vasodilation effects.
15,14c
 




 and arboloscine (III-
13)
18
 are isolated from the plants of genus Kopsia. Novel pentacyclic indole alkaloids, 
tronocarpine (III-10)
19
 and dippinine (III-12)
20
 are isolated from the plants of the genus 
Tabernaemontana. (-)-Goniomitine (III-15) isolated from the root bark of Gonioma 







3.2. SYNTHESIS OF FUNCTIONALIZED HYDROPYRIDO[1,2-a]INDOLES  
Owing to hydropyrido[1,2-a]indoles existence in a wide variety of natural 
products and molecules with interesting biological properties, extensive efforts have been 
devoted towards the synthesis of functionalized annulated indoles. The majority of 
synthetic approaches to construct these skeletons begin with an indole framework and the 
















 and domino 
reactions.
29
 Due to the sheer number of strategies reported, the following section provides 
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a brief overview of some representative approaches to hydropyrido[1,2-a]indoles with an 
example given for each synthetic route.  
 
3.2.1. TRANSITION METAL-CATALYZED C-C BOND FORMATION 
In 2007, the Zhang group elegantly presented a Pt-catalyzed synthesis of 
substituted indoles fused to cyclic ketones (Figure 3.2).
22b
 N-(2-alkynylphenyl)lactams 
III-16 were heated to reflux in 1,2-dichloroethane in the presence of catalytic amounts of 
PtCl4 under an atmosphere of O2 to furnish annulated indole products III-17. This 
reaction proceeds through an intramolecular insertion at one end of the C-C triple bond 
into the lactam amide bond with concurrent 1,2-acyl migration of the substituent on the 
triple bond. When reactions were performed using either PtCl2 or under nitrogen 
atmosphere, increased reaction time was observed. Studies indicated that the reaction 
time was shortened upon the use of O2. The Zhang group also demonstrated that the 
reaction works well when alkyl, cycloalkanes, aryl, and alkenyl groups were present at 
the alkyne terminus. The reaction did not show any electronic effect from the substituent 






3.2.2. INTRA/INTERMOLECULAR CONDENSATIONS 
 
In 1998, Skibo et al. designed a system that could form a cyclopropyl quinone 
methide from a pyrrolo[1,2-a]-fused system upon reduction of the quinone. In the 
continuation of their effort, the Skibo group utilized pyrido[1,2-a]-fused systems to 
develop cyclopropyl quinone methide reductive alkylating agents.
23b
 The required 
annulated pyrido ring products III-19 were synthesized by condensation of indole III-18 




3.2.3 RADICAL CYCLIZATION APPROACH 
A more common approach in the synthesis of hydropyrido[1,2-a]indole 
compounds  is the construction of the 6-membered ring via a radical cyclization. More 
recently, the Kerr group demonstrated the utility of this route to generate 1,2-annulated 
indole/pyrroles.
24c
 A variety of N-acylated or alkylated indoles/pyrroles were subjected to 
oxidative cyclization with excess Mn(OAc)3
 
in methanol to furnish products III-21 in 
high yields (Figure 3.4). However, the substrate derived from indole-3-carbaldehyde did 
not cyclize under the optimized conditions. The reaction is postulated to proceed through 
the oxidation of a malonic enolate derived from III-20 to yield a malonic radical. 
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Cyclization onto the 2-position of an indole or pyrrole yields a resonance stabilized 
radical which undergoes further oxidation to carbonium ion. Aromatization via proton 
loss gives the product III-21. Further studies showed that indolines can also be employed 
as substrate to form 1,2-annulated products in a one-pot fashion. To showcase the 
application of the method, the tetracyclic core of tronocarpine III-22 was synthesized. In 





3.2.4. NUCLEOPHILIC SUBSTITUTION APPROACH 
The Okda group reported the application of nucleophilic substitution approach 
towards the synthesis of (+)-dihydroeburnamenine III-25  and (-)-
epidihydroeburnamenine III-26 natural products in 2004 (Figure 3.5).
25b
 When mesylate 
III-23 was treated with NaOH in THF, it readily formed N-alkylated pentacyclic product 
III-24 in 88% yield. Reduction of lactam III-24 was then performed with LiAlH4 in THF 
at reflux to provide III-25 in 91% yield. Similarly, reduction of another isomer of III-24 






3.2.5. ACID-INDUCED CYCLIZATION ROUTES 
In their synthetic studies towards the discovery of novel protein kinase Cβ 
(PKCβ)- selective inhibitors possessing oral bioavailability as a potential candidate in the 
treatment of diabetes mellitus, the Inaba group designed and synthesized pyrido[1,2-
a]indole derivatives.
26a
 An intramolecular Pictet-Spengler cyclization of N-alkylated 
indole III-27 in the presence of TFA allowed the formation of 1,2-annulated indole 
derivative III-28 (Figure 3.6). Ultimately, it was used in the synthesis of 





3.2.6. CYCLOADDITIONS APPROACHES 
The Bodwell group developed a novel transannular inverse electron demand 
Diels-Alder (IEDDA) reaction that utilizes small cyclophanes as key intermediates to 
natural products.
27c, 30
 When indolophane III-30 was heated with N,N-dimethylaniline it 
formed a pentacyclic pyrido[1,2-a]indole product III-32, which appears to be well suited 
as a precursor to a variety of indole alkaloids, such as strychnine. The reaction 
presumably proceeds via an IEDDA reaction to give adduct III-31, followed by 
expulsion of N2 in a retro Diels-Alder fashion (Figure 3.7). Furthermore Bodwell 
disclosed a concise formal synthesis of (±)-strychnine with an overall yield of 2.6% over 






3.2.7. PAUSON-KHAND REACTION APPROACH 
The Pauson-Khand reaction is one of the least explored strategies in indole 
chemistry. More specifically, it remains an uncommon route in the synthesis of the 
pyrido[1,2-a]indole framework. In 2004, the Pe´rez-Castells group demonstrated the 
utility of this reaction towards the construction of tetracyclic compounds fused at 
positions 1 and2 (III-35); 2 and 3 (III-34); and 3,3a and 4  (III-36) of the indole nucleus 
(Figure 3.8).
28
 Indoles bearing an alkenyl and alkynyl moiety III-37 was heated in the 
presence of Co2(CO)8/TMANO to furnish the 1,2-annulated indole product in high yield. 
The group also showed the scope of the reaction by screening indoles bearing a wide 
variety of alkenyl and alkynyl moieties to provide tetracyclic cyclopentenone products in 
moderate to high yield. Further studies showed that that the starting materials with bulky 
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groups such as TBDMS or Phth, a single diastereomer was observed. The bulkier group 
is found to be on the same side as the hydrogen at the ring junction (III-38).  
 
3.2.8. DOMINO REACTION APPROACH 
Domino reactions are considered to be one of the most valuable methods for an 
efficient construction of complex skeletons in contemporary organic synthesis.
31
 Wang et 
al. reported NHC-catalyzed domino reactions of 1,1-diactivated FCPs with 
salicylaldehyde to generate coumarin skeletons.
32
 In a continuation of their studies, the 
Wang group developed a domino ring-opening/redoxamidation/cyclization reaction of 
readily available formylcyclopropane 1,1-diesters III-40 with 2-chloro-1H-indole-3-
carboaldehydes III-39 to generate hydropyrido[1,2-a]indoles III-41 (Figure 3.9).
29
 
Further studies on the reaction scope showed that substituent on the phenyl ring of the 
indole significantly affect the reaction yield and conversions. Substrates with an EWG 
showed low to moderate yields and conversions. Even 2-chloro-1H-benzimidazole was 
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found to be suitable substrate for the reaction. Finally, the utility of this efficient protocol 
was established by synthesizing the tetracyclic unit of tronocarpine (III-42).  
 
 
Unfortunately, many of these strategies usually provide products in modest yields, 
requires high catalyst loadings, and involve either extensive multi-step sequences to 
construct the 1,2-annulated indole ring system or do not allow for a large range of 
functionality to be accessed. Therefore, the discovery of a more general and efficient 
method for the facile construction of this polycyclic core remains a formidable goal for 
organic chemists. In the following section, the France Lab efforts directed towards the 
development of an efficient methodology for the synthesis of densely functionalized 






3.3. THE DEVELOPMENT OF INDIUM(III)-CATALYZED TANDEM 
CYCLOPROPANE RING-OPENING/FRIEDEL-CRAFTS ALKYLATION  
 
3.3.1. PRIOR CONTRIBUTIONS MADE BY THE FRANCE GROUP 
The previous work from the France group demonstrated that the formal homo-
Nazarov cyclization of alkenyl and heteroaryl cyclopropyl ketones could be significantly 
facilitated if the cyclopropanes were functionalized to bear an additional electron 





The successful synthesis of heteroaromatic-ring fused cyclohexanone via the 
formal homo-Nazarov cyclization of heteroaryl cyclopropyl ketones under mild reaction 
conditions suggested that by employing these donor-acceptor-acceptor (D-A-A) 
cyclopropanes with N-acylated indoles as reactive π-systems, would easily generate 






3.3.2. SUBSTRATE SYNTHESIS  
In order to test our hypothesis, cyclopropane precursors III-45 were prepared in 
three steps according to Figure 3.11. N-Acylation of an indole with commercially-
available methyl malonyl chloride afforded the β-amidoester compounds III-43. Next, 
diazo transfer provided α-diazoester III-44. Lastly, cyclopropanation
34
 with Rh2esp2 
(bis[rhodium(α,α,α’,α’-tetramethyl-1,3-benzenedipropionic acid)]) in the presence of a 
requisite alkene provided the desired methyl 1-(1H-indole-carbonyl)-1-
cyclopropanecarboxylates III-45  with a overall yields (over three steps) up to 70%.   
 
 
Given the 3-methyl-1H-indole’s ability to act as a good nucleophile and the cation 
stabilizing ability of 4-methoxyphenyl, an N-substituted indolyl cyclopropane bearing a 
4-methoxyphenyl group was chosen as the model substrate for preliminary investigation. 





3.3.3. PROOF OF CONCEPT/REACTION OPTIMIZATION 
With a diverse set of substrates in hand, it was necessary to find conditions that 
allowed for the successful cyclization of the methyl 1-(1H-indole-carbonyl)-1-
cyclopropanecarboxylates. Based on our recent success with In(OTf)3 as an effective 
catalyst in the formal homo-Nazarov cyclization reaction of alkenyl and heteroaryl 
cyclopropyl ketones, we utilized In(OTf)3. The model substrate III-45a was subjected to 
30 mol% In(OTf)3 in dichloromethane at room temperature. We were delighted to see a 









3.3.4. AN EXAMININATION OF THE REACTION SCOPE AND LIMITATIONS 
With promising preliminary reaction conditions identified, the effects of various 
aryl/heteroaryl substituents as donor groups on the cyclopropane were examined. As 
mentioned on previous page, cyclopropane III-45a rapidly cyclized to afford the product 
III-46a in almost quantitative yield with 2.6:1 trans:cis dr (Table 3.1, entry 1). Likewise, 
2-methoxy phenyl cyclopropane III-45b provided product III-46b in 95% yield with 
3.2:1 dr (Table 3.1, entry 2). Thus, electron-donating groups such as methoxy group in 
both ortho- and para-position favored the reaction, providing the corresponding products 
in excellent yields. Next, to probe the electronic effects of the para-substituted aromatic 
cyclopropane on the reaction outcome, cyclopropanes with the phenyl, 4-fluorophenyl, 4-
chlorophenyl and the 4-nitrophenyl as the EWG donor group were synthesized. 
Disappointingly, when the phenyl derivative III-45c was subjected to the reaction 
conditions, the reaction failed to produce any of the desired product III-46c. Instead, only 
starting material was recovered even after long reaction times (>24 h). It was thought that 
the use of higher temperature may prove more successful. Therefore, the substrate III-
45c was heated to reflux in 1,2-dichloroethane. As anticipated, it cyclized to provide 
corresponding product III-46c in 52% yield with 2.6:1 dr (Table 3.1, entry 3). Similarly, 
substrates with electron-withdrawing groups such as F, Cl, and NO2 groups on the para-
position of the phenyl ring III-45(d-f) did not provide any of the desired products at 
room temperature. However, upon subjecting the substrate to reflux in 1,2-DCE, the 
cyclized products were observed. The 4-fluorophenyl and 4-chlorophenyl derivatives 
furnished cyclized products III-46d and III-46e in 48% and 50% yield, respectively 






This result is noteworthy as the aromatic halogen may serve as a chemical handle 
for further synthetic functionalization. The 4-nitro derivative III-45f only afforded trace 
amounts of the desired product III-45f as indicated by crude 
1
H NMR (Table 3.1, entry 
6). Consideration of the electronics of the reaction suggested that there would be an 
increased destabilizing effect on the benzylic carbocation formed upon cyclopropane ring 
opening in the transition state (Figure 3.12). This effect is more pronounced as the 
substituents are varied from the electron-donating 4-methoxy group to the electron-
withdrawing 4-nitro group and thus contributing to the observed failure of the reaction. 
These observations correlate well with known Hammett substituent values for benzylic 
cations.
35
 Similar reactivity was observed when a heteroaromatic group was employed as 
the donor substituent. For example, with furan as the donor group, cyclized product III-
46g is readily obtained in 99% yield with 4.5:1 dr (Table 3.1, entry 7). This result is 




Next, the reaction scope of was examined using cyclopropanes with another 
cation stabilizing donor substituent. The geminally disubstituted cyclopropane substrate 
III-45h was subjected to the standard reaction conditions. As anticipated, it resulted in a 
dramatic accelerating effect. This effect can be seen in that III-45h readily cyclizes at 
room temperature to afford III-46h in excellent yield (94%) with 1.1:1 dr (Table 3.2, 
entry 1), whereas III-45c does not cyclize at room temperature. The enhanced reactivity 
of III-45h is presumably attributed to faster ring-opening of the cyclopropane due to a 
release of steric ring strain and the formation of the more stable 3° benzylic carbocation. 








The increased reaction rate and excellent yield observed in the case of III-45h 
substrate indicated that the reaction might be proceeding through a more stable 3° 
benzylic carbocationic intermediate. This interesting result prompted us to investigate the 
use of geminal disubstituted alkyl groups as a donor on the cyclopropanes. Previous 
literature findings showed that the tertiary carbocations are very close in energy to 
benzylic carbocations.
37
 Thus, the cyclopropane ring-opening should be favored to 
generate a more stable 3° carbocation, providing the corresponding hydropyrido[1,2-
a]indole derivatives. To confirm this hypothesis, substrate III-45i (derived from 3-
methylene pentane) was chosen as a substrate of choice for initial testing because it has 
an easily identifiable 
1
H NMR spectra and would simplify interpretation of the cyclized 
product in the spectrum. Disappointingly, using identical reaction conditions as before, 
the geminal diethyl substituted cyclopropane did not undergo any appreciable cyclization 
(Table 3.3, entry 1). As it was our intention to develop the method to be applicable to 
dialkyl substituted cyclopropanes, further optimization was undertaken varying the 
temperature, order of addition of the reagent, and solvent. The optimization study began 
by examining the reaction at slightly higher temperature. Interestingly, no reaction 
occurred when substrate III-45i was reacted in dichloromethane at reflux (Table 3.3, 
entry 2). The next stage of the optimization process was to investigate the order and 
temperature at which the reagents were combined. When the cyclopropane was added to 
a refluxing solution of the Lewis acid in dichloromethane, disappointingly cyclopropane 
ring-opening was still disfavored (Figure 3.3 entry 3). Next, the substrate was treated 
with 30 mol % In(OTf)3 in 1,2-dichloroethane at room temperature and  gradually heated 
to reflux (Figure 3.3, entry 4). However, this condition also proved unsuccessful to 
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furnish any cyclized product even after long reaction times (>24 h). Later when the 
reaction was repeated by combining the Lewis acid and 1,2-DCE at room temperature 
and then heating to reflux for 5 min. The cyclopropane substrate was then added rapidly 
in one portion. The reaction progress was monitored by TLC. Gratifyingly, a complete 
disappearance of the starting material after 6 h was observed, providing product in 85 % 
yield (Figure 3.3, entry 5). The results of the screening reactions indicated that the Lewis 
acid and cyclopropane could not be mixed together at room temperature and then heated 
to reflux. The reason for the reaction outcome on the temperature dependent order of 






Having determined that addition of cyclopropane to a refluxing solution of the 
Lewis acid in DCE improved the yield, substrate III-45j (derived from methylene 
cyclopentane) and III-45k (derived from methylene cyclohexane) was subjected to this 
modified protocol to afford their respective hydropyrido[1,2-a]indole products III-45j, 
and III-45k in 88% and 79% yield (Table 3.2, entries 3 and 4). These results are 
particularly notable for several reasons: (1) spirocyclic compounds (as in III-45j and III-
45k) can be readily accessed from an appropriate 1,1-disubstituted alkene; (2) the 
successful use of alkyl groups as donors were limited to Tsuge’s seminal report;
38
 and (3) 
a number of hydropyrido[1,2-a]indole natural products have gem-dialkyl substituents at 
C(9). 
Inspired by Yadav and co-workers recent work on the development of formal 
homo-Nazarov cyclization of heteroaryl 2-silylmethyl-substituted cyclopropanes to 
generate 2,3-heteroaromatic ring-fused cyclohexanones,
39
 scope of the reaction was 
further extended to the activated alkyl donor substituents, such as the 2-
trialkylsilymethyl. In one representative example, the 2-t-butyldiphenylsilylmethyl 
cyclopropane III-45l was synthesized.  It was hypothesized that the high level of 
diastereoselectivity could be achieved in the reactions due to the large size of the 
substituents on the silicon. When III-45l was subjected to previously optimized reaction 
condition, to our surprise, no product formation was observed. However, upon reacting 
under modified conditions, the product III-46l was formed in 82% yield, with only one 
observable diastereomer (Table 3.2, entry 5). This silyl group not only stabilizes the 
carbocation during the transition state through the β-silyl effect, but more importantly, 
acts as a point of further functionalization. 
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Next, the influence of a heteroatom-donating group on the cyclopropane was 
investigated. In particular, oxygen, sulfur and nitrogen groups were employed due to their 
established success in donor–acceptor cyclopropane chemistry.
21a,39
 When a phthalimide 
group was the substituent, the desired cyclized product III-46m was obtained in 55% 
yield and 4.8:1 dr (Table 3.4, entry 1). This result is interesting since phthalimide group 
acts as a masked amine and thus provides handle for further functionalization. 
Heterocyclic aryl thioether structural motifs play important roles in biological and 
pharmaceutical areas.
40
 Therefore, phenyl thioether III-45n was synthesized and 
subjected to modified cyclization condition to provide its cyclization product III-46n in 
81% yield with 6.3:1 dr (Table 3.4, entry 2). The resulting thioether can be oxidized into 
a sulfoxide, which provides a point for further functionalization. Tetrahydrofuran, 
tetrahydropyran, and piperidinyl motifs are commonly found in an array of biologically 
active natural products. For this reason, we decided to examine cyclopropanes III-45o, 
III-45p, and III-45q derived from dihydrofuran, dihydropyran, and Cbz-protected 3,4-
dihydropyridine, respectively. Cyclopropanes III-45o and III-45p readily cyclized to 
give products III-46o, and III-46p in 97 and 93% yield, respectively (Table 3.4, entry 3 
and 4). In both cases, the major diastereomer had the all-cis configuration, as determined 
by NMR spectroscopy. Likewise, the Cbz-protected ring-fused piperidinyl cyclopropane 
III-45q afforded III-46q in 97% with a 7.1:1 dr (Table 3.4, entry 5). These experiments 
indicated that heteroatom-donating groups had a significant effect on the ability of 
cyclopropanes to undergo ring-opening, and provided the corresponding 
hydropyrido[1,2-a]indoles in high yields. This conclusion is in agreement with the 








To further demonstrate the modular nature of our protocol, the indole moiety was 
changed from 3-methyl indole (Table 3.5). To probe whether a substituent in the 3-
position is not required for cyclization, cyclopropane III-45r (derived from indole) was 
tested in the reaction. Cyclization of substrate III-45r readily occurred to give III-46r in 





Next, the 3-(2-bromoethyl)-1H-indole derived cyclopropane III-45s provided its 
cyclization product III-46s in near quantitative yield with 2.7:1 dr (Table 3.5, entry 2). 
The bromide remains intact throughout the cyclization and, thus, is available for further 
functionalization. Similarly, when the phthalimide-protected tryptamine derivative III-
45t was subjected to the reaction conditions, hydropyrido[1,2-a]indole product III-46t 
was generated in 76% yield with 2.8:1 dr (Table 3.5, entry 3). This result is notable since 
the resulting product III-46t can be readily deprotected under standard conditions to 
provide the free amine. Lastly, the methyl acetate substituted indole derivative III-45u 
provided the cyclized product III-46u in 88% yield with 2.0:1 dr (Table 3.5, entry 4).  
An interesting result was obtained when a geminally halo-alkyl disubstituted 
cyclopropane was examined. In one representative example, cyclopropane III-45v (from 
α-bromostyrene) was subjected to the reaction conditions, and pyrido[1,2-a]indole III-47 
was observed in 29% yield (Figure 3.13). This product seemingly arises from the rapid 
elimination of HBr from the cyclized intermediate A to generate the new aromatic ring. 








In conclusion, an efficient method for the facile generation of hydropyrido[1,2-
a]indole based derivatives has been developed. An In(OTf)3-catalyzes cyclopropane ring-
opening/Friedel-Crafts alkylation sequence to provide these 1,2-annulated products in 
good to excellent yields (48-99%) in four steps from readily-available indoles and 
alkenes. The methodology is highly modular, operationally simple and amenable to a 
large variety of functional groups and substitution patterns. The new strategy for 
generation of hydropyrido[1,2-a]indole derivative should pave the way towards the 


















3.5.1. General Methods 
All reactions were carried out in pre-dried glassware from the oven where 
additional moisture was removed by flame-drying the reaction vessel.  Each reaction 
proceeded under a nitrogen atmosphere, and dry solvents were used, unless stated 
otherwise. Tetrahydrofuran and diethyl ether were distilled from a sodium/benzophenone 
ketyl under nitrogen and stored in a Schlenk flask. 1,2-Dichloroethane and 
dichloromethane were purified by distillation from calcium hydride under N2 prior to use. 
Acetonitrile was dried by fractional distillation over CaH2. Benzene was purified by 
drying with CaH2. All other reagents were purchased from Acros, Sigma-Aldrich, Fluka, 
VWR, Merck, Alfa Aesar, TCI and Strem (for metal catalysts) and used without further 
purification.  
Chromatographic purification was performed as flash chromatography with 
Silicycle silica gel (40-63 µm) and solvents indicated as eluent with 0.1-0.5 bar pressure. 
For quantitative flash chromatography, technical grade solvents were utilized. Analytical 
thin-layer chromatography (TLC) was performed on EMD silica gel 60 F254 TLC glass 
plates. Visualization was accomplished with UV light, aqueous basic potassium 
permanganate (KMnO4) solution, iodine, aqueous acidic dinitrophenylhydrazine (DNP) 
solution, aqueous acidic p-anisaldehyde (PAA) solution, and ethanol solution of 
phosphomolybdic acid (PMA) followed by heating.  Each yield refers to isolated 
analytically pure material.  
Infrared (IR) spectra were obtained using a Nicolet 4700 FTIR with an ATR 
attachment from SmartOrbit Thermoelectronic Corp. The IR bands are characterized as 
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broad (br), weak (w), medium (m), and strong (s). Proton and carbon nuclear magnetic 
resonance spectra (
1
H NMR and 
13
C NMR) were recorded on a Varian Mercury Vx 300 
spectrometer or a Varian Mercury Vx 400 spectrometer with solvent resonances as the 
internal standard (
1
H NMR: CDCl3 at 7.26 ppm; 
13
C NMR: CDCl3 at 77.0 ppm). 
1
H 
NMR data are reported as follows: chemical shift (ppm), multiplicity (s = singlet, d = 
doublet, dd = doublet of doublets, dt = doublet of triplets, ddd = doublet of doublet of 
doublets, t = triplet, m = multiplet), coupling constants (Hz), and integration. Mass 
spectra were obtained using a VG-70SE instrument. Diastereomeric ratios for cyclized 
products III-46 were determined by 
1
H NMR based on comparing the integral ratios of 
the benzylic protons (~4.0-5.0 ppm) for the two diastereomeric protons.  The first signal 
represents the trans isomer and the second signal represents the cis isomer.  This 
assignment is based on the coupling constants assigned from 
1
H NMR in conjunction 
with decoupling experiments to assign all the coupled proton signals. 
 
3.5.2. Experimental Procedures 
3.5.2.1. N-Acylation of Indole Compounds 
 Sodium hydride (1.1 equiv.) was suspended in THF (20 mL) and cooled to 0 
°
C.  
In a separate flask, the desired indole (1.0 equiv.) was dissolved in 30 mL of THF and 
syringed into the reaction vessel. After 30 min, methyl-3-chloro-3-oxopropanoate (1.1 
equiv.) was slowly added. The reaction was stirred for 14 h at room temperature. The 
reaction mixture was quenched with water. The organic layer was separated, and the 
aqueous layer was extracted three times with EtOAc.  The combined organic layers were 
washed with brine, dried with anhydrous sodium sulfate, filtered, and concentrated under 
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reduced pressure.  The residue was purified by silica gel flash chromatography for 
product isolation.  
 
Methyl 3-(3-methyl-1H-indol-1-yl)-3-oxopropanoate (III-43a): The general procedure 
was followed using sodium hydride (1.90 g, 47.7 mmol), 3-methyl-1H-indole (5.00 g, 
38.1 mmol), methyl-3-chloro-3-oxopropanoate (4.9 mL, 45.7 mmol), and THF (50 mL). 
After 14 h, the reaction was quenched, and column chromatography (20% EtOAc/Hex, Rf 
0.26 and Rf 0.15 for keto and enol tautomers) afforded III-43a as a light brown solid 
(6.44 g, 73%). [m.p. 49-5 °C] 
1
H NMR (300 MHz, CDCl3) δ 8.43 (d, J = 7.1 Hz, 1H), 
7.52 – 7.47 (m, 1H), 7.41 – 7.28 (m, 2H), 7.10 (s, 1H), 3.92 (s, 2H), 3.79 (s, 3H), 2.27 (s, 
J = 1.3 Hz, 3H). 
13
C NMR (75 MHz, CDCl3) δ 166.8, 163.4, 136.0, 131.5, 125.5, 124.0, 
121.4, 119.7, 118.9, 116.7, 52.9, 43.6, 9.7. IR: 3051.9 (w), 2937.6 (w), 1747.0 (s), 1685.1 
(s), 1604.1 (w), 1447.0 (s), 1375.5 (s), 1232.6 (m), 1070.7 (m), 913.5 (m), 732.6 (s) cm
-1
. 




 A mixture 
of potassium carbonate (0.100 g, 0.724 mmol) and 3-(2-bromoethyl)-1H-indole (0.250 g, 
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1.1 mmol), methyl-3-chloro-3-oxopropanoate (0.21 mL, 1.95 mmol) and acetonitrile (13 
mL) were heated to reflux. After 16 h, the reaction mixture was cooled, filtered and dried 
in vacuo.  The residue was dissolved in EtOAc/Hex (1:2.5). The organic layer was 
separated, and the aqueous layer was extracted three times with EtOAc. The combined 
organic layers were dried with anhydrous sodium sulfate, filtered, and concentrated. 
Column chromatography (20% EtOAc/Hex, Rf 0.35) afforded III-43b as a yellow-brown 
solid (0.290 g, 81%). [m.p. 68-70 °C] 
1
H NMR (300 MHz, CDCl3) δ 8.41 (d, J = 7.8 Hz, 
1H), 7.47 (d, J = 7.6 Hz, 1H), 7.40 – 7.24 (m, 2H), 7.22 (s, 1H), 3.92 (s, 2H), 3.76 (s, 
3H), 3.61 (t, J = 7.2 Hz, 2H), 3.22 (t, J = 7.2 Hz, 2H). 
13
C NMR (75 MHz, CDCl3) δ 
166.5, 163.5, 135.7, 129.8, 125.6, 123.9, 122.1, 120.4, 118.4, 116.7, 52.7, 43.3, 31.1, 
28.5. IR: 3091.7 (w), 2940.7 (w), 2878.8 (w), 1760.1 (s), 1657.8 (s), 1615.6 (s), 1535.5 
(s), 1440.9 (s), 1239.4 (s), 1191.4 (s), 1040.8 (m), 820.8 (m), 777.4 (m) cm
-1
. HRMS 
(ESI) M/Z+ Calc. 323.0157, Obs. 323.0162. 
 
Methyl 3-(3-(2-(1,3-dioxoisoindolin-2-yl)ethyl)-1H-indol-1-yl)-3-oxopropanoate 
(III-43c): The general procedure was followed using sodium hydride (0.459 g, 11.5 
mmol), 2-(2-(1H-indol-3-yl)ethyl)isoindoline-1,3-dione
42
 (3.01 g, 10.4 mmol), 
methyl-3-chloro-3-oxopropanoate (1.4 mL, 13.0 mmol), and THF (90 mL). After 16 
h, the reaction was quenched, and column chromatography (30% EtOAc/Hex, Rf 





(300 MHz, CDCl3) δ 8.41 (d, J = 7.7 Hz, 1H), 7.88 – 7.77 (m, 2H), 7.75 – 7.67 (m, 
2H), 7.64 (d, J = 7.7 Hz, 1H), 7.40 – 7.27 (m, 3H), 4.04 (t, J = 7.2 Hz, 2H), 3.96 (s, 
2H), 3.78 (s, 3H), 3.10 (t, J = 7.4 Hz, 2H). 
13
C NMR (75 MHz, CDCl3) δ 171.0, 
168.3, 167.2, 166.7, 163.7, 136.0, 134.1, 131.9, 130.4, 125.7, 124.2, 123.3, 121.9, 
120.0, 118.9, 116.8, 52.9, 52.8, 43.4, 40.5, 37.2, 24.1. IR: 2937.6 (w), 1742.2 (s), 
1703.2 (s), 1691.8 (s), 1599.3 (w), 1456.5 (m), 1383.6 (m), 1329.9 (m), 1210.0 (m), 
1153.5 (s), 1008.8 (m), 923.1 (w), 719.7 (s) cm
-1
. HRMS (ESI) M/Z+ Calc. 
390.1216, Obs. 390.1213. 
 
Methyl 3-(3-(2-methoxy-2-oxoethyl)-1H-indol-1-yl)-3-oxopropanoate (III-43d): 
The general procedure was followed using sodium hydride (0.702 g, 17.6 mmol), 
methyl 2-(1H-indol-3-yl)acetate (3.00 g, 15.9 mmol), methyl-3-chloro-3-
oxopropanoate (2.0 mL, 18.6 mmol), and THF (60 mL). After 16 h, the reaction was 
quenched, and column chromatography (30% EtOAc/Hex, Rf 0.24) afforded III-43d 
as a dark brown oil (3.55 g, 77%). 
1
H NMR (300 MHz, CDCl3) δ 8.43 (d, J = 8.0 
Hz, 1H), 7.57 – 7.49 (m, 1H), 7.43 – 7.27 (m, 3H), 3.96 (s, 2H), 3.79 (s, 3H), 3.73 (s, 
2H), 3.72 (s, 3H). 
13
C NMR (75 MHz, CDCl3) δ 171.0, 166.6, 163.6, 135.8, 130.1, 
125.8, 124.2, 123.1, 118.9, 116.8, 116.0, 52.8, 52.2, 43.4, 30.6. IR: 3009.3 (w), 
2952.1 (w), 1737.4 (s), 1703.2 (s), 1595.1 (m), 1366.0 (s), 1265.7 (m), 1204.7 (s), 
1148.4 (s), 1015.7 (m), 909.4 (m), 728.3 (s) cm
-1
. HRMS (ESI) M/Z+ Calc. 




Methyl 3-(1H-indol-1-yl)-3-oxopropanoate (III-43e): Following a modification of 
Kerr’s reported procedure,
24a
 indoline (4.0 g, 33.56 mmol) was dissolved in THF (70 mL) 
in a round bottom flask equipped with a magnetic stir bar. K2CO3 (9.28 g, 67.14 mmol) 
was added and the mixture was cooled to 0
o
C. Methyl malonyl chloride (3.977mL, 37.09 
mmol) was added drop-wise with rapid stirring. Formation of white precipitate was 
immediately observed. After 30 min, the reaction mixture was filtered, and the solvent 
was removed under reduced pressure to yield the indoline β-amide ester, which was used 
without purification.  
In a dry round bottom flask equipped with a reflux condenser, the resulting β-
amide ester (4.26 g, 19.43 mmol) was dissolved in dry toluene (55 mL), and DDQ (5.28 
g, 23.26 mmol) was added. The reaction mixture was heated to a reflux for 12 hours. The 
reaction was cooled to room temperature, diluted with EtOAc, washed with water and 
brine and dried over anhydrous MgSO4. The solvent was removed in vacuo and 
purification of the crude reaction mixture by flash column chromatography (15% 
EtOAc/Hex, Rf 0.35) yielded III-43e as a yellow-brown oil (2.72 g, 37.3% over the two 
steps). 
1
H NMR (300 MHz, CDCl3) δ 8.44 (d, J = 8.1 Hz, 1H), 7.56 – 7.51 (m, 1H), 7.38 
– 7.23 (m, 3H), 6.61 (dd, J = 3.8, 0.8 Hz, 1H), 3.91 (s, 2H), 3.74 (s, 3H). 
13
C NMR (75 
MHz, CDCl3) δ 166.5, 163.8, 135.4, 130.2, 125.1, 124.5, 123.9, 120.7, 116.3, 109.8, 
52.6, 43.1. IR: 3109.7 (w), 3152.9 (w), 3036.6 (w), 2953.6 (w), 2850.7 (w), 1737.9 (m), 
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1703.1 (s), 1691.8 (m), 1529.04 (w), 1472.2 (w), 1450.6 (m), 1383.1 (m), 1346.9 (s), 
1261.2 (m), 1204.9 (s), 1150.2 (s), 1015.7 (m), 925.7 (m), 747.3 (s), 715.2 (m), 689.3 (m) 
cm
-1
. HRMS (ESI) M/Z+ Calc. 217.0739, Obs. 217.0738.  
 
3.5.2.2. Formation of the Diazo Compounds 
 The β-amide ester (1.0 equiv.) was dissolved in acetonitrile. Triethylamine (1.2 
equiv.) was added to the reaction mixture and stirred for 10 min. Tosyl azide (1.2 equiv.) 
was placed in the reaction flask. The mixture was stirred at room temperature for 12 h 
and concentrated under reduced pressure. The resulting residue was purified by silica gel 
flash chromatography to afford the diazo compound III-44.  
 
Methyl 2-diazo-3-(3-methyl-1H-indol-1-yl)-3-oxopropanoate (III-44a): The general 
procedure was followed using methyl 3-(3-methyl-1H-indol-1-yl)-3-oxopropanoate (2.71 
g, 11.7 mmol), triethylamine (2.0 mL, 14.4 mmol), tosyl azide (2.81 g. 14.2 mmol), and 
acetonitrile (30 mL). After 12 h, the reaction mixture was concentrated, and column 
chromatography (20% EtOAc/Hex, Rf 0.41) afforded III-44a as a yellow solid (2.79 g, 
93%). [m.p. 74-76 °C] 
1
H NMR (300 MHz, CDCl3) δ 8.17 (d, J = 8.6 Hz, 1H), 7.51 – 
7.47 (m, 1H), 7.39 – 7.26 (m, 2H), 7.11 (s, 1H), 3.85 (s, 3H), 2.28 (s, 3H). 
13
C NMR (75 
MHz, CDCl3) δ 161.5, 158.9, 136.0, 131.7, 124.8, 123.7, 123.3, 118.9, 117.7, 115.7, 
69.7, 52.6, 9.7. IR: 3047.1 (w), 2956.6 (w), 2918.5 (w), 2132.7 (s), 1708.9 (s), 1651.7 (s), 
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1601.0 (m), 1466.0 (s), 1349.6 (s), 1302.9 (s), 1254.3(s), 1127.9(s), 1046.9 (s), 865.9 (m), 
732.7 (s) cm
-1
. HRMS (ESI) M/Z+ Calc. 257.0800, Obs. 257.0805.  
 
Methyl 3-(3-(2-bromoethyl)-1H-indol-1-yl)-2-diazo-3-oxopropanoate (III-43b): The 
general procedure was followed using methyl 3-(3-(2-bromoethyl)-1H-indol-1-yl)-3-
oxopropanoate (0.110 g, 0.339 mmol), triethylamine (0.0412 g, 0.407 mmol), tosyl azide 
(0.080 g, 0.407 mmol), and acetonitrile (10 mL). After 16 h, the reaction mixture was 
concentrated, and column chromatography (20% EtOAc/Hex, Rf 0.50) afforded III-43b 
as a yellow oil (0.104 g, 88%). 
1
H NMR (300 MHz, CDCl3) δ 8.15 (d, J = 8.0 Hz, 1H), 
7.47 (d, J = 7.6 Hz, 1H), 7.36 – 7.23 (m, 2H), 7.22 (s, 1H), 3.81 (s, 3H), 3.61 (t, J = 7.3 
Hz, 2H), 3.23 (t, J = 7.2 Hz, 2H). 
13
C NMR (75 MHz, CDCl3) δ 161.2, 159.1, 136.0, 
130.1, 125.0, 124.2, 123.8, 118.7, 118.5, 115.8, 70.1, 52.7, 31.2, 28.7. IR: 3018.6 (w), 
2947.1, (w), 2142.0 (s), 1732.7 (s), 1656.5 (s), 1604.1 (w), 1451.7 (s), 1380.4 (s), 1306.8 
(s), 1251.7 (m), 1056.4 (m), 861.2 (w), 734.3 (s), 708.8 (m) cm
-1
. HRMS (ESI) M/Z+ 





propanoate (III-43c): The general procedure was followed using methyl 3-(3-(2-(1,3-
dioxoisoindolin-2-yl)ethyl)-1H-indol-1-yl)-3-oxopropanoate (1.48 g, 3.78 mmol), 
triethylamine (700 μL, 5.02 mmol), tosyl azide (0.896 g, 4.54 mmol), and acetonitrile (20 
mL). After 18 h, the reaction mixture was concentrated, and column chromatography 
(40% EtOAc/Hex, Rf 0.44) afforded III-43c as a yellow-brown solid (1.49 g, 95%). [m.p. 
98-100 °C] 
1
H NMR (300 MHz, CDCl3) δ 8.18 – 8.13 (m, 1H), 7.86 – 7.80 (m, 2H), 7.74 
– 7.64 (m, 3H), 7.37 – 7.27 (m, 2H), 7.23 (s, 1H), 4.00 (t, J = 6.0 Hz, 2H), 3.81 (s, 3H), 
3.10 (t, J = 6.0 Hz, 2H). 
13
C NMR (75 MHz, CDCl3) (Rotamers!!!) δ 168.2, 161.2, 159.2, 
136.1, 133.9, 133.8, 132.1, 130.5, 125.0, 124.1, 123.9, 123.2, 123.1, 122.1, 122.0, 119.4, 
119.0, 118.8, 118.0, 115.8, 112.4, 111.1, 69.8, 52.7, 38.5, 37.4, 24.4, 24.2. IR: 3032.8 (s), 
2942.4 (w), 2137.5 (s), 1708.4 (s), 1642.2 (m), 1604.1 (w), 1451.7 (w), 1379.6 (s), 
1306.8 (s), 1256.4 (m), 1170.7 (m), 1095.3 (m), 1004.0 (w), 861.2 (m), 732.4 (s) cm
-1
. 
HRMS (ESI) M/Z+ Calc. 416.1121, Obs. 416.1105.   
 
Methyl 2-diazo-3-(3-(2-methoxy-2-oxoethyl)-1H-indol-1-yl)-3-oxopropanoate (III-
43d): The general procedure was followed using methyl 3-(3-(2-methoxy-2-oxoethyl)-
1H-indol-1-yl)-3-oxopropanoate (1.49 g, 5.16 mmol), triethylamine (880 μL, 6.31 mmol), 
tosyl azide (1.22 g, 6.19 mmol), and acetonitrile (20 mL).  After 18 h, the reaction 
mixture was concentrated, and column chromatography (40% EtOAc/Hex, Rf 0.43) 
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afforded III-43d as a brown solid (1.36 g, 83%). [m.p. 77-79 °C] 
1
H NMR (300 MHz, 
CDCl3) δ 8.17 (d, J = 7.8 Hz, 1H), 7.52 (d, J = 7.7 Hz, 1H), 7.41 – 7.26 (m, 3H), 3.84 (s, 
3H), 3.73 (s, 2H), 3.72 (s, 3H). 
13
C NMR (75 MHz, CDCl3) δ 171.1, 161.3, 159.2, 135.9, 
130.3, 125.2, 125.1, 123.9, 118.9, 115.8, 114.1, 70.1, 52.7, 52.1, 30.7. IR: 2999.5 (w), 
2961.4 (w), 2137.5 (s), 1721.8 (s), 1637.44 (s), 1599.3 (w), 1446.9 (s), 1364.2 (s), 1305.1 
(s), 1253.8 (s), 1139.6 (s), 1051.6 (w), 870.7 (m), 747.9 (s) cm
-1
. HRMS (ESI) M/Z+ 
Calc. 315.0855, Obs. 315.0860.   
Methyl 2-diazo-3-(1H-indol-1-yl)-3-oxopropanoate (III-43e): The general procedure 
was followed using methyl 3-(1H-indol-1-yl)-3-oxopropanoate (1.42 g, 6.54 mmol), 
triethylamine (1.82 mL, 13.07 mmol), tosyl azide (1.547 g, 7.845 mmol), and acetonitrile 
(30 mL).  After 12 h, the reaction mixture was concentrated, and column chromatography 
(10% EtOAc/Hex, Rf 0.35) afforded III-43e as a yellow oil (1.49 g, 93.7%). 
1
H NMR 
(300 MHz, CDCl3) δ 8.22 – 8.16 (m, 1H), 7.59 – 7.53 (m, 1H), 7.40 – 7.23 (m, 3H), 6.61 
(dd, J = 3.8, 0.7 Hz, 1H), 3.83 (s, 3H). 
13
C NMR (75 MHz, CDCl3) δ 161.3, 159.5, 135.7, 
130.6, 127.4, 126.7, 124.7, 123.8, 120.9, 115.5, 108.2, 52.7. IR: 3162.8 (w), 3053.2 (w), 
2953.6 (w), 2140.3 (s), 1710.8 (s), 1721.3 (s), 1657.8 (s), 1649.7 (s), 1529.0 (w), 1451.1 
(s), 1380.5 (s), 1342.4 (s), 1298.4 (s), 1244.9 (m), 1139.5 (m), 1121.6 (m), 1090.6 (m), 
1067.0 (m), 945.5 (w), 883.1 (m), 859.7 (m), 746.5 (s), 640.3 (w) cm
-1
. HRMS (ESI) 




3.5.2.3. Synthesis of the Cyclopropanes 
The cyclopropanes were prepared using a modified version of Gonzalez-Bobes’ 
protocol:
34
 A round bottom flask was charged with Rh2esp2 (0.1 mol%) and a magnetic stir 
bar. DCM (2.0 mL) was added to the flask. The reaction vessel was cooled to 0
°
C, and the 
corresponding alkene (1.0 equiv.) was added. After 10 min, the diazo reagent (1.3 equiv.) 
was dissolved in DCM (5 mL) and syringed into the reaction mixture. After 10 min, the ice 
bath was removed and the reaction proceeded at room temperature. Upon completion 
(monitored by TLC) or 12 h of reactivity, the reaction was quenched with saturated 
thiourea and stirred for 30 min. The organic layer was separated, and the aqueous layer 
extracted three times with DCM. The combined organic layers were washed with brine, 
dried with anhydrous sodium sulfate, filtered, concentrated under reduced pressure. The 
residue was purified by silica gel flash chromatography.  
 
Methyl 2-(4-methoxyphenyl)-1-(3-methyl-1H-indole-1-carbonyl) cyclopropane 
carboxylate (III-45a): The general procedure was followed using 4-methoxystyrene 
(0.201 g, 1.49 mmol), methyl 2-diazo-3-(3-methyl-1H-indol-1-yl)-3-oxopropanoate
 
(0.500 g, 1.94 mmol), Rh2esp2 (1.5 mg, 1.98 μmol) and DCM (8 mL). After 12 h, the 
reaction was quenched, and column chromatography (20% EtOAc/Hex, Rf 0.52) afforded 
III-45a as a pale yellow solid (0.328 g, 60%). [m.p. 110-112 °C] 
1
H NMR (300 MHz, 
CDCl3) δ 8.45 (d, J = 8.0 Hz, 1H), 7.61 - 7.45 (m, 1H), 7.44 – 7.26 (m, 5H), 6.90 – 6.83 
(m, 2H), 3.81 (s, 3H), 3.41 (t, J = 4Hz, 1H), 3.41 (s, 3H), 2.40 (dd, J = 8.3, 5.2 Hz, 1H), 
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2.28 (s, 3H), 1.82 (dd, J = 9.3, 5.2 Hz, 1H). 
13
C NMR (75 MHz, CDCl3) δ 168.0, 165.8, 
158.9, 136.0, 131.5, 130.2, 126.1, 125.4, 123.8, 121.5, 119.2, 118.9, 116.5, 113.6, 55.2, 
52.8, 39.5, 31.1, 18.8, 9.8. IR: 3050.0 (w), 2914.3 (m), 1742.9 (m), 1681.0 (s), 1600.0 
(m), 1514.29 (m), 1450.0 (s), 1346.3 (s), 1246.8 (s), 1176.5 (s), 1028.6 (s), 838.1 (s), 
748.2 (s) cm
-1
. HRMS (ESI) M/Z+ Calc. 363.1471, Obs. 363.1471.  
 
Methyl 2-(2-methoxyphenyl)-1-(3-methyl-1H-indole-1-carbonyl)cyclopropane 
carboxylate (III-45b): The general procdure was followed using 1-methoxy-2-
vinylbenzene (0.095 g, 0.709 mmol), methyl 2-diazo-3-(3-methyl-1H-indol-1-yl)-3-
oxopropanoate
 
(0.210 g, 0.816 mmol), Rh2esp2 (1.0 mg, 1.31 μmol), and DCM (10 mL). 
After 12 h, the reaction was quenched, and column chromatography (20% EtOAc/Hex, Rf 
0.35) afforded III-45b as a pale yellow solid (0.196 g, 76%). [m.p. 106-108 °C] 
1
H 
NMR (300 MHz, CDCl3) δ 8.54 (d, J = 7.9 Hz, 1H), 7.57 – 7.27 (m, 6H), 7.04 – 6.95 (m, 
1H), 6.91 (d, J = 8.2 Hz, 1H), 3.88 (s, 3H), 3.45 (s, 3H), 3.45 (t, 1H), 2.35 (dd, J = 7.9, 
4.5 Hz, 1H), 2.32 (d, J = 1.3 Hz, 3H), 1.97 (dd, J = 9.3, 5.0 Hz, 1H). 
13
C NMR (75 MHz, 
CDCl3) δ 168.4, 165.9, 158.5, 136.0, 131.4, 130.0, 129.7, 128.7, 127.7, 125.0, 123.5, 
122.8, 122.2, 120.0, 118.6, 118.1, 116.5, 109.9, 66.7, 55.2, 52.4, 38.0, 28.3, 21.5, 19.0, 
14.6, 9.7. IR: 3059.9 (w), 2983.6 (w), 1720.3 (s), 1658.0 (s), 1441.1 (s), 1338.7 (s), 
1233.7 (m), 712.5 (s), 674.4 (m) cm
-1






45c): The general procedure was followed using styrene (0.100 g, 0.960 mmol), methyl 
2-diazo-3-(3-methyl-1H-indol-1-yl)-3-oxopropanoate
 
(0.329 g, 1.28 mmol), Rh2esp2 (1.0 
mg, 1.32 μmol), and DCM (13 mL). After 12 h, the reaction was quenched, and column 
chromatography (20% EtOAc/Hex, Rf 0.60) afforded III-45c as a white solid (0.273 g, 
85%). [m.p. 130-132 °C] 
1
H NMR (300 MHz, CDCl3) δ 8.46 (d, J = 8.0 Hz, 1H), 7.55 – 
7.48 (m, 1H), 7.45 – 7.26 (m, 8H), 3.48 (t, J = 8.8 Hz, 1H), 3.40 (s, 3H), 2.46 (dd, J = 
8.3, 5.2 Hz, 1H), 2.29 (s, 3H), 1.84 (dd, J = 9.3, 5.2 Hz, 1H). 
13
C NMR (75 MHz, CDCl3) 
δ 167.9, 165.6, 136.0, 134.2, 131.5, 129.1, 128.2, 127.4, 125.4, 123.8, 121.4, 119.2, 
118.9, 116.5, 52.8, 39.5, 31.5, 18.5, 9.8. IR: 3037.6 (w), 2951.9 (w), 2918.5 (w), 1732.7 
(s), 1692.0 (s), 1446.9 (s), 1390.8 (s), 1348.3 (s), 1208.8 (m), 1051.6 (m), 742.1 (m), 
684.9 (m) cm
-1
.  HRMS (ESI) M/Z+ Calc. 333.1365, Obs. 333.1367. 
 
Methyl 2-(4-fluorophenyl)-1-(3-methyl-1H-indole-1-carbonyl)cyclopropane 
carboxylate (III-45d): The general procedure was followed using 4-fluorostyrene (0.146 
g, 1.19 mmol), methyl 2-diazo-3-(3-methyl-1H-indol-1-yl)-3-oxopropanoate
 
(0.356 g, 
1.38 mmol), Rh2esp2 (1.6 mg, 2.10 μmol), and DCM (8 mL). After 10 h, the reaction was 
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quenched, and column chromatography (20% EtOAc/Hex, Rf 0.64) afforded III-45d as a 
pale green solid (0.273 g, 65%). [m.p. 120-122 °C] 
1
H NMR (300 MHz, CDCl3) δ 8.45 
(d, J = 8.0 Hz, 1H), 7.52 (d, J = 8.3 Hz, 1H), 7.44 – 7.29 (m, 4H), 7.25 (s, 1H), 7.07 – 
6.98 (m, 2H), 3.46 (t, J = 8.5 Hz, 1H), 3.42 (s, 3H), 2.42 (dd, J = 8.2, 5.3 Hz, 1H), 2.29 
(s, 3H), 1.84 (dd, J = 9.3, 5.3 Hz, 1H). 
13
C NMR (75 MHz, CDCl3) δ 167.8, 165.4, 163.8, 
160.5, 136.0, 131.5, 130.7, 130.0, 125.4, 123.9, 121.3, 119.4, 118.9, 116.5, 115.3, 115.0, 
52.9, 39.5, 30.8, 18.7, 9.8. IR: 3010.0 (w), 2947.1 (w), 2904.3 (w), 1727.9 (m), 1685.1 
(s), 1518.4 (s), 1456.5 (s), 1399.3 (s), 1337.4 (s), 1215.2 (s), 1146.9 (s), 1051.7 (m), 
846.9 (m), 723.1 (s), 608.7 (m) cm
-1




carboxylate (III-45e): The general procedure was followed using 4-chlorostyrene (0.124 
g, 0.898 mmol), methyl 2-diazo-3-(3-methyl-1H-indol-1-yl)-3-oxopropanoate
 
(0.250 g, 
0.973 mmol), Rh2esp2 (1.5 mg, 1.71 μmol), and DCM (8 mL). After 12 h, the reaction 
was quenched, and column chromatography (20% EtOAc/Hex, Rf 0.64) afforded III-45e 
as a white solid (0.275 g, 83%). [m.p. 129-131 °C] 
1
H NMR (300 MHz, CDCl3) δ 8.46 
(d, J = 8.0 Hz, 1H), 7.55 – 7.50 (m, 1H), 7.45 – 7.29 (m, 6H), 7.26 (d, J = 1.3 Hz, 1H), 
3.44 (t, J = 6.8 Hz, 1H), 3.44 (s, 3H), 2.43 (dd, J = 8.3, 5.3 Hz, 1H), 2.30 (s, 3H), 1.86 
(dd, J = 9.3, 5.3 Hz, 1H). 
13
C NMR (75 MHz, CDCl3) δ 167.7, 165.3, 136.0, 133.3, 
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132.8, 131.5, 130.4, 128.3, 125.4, 123.9, 121.2, 119.4, 118.9, 116.5, 52.9, 39.5, 30.8, 
18.6, 9.7. IR: 3010.0 (w), 2951.9 (w), 2913.8 (w), 1727.9 (s), 1691.9 (s), 1485.0 (m), 
1451.0 (s), 1389.9 (s), 1347.9 (s), 1218.3 (m), 1156.4 (m), 1080.2 (m), 842.1 (m), 742.1 
(m) 708.7 (w) cm
-1
. HRMS (ESI) M/Z+ Calc. 367.0975, Obs. 367.0981. 
 
Methyl 1-(3-methyl-1H-indole-1-carbonyl)-2-(4-nitrophenyl)cyclopropane 
carboxylate (III-45f): The general procedure was followed using 4-nitrostyrene (0.252 
g, 1.69 mmol), methyl 2-diazo-3-(3-methyl-1H-indol-1-yl)-3-oxopropanoate
 
(0.505 g, 
1.97 mmol), Rh2esp2 (1.2 mg, 1.98 μmol), and DCM (8 mL). After 10 h, the reaction was 
quenched, and column chromatography (20% EtOAc/Hex, Rf 0.69) afforded III-45f as a 
yellow solid (0.325 g, 51%). [m.p. 163-165 °C] 
1
H NMR (300 MHz, CDCl3) δ 8.43 (d, J 
= 7.9 Hz, 1H), 8.24 – 8.17 (m, 2H), 7.58 – 7.50 (m, 3H), 7.45 – 7.30 (m, 2H), 7.21 (s, 
1H), 3.54 (t, J = 8.8 Hz, 1H), 3.43 (s, 3H), 2.51 (dd, J = 8.3, 5.4 Hz, 1H), 2.29 (s, 3H), 
1.94 (dd, J = 9.2, 5.4 Hz, 1H). 
13
C NMR (75 MHz, CDCl3) δ 167.5, 164.8, 147.3, 142.0, 
136.0, 131.5, 130.0, 125.6, 124.1, 123.4, 120.9, 119.8, 119.0, 116.5, 53.1, 40.0, 30.9, 
18.9, 9.8. IR: 3000.0 (w), 2913.8 (w), 2851.9 (w), 1727.9 (m), 1691.2 (s), 1599.3 (m), 
1508.9 (s), 1449.8 (s), 1390.3 (s), 1342.9 (s), 1216.9 (s), 1142.1 (m), 1046.9 (m), 856.4 
(m), 736.7 (s), 699.2 (m) cm
-1






(III-45g): The general procedure was followed using 2-vinylfuran (0.059 g, 0.627 
mmol), methyl 2-diazo-3-(3-methyl-1H-indol-1-yl)-3-oxopropanoate
 
(0.210 g, 0.816 
mmol), Rh2esp2 (1.0 mg, 1.31 μmol), and DCM (10 mL). After 12 h, the reaction was 
quenched, and column chromatography (15% EtOAc/Hex, Rf  0.35) afforded III-45g as a 
white solid (0.084 g, 41%). [m.p. 95-97 °C] 
1
H NMR (300 MHz, CDCl3) δ 8.45 (d, J = 
7.9 Hz, 1H), 7.56 – 7.50 (m, 1H), 7.44 – 7.30 (m, 4H), 6.41 – 6.35 (m, 1H), 6.32 – 6.28 
(m, 1H), 3.54 (s, 3H), 3.25 (t, J = 8.7 Hz, 1H), 2.34 (dd, J = 6.9, 4.2 Hz, 1H), 2.31 (d, J = 
1.3 Hz, 3H), 1.96 (dd, J = 9.5, 5.2 Hz, 1H). 
13
C NMR (75 MHz, CDCl3) 167.6, 164.9, 
149.1, 142.3, 136.0, 131.5, 125.3, 123.9, 121.7, 119.3, 118.8, 116.5, 110.5, 108.8, 52.9, 
38.2, 24.7, 18.7, 9.8. IR: 3086.97 (w), 2972.5 (w), 1726.4 (m), 1711.4 (m), 1441.3 (m), 
1382.7 (m), 759.9 (s), 663.0 (s) cm
-1




carboxylate (III-45h): The general procedure was followed using prop-1-en-2-ylbenzene 




(0.350 g, 1.360 mmol), Rh2esp2 (1.0 mg, 1.31 μmol), and DCM (10 mL). After 12 h, the 
reaction was quenched, and column chromatography (20% EtOAc/Hex, Rf  0.38) 
afforded III-45h as a colorless oil (0.225 g, 62%). 
1
H NMR (300 MHz, CDCl3) δ 8.61 
(d, J = 7.8 Hz, 0.90), 7.88 – 7.80 (m, 0.16), 7.63 – 7.55 (m, 1.05), 7.54 – 7.28 (m, 8.37), 
7.24 – 7.20 ( m, 0.51), 3.69 (s, 0.40), 3.46 (d, J = 0.8 Hz, 3), 2.67 (d, J = 5.5 Hz, 0.14), 
2.53 (d, J = 5.1 Hz, 1.33), 2.39 (s, 2.99), 2.26 (d, J = 1.3 Hz, 0.42), 1.96 (d, J = 6.6 Hz, 
0.55) 1.85 (d, J = 5.1 Hz, 1.03), 1.64 (s, 0.27), 1.55 (s, 2.91). 
13
C NMR (75 MHz, CDCl3) 
δ 168.4, 164.9, 140.6, 136.0, 131.5, 128.4, 128.0, 127.8, 127.2, 125.3, 123.8, 122.3, 
118.8, 118.7, 116.8, 52.6, 41.9, 38.4, 26.0, 25.7, 9.8. IR: 3080.6 (w), 2939.6 (w), 2896.9 
(w), 1724.3 (s), 1657.6 (s), 1421.8 (s), 1382.7 (s), 1267.7 (s), 789.5 (s), 664.3 (s) cm
-1
. 
HRMS (ESI) M/Z+ Calc. 347.1521, Obs. 347.1516.  
 
Methyl 2,2-diethyl-1-(3-methyl-1H-indole-1-carbonyl)cyclopropanecarboxylate (III-
45i): The general procedure was followed using 3-methylenepentane (0.062 g, 0.747 
mmol), methyl 2-diazo-3-(3-methyl-1H-indol-1-yl)-3-oxopropanoate
 
(0.250 g, 0.971 
mmol), Rh2esp2 (1.0 mg, 1.31 μmol), and DCM (10 mL). After 12 h, the reaction was 
quenched, and column chromatography (15% EtOAc/Hex, Rf 0.35) afforded III-45i as a 




H NMR (300 MHz, CDCl3) δ 8.40 (d, J = 
8.0 Hz, 1H), 7.45 – 7.39 (m, 1H), 7.33 – 7.21 (m, 3H), 3.58 (s, 3H), 2.21 (d, J = 1.3 Hz, 
3H), 1.97 – 1.73 (m, 3H), 1.62 (dd, J = 4.8, 1.2 Hz, 1H), 1.51 (d, J = 4.8 Hz, 1H), 0.99 (t, 
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J = 7.5 Hz, 3H), 0.91 – 0.71 (m, 4H). 
13
C NMR (75 MHz, CDCl3) δ 169.7, 165.7, 135.9, 
131.4, 125.0, 123.6, 122.7, 118.6, 118.0, 116.7, 52.6, 41.4, 40.1, 27.4, 26.2, 21.5, 10.7, 
10.6, 9.7. IR: 3059.7 (w), 2946.2 (m), 1714.5 (s), 1657.6 (s), 1414.8 (s), 1381.3 (s), 
1292.4 (s), 1081.2 (s), 728.5 (s), 663.3 (m) cm
-1
. HRMS (ESI) M/Z+ Calc. 313.1678, 
Obs. 313.1683.  
Methyl 1-(3-methyl-1H-indole-1-carbonyl)spiro[2.4]heptane-1-carboxylate (III-45j): 
The general procedure was followed using methylenecyclopentane (0.098 g, 1.20 mmol), 
methyl 2-diazo-3-(3-methyl-1H-indol-1-yl)-3-oxopropanoate
 
(0.400 g, 1.55 mmol), 
Rh2esp2 (1.0 mg, 1.31 μmol), and DCM (10 mL). After 4 h, the reaction was quenched, 
and column chromatography (15% EtOAc/Hex, Rf 0.35) afforded III-45j as a colorless 
oil (0.342 g, 92%). 
1
H NMR (300 MHz, CDCl3) δ 8.52 (s, 1H), 7.55 – 7.48 (m, 1H), 7.43 
– 7.27 (m, 2H), 7.10 (s, 1H), 3.65 (s, 3H), 2.31 (s, 3H), 2.24 – 1.98 (m, 2H), 1.90 – 1.62 
(m, 7H), 1.46 – 1.33 (m, 1H). 
13
C NMR (75 MHz, CDCl3) δ 170.1, 165.6, 135.7, 131.2, 
124.9, 123.4, 121.9, 118.5, 118.3, 116.3, 52.2, 40.0, 39.2, 34.4, 34.2, 33.6, 31.6, 31.3, 
29.0, 25.5, 25.5, 25.0, 22.4, 20.4, 13.9, 9.5. IR: 3040.0 (w), 2892.6 (w), 1765.3 (s), 
1711.65 (s), 1439.1 (s), 1359.7 (s), 715.5 (s), 662.9 (m) cm
-1
. HRMS (ESI) M/Z+ Calc. 




Methyl 1-(3-methyl-1H-indole-1-carbonyl)spiro[2.5]octane-1-carboxylate (III-45k): 
The general procedure was followed using methylenecyclohexane (0.068 g, 0. 709 
mmol), methyl 2-diazo-3-(3-methyl-1H-indol-1-yl)-3-oxopropanoate
 
(0.210 g, 0.816 
mmol), Rh2esp2 (1.0 mg, 1.31 μmol), and DCM (10 mL). After 6 h, the reaction was 
quenched, and column chromatography (15% EtOAc/Hex, Rf 0.40) afforded III-45k as a 




H NMR (300 MHz, CDCl3) δ 8.49 (d, J 
= 5.7 Hz, 1H), 7.60 – 7.48 (m, 1H), 7.44 – 7.27 (m, 2H), 7.14 (s, 1H), 3.65 (s, 3H), 2.32 
(d, J = 1.2 Hz, 3H), 2.18 (d, J = 12.5 Hz, 1H), 1.92 – 1.21 (m, 10H), 1.05 – 0.94 (m, 1H). 
13
C NMR (75 MHz, CDCl3) δ 169.5, 165.7, 135.8, 131.4, 125.0, 123.5, 122.5, 118.6, 
118.2, 116.5, 52.5, 41.1, 37.5, 33.9, 28.7, 26.4, 25.8, 25.6, 25.5, 9.7. IR: 2998.1 (w), 
2878.5 (w), 1720.8 (m), 1711.4 (m), 1439.8 (m), 1340.7 (m), 1138.1 (w), 759.5 (s), 674.3 
(s) cm
-1
. HRMS (ESI) M/Z+ Calc. 325.1678, Obs. 325.1681.  
 
Methyl 2-((tert-butyldiphenylsilyl)methyl)-1-(3-methyl-1H-indole-1-carbonyl) 
cyclopropanecarboxylate (III-45l): The general procedure was followed using 
allyl(tert-butyl)diphenylsilane (0.294 g, 1.05 mmol), methyl 2-diazo-3-(3-methyl-1H-
indol-1-yl)-3-oxopropanoate
 
(0.350 g, 1.36 mmol), Rh2esp2 (1.0 mg, 1.31 μmol), and 
DCM (8 mL). After 6 h, the reaction was quenched, and column chromatography (20% 




H NMR (300 MHz, CDCl3) δ 8.39 (d, J = 7.9 Hz, 1H), 7.76 – 7.64 (m, 4H), 7.57 – 7.23 
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(m, 9H), 7.17 (s, 1H), 3.69 (s, 3H), 2.28 (s, 3H), 1.74 – 1.66 (m, 1H), 1.57 – 1.40 (m, 
2H), 1.31 (dd, J = 8.5, 5.5 Hz, 2H), 1.13 (s, 9H). 
13
C NMR (75 MHz, CDCl3) δ 169.6, 
166.3, 136.0, 136.9, 135.8, 134.1, 133.8, 131.4, 129.3, 129.2, 127.7, 127.6, 125.1, 123.6, 
121.6, 118.7, 118.6, 116.4, 52.7, 37.3, 27.8, 25.7, 23.0, 18.1, 9.7, 8.0. IR: 3066.2 (w), 
2932.8 (m), 2842.4 (m), 1728.1 (s), 1692.7 (s), 1451.6 (s), 1389.5 (m), 1348.5 (s), 1213.1 
(m), 1153.3 (m), 1106.0 (m), 818.3 (w), 749.1 (m), 701.5 (s) cm
-1
. HRMS (ESI) M/Z+ 
Calc. 509.2386, Obs. 509.2388. 
Methyl 2-(1,3-dioxoisoindolin-2-yl)-1-(3-methyl-1H-indole-1-carbonyl)cyclopropane 
carboxylate (III-45m): The general procedure was followed using N-vinyl-phthalimide 
(0.155 g, 897 μmol), methyl 2-diazo-3-(3-methyl-1H-indol-1-yl)-3-oxopropanoate
 
(0.300 
g, 1.17 mmol), Rh2esp2 (1.1 mg, 1.45 μmol), and DCM (8 mL). After 12 h, the reaction 
was quenched, and column chromatography (20% EtOAc/Hex, Rf 0.20) afforded III-45m 
as a white solid (0.247 g, 68%). [m.p. 88-90 
o
C] Diastereomeric Ratio: (2.5:1). 
1
H NMR 
(300 MHz, CDCl3) 
1
H NMR (300 MHz, CDCl3) δ 8.43 (d, J = 7.4 Hz, 0.83), 8.22 (d, J = 
6.1 Hz, 0.27), 7.98 (s, 1.00), 7.83 (dt, J = 6.9, 3.5 Hz, 2.19), 7.76 – 7.66 (m, 2.80), 7.66 – 
7.58 (m, 1.00), 7.51 – 7.45 (m, 1.16), 7.42 – 7.18 (m, 3.88), 4.16 (dd, J = 9.2, 6.8 Hz, 
0.23), 3.71 (s, 1.11), 3.67 (dd, J = 8.0, 6.5 Hz, 1.18), 3.57 (s, 3.00), 3.47 (t, J = 6.5 Hz, 
0.63), 2.59 (t, J = 6.4 Hz, 1.00), 2.35 – 2.27 (m, 4.00), 2.23 (s, 1.45), 2.17 (dd, J = 9.2, 
6.2 Hz, 0.60). 
13
C NMR (75 MHz, CDCl3) δ 169.7, 168.2, 168.0, 167.8, 164.0, 136.0, 
134.3, 134.2, 134.2, 131.8, 131.4, 131.3, 125.3, 125.1, 124.0, 123.8, 123.6, 123.4, 122.5, 
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122.1, 119.0, 118.9, 118.8, 118.7, 116.5, 116.3, 53.4, 53.3, 48.8, 35.9, 33.9, 20.6, 17.4, 
9.8, 9.6. IR: 3056.7 (w), 2951.9 (w), 1770.8 (w), 1720.5 (s), 1680.3 (s), 1604.1 (w), 
1442.2 (m), 1389.3 (s), 1308.8 (s), 1223.1 (s), 1070.7 (m), 970.7 (w), 865.9 (w), 714.8 (s) 
cm
-1
. HRMS (ESI) M/Z+ Calc. 402.1216, Obs. 402.1213. 
Methyl 1-(3-methyl-1H-indole-1-carbonyl)-2-(phenylthio)cyclopropanecarboxylate 
(III-45n): The general procedure was followed using phenyl(vinyl)sulfane (0.311 g, 2.29 
mmol), methyl 2-diazo-3-(3-methyl-1H-indol-1-yl)-3-oxopropanoate
 
(0.722 g, 2.81 
mmol), Rh2esp2 (1.8 mg, 2.4 μmol), and DCM (13 mL). After 12 h, the reaction was 
quenched, and column chromatography (20% EtOAc/Hex, Rf 0.40) afforded III-45n as a 
colorless oil (0.125 g, 15%).
 1
H NMR (300 MHz, CDCl3) δ 8.44 (d, J = 7.9 Hz, 1H), 7.55 
– 7.47 (m, 3H), 7.43 – 7.28 (m, 4H), 7.23 – 7.16 (m, 2H), 3.56 (dd, J = 7.5, 5.6 Hz, 1H), 
3.52 (s, 3H), 2.25 (d, J = 1.3 Hz, 3H), 2.15 (dd, J = 7.3, 5.7 Hz, 1H), 1.92 (dd, J = 9.2, 5.7 
Hz, 1H). 
13
C NMR (75 MHz, CDCl3) δ 167.3, 164.6, 135.9, 135.4, 131.6, 129.0, 127.7, 
126.0, 125.7, 124.0, 121.1, 119.7, 119.0, 116.6, 53.1, 39.8, 28.2, 20.0, 9.7. IR: 3080.6 
(w), 2939.6 (w), 2896.9 (w), 1724.3 (s), 1657.6 (s), 1421.8 (s), 1382.7 (s), 1267.7 (s), 
789.5 (s), 664.3 (s) cm
-1






(III-45o): The general procedure was followed using 2,3-dihydrofuran (0.073 g, 1.05 
mmol), methyl 2-diazo-3-(3-methyl-1H-indol-1-yl)-3-oxopropanoate
 
(0.350 g, 1.36 
mmol), Rh2esp2 (1.0 mg, 1.31 μmol), and DCM (9 mL). After 10 h, the reaction was 
quenched and column chromatography (20% EtOAc/Hex, Rf 0.30) afforded III-45o as a 




H NMR (300 MHz, CDCl3) δ 7.72 – 7.63 
(m, 1H), 7.56 – 7.49 (m, 2H), 7.31 – 7.17 (m, 2H), 6.27 (d, J = 6.2 Hz, 1H), 4.19 – 4.10 
(m, 1H), 4.05 – 3.97 (m, 1H), 3.96 – 3.85 (m, 1H), 3.72 (s, 3H), 2.35 (s, 3H), 2.25 – 2.16 
(m, 2H). 
13
C NMR (75 MHz, CDCl3) δ 164.1, 156.4, 135.8, 130.3, 125.0, 123.2, 121.7, 
118.8, 115.2, 114.2, 108.3, 89.2, 67.1, 50.9, 47.3, 32.0, 9.5. IR: 2951.9 (w), 2880.5 (w), 
1740.9 (s), 1691.3 (s), 1599.3 (w), 1449.2 (s), 1348.9 (s), 1105.2 (s), 1064.3 (s), 995.6 
(s), 734.8 (s) cm
-1
. HRMS (ESI) M/Z+ Calc. 299.1158, Obs. 299.1155.  
Methyl 7-(3-methyl-1H-indole-1-carbonyl)-2-oxabicyclo[4.1.0]heptane-7-carboxylate 
(III-45p): The general procedure was followed using 2,3-dihydropyran (95 μL, 1.04 
mmol), methyl 2-diazo-3-(3-methyl-1H-indol-1-yl)-3-oxopropanoate
 
(0.350 g, 1.36 
mmol), Rh2esp2 (1.0 mg, 1.31 μmol), and DCM (8 mL). After 12 h, the reaction was 
quenched, and column chromatography (20% EtOAc/Hex, Rf 0.40) afforded III-45p as a 




H NMR (300 MHz, CDCl3) δ 8.45 (d, 
J = 8.1 Hz, 1H), 7.51 – 7.43 (m, 1H), 7.42 – 7.22 (m, 2H), 7.17 (s, 1H), 6.54 (s, 1H), 4.60 
(s, 1H), 4.00 – 3.87 (m, 2H), 3.77 (s, 3H), 2.39 – 2.27 (m, 1H), 2.26 (s, 3H), 2.14 – 2.02 
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(m, 1H), 1.97 – 1.77 (m, 2H). 
13
C NMR (75 MHz, CDCl3) δ 168.8, 165.6, 144.5, 136.0, 
131.2, 125.3, 123.8, 121.1, 119.2, 118.7, 116.7, 106.4, 80.7, 65.6, 56.0, 52.6, 21.8, 21.5, 
9.6. IR: 2942.4 (w), 2866.2 (w), 1756.5 (s), 1694.6 (s), 1651.7 (s), 1608.9 (w), 1451.7 
(s), 1385.0 (s), 1349.3 (s), 1140.7 (s), 1065.9 (s), 1018.3 (m), 937.4 (m), 745.4 9 (s) cm
-1
. 
HRMS (ESI) M/Z+ Calc. 313.1314, Obs. 313.1312. 
2-Benzyl 7-methyl 7-(3-methyl-1H-indole-1-carbonyl)-2-azabicyclo[4.1.0]heptane-
2,7-dicarboxylate (III-45q). The general procedure was followed using benzyl 3,4-
dihydropyridine-1(2H)-carboxylate (0.179 g, 0.897 mmol), methyl 2-diazo-3-(3-methyl-
1H-indol-1-yl)-3-oxopropanoate
 
(0.300 g, 1.17 mmol), Rh2esp2 (1.3 mg, 1.79 μmol), and 
DCM (9 mL). After 12 h, the reaction was quenched, and column chromatography (20% 
EtOAc/Hex, Rf 0.25) afforded III-45q as a colorless oil (0.295 g, 74%). 
1
H NMR (300 
MHz, CDCl3) δ 8.48 (d, J = 7.9 Hz, 1H), 7.49 (d, J = 7.5 Hz, 1H), 7.42 – 7.26 (m, 6H), 
7.13 (t, J = 32.4 Hz, 2H), 5.20 (s, 2H), 4.77 (d, J = 26.5 Hz, 1H), 3.76 (d, J = 11.9 Hz, 
3H), 3.71 – 3.44 (m, 2H), 2.27 (s, 3H), 2.51 – 2.02 (m, 2H), 1.96 – 1.74 (m, 2H). 
13
C 
NMR (75 MHz,CDCl3) δ 168.5, 165.4, 153.4, 152.6, 135.9, 135.8, 131.2, 128.4, 128.1, 
128.0, 126.2, 125.7, 125.4, 123.8, 121.1, 119.3, 118.7, 116.7, 111.5, 110.8, 67.6, 57.5, 
52.7, 41.9, 41.7, 23.5, 22.8, 21.1, 14.5, 9.6. IR: 2942.4 (w), 2880.5 (w), 1751.6 (w), 
1703.3 (s), 1691.6 (s), 1449.2 (m), 1406.5 (m), 1319.9 (m), 1260.5 (m), 1172.1 (m), 
747.1 (m) cm
-1




(III-45r): The general procedure was followed using 4-methoxystyrene (0.061 g, 0.459 
mmol) methyl 2-diazo-3-(5-methyl-1H-indol-1-yl)-3-oxopropanoate
 
(0.331 g, 2.466 
mmol), Rh2esp2 (1.87 mg, 2.4 μmol), and DCM (20 mL). After 12 h, the reaction was 
quenched, and column chromatography (20% EtOAc/Hex, Rf 0.30) afforded III-45r as a 
white solid (0.625 g, 72.8%). [m.p. 83-85 °C] 
1
H NMR (300 MHz, CDCl3) δ 8.44 (d, J = 
8.2 Hz, 1H), 7.56 – 7.46 (m, 2H), 7.39 – 7.19 (m, 4H), 6.86 – 6.80 (m, 2H), 6.63 – 6.60 
(m, 1H), 3.76 (s, 3H), 3.44 – 3.34 (m, 4H), 2.38 (dd, J = 8.3, 5.3 Hz, 1H), 1.82 (dd, J = 
9.7, 5.6, 0.7 Hz, 1H). 
13
C NMR (75 MHz, CDCl3) δ 167.8, 166.2, 158.9, 135.7, 130.4, 
130.1, 125.8, 125.2, 124.7, 124.0, 120.9, 116.4, 113.5, 109.7, 55.1, 52.7, 39.3, 31.2, 18.8. 
IR: 3109.7 (w), 3010.1 (w), 2947.0 (w), 2827.4 (w), 1741.56 (m), 1715.0 (s), 1685.1 (s), 
1615.4 (m), 1505.8 (m), 1450.0 (s), 1376.29 (m), 1333.4 (s), 1306.6 (s), 1246.1 (s), 
1160.6 (s), 1149.4 (s), 1123.91 (m), 1074.1 (m), 1030.9 (m), 951.2 (m), 841.7(m), 747.6 
(s), 629.1 (m) cm
-1
. HRMS (ESI) M/Z+ Calc. 349.1314, Obs. 349.1310.     
Methyl 1-(3-(2-bromoethyl)-1H-indole-1-carbonyl)-2-(4-methoxyphenyl) 
cyclopropanecarboxylate (III-45s): The general procedure was followed using 4-
methoxy styrene (0.073 g, 0.549 mmol), methyl 3-(3-(2-bromoethyl)-1H-indol-1-yl)-2-
diazo-3-oxopropanoate
 
(0.250 g, 0.713 mmol), Rh2esp2 (1.0 mg, 1.31 μmol), and DCM 
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(15 mL). After 12 h, the reaction was quenched, and column chromatography (20% 




H NMR (300 MHz, CDCl3) δ 8.43 (d, J = 8.1 Hz, 1H), 7.51 – 7.45 (m, 1H), 7.41 – 
7.19 (m, 5H), 6.86 – 6.79 (m, 2H), 3.76 (s, 3H), 3.61 (t, J = 7.0 Hz, 2H), 3.42 – 3.34 (m, 
4H), 3.23 (t, J = 7.3, 4.4 Hz, 2H), 2.38 (dd, J = 8.3, 5.3 Hz, 1H), 1.82 (dd, J = 9.4, 5.2 Hz, 
1H). 
13
C NMR (75 MHz, CDCl3) δ 167.8, 166.0, 158.9, 136.0, 130.1, 130.0, 126.0, 
125.6, 124.0, 122.4, 120.1, 119.3, 118.5, 116.7, 113.6, 55.2, 52.8, 43.4, 39.3, 31.4, 31.3, 
28.7, 18.9. IR: 2982.4 (w), 2917.1 (w), 1722.1 (s), 1658.4 (s), 1441.3 (s), 1375.7 (s), 
934.5 (s), 700.5 (s), 662.9 (m) cm
-1
. HRMS (ESI) M/Z+ Calc. 455.0708, Obs. 455.0732. 
Methyl 1-(3-(2-(1,3-dioxoisoindolin-2-yl)ethyl)-1H-indole-1-carbonyl)-2-(4-methoxy 
phenyl)cyclopropanecarboxylate (III-45t): The general procedure was followed using 
4-methoxystyrene (0.208 g, 1.55 mmol), methyl 3-(3-(2-(1,3-dioxoisoindolin-2-yl)ethyl)-
1H-indol-1-yl)-3-oxopropanoate
 
(0.810 g, 1.95 mmol), Rh2esp2 (1.3 mg, 1.71 μmol), and 
DCM (8 mL). After 12 h, the reaction was quenched, and column chromatography (40% 





H NMR (300 MHz, CDCl3) δ 8.44 (d, J = 7.9 Hz, 1H), 7.88 – 7.81 (m, 2H), 
7.78 – 7.65 (m, 3H), 7.44 – 7.24 (m, 5H), 6.92 – 6.83 (m, 2H), 4.02 (t, J = 7.2 Hz, 2H), 
3.81 (s, 3H), 3.39 (t, J = 9.0, 1H), 3.38 (s, 3H), 3.11 (t, J = 7.7 Hz, 2H), 2.41 (dd, J = 8.3, 
5.3 Hz, 1H), 1.79 (dd, J = 9.4, 5.3 Hz, 1H). 
13
C NMR (75 MHz, CDCl3) (Rotamers!!) δ 
168.2, 167.7, 166.0, 158.9, 136.1, 134.0, 133.8, 132.0, 130.4, 130.2, 126.0, 125.6, 124.0, 
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123.3, 123.2, 122.1, 122.0, 119.6, 119.5, 119.0, 118.9, 116.6, 113.6, 55.2, 53.4, 52.7, 
39.6, 38.5, 37.4, 31.3, 24.3, 18.9. IR: 3051.9 (w), 2942.4 (w), 1760.0 (w), 1708.8 (s), 
1685.1 (s), 1594.6 (m), 1513.6 (m), 1442.2 (m), 1375.5 (m), 1242.2 (m), 1104.0 (w), 
832.6 (m), 732.8 (s), cm
-1
. HRMS (ESI) M/Z+ Calc. 522.1791, Obs. 522.1777. 
Methyl 1-(3-(2-methoxy-2-oxoethyl)-1H-indole-1-carbonyl)-2-(4-methoxyphenyl) 
cyclopropanecarboxylate (III-45u): The general procedure was followed using 4-
methoxystyrene (0.211 g, 1.57 mmol), methyl 2-diazo-3-(3-(2-methoxy-2-oxoethyl)-1H-
indol-1-yl)-3-oxopropanoate
 
(0.611 g, 1.94 mmol,), Rh2esp2 (1.5 mg, 1.98 μmol), and 
DCM (8 mL). After 14 h, the reaction was quenched, and column chromatography 




H NMR (300 MHz, CDCl3) δ 8.46 (d, J = 8.1 Hz, 1H), 7.58 – 7.49 (m, 2H), 7.46 – 
7.26 (m, 4H), 6.92 – 6.82 (m, 2H), 3.81 (s, 3H), 3.73 (s, 2H), 3.73 (s, 3H), 3.43 (s, 3H), 
3.43 (t, J = 4.5 Hz, 1H), 2.42 (dd, J = 8.3, 5.3 Hz, 1H), 1.86 (dd, J = 9.4, 5.2 Hz, 1H). 
13
C 
NMR (75 MHz, CDCl3) δ 171.0, 167.8, 166.0, 158.9, 135.9, 130.2, 130.1, 125.9, 125.6, 
124.0, 123.3, 119.0, 116.6, 115.7, 113.6, 55.2, 52.8, 52.2, 39.3, 31.3, 30.8, 18.9. IR: 
3009.0 (w), 2947.1 (w), 1742.2 9 (s), 1694.6 (s), 1608.9 (m), 1504.1 (m), 1446.9 (s), 
1356.5 (s), 1246.9 (s), 1032.6 (m), 827.8 (m), 732.8 (s) cm
-1
. HRMS (ESI) M/Z+ Calc. 





carboxylate (III-45v): The general procedure was followed using (1-
bromovinyl)benzene (0.150 g, 0.819 mmol), methyl 2-diazo-3-(3-methyl-1H-indol-1-yl)-
3-oxopropanoate
 
(0.274 g, 1.065 mmol), Rh2esp2 (1.0 mg, 1.319 μmol), and DCM (12 
mL). After 12 h, the reaction was quenched, and column chromatography (20% 




H NMR (300 MHz, CDCl3) δ 8.12 – 8.04 (m, 1H), 7.48 – 7.37 (m, 3H), 7.27 – 7.18 
(m, 3H), 7.17 – 7.04 (m, 3H), 3.80 (s, 3H), 2.86 (d, J = 7.3 Hz, 1H), 2.56 (d, J = 7.3 Hz, 
1H), 2.27 (d, J = 1.3 Hz, 3H). 
13
C NMR (75 MHz, CDCl3) δ 166.76, 161.38, 136.52, 
135.61, 131.27, 128.86, 128.57, 127.85, 125.06, 123.77, 122.47, 118.71, 118.60, 116.25, 
53.54, 43.79, 40.49, 26.14, 9.70. IR: 3066.5 (w), 2960.3 (w), 2920.4 (w), 2867.3 (w), 
1737.9 (m), 1691.2 (m), 1678.5 (m), 1612.1 (w), 1448.6 (m), 1388.6 (m), 1346.9 (s), 
1238.1 (s), 1218.1 (m), 1146.1 (m), 1120.2 (s), 1063.0 (m), 1018.9 (m), 914.7 (w), 749.3 
(s), 693.5 (s), 632.5 (w) cm
-1
. HRMS (ESI) M/Z+ Calc. 411.0470, Obs. 411.0461. 
3.5.2.4. In(OTf)3-Catalyzed Homo-Nazarov Cyclizations 
General Method A: The cyclopropyl β-amide ester III-45 (1.0 equiv.) was added to a 
solution of In(OTf)3 (0.30 equiv.) in anhydrous dichloromethane (2 mL) at room 
temperature. Upon completion, the reaction mixture was quenched with water and the 
product was extracted from the aqueous phase with dichloromethane. The combined 
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organic layers were washed with brine and dried over MgSO4. The organic layers were 
concentrated for silica gel flash column chromatography.  
General Method B: To a mixture of In(OTf)3 (0.30 equiv.) in anhydrous 1,2-
dichloroethane heated to a reflux, dissolved cyclopropyl β-amide ester III-45 (1.0 equiv.) 
was syringed into the reaction vessel. The reaction was monitored by TLC and quenched 
with water. The phases were separated, and the product was extracted from the aqueous 
phase with dichloromethane. The combined organic layers were washed with brine, dried 




1-carbonyl)cyclopropanecarboxylate (0.100 g, 0.275 mmol), In(OTf)3 (0.046 g, 0.082 
mmol) and DCM (4 mL) were combined according to general method A to afford III-46a 
as a pale brown oil (0.099 g, 99%)  after 2 h. Rf 0.35 (20% EtOAc/Hex). Diastereomeric 
ratio: (2.6:1). 
1
H NMR (300 MHz, CDCl3) δ 8.55 – 8.47 (m, 1.34), 7.50 – 7.28 (m, 4.53), 
7.15 – 7.09 (m, 0.86), 7.01 – 6.95 (m, 2.09), 6.88 – 6.80 (m, 3.05), 4.59 (t, J = 4.3 Hz, 
0.94), 4.34 (dd, J = 8.5, 5.1 Hz, 0.36), 3.81 – 3.78 (m, 8.28), 3.69 (d, J = 4.5 Hz, 0.56), 
3.65 (d, J = 4.5 Hz, 0.56), 3.56 (d, J = 1.1 Hz, 1.37), 2.92 – 2.68 (m, 1.40), 2.59 – 2.34 
(m, 1.39), 2.00 (s, 3.0), 1.75 (s, 1.26). 
13
C NMR (75 MHz, CDCl3) δ 169.6, 169.2, 165.0, 
164.9, 158.5, 158.5, 134.5, 134.4, 133.7, 133.5, 132.8, 132.3, 131.3, 131.0, 128.9, 128.3, 
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124.8, 124.8, 124.1, 124.0, 118.1, 118.0, 116.5, 115.2, 114.8, 114.1, 113.9, 55.1, 52.5, 
52.4, 49.7, 47.1, 43.4, 37.9, 35.2, 33.8, 33.0, 8.7, 8.3. IR: 3051.9 (w), 2932.8 (w), 1747.0 
(s), 1685.1 (s), 1618.4 9 (w), 1451.7 (s), 1366.0 (s), 1242.2 (s), 1170.7 (s), 1156.4 (s), 
1023.1 (s), 899.2 (m), 729.0 (s) cm
-1




indole-7-carboxylate (III-46b): Methyl 2-(2-methoxyphenyl)-1-(3-methyl-1H-indole-1-
carbonyl)cyclopropanecarboxylate (0.070 g, 0.192 mmol), In(OTf)3 (0.032 g, 0.057 
mmol) and DCM (3 mL) were mixed according to general method A to afford III-46b as 
a pale yellow oil (0.066 g, 95.0%) after 3 h. Rf 0.37 (20% EtOAc/Hex). Diastereomeric 
ratio: (3.2:1). 
1
H NMR (300 MHz, CDCl3) δ 8.59 – 8.48 (m, 1.32), 7.50 – 7.29 (m, 4.33), 
7.28 – 7.19 (m, 1.66), 6.93 (dd, J = 8.3, 3.2 Hz, 1.57), 6.84 – 6.74 (m, 1.84), 6.57 (dd, J = 
7.5, 1.6 Hz, 1.12), 4.95 (dd, J = 4.9, 3.0 Hz, 1.03), 4.80 (t, J = 6.1 Hz, 0.32), 3.97 – 3.88 
(m, 4.23), 3.83 – 3.75 (m, 3.52), 3.74 – 3.62 (m, 1.07), 3.45 (s, 0.94), 2.95 (dt, J = 13.8, 
7.0 Hz, 0.37), 2.81 – 2.66 (m, 1.36), 2.61 – 2.44 (m, 1.44), 2.31 (q, J = 7.8 Hz, 0.37), 2.00 
(s, 2.89), 1.81 (s, 0.94).  
13
C NMR (75 MHz, CDCl3) δ 169.9, 169.4, 165.5, 156.8, 156.5, 
134.6, 134.0, 131.2, 129.0, 128.6, 128.5, 128.4, 128.3, 124.7, 124.66, 124.15, 124.0, 
122.1, 120.5, 120.4, 118.2, 117.9, 116.7, 116.6, 114.4, 110.5, 110.3, 55.4, 55.3, 52.5, 
52.3, 49.5, 47.6, 31.0, 30.7, 30.1, 8.3, 8.3. IR: 3097.4 (w), 2986.9 (w), 2854.2 (w), 
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1724.1 (s), 1711.7 (m), 1657.3 (s), 1591.8 (m), 1440.0(s), 1374.7(s), 1221.0(s), 1044.7(s), 
784.2 (s), 674.3 (m) cm
-1
. HRMS (ESI) M/Z+ Calc. 363.1471, Obs. 363.1472. 
 
Methyl 10-methyl-6-oxo-9-phenyl-6,7,8,9-tetrahydropyrido[1,2-a]indole-7-
carboxylate (III-46c): Methyl 1-(3-methyl-1H-indole-1-carbonyl)-2-
phenylcyclopropane carboxylate (0.100 g, 0.300 mmol), In(OTf)3 (0.050 g, 0.090 mmol) 
and DCE (4 mL) were combined according to general method B to afford III-46c as a 
brown oil (0.051 g, 52%)  after 8 h. Rf 0.25 (20% EtOAc/Hex). Diastereomeric ratio: 
(2.6:1). 
1
H NMR (300 MHz, CDCl3) δ 8.57 – 8.47 (m, 1.37), 7.53 – 7.27 (m, 10.63), 7.07 
(d, J = 7.4 Hz, 2.24), 4.64 (t, J = 4.3 Hz, 1.00), 4.40 (dd, J = 8.2, 5.7 Hz, 0.39), 3.80 (dd, 
J = 9.4, 3.3 Hz, 3.61), 3.75 – 3.63 (m, 1.46), 3.53 (d, J = 1.1 Hz, 1.28), 2.95 – 2.74 (m, 
2.28), 2.64 – 2.42 (m, 2.12), 2.00 (s, 3.13), 1.74 (s, 1.24). 
13
C NMR (75 MHz, CDCl3) δ 
169.6, 169.2, 165.0, 164.9, 140.8, 140.5, 134.6, 133.3, 133.2, 131.3, 131.1, 128.9, 128.7, 
128.6, 128.3, 128.0, 127.6, 127.3, 127.2, 127.2, 125.7, 125.0, 124.2, 124.1, 118.2, 118.0, 
116.7, 116.6, 115.47, 115.12, 52.6, 52.4, 49.8, 47.1, 38.7, 36.1, 33.8, 32.9, 8.8, 8.4. IR: 
3032.9 (w), 2961.4 (w), 2904.3 (w), 1744.6 (s), 1699.4 (s), 1537.4 (w), 1457.6 (s), 1382.5 
(s), 1242.2 (m), 1018.3 (w), 749.9 (s) cm
-1






carboxylate (III-46d): Methyl 2-(4-fluorophenyl)-1-(3-methyl-1H-indole-1-carbonyl) 
cyclopropanecarboxylate (0.100 g, 0.285 mmol), In(OTf)3 (0.047 g, 0.085 mmol, 30 
mol%) and DCE (4 mL) were combined according to general method B to afford III-46d 
as a brown oil (0.048 g, 48%) after 8 h. Rf 0.28 (20% EtOAc/Hex). Diastereomeric ratio: 
(2.6:1). 
1
H NMR (300 MHz, CDCl3) δ 8.57 – 8.46 (m, 1.37), 7.76 (d, J = 8.1 Hz, 0.68), 
7.53 – 7.29 (m, 5.16), 7.26 – 6.77 (m, 12.82), 5.75 (s, 0.62), 4.62 (t, J = 4.4 Hz, 1.00), 
4.39 (dd, J = 8.2, 5.3 Hz, 0.35), 3.80 (s, 3.03), 3.65 (dd, J = 11.8, 4.5 Hz, 1.24), 3.55 (s, 
1.24), 2.93 – 2.79 (m, 2.17), 2.61 – 2.38 (m, 1.87), 2.00 (s, 3.18), 1.76 (s, 1.43). 
13
C 
NMR (75 MHz, CDCl3) δ 169.5, 169.2, 164.8, 160.2, 136.2, 134.6, 132.9, 131.0, 129.6, 
129.4, 128.9, 128.8, 125.1, 124.3, 124.2, 118.3, 118.1, 116.6, 115.9, 115.6, 115.4, 115.2, 
52.7, 52.5, 49.6, 47.8, 47.1, 35.9, 35.4, 33.8, 33.0, 33.1, 8.4. IR: 3051.9 (w), 2932.8 (w), 
2861.4 (w), 1738.3 (m), 1664.6 (m), 1604.1 (m), 1535.1 (m), 1508.3 (m), 1314.8 (m), 
1250.8 (s), 1209.5 (s), 1097.4 (m), 989.0 (w), 832.4 (m), 736.0 (s) cm
-1
.  HRMS (ESI) 





carboxylate (III-46e): Methyl 2-(4-chlorophenyl)-1-(3-methyl-1H-indole-1-carbonyl) 
cyclopropanecarboxylate (0.100 g, 0.272 mmol), In(OTf)3 (0.045 g, 0.081 mmol) and 
DCE (4 mL) were mixed according to general method B to yield III-46e as a brown oil 
(0.049 g, 49.7%)  after 12 h. Rf 0.43 (15% EtOAc/Hex). Diastereomeric ratio: (1.9:1). 
1
H 
NMR (300 MHz, CDCl3) δ 8.55 – 8.46 (m, 1.38), 7.50 – 7.27 (m, 8.02), 7.17 – 7.13 (m, 
1.05), 7.04 – 6.98 (m, 2.15), 6.81 – 6.77 (m, 0.45), 4.61 (t, J = 4.6 Hz, 1.00), 4.40 (dd, J = 
7.6, 5.8 Hz, 0.52), 3.80 (s, 3.14), 3.65 (d, J = 4.5 Hz, 0.55), 3.61 (d, J = 4.5 Hz, 0.55), 
3.54 (s, 1.24), 2.93 – 2.70 (m, 2.53), 2.62 – 2.37 (m, 2.54), 1.99 (s, 2.80), 1.77 (s, 1.20). 
13
C NMR (75 MHz, CDCl3) δ 169.4, 164.7, 139.1, 134.6, 133.2, 132.6, 131.0, 129.3, 
129.1, 129.0, 128.8, 128.7, 127.1, 125.2, 124.4, 124.3, 118.3, 118.2, 116.7, 115.3, 77.4, 
77.2, 77.0, 76.5, 52.7, 52.5, 49.6, 47.1, 38.0, 35.6, 33.6, 32.9, 8.9, 8.5. IR: 3051.9 (w), 
2956.6 (m), 2918.6 (m), 2847.1 (m), 1747.0 (m), 1699.4 (m), 1613.6 (m), 1542.2 (s), 
1313.6 (m), 1251.5 (m), 1208.8 (m), 1094.5 (w), 1004.0 (w), 832.6 (w), 737.7 (s) cm
-1
. 






carboxylate (III-46f): Methyl 1-(3-methyl-1H-indole-1-carbonyl)-2-(4-nitrophenyl) 
cyclopropanecarboxylate (0.100 g, 0.264 mmol), In(OTf)3 (0.044 g, 0.079 mmol) and 
DCE (4 mL) were mixed according to general method B to yield a brown oil after 20 h. 
The reaction afforded an inseparable mixture of trace amounts of III-46f and other by-
products as observed by crude 
1
H NMR. Rf 0.35 (15% EtOAc/Hex).  
 
Methyl 9-(furan-2-yl)-10-methyl-6-oxo-6,7,8,9-tetrahydropyrido[1,2-a]indole-7-
carboxylate (III-46g): Methyl 2-(furan-2-yl)-1-(3-methyl-1H-indole-1-
carbonyl)cyclopropane carboxylate (0.050 g, 0.154 mmol), In(OTf)3 (0.026 g, 0.046 
mmol) and DCM (3 mL) were mixed according to general method A to afford III-46g as 
a colorless oil (0.049 g, 99.0%) after 2 h. Rf 0.40 (20% EtOAc/Hex). Diastereomeric 
ratio: (4.5:1). 
1
H NMR (300 MHz, CDCl3) δ 8.57 – 8.51 (m, 0.37), 8.50 – 8.42 (m, 0.97), 
7.53 – 7.46 (m, 1.50), 7.42 – 7.29 (m, 3.77), 6.30 – 6.25 (m, 1.21), 5.91 – 5.87 (m, 1.16), 
4.65 (t, J = 3.9 Hz, 1), 4.52 (t, J = 5.2 Hz, 0.22), 3.84 (d, J = 1.0 Hz, 3.24), 3.81 – 3.72 
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(m, 1.42), 3.51 (d, J = 0.8 Hz, 0.69), 3.08 (dt, J = 13.8, 5.6 Hz, 0.25), 2.72 (dt, J = 4.4, 
3.6 Hz, 2.07), 2.53 (dt, J = 13.8, 5.3 Hz, 0.27), 2.15 (d, J= 0.3 Hz, 3.09), 2.00 (d, J = 0.9 
Hz, 0.67). 
13
C NMR (75 MHz, CDCl3) δ 169.6, 164.8, 152.4, 142.4, 142.1, 134.6, 131.1, 
130.8, 125.1, 124.2, 118.3, 116.6, 115.3, 110.3, 110.2, 108.1, 107.6, 52.7, 47.7, 31.3, 
30.7, 29.3, 8.3. IR: 3090.2 (w), 2936.8 (w), 1767.1 (s), 1725.6 (s), 1469.4(s), 1376.2(m), 
1269.5(m), 785.4 (s), 663.0 (m) cm
-1




carboxylate (III-46h): Methyl 2-methyl-1-(3-methyl-1H-indole-1-carbonyl)-2-phenyl 
cyclopropanecarboxylate (0.070 g, 0.201 mmol), In(OTf)3 (0.033 g, 0.060 mmol) and 
DCM (3 mL) were combined according to general Method A to afford a III-46h as a 
white solid (0.065 g, 94.14%)  after 2 h. Rf 0.28 (20% EtOAc/Hex). [m.p. 139-141 
o
C]  
Diastereomeric ratio: (1.1:1). 
1
H NMR (300 MHz, CDCl3) δ 8.58 – 8.50 (m, 1.81), 7.54 
(ddt, J = 7.6, 4.3, 2.2 Hz, 1.0), 7.45 – 7.25 (m, 13.52), 7.13 – 7.08 (m, 2.11), 3.99 (dd, J = 
12.2, 5.0 Hz, 0.80), 3.80 (s, 3.0), 3.72 (s, 2.71), 3.43 (dd, J = 13.2, 4.4 Hz, 0.99), 2.84 (dt, 
J = 26.7, 13.4 Hz, 1.88), 2.50 – 2.41 (m, 1.35), 2.26 – 2.18 (m, 4.15), 1.99 (s, 2.99), 1.85 
(s, 2.62), 1.65 (s, 2.68). 
13
C NMR (75 MHz, CDCl3) δ 169.5, 169.4, 165.3, 164.9, 145.9, 
143.8, 138.5, 136.9, 134.3, 134.2, 131.6, 131.9, 128.9, 128.5, 127.1, 126.8, 126.4, 125.9, 
125.1, 124.9, 124.1, 124.1, 118.0, 117.9, 116.7, 115.6, 114.6, 52.6, 48.5, 47.9, 42.1, 
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41.23, 40.74, 39.56, 29.4, 24.6, 10.0, 9.2. IR: 3040.9 (w), 2963.4 (w), 2890.4 (w), 1722.2 
(s), 1640.6 (s), 1483.9 (s), 1383.5 (s), 1270.4 (m), 1182.4 (m), 1134.3 (w), 740.1 (s), 
640.4 (s) cm
-1
. HRMS (ESI) M/Z+ Calc. 347.1521, Obs. 347.1516. 
 
Methyl 9,9-diethyl-10-methyl-6-oxo-6,7,8,9-tetrahydropyrido[1,2-a]indole-7-
carboxylate (III-46i): Methyl 2,2-diethyl-1-(3-methyl-1H-indole-1-
carbonyl)cyclopropane carboxylate (0.055 g, 0.175 mmol), In(OTf)3 (0.029 g, 0.052 
mmol) and DCE (3 mL) were mixed according to general method B to yield III-46i as a 
colorless oil (0.046 g, 84.8%) after 6 h.  Rf 0.38 (20% EtOAc/Hex). 
1
H NMR (300 MHz, 
CDCl3) δ 8.51 – 8.44 (m, 1H), 7.44 (ddd, J = 6.7, 4.5, 2.6 Hz, 1H), 7.34 – 7.28 (m, 2H), 
3.94 – 3.83 (m, 4H), 2.58 (t, J = 13.5 Hz, 1H), 2.30 (d, J = 0.7 Hz, 3H), 2.21 (dt, J = 14.6, 
7.4 Hz, 1H), 1.95 (dd, J = 13.7, 5.0 Hz, 1H), 1.87 – 1.65 (m, 3H), 0.93 (dt, J = 10.0, 7.4 
Hz, 6H). 
13
C NMR (75 MHz, CDCl3) δ 170.2, 165.3, 136.9, 134.4, 131.7, 124.7, 123.9, 
117.6, 116.6, 113.7, 77.4, 76.9, 76.5, 52.7, 47.4, 39.3, 32.3, 31.6, 29.1, 9.7, 8.5, 8.3. IR: 
3025.9 (w), 2894.8 (w), 1786.6 (s), 1725.4 (s), 1484.2 (s), 1383.2 (m), 1283.0 (m), 
1180.6 (m), 713.41 (s), 662.9 (m) cm
-1







a]indole]-7'-carboxylate (III-46j): Methyl 1-(3-methyl-1H-indole-1-carbonyl)spiro[2.4] 
heptane-1-carboxylate (0.050 g, 0.160 mmol), In(OTf)3 (0.027 g, 0.048 mmol) and DCE 
(3 mL) were mixed according to general method B to yield III-46j as a colorless oil 
(0.044 g, 88.8%) after 6 h.  Rf 0.35 (20% EtOAc/Hex). 
1
H NMR (300 MHz, CDCl3) δ 
8.48 – 8.41 (m, 1H), 7.47 – 7.41 (m, 1H), 7.30 (ddd, J = 4.6, 4.2, 2.9 Hz, 2H), 3.85 (d, J = 
0.8 Hz, 3H), 3.84 – 3.79 (m, 1H), 2.69 – 2.54 (m, 1H), 2.47 (t, J = 13.2 Hz, 1H), 2.30 (d, 
J = 0.7 Hz, 3H), 2.13 (dd, J = 13.4, 4.6 Hz, 1H), 2.02 – 1.83 (m, 5H), 1.83 – 1.70 (m, 
2H).
  13
C NMR (75 MHz, CDCl3) δ 169.9, 165.4, 139.3, 134.0, 131.9, 124.7, 124.0, 
117.6, 116.5, 112.6, 52.7, 48.8, 42.6, 39.0, 38.7, 37.8, 25.8, 25.3, 9.73. IR: 2998.5 (w), 
2893.7 (w), 1786.8 (s), 1724.9 (s), 1470.0 (s), 1385.1 (m), 1269.5 (m), 1180.4 (m), 714.3 
(s), 662.7 (m) cm
-1
. HRMS (ESI) M/Z+ Calc. 311.1521, Obs. 311.1520.  
 
Methyl 10'-methyl-6'-oxo-7',8'-dihydro-6'H-spiro[cyclohexane-1,9'-pyrido[1,2-
a]indole]-7'-carboxylate (III-46k): Methyl 1-(3-methyl-1H-indole-1-
carbonyl)spiro[2.5]octane-1-carboxylate (0.080 g, 0.246 mmol), In(OTf)3 (0.041 g, 0.073 
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mmol) and DCE (3 mL) were mixed according to general method B to yield III-46k as a 
colorless oil (0.062 g, 78.6%) after 6 h.  Rf 0.39 (20% EtOAc/Hex). (Conformers!!) 
1
H 
NMR (300 MHz, CDCl3) δ 8.49 – 8.41 (m, 1H), 7.47 – 7.42 (m, 1H), 7.36 – 7.27 (m, 
2H), 3.86 (dd, J = 2.9, 0.6 Hz, 3H), 3.76 (dd, J = 13.1, 4.6 Hz, 1H), 2.71 – 2.59 (m, 3H), 
2.54 – 2.39 (m, 4H), 2.36 – 2.17 (m, 2H), 1.91 – 1.76 (m, 4H), 1.70 (d, J = 11.9 Hz, 3H). 
13
C NMR (75 MHz, CDCl3) δ 170.2, 165.5, 139.5, 134.0, 132.1, 125.1, 124.8, 123.9, 
121.7, 119.4, 117.7, 116.6, 114.4, 113.1, 58.6, 52.7, 47.2, 36.1, 35.6, 33.9, 33.7, 32.7, 
31.2, 30.8, 25.6, 25.4, 23.1, 21.5, 21.3, 10.8, 10.2. IR: 2969.7 (w), 2890.9 (w), 1736.7 
(m), 1689.1 (m), 1469.0 (m), 1382.7 (m), 1269.5 (s), 759.9 (s), 662.9 (s) cm
-1
. HRMS 
(ESI) M/Z+ Calc. 325.1678, Obs. 325.1681. 
 
Methyl 9-((tert-butyldiphenylsilyl)methyl)-10-methyl-6-oxo-6,7,8,9-
tetrahydropyrido[1,2-a]indole-7-carboxylate (III-46l): Methyl 2-((tert-
butyldiphenylsilyl) methyl)-1-(3-methyl-1H-indole-1-carbonyl)cyclopropanecarboxylate 
(0.100 g, 0.196 mmol), In(OTf)3 (0.033 g, 0.058 mmol) and DCE (4 mL) were combined 
according to general method B to afford III-46fl as a colorless oil (0.082 g, 82%) after 16 
h. Rf 0.41 (20% EtOAc/Hex). 
1
H NMR (300 MHz, CDCl3) δ 8.37 (ddd, J = 4.3, 2.2, 0.6 
Hz, 1H), 7.72 – 7.66 (m, 4H), 7.45 – 7.32 (m, 7H), 7.29 – 7.24 (m, 2H), 3.89 (dd, J = 
13.5, 4.8 Hz, 1H), 3.72 (s, 3H), 3.45 – 3.33 (m, 1H), 2.19 (ddd, J = 18.1, 8.8, 3.1 Hz, 1H), 
1.99 (s, 3H), 1.83 (ddd, J = 13.5, 4.8, 2.5 Hz, 1H), 1.55 (dd, J = 8.3, 4.6 Hz, 2H), 1.06 – 
191 
 
1.00 (m, 9H). 
13
C NMR (75 MHz, CDCl3) δ 169.7, 165.1, 138.5, 135.8, 135.7, 134.4, 
134.1, 133.0, 131.2, 129.5, 129.4, 127.9, 124.5, 124.0, 117.9, 116.5, 112.0, 52.4, 46.7, 
29.9, 27.7, 26.5, 18.3, 14.9, 8.5. IR: 3061.4 (w), 2951.9 (m), 2928.1 (m), 2851.9 (m), 
1745.6 (s), 1692.0 (s), 1457.2 (s), 1381.4 (s), 1270.6 (m), 1103.8 (m), 740.4 (s), 702.1 (s) 
cm
-1
.  HRMS (ESI) M/Z+ Calc. 509.2386, Obs. 509.2383. 
 
Methyl 9-(1,3-dioxoisoindolin-2-yl)-10-methyl-6-oxo-6,7,8,9-tetrahydropyrido[1,2-
a]indole-7-carboxylate (III-46m): Methyl 2-(1,3-dioxoisoindolin-2-yl)-1-(3-methyl-1H-
indole-1-carbonyl) cyclopropane carboxylate (0.090 g, 0.224 mmol), In(OTf)3 (0.037 g, 
0.067 mmol) and DCE (4 mL) were mixed according to general method B to yield III-
46m as a yellow-green solid (0.049 g, 55%) after 8 h. Rf 0.38 (20% EtOAc/Hex). [m.p. 
167–169
o
C] Diastereomeric ratio: (4.8:1). 
1
H NMR (300 MHz, CDCl3) δ 8.52 – 8.47 (m, 
1.27), 7.89 – 7.70 (m, 5.64), 7.46 – 7.28 (m, 4.18), 5.96 (t, J = 4.5 Hz, 1.00), 4.19 (dt, J = 
12.5, 6.3 Hz, 0.70), 3.83 – 3.79 (m, 3.92), 2.86 (ddd, J = 14.1, 11.8, 5.3 Hz, 0.75), 2.58 
(ddd, J = 14.3, 4.9, 4.0 Hz, 0.75), 2.29 – 2.26 (m, 0.22), 2.07 (s, 2.75), 2.04 (s, 0.38). 
13
C 
NMR (75 MHz, CDCl3) δ 169.5, 167.6, 164.4, 134.8, 134.5, 131.3, 130.3, 128.2, 125.8, 
124.1, 123.6, 118.5, 116.7, 116.3, 52.8, 48.2, 40.3, 30.7, 8.3. IR: 3061.6 (w), 2942.6 (w), 
2928.32 (w), 1733.2 (m), 1708.2 (s), 1614.2 (w), 1452.3 (m), 1452.3 (m), 1383.6 (s), 
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1309.5 (s), 1261.0 (s), 1104.7 (m), 890.4 (m), 734.4 (s) cm
-1
. HRMS (ESI) M/Z+ Calc. 
402.1216, Obs. 402.1219.  
 
Methyl 10-methyl-6-oxo-9-(phenylthio)-6,7,8,9-tetrahydropyrido[1,2-a]indole-7-
carboxylate (III-46n): Methyl 1-(3-methyl-1H-indole-1-carbonyl)-2-
(phenylthio)cyclopropane carboxylate (0.018 g, 0.049 mmol), In(OTf)3 (0.008 g, 0.014 
mmol) and DCE (1 mL) were mixed according to general method B to yield III-46n as a 
colorless oil (0.014 g, 81%) after 7 h. Rf 0.30 (20% EtOAc/Hex). Diastereomeric ratio: 
(10:1). 
1
H NMR (300 MHz, CDCl3) δ 8.54 (d, J = 8.6 Hz, 0.10), 8.47 – 8.40 (m, 1), 7.54 
– 7.29 (m, 9.0), 4.91 – 4.84 (m, 1.06), 4.48 (dd, J = 13.1, 4.8 Hz, 1.04), 3.94 – 3.76 (m, 
3.80), 2.72 (td, J = 13.6, 3.9 Hz, 1.19), 2.42 – 2.32 (m, 1.42), 2.20 (s, 0.31), 2.04 (s, 
3.10). 
13
C NMR (75 MHz, CDCl3) δ 169.6, 164.5, 134.7, 134.5, 132.5, 130.5, 130.4, 
129.3, 129.2, 128.8, 128.6, 125.6, 124.3, 118.5, 116.6, 52.8, 46.9, 40.0, 29.6, 8.3. IR: 
2997.7 (w), 2890.9 (w), 1766.6 (m), 1711.7 (m), 1468.2 (m), 1269.7 (s), 760.1 (s), 663.0 
(s) cm
-1
. HRMS (ESI) M/Z+ Calc. 365.1119, Obs. 365.1089. 
Methyl 11-methyl-5-oxo-2,3,3a,4,5,11b-hexahydrofuro[2',3':3,4]pyrido[1,2-a]indole-
4-carboxylate (III-46o): Methyl 6-(3-methyl-1H-indole-1-carbonyl)-2-oxabicyclo[3.1.0] 
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hexane-6-carboxylate (0.025 g, 0.083 mmol), In(OTf)3 (0.014 g, 0.025 mmol) and DCM 
(2 mL) were combined according to general method A to afford III-46o as a colorless oil 
(0.024 g, 97%) after 2.5 h. Rf 0.30 (20% EtOAc/Hex). 
1
H NMR (300 MHz, CDCl3) δ 
8.39 (d, J = 4.9, 3.3 Hz, 1H), 7.51 (d, J = 6.8, 1.3 Hz, 1H), 7.41 – 7.27 (m, 2H), 5.05 (d, J 
= 4.5 Hz, 1H), 4.17 – 3.99 (m, 2H), 3.87 (s, 3H), 3.78 (d, J = 10.7 Hz, 1H), 3.32 – 3.21 
(m, 1H), 2.47 – 2.22 (m, 1H), 2.32 (s, 3H), 1.96 – 1.82 (m, 1H). 
13
C NMR (75 MHz, 
CDCl3) δ 169.2, 164.0, 134.5, 130.9, 128.8, 125.8, 124.2, 119.5, 118.8, 116.4, 69.9, 66.3, 
52.8, 52.3, 40.7, 30.7, 8.5. IR: 2947.1 (w), 2923.3 (w), 2856.6 (w), 1744.8 (s), 1703.1 (s), 
1623.2 (w), 1459.5 (m), 1382.2 (s), 1265.2 (m), 1035.5 (m), 751.0 (s) cm
-1
.  HRMS 
(ESI) M/Z+ Calc. 299.1158, Obs. 299.1158. 
 
Methyl 12-methyl-6-oxo-3,4,4a,5,6,12b-hexahydro-2H-pyrano[2',3':3,4]pyrido[1,2-
a]indole-5-carboxylate (III-46p): Methyl 7-(3-methyl-1H-indole-1-carbonyl)-2-
oxabicyclo[4.1.0]heptane-7-carboxylate (0.025 g, 0.079 mmol), In(OTf)3 (0.013 g, 0.023 
mmol) and DCM (2 mL) were mixed according to general method A to yield III-46p as a 





H NMR (300 MHz, CDCl3) δ 8.41 (d, 1H), 7.50 (d, 1H), 7.40 – 7.25 (m, 2H), 
4.81 (s, 1H), 4.33 (d, J = 12.2 Hz, 1H), 4.08 (d, 1H), 3.86 (s, 3H), 3.71 (t, J = 11.6, 2.4 
Hz, 2H), 2.72 (d, 1H), 2.30 (s, 3H), 1.98 – 1.73 (m, 2H), 1.56 – 1.47 (m, 1H). 
13
C NMR 
(75 MHz, CDCl3) δ 169.5, 165.2, 134.3, 130.8, 125.8, 124.2, 122.2, 118.8, 117.7, 116.6, 
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68.3, 68.1, 52.6, 50.1, 35.7, 25.7, 20.4, 8.4. IR: 2737.5(w), 1746.9(m), 1632.6(w), 
1532.6(m), 1056.8(w), 751.6(s), 680.1(s) cm
-1
. HRMS (ESI) M/Z+ Calc. 313.1314, Obs. 
313.1315. 
 
1-Benzyl 5-methyl 12-methyl-6-oxo-2,3,4,4a,5,6-hexahydroindolo[1,2-h][1,7] 
naphthyridine-1,5(12bH)-dicarboxylate (III-46q): 2-benzyl 7-methyl 7-(3-methyl-1H-
indole-1-carbonyl)-2-azabicyclo[4.1.0]heptane-2,7-dicarboxylate (0.100 g, 0.223 mmol), 
In(OTf)3 (0.037 g, 0.067 mmol) and DCM (4 mL) were combined according to general 
method A to afford  III-46q as a colorless oil (0.098 g, 98.0%) after 2 h. Rf 0.25 (25% 
EtOAc/Hex). Diastereomeric ratio: (7.1:1). 
1
H NMR (300 MHz, CDCl3) δ 8.55 – 8.40 
(m, 1.22), 7.52 – 7.27 (m, 10.67), 5.98 (d, 1), 5.91 (d, 0.14), 5.38 – 5.16 (m, 2.64), 4.20 - 
4.04 (m, 1.20), 3.95 (dd, J = 13.9, 3.7 Hz, 0.23), 3.85 (s, 0.77), 3.74 (s, 3), 3.68 (d, J = 1.7 
Hz 1.41), 2.81 – 2.50 (m, 2.68), 2.35 – 2.20 (m, 0.32), 2.08 – 2.03 (m, 3.99), 1.79 – 1.85 
(m, 1.54), 1.58 – 1.70 (m, 2.70), 1.51 – 1.33 (m, 1.42). 
13
C NMR (75 MHz, CDCl3) δ 
168.4, 167.6, 162.6, 155.0, 136.3, 134.5, 131.3, 128.4, 128.3, 128.1, 127.8, 127.7, 125.1, 
124.1, 122.0, 117.9, 116.4, 116.3, 67.5, 56.0, 53.5, 53.0, 52.4, 48.3, 39.4, 37.9, 34.5, 31.4, 
26.5, 25.1, 24.6, 22.5, 14.6, 7.6. IR: 3042.4 (w), 2932.8 (w), 2861.4 (w), 1738.4 (s), 
1702.9 (s), 1457.3 (m), 1373.1 (s), 1256.6 (m), 1201.5 (m), 1164.4 (m), 1113.6 (w), 
761.1 (m), 689.7 (m) cm
-1





carboxylate (III-46r): Methyl 1-(1H-indole-1-carbonyl)-2-(4-
methoxyphenyl)cyclopropanecarboxylate (0.75 g, 0.215 mmol), In(OTf)3 (0.036 g, 0.064 
mmol) and DCM (4 mL) were combined according to general method A to afford  III-
46r as a colorless oil (0.742 g, 98.99%) after 45 min. Rf 0.30 (20% EtOAc/Hex). 
Diastereomeric ratio: (1.1:1). 
1
H NMR (300 MHz, CDCl3) δ 8.53 – 8.42 (m, 1.77), 7.45 
– 7.20 (m, 8.18), 7.19-7.12 (m, 1.68), 6.96 – 6.85 (m, 3.86), 6.08 (s, 0.78), 6.00 – 5.89 
(m, 1), 4.36 (dd, J = 9.9, 4.2 Hz, 0.76H), 4.13 (dd, J = 13.0, 2.6 Hz, 1.09), 3.97 – 3.79 (m, 
13.94), 2.79 – 2.64 (m, 1.92), 2.54 – 2.37 (m, 1.88). 
13
C NMR (75 MHz, CDCl3) δ 169.5, 
169.3, 165.3, 164.7, 159.1, 158.9, 141.5, 140.6, 135.2, 135.1, 132.7, 132.3, 129.6, 129.5, 
129.3, 129.0, 124.7, 124.4, 124.4, 120.1, 120.1, 116.6, 116.5, 114.2, 107.6, 55.3, 53.0, 
52.8, 51.6, 49.2, 40.3, 37.4, 33.6, 33.2. IR: 2997.1 (w), 2950.6 (w), 2834.32 (w), 1737.9 
(s), 1703.3 (s), 1555.7 (w), 1512.5 (m), 1453.1 (s), 1379.0 (s), 13050.2 (s), 1247.2 (s), 
1177.1 (s), 1034.6 (s), 838.4 (m), 798.5 (m), 752.0 (m), 688.9 (w) cm
-1
. HRMS (ESI) 






a]indole-7-carboxylate (III-46s):  Methyl 1-(3-(2-bromoethyl)-1H-indole-1-carbonyl)-
2-(4-methoxyphenyl)cyclopropane carboxylate (0.050 g, 0.109 mmol), In(OTf)3 (0.018 g, 
0.032 mmol) and DCM (3 mL) were mixed according to general method A to afford III-
46s as a colorless oil (0.049 g, 98.2%) after 1 h. Rf 0.35 (20% EtOAc/Hex). 
Diastereomeric ratio: (2.7:1). 
1
H NMR (300 MHz, CDCl3) δ 8.54 (ddd, J = 10.3, 6.9, 1.4 
Hz, 1.38), 7.53 – 7.29 (m, 4.31), 7.16 – 7.11 (m, 0.81), 6.95 (dd, J = 6.9, 4.7 Hz, 2.07), 
6.89 – 6.80 (m, 2.88), 4.68 (t, J = 4.2 Hz, 1), 4.43 (dd, J = 8.8, 5.3 Hz, 0.37), 3.86 – 3.77 
(m, 7.57), 3.69 (dd, J = 12.2, 4.6 Hz, 1.29), 3.57 (d, J = 3.5 Hz, 1.28), 3.53 – 3.05 (m, 
4.08), 3.03 – 2.73 (m, 3.37), 2.66 – 2.37 (m, 2.03). 
13
C NMR (75 MHz, CDCl3) δ 169.4, 
165.2, 158.8, 135.5, 134.7, 132.3, 129.6, 129.1, 128.3, 125.2, 124.4, 118.0, 116.9, 116.0, 
114.3, 114.2, 55.3, 52.7, 47.1, 35.4, 33.0, 30.9, 27.7. IR: 3023.9 (w), 2918.9 (w), 1725.1 
(s), 1658.6 (s), 1591.0 (m), 1493.2 (s), 1349.0 (m), 993.6(s), 725.0 s), 663.0 (m) cm
-1
. 






tetrahydro-pyrido[1,2-a]indole-7-carboxylate (III-46t): Methyl 1-(3-(2-(1,3-
dioxoisoindolin-2-yl)ethyl)-1H-indole-1-carbonyl)-2-(4-methoxyphenyl)cyclopropane 
carboxylate (0.050 g, 0.096 mmol), In(OTf)3 (0.016 g, 0.028 mmol) and DCM (3 mL) 
were mixed according to general method A to yield III-46t as a white solid (0.038 g, 
76.0%) after 2 h. [m.p. 166–168
o
C]  Rf 0.38 (40% EtOAc/Hex). Diastereomeric ratio: 
(2.8:1).
 1
H NMR (300 MHz, CDCl3) δ 8.52 – 8.46 (m, 1.35), 7.79 – 7.58 (m, 7.24), 7.41 
– 7.26 (m, 2.90), 7.18 – 7.13 (m, 0.89), 7.00 – 6.93 (m, 2.37), 6.86 - 6.72 (m, 2.97), 4.70 
(t, J = 4.1 Hz, 1), 4.48 (dd, J = 8.3, 5.1 Hz, 0.35), 3.85 – 3.80 (m, 0.84), 3.79- 3.63 (m, 
11.93), 3.54 (s, 1.09), 3.02 – 2.90 (m, 1.23), 2.88 – 2.71 (m, 3.21), 2.61 – 2.50 (m, 0.57), 
2.44 – 2.33 (m, 1.73). 
13
C NMR (75 MHz, CDCl3) δ 169.6, 169.2, 168.0, 165.3, 165.1, 
158.8, 158.7, 135.5, 135.3, 134.7, 134.6, 133.8, 132.5, 131.9, 131.9, 130.4, 130.0, 129.1, 
128.3, 125.1, 125.0, 124.5, 124.4, 123.1, 123.0, 118.4, 118.2, 116.8, 116.7, 115.7, 115.2, 
114.2, 114.1, 55.2, 55.2, 52.7, 52.5, 49.6, 47.0, 37.7, 36.9, 36.8, 35.3, 33.7, 33.2, 23.1, 
22.8. IR: 3047.1 (w), 2947.1 (w), 2847.1 (w), 1766.03 (w), 1751.74 (m), 1708.8 (s), 
1618.4 (m), 1504.1 (m), 1451.7 (m), 1376.6 (s), 1245.9 (s), 1032.6 (s), 837.3 (m), 715.9 
(s) cm
-1





tetrahydropyrido[1,2-a]indole-7-carboxylate (III-46u): Methyl 1-(3-(2-methoxy-2-
oxoethyl)-1H-indole-1-carbonyl)-2-(4-methoxyphenyl) cyclopropanecarboxylate (0.070 
g, 0.167 mmol), In(OTf)3 (0.028 g, 0.049 mmol) and DCM (3 mL) were combined 
according to general method A to afford III-46u as a brown oil (0.062 g, 88.0%) after 3 
h. Rf 0.45 (40% EtOAc/Hex). Diastereomeric ratio: (2.0:1).
 1
H NMR (300 MHz, CDCl3) 
δ 8.56 – 8.47 (m, 1.45), 7.56 – 7.48 (m, 1.05), 7.44 – 7.28 (m, 3.67), 7.18 – 7.11 (m, 
1.06), 7.01 – 6.90 (m, 2.29), 6.88 – 6.78 (m, 3.02), 4.66 (t, J = 4.5 Hz, 1), 4.40 (dd, J = 
9.7, 5.1 Hz, 0.48), 3.90 – 3.81 (m, 1.32), 3.81 – 3.78 (m, 7.54), 3.73 – 3.67 (m, 1.32), 
3.64 (s, 1.44), 3.55 (s, 1.42), 3.53 (s, 2.98), 3.52 (s, 0.31), 3.43 (d, J = 17.3 Hz, 1.59), 
3.32 (d, J = 17.7 Hz, 0.85), 3.02 – 2.69 (m, 2.34), 2.58 – 2.38 (m, 1.62). 
13
C NMR (75 
MHz, CDCl3) δ 170.8, 170.6, 169.4, 169.1, 165.2, 158.9, 158.8, 136.3, 135.8, 134.6, 
134.5, 132.3, 131.9, 130.3, 129.9, 129.2, 128.5, 125.2, 125.2, 124.5, 124.4, 118.4, 118.0, 
116.7, 114.2, 114.1, 112.3, 112.0, 55.3, 52.7, 52.6, 52.0, 51.9, 50.1, 47.2, 38.5, 35.4, 34.0, 
33.2, 29.7, 29.4. IR: 3013.8 (w), 2918.6 (w), 2832.8 (w), 1747.0 (s), 1737.7 (s), 1699.3 
(s), 1613.6 (m), 1518.4 (m), 1456.5 (s), 1366.0 (s), 1245.6 (s), 1152.1 (s), 1032.6 (s), 
837.3 (m), 731.8 (s) cm
-1





Methyl 6-hydroxy-10-methyl-9-phenylpyrido[1,2-a]indole-7-carboxylate (III-47): 
Methyl 2-bromo-1-(3-methyl-1H-indole-1-carbonyl)-2-phenylcyclopropanecarboxylate 
(0.060 g, 0.145 mmol), In(OTf)3 (0.0245 g, 0.043 mmol) and DCM (3 mL) were 
combined according to general method A to afford III-47 as a yellow-green oil (0.013 g, 
28.5%) after 4 h. Rf 0.55 (20% EtOAc/Hex). 
1
H NMR (300 MHz, CDCl3) δ 12.12 (s, 
1H), 8.57 – 8.50 (m, 1H), 7.86 (s, 1H), 7.71 – 7.66 (m, 1H), 7.63 – 7.46 (m, 2H), 7.38 – 
7.32 (m, 1H), 7.23 – 7.06 (m, 3H), 6.95 (m, 1H), 3.98 (s, 3H), 2.45 (d, J = 1.1 Hz, 3H).
 
13
C NMR (75 MHz, CDCl3) δ 170.9, 160.7, 138.5, 134.6, 130.3, 128.7, 127.4, 126.5, 
125.4, 124.3, 123.7, 123.4, 122.1, 119.4, 119.0, 112.0, 110.5, 105.0, 52.5, 9.7. IR: 3600-
2800 (br), 2960.3 (m), 2923.7 (m), 2847.4 (m), 1657.1 (s), 1649.7 (s), 1525.7 (m), 1449.7 
(s), 1334.3 (m), 1321.1 (m), 1255.4 9s), 1226.3 (s), 1193.8 (w), 1122.6 (m), 1020 (m), 
796.6 (s), 740.7 (s), 705.2 (m).
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THE SYNTHESIS OF 1H-PYRROLO[1,2-a]INDOLES FROM 
DIASTEREOSELECTIVE INTRAMOLECULAR FRIEDEL-CRAFTS 






4.1. INTRODUCTION TO PYRROLO[1,2-a]INDOLES 
 
[a]-Annelated indoles are heterocyclic ring systems that frequently occur in a 
wide range of heterocyclic compounds that play important roles in medicinal chemistry 
and organic synthesis.
1
 The pyrrolo[1,2-a]-indole ring system, in particular, is a primary 
target for synthetic chemists due to its structural diversity.
2
 The pyrrolo[1,2-a]indole 
heterocyclic skeleton IV-1 derives the [1,2-a] designation through the conceptual fusion 
of a face of an indole IV-2 with the 1 and 2 positions of a pyrrolidine ring IV-3. The 
positional numbering and ring lettering about the pyrrolo[1,2-a]indole core along with 
above mentioned ring fusion are shown in Figure 4.1.  
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The pyrrolo[1,2-a]indoles are primarily characterized by three isomeric structures 
(the 9H-pyrrolo[1,2-a]indoles IV-4, the 3H-pyrrolo[1,2-a]indoles IV-5, and the 1H-




Compounds containing pyrrolo[1,2-a]-indole core skeleton demonstrate 
interesting physiological and therapeutic properties.
3
 For example, mitomycin C (IV-9)
4
 
exhibits strong anticancer activity; yuremamine (IV-10)
5
 shows hallucinogenic and 
psychoactive effects; isatisine A (IV-11) possesses antiviral activity;
6
 and flinderole C 
(IV-12)
7




4.2. PREVIOUS SYNTHETIC METHODS 
 
Numerous routes have been developed to synthesize and functionalize 
pyrrolo[1,2-a]indoles in recent years,
8,9 
underlining the continued importance of this 
framework to the synthetic community. These routes can be broadly categorized in five 
main classes A-E based upon the order in which the individual ring substructures are 
introduced. The first three approaches A, B, and C involve synthetic strategies which rely 
on the construction of A, B, or C rings respectively. The fourth major route D comprises 
the synthesis of the B and C rings via a transannular ring closure between N4 and C9a. 
The final class E entails the generation of the B and C rings employing other synthetic 
strategies. This section will provide a brief overview of some representative approaches 
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for the construction of pyrrolo[1,2-a]indole derivatives with an example given for each 
synthetic pathway as mentioned in Figure 4.4. 
 
 
4.2.1. PYRROLO[1,2-a]INDOLES VIA SYNTHESIS OF THE A RING  
The synthesis of pyrrolo[1,2-a]indole based derivatives through the formation of 
A ring is one of the least explored strategies. In 1967, Morlacchi and group reported the 
formation of pyrrolo[1,2-a]benzo[f]indole derivatives IV-17 utilizing a method that 
generated A ring (Figure 4.5).
10
 Upon heating 1-acetamido-1,2-dihydro-pyrrolizine IV-14 
and  phthalic anhydride IV-15 in the presence of large excess of aluminum trichloride, 
pyrrolo[1,2-a]indoles were generated. The reaction proceeds via two sequential Friedel-
Crafts reactions. Furthermore, their studies revealed that the when the reaction was 
carried out at lower temperature and a lower catalyst loading, an intermediate carboxylic 
acid IV-16 was observed, which would then undergo second a Friedel-Crafts cyclization 
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to provide the quinone A ring. An improvement in the yield was observed when the 
reaction was performed at higher temperature and in one-pot fashion.  
 
 
4.2.2. PYRROLO[1,2-a]INDOLES VIA SYNTHESIS OF THE B RING  
In an effort to devise an efficient methodology that provides direct access to the 
privileged N-fused indoline scaffold through C(sp
3
)-H bond functionalization, the Fillion 
group developed a novel pyrrolo[1,2-a]indole synthesis which falls into the path B 
classification (Figure 4.6.).
11
  They elegantly utilized the ability of N-aziridinyl imine IV-
18 to function as a carbene precursor to achieve the desired transformation. The reactions 
are proposed to proceed through a non-carbonyl-stabilized rhodium carbenoid C-H 
insertion mechanism to form a five-membered B ring of the pyrrolo[1,2-a]indole 
products. The method furnished N-fused indoline products IV-19 in moderate to high 
yields. The reactions were optimal at 100 °C in toluene and are usually completed within 
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3-22 h. The reaction also proceeded in good to high yields with both electron-rich and 





4.2.3. PYRROLO[1,2-a]INDOLES VIA SYNTHESIS OF THE C RING 
The generation of pyrrolo[1,2-a]indoles via synthesis of the C ring is by far the 
most common approach. It involves beginning the synthesis with an indole skeleton, and 
the additional pyrrolo skeleton is built through different transformations. Recently, Wang 
group reported N-heterocyclic carbene catalyzed synthesis of pyrrolo[1,2-a]indoles 
(Figure 4.7.).
9a
 The reaction employed 1,1-diactivated FCP with indole-2-
carboxaldehydes through NHCs. The reactions are suggested to proceed by NHC-
catalyzed domino ring opening/redox amidation/Knoevenagel condensation (a formal 
hetero-[3+2] cycloaddition) between 1H-indole-2-carbaldehyde IV-21 and readily-
available 1,1-diactivated FCP IV-20 to form the C ring of the pyrrolo[1,2-a]indole 
products. The reactions were optimal at 60-70° C in toluene and are usually completed 
within 20 h to provide the pyrrolo[1,2-a]indole products in moderate to good yields. The 
Wang group also screened 5-substituted indoles IV-21, with both electron-rich and poor 
211 
 
groups and monoactivated FCP, providing products IV-22 in moderate yields.  However, 
reactions were unsuccessful when tetrasubstituted FCP were tested.   
 
4.2.4. PYRROLO[1,2-a]INDOLES VIA SYNTHESIS OF THE D RING 
While exploring the utility of the tetrahydro-1,2-oxazine products generated 
through the reaction of nitrones IV-23 with 1,1-cyclopropanediesters IV-24, the Kerr 
group developed an efficient route for the synthesis of pyrrolo[1,2-a]indoles which relied 
on a late stage transannular ring closure of amino alcohol IV-26 (Figure 4.8).
12
 Initial 
studies focused on N-O bond cleavage of FR900482 skeletal congener IV-25 using an 
acid zinc reduction and a hydrogenolysis route. However, reactions under these 
conditions either failed to provide higher product conversions or desired products. 
Fortunately, SmI2-mediated N-O bond reduction of the monoester occurred to afford 
amino alcohol IV-26. The resulting alcohol was subjected to acid-catalyzed transannular 
ring closure to form the desired product IV-27. Therefore, synthesis of desired 
pyrrolo[1,2-a]indole skeletons involves a  five-step sequence (cycloaddition, Heck 
cyclization, Krapcho decarboxylation, SmI2-mediated N-O bond reduction, and acid-




4.2.5. PYRROLO[1,2-a]INDOLES VIA SYNTHESIS OF THE E RING 
The final class of reaction towards the synthesis of pyrrolo[1,2-a]indoles involves 
the formation of the B and C rings. Recently, the Feldman group reported allenyl azide 
cycloaddition chemistry to generate cyclopentannelated indoles (Figure 4.9).
13
 The 
reaction employed a 2-(allenyl)phenyl azide as a cyclization substrate. Upon subjecting 
this azide to toluene solution at reflux conditions, it furnished the expected product C(2)-
C(3) annelated indole IV-29 accompanied by N-C(2) annelated indole product IV-30. 
This reaction proceeds through an indolidene intermediate. The reaction tolerates silyl 
ether and steric bulk at the R
2
 position. Interestingly, these studies revealed that upon 
addition of steric bulk at the R
2
 positions, ratios of C(2)-C(3) to N-(C2) products can be 






4.3. THE DEVELOPMENT OF INDIUM(III)-CATALYZED 
DIASTEREOSELECTIVE INTRAMOLECULAR FRIEDEL-CRAFTS 
CYCLIZATION OF METHYL 2-(1H-INDOLE-1-CARBONYL) 
ACRYLATES  
The Michael-type F-C reaction of indoles with α,β-unsaturated carbonyl 
compounds is a powerful strategy in the total synthesis of complex products.
14
 While 
intermolecular examples of these reactions are prevalent in the literature,
15
 the lesser 
studied intramolecular variants offer tremendous utility for the synthesis of complex 
indole-containing polycycles.
16
 Following our success with the development of an 
efficient synthesis of hydropyrido-[1,2-a]indole-6(7H)-ones via an In(III)-catalyzed 
tandem cyclopropane ring-opening/intramolecular F-C alkylation sequence,
17
 we 
reasoned that an intramolecular F-C reaction should occur if the corresponding methyl 2-
(1H-indole-1-carbonyl)acrylates IV-35 were employed as the cyclization precursors.  
Adding credence to this hypothesis, Hadjipavlou-Litina and Papaioannou recently 
reported the formation of a 1H-pyrrolo[1,2-a]indole-3(2H)-one.
18
 While performing 
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TFA-mediated deprotection of an N-cinnamoyl indole ester derivative IV-31 to its 
corresponding acid, the rearranged acid IV-32 was isolated in 84% yield. The reaction 
was proposed to go through an acid-mediated Michael-type nucleophilic attack 
mechanism for the formation of this unexpected product (Figure 4.10). This reaction only 
occurred when the aryl portion of the cinnamate had electron-donating ortho- and para-
methoxy substituents. When no methoxy group was present or if the aryl ring had only 




4.3.1. PROOF OF PRINCIPLE 
In hopes of circumventing this limitation and given that alkylidene malonates 
have been shown to offer enhanced reactivity as Michael acceptors in comparison to 
simple α, β-unsaturated alkenes,
19
 N-acylated indoles IV-35a were synthesized as shown 
in Figure 4.11. Treatment of 3-methyl-1H-indole IV-33a with methyl malonyl chloride 
(MMC) afforded the β-amide ester IV-34a, and Knoevenagel condensation with a p-






With a model substrate in our hand, we set out to test the feasibility of our 
hypothesis by subjecting it to the reaction conditions (30 mol% In(OTf)3, DCM, rt) 
employed in our recent synthesis of hydropyrido[1,2-a]indoles. To our surprise, the 
utilization of this reaction conditions at room temperature or even at higher temperature 
(40 
o
C) did not lead to the formation of any products (Table 4.1, entry 1-2). Interestingly, 
a quantitative conversion to the desired product (>98% yield) of IV-36a was realized 
when the reaction was heated at 110 °C for 0.5 h using 30 mol% In(OTf)3 in toluene and 
column chromatography (Table 4.1, entry 3). Using the model substrate IV-35a, a series 
of experiments were performed with variation of reaction parameters such as catalyst, % 
loading of catalyst, solvent, temperature, etc., in hopes of optimizing the formation of  
pyrrolo[1,2-a]indole product IV-36a.  Selected results are summarized in Table 4.1. In 
order to find the effect of temperature, toluene solvent was replaced by 1,2-
dichloroethane and the reaction was performed at 80 °C. Gratifyingly, the reaction still 
showed quantitative conversion to the product (Table 4.1, entry 4). Next, the 
substoichiometric amounts of various metal catalysts, primarily focusing on readily 









showed complete consumption of starting material. While it was possible to move 
forward with any of the above catalyst system, In(OTf)3 was chosen as the catalyst 
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system given the slightly shorter reaction times. Finally, the effect of varying catalyst 
amounts was examined. Using 5 mol % In(OTf)3 led to a increased reaction time. 
Therefore, heating the reactants in 1,2-dichloromethane at reflux in the presence of 10 







4.3.2. RESULTS AND DISCUSSION  
 
Having established the optimized reaction conditions (Table 4.1, entry 5), next 
extension of the reaction scope to a variety of aryl substituted acrylates was sought (Table 
4.2). The sequence proved to be quite general, providing rapid access to a range of 
diversely functionalized 1H-pyrrolo[1,2-a]indole products IV-36. The model substrate 
IV-35a furnished 1H-pyrrolo[1,2-a]indole product IV-36a in 95% yield with a 15:1 
trans/cis dr (Table 4.2, entry 1). To determine the electronic effect of the aryl substituent 
on the product formation, substrates with the phenyl group IV-35b and the electron-
withdrawing 4-bromophenyl (IV-35c), 4-trifluoromethylphenyl (IV-35d), and the 4-
nitrophenyl (IV-35e) groups were prepared using our three step sequence. The phenyl 
derivative readily cyclized to afford IV-36b in 97% yield with a 16:1 dr (Table 4.2, entry 
2). The reaction was found to be equally effective with the electron deficient arenes to 
furnish products in high yields (Table 4.2, entries 3-5). Therefore, no discernible effect 
on the reaction outcome was observed due the variation of electronic properties of the 
functional groups attached with the aryl acrylates. Next, electron-rich heteroaromatic 
substituted acrylates were considered. The 2-substituted furanyl derivative IV-35f and 2-
thienyl derivative IV-35g, proved to be suitable substrates, providing 1H-pyrrolo[1,2-
a]indole products IV-36f and IV-36g in 97% and 98% yield, respectively, with high dr 
(Table 4.2, entries 6 and 7). In contrast, the 2-pyridyl substrate IV-35h did not undergo 
any appreciable cyclization (Table 4.2, entry 8). This lack of reactivity may be attributed 
to inductive effects, given that the 2-pyridyl group prefers to serve as an electron 
acceptor. Moreover, the nitrogen of the pyridine could serve to deactivate the Indium 
catalyst by forming a stable complex.  
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The cyclization protocol is also amenable to substituent changes about the 3-
position of the indole moiety (Table 4.3). For example, when the phthalimide-protected 
tryptamine derivative IV-35i was subjected to the reaction conditions, 1H-pyrrolo[1,2-a]- 
indole product IV-36i was generated in 96% yield with 14:1 dr (Table 4.3, entry 1). 
Moreover, IV-36i can then be readily deprotected to provide the free amine, which is 
important for several natural product targets, such as the flinderoles IV-12. The 3-(2-
bromoethyl)-1H-indole derivative IV-35j also provided its cyclization product IV-36j in 
69% yield with a 25:1 dr (Table 4.3, entry 2). The bromide on this molecular scaffold 
provides an excellent handle for further functionalization. The methyl acetate substituted 
indole derivative IV-35k generated its cyclized product IV-36k in 93% yield with 13:1 
dr (Table 4.3, entry 3). Finally, when substrate IV-35l (derived from indole) was 
employed, the cyclization readily occurred to afford IV-36l in 98% yield and 10:1 dr 
(Table 4.3, entry 4).  
While pleased with the performance of the aromatic substrates, nonaromatic 
substituents on the acrylates were considered for further expansion of the substrate scope 
(Table 4.4). In particular, we were interested in systems derived from alkyl aldehydes and 
cinnamaldehyde. The ethyl substituted acrylate IV-35m was the first nonaromatic 
substrate synthesized. Unfortunately, no reaction was observed by subjecting IV-35m to 
the optimized conditions. After careful screening of various conditions, it was found that 
the cyclization of IV-35m could be achieved at a slightly higher catalyst loading (15%) in 
toluene heated at reflux. Under these new conditions, the cyclized product IV-36m was 










Similar reactivity was observed for the propyl substituted derivative IV-35n 
(Table 4.4, entry 2). The parent compound, methyl 2-(1H-indole-1-carbonyl)acrylate IV-
35o (derived from formaldehyde), gave the 1H-pyrrolo[1,2-a]indole product IV-36o  in 
47% yield (Table 4.4, entry 3). Cinnamate IV-35p (from cinnamaldehyde) afforded its 
product IV-36p in 71% yield with 8:1 dr (Table 4.4, entry 4). We were delighted to find 
that the 2,2-disubstituted acrylate IV-35q (derived from 3-pentanone) cyclized to 
generate product IV-36q, containing a quaternary carbon, in 98% yield (Table 4.4, entry 
5). This reaction proceeds quite well even with a substrates derived from ketones and 
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offers a powerful method to generate a functionalized quaternary carbon, especially, if an 








An interesting result was obtained when acrylate IV-35r (derived from 
isobutyraldehyde) was subjected to the modified conditions. While the reaction formed 
the anticipated trans-1H-pyrrolo[1,2-a]indole product IV-36r  in 86% yield, a small 
amount of the hydropyrido[1,2-a]-indole product IV-37 was also observed. The 
formation of this minor product could be attributed to a mechanistic pathway delineated 
in Figure 4.12. This product seemingly arises from a putative carbocationic intermediate 
A that undergoes a 1,2-hydride shift to generate carbocation B, an intermediate observed 
in our tandem cyclopropane ring-opening/intramolecular FC cyclization.
17
 Intermediate B 
then undergoes an intramolecular FC reaction to generate the six-membered ring in IV-
37. Frontier recently noted this type of transformation for alkenyl 2-furyl and alkenyl 2-




 Both examples 
highlight the existence of two possible pathways that depend on the aromatic character of 





Finally, to expand the scope of this synthetic approach, we set out to perform a 
preliminary test reaction on a different heteroaromatic. Given that the cyclization readily 
occurs with indoles, we anticipated that pyrroles would behave similarly under the 
reaction conditions to form 1H-pyrrolizin-3(2H)-ones. Pyrrolizine derivatives, many of 
which are naturally occurring, have attracted considerable attention from both synthetic 
and medicinal chemists for their interesting biological activities and therapeutic 
potential.
21
 To our satisfaction, when N-acyl pyrrole IV-38 was treated with In(OTf)3 in 
1,2-dichloroethane at reflux, the expected pyrrolizine product IV-39 was obtained in 54% 













4.4. CONCLUSIONS AND FUTURE WORK 
In conclusion, a facile and efficient method for the synthesis of functionalized 
1H-pyrrolo-[1,2-a]indole-3(2H)-ones has been through a Lewis acid-catalyzed 
diastereoselective intramolecular Friedel-Crafts reaction of substituted methyl 2-(1H-
indole-1-carbonyl)acrylates. The method is fast, operationally simple, and versatile 
enough to access a variety of pyrrolo[1,2-a]indoles. The reactions proceeded efficiently 
with a wide variety of substrates and afforded the corresponding products in high yields 
(up to 98%) with high diastereoselectivities (up to >25:1 dr) from simple, readily 
available substances such as indoles and aldehydes. 
In future, this methodology may find application in the total synthesis of the 
yuremamine and Flinderole C natural products. Efforts to employ chiral catalyst 
complexes to promote enantioselectivity as well as further examination of the cationic 














4.5.1. General Methods 
All reactions were carried out in pre-dried glassware from the oven and any 
additional moisture was removed by flame-drying the reaction vessel.  Each reaction 
proceeded under a nitrogen atmosphere with anhydrous solvents, unless stated otherwise. 
Tetrahydrofuran and diethyl ether were distilled from a sodium/benzophenone ketyl 
under nitrogen and stored in a Schlenk flask. Benzene, toluene, 1,2-dichloroethane and 
dichloromethane were purified by distillation from calcium hydride. Acetonitrile was 
dried by fractional distillation over CaH2. All other reagents were purchased from Acros, 
Sigma-Aldrich, Fluka, VWR, Merck, Alfa Aesar, TCI and Strem (for metal catalysts) and 
used without further purification.  All methyl 3-(1H-indol-1-yl)-3-oxopropanoates IV-34 
were synthesized as previously reported.
17 
 
Chromatographic purification was performed as flash chromatography with 
Dynamic Adsorbents silica gel (32-65µm) and solvents indicated as eluent with 0.1-0.5 
bar pressure. For quantitative flash chromatography, technical grades solvents were 
utilized. Analytical thin-layer chromatography (TLC) was performed on EMD silica gel 
60 F254 TLC glass plates. Visualization was accomplished with UV light, aqueous basic 
potassium permanganate (KMnO4) solution, iodine, aqueous acidic 
dinitrophenylhydrazine (DNP) solution, aqueous acidic p-anisaldehyde (PAA) solution, 
and an ethanol solution of phosphomolybdic acid (PMA) followed by heating.  Each 
yield refers to an isolated, analytically-pure material.  
Infrared (IR) spectra were obtained using a Nicolet 4700 FTIR with an ATR 
attachment from SmartOrbit Thermoelectronic Corp. The IR bands are characterized as 
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weak (w), medium (m), and strong (s). Proton and carbon nuclear magnetic resonance 
spectra (
1
H NMR and 
13
C NMR) were recorded on a Varian Mercury Vx 300 MHz 
spectrometer, Varian Mercury Vx 400 MHz spectrometer or Bruker 400 MHz 
spectrometer with solvent resonances as the internal standard (
1
H NMR: CDCl3 at 7.26 
ppm; 
13
C NMR: CDCl3 at 77.0 ppm). 
1
H NMR data are reported as follows: chemical 
shift (ppm), multiplicity (s = singlet, d = doublet, dd = doublet of doublets, dt = doublet 
of triplets, ddd = doublet of doublet of doublets, t = triplet, m = multiplet), coupling 
constants (Hz), and integration. Mass spectra were obtained using a VG-70SE instrument.  
 
4.5.2. Preparation of Acrylate Products IV-35a-r, IV-38 
General Method A:
22
 The β-ester-amide (1.0 equiv.), aldehyde (1.3 equiv.), glacial acetic 
acid (0.5 equiv.), and piperidine (0.1 equiv.) were heated to a reflux in benzene using a 
Dean-Stark trap for 12 h. After cooling the reaction mixture to room temperature, water 
was added to the reaction vessel, and the organic layer was collected. Subsequently, the 
aqueous phase was extracted with EtOAc three times. The combined organic layers were 
washed with 1 M HCl and saturated sodium bicarbonate. The combined organic layers 
were dried with Na2SO4, filtered, concentrated, and purified by silica gel column 
chromatography (gradient EtOAc/Hex). 
General Method B:
23
 A round bottom flask was charged with the β-ester-amide (1.0 
equiv.) and THF (25 mL). After cooling the solution to 0 ˚C, titanium(IV) chloride 
tetrahydrofuran complex (2.0 equiv.) and CCl4 (2.0 equiv.) were added to the reaction 
vessel. After 1h at 0 ˚C, the aldehyde (1.0 equiv.) was added slowly, and the reaction was 
stirred for an hour. Then, pyridine (4.0 equiv.) was added to the solution drop-wise. The 
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reaction mixture was warmed to room temperature and allowed to stir for 14 h. The 
reaction was quenched with water and the organic layer was collected. The aqueous layer 
was extracted with ether, and the combined organic layers were washed with saturated 
NaHCO3 and brine. The organic layer was dried with MgSO4, filtered, concentrated, and 





Methyl 3-(3-methyl-1H-indol-1-yl)-3-oxopropanoate (0.800 g, 3.46 mmol), 4-
methoxybenzaldehyde (0.53 mL, 4.32 mmol), glacial acetic acid (0.0956 g, 1.59 mmol), 
piperidine (0.0295 g, 0.346 mmol) and benzene (15 mL) were mixed according to general 
method A to afford IV-35a as a white solid (0.920 g, 76%) after 18 h. Rf 0.30 (20% 
EtOAc/Hex). [m.p. 138-140 °C]  
1
H NMR (300 MHz, CDCl3) δ 8.69 (d, J = 8.1 Hz, 1H), 
7.94 (s, 1H), 7.53 – 7.32 (m, 5H), 7.01 (s, 1H), 6.79 – 6.72 (m, 2H), 3.80 (s, 3H), 3.70 (s, 
3H), 2.18 (d, J = 0.6 Hz, 3H). 
13
C NMR (75 MHz, CDCl3) δ 165.2, 164.9, 161.7, 142.9, 
135.3, 132.1, 131.9, 125.2, 124.6, 124.1, 123.3, 122.4, 119.1, 118.8, 116.7, 114.5, 55.1, 
52.6, 9.5. IR: 3070.1 (w), 3007.0 (w), 2930.6 (w), 2824.4 (w), 1715.1 (m), 1678.1 (s), 
1598.3 (s), 1511.9 (m), 1448.1 (m), 1395.8 (m), 1341.2 (m), 1254.3 (s), 1170.5 (s), 
1047.5 (s), 874.9 (m), 732.2 (s), 698.5 (m), 536.2 (m) cm
-1
. HRMS (ESI) M/Z+ Calc. 




(Z)-Methyl 2-(3-methyl-1H-indole-1-carbonyl)-3-phenylacrylate (IV-35b): Methyl 3-
(3-methyl-1H-indol-1-yl)-3-oxopropanoate (0.350 g, 1.51 mmol), benzaldehyde (0.19 
mL, 1.89 mmol), glacial acetic acid (0.0418 g, 0.696 mmol), piperidine (0.0129 g, 0.151 
mmol) and benzene (15 mL) were combined according to general method A to yield IV-
35b as a pale yellow solid (0.260 g, 52%) after 12 h. Rf 0.50 (20% EtOAc/Hex). [m.p. 
112-114 °C]  
1
H NMR (300 MHz, CDCl3) δ 8.59 (d, J = 8.1 Hz, 1H), 7.92 (s, 1H), 7.47 – 
7.17 (m, 8H), 6.90 (s, 1H), 3.76 (s, 3H), 2.12 (s, 3H). 
13
C NMR (75 MHz, CDCl3) δ 
164.8 (2), 143.3, 135.5, 132.2, 132.1, 131.1, 129.9, 129.1, 126.2, 125.4, 124.2, 122.3, 
119.5, 118.9, 116.9, 52.9, 9.7. IR: 3056.8 (w), 3026.9 (w), 2957.2 (w), 2914.0 (w), 
2850.9 (w), 1723.0 (s), 1711.5 (s), 1687.9 (s), 1678.3 (s), 1615.5 (m), 1449.5 (m), 1396.5 
(m), 1341.9 (m), 1256.7 (s), 1212.4 (s), 1198.5 (s), 1046.7 (m), 881.6 (m), 731.6 (s), 
687.4 (s) cm
-1
. HRMS (ESI) M/Z+ Calc. 319.1208, Obs. 319.1217.   
 
(Z)-Methyl 3-(4-bromophenyl)-2-(3-methyl-1H-indole-1-carbonyl)acrylate (IV-35c): 
Methyl 3-(3-methyl-1H-indol-1-yl)-3-oxopropanoate (0.500 g, 2.16 mmol), 4-
bromobenzaldehyde (0.500 g, 2.70 mmol), glacial acetic acid (0.0520 g, 0.867 mmol), 
piperidine (0.184 g, 0.216 mmol) and benzene (30 mL) were mixed according to general 
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method A to afford IV-35c as a colorless oil (0.418 g, 49%) after 12 h. Rf 0.30-0.35 (20% 
EtOAc/Hex). 
1
H NMR (300 MHz, CDCl3) δ 8.54 (d, J = 8.1 Hz, 1H), 7.82 (s, 1H), 7.47 
– 7.17 (m, 7H), 6.84 (s, 1H), 3.74 (s, 3H), 2.10 (d, J = 1.1 Hz, 3H). 
13
C NMR (75 MHz, 
CDCl3) δ 164.5, 164.4, 141.8, 135.4, 132.4, 132.1, 131.2, 131.0, 126.9, 125.7, 125.5, 
124.4, 122.0, 119.8, 119.0, 116.8, 53.0, 9.7. IR: 3030.2 (w), 2940.6 (w), 2914.0 (w), 
2841.0 (w), 1731.7 (m), 1698.5 (s), 1672.0 (m), 1619.7 (s), 1585.6 (m), 1439.5 (m), 
1392.7 (m), 1250.8 (s), 1212.1 (m), 1178.7 (m), 1073.0 (m), 1006.8 (m), 964.6 (m), 737.1 
(s), 700.3 (s) cm
-1
. HRMS (ESI) M/Z+ Calc. 397.0314, Obs. 397.0303. 
 
(Z)-Methyl2-(3-methyl-1H-indole-1-carbonyl)-3-(4-(trifluoromethyl)phenyl)acrylate 
(IV-35d): Methyl 3-(3-methyl-1H-indol-1-yl)-3-oxopropanoate (0.500 g, 2.16 mmol), 4-
(trifluoromethyl)benzaldehyde (0.470 g, 2.70 mmol), glacial acetic acid (0.0520 g, 0.867 
mmol), piperidine (0.184 g, 0.216 mmol) and benzene (30 mL) were combined according 
to general method A to afford IV-35d as a white solid (0.523 g, 62%) after 12 h. Rf 0.30-
0.35 (20% EtOAc/Hex). [m.p. 78-80 °C] 
1
H NMR (300 MHz, CDCl3) δ 8.62 (d, J = 8.1 
Hz, 1H), 7.98 (s, 1H), 7.63 – 7.33 (m, 7H), 6.91 (s, 1H), 3.84 (s, 3H), 2.18 (s, 3H). 
13
C 
NMR (75 MHz, CDCl3) δ 164.3, 164.0, 141.3, 135.6, 135.4, 132.5, 132.1, 129.9, 128.7, 
126.05, 126.0, 125.6, 125.3, 124.5, 121.8, 120.1, 119.0, 116.9, 53.1, 9.7. IR: 3096.7 (w), 
3066.8 (w), 2920.7 (w), 2854.2 (w), 1725.9 (s), 1688.2 (s), 1678.6 (s), 1622.1 (w), 1450.6 
(s), 1396.8 (s), 1322.3 9s), 1257.5 (s), 1213.2 (m), 1167.8 (m), 1118.6 (s), 1068.1 (s), 
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1014.4 (m), 874.9 (w), 835.1 (w), 748.0 (s), 682.3 (w) cm
-1
.   HRMS (ESI) M/Z+ Calc. 
387.1082, Obs. 387.1084.  
 
(Z)-Methyl 2-(3-methyl-1H-indole-1-carbonyl)-3-(4-nitrophenyl)acrylate (IV-35e): 
Methyl 3-(3-methyl-1H-indol-1-yl)-3-oxopropanoate (0.350 g, 1.51 mmol), 4-
nitrobenzaldehyde (0.286 g, 1.89 mmol), glacial acetic acid (0.0418 g, 0.696 mmol), 
piperidine (0.0128 g, 0.151 mmol) and benzene (15 mL) were mixed according to general 
method A to afford IV-35e as a yellow solid (0.246 g, 43%) after 12 h. Rf 0.30 (20% 
EtOAc/Hex). [m.p. 147-149 °C] 
1
H NMR (300 MHz, CDCl3) δ 8.58 (d, J = 7.4 Hz, 1H), 
8.12 (d, J = 8.3 Hz, 2H), 7.99 (s, 1H), 7.60 (d, J = 8.5 Hz, 2H), 7.53 – 7.34 (m, 3H), 6.86 
(s, 1H), 3.85 (s, 3H), 2.17 (s, 3H). 
13
C NMR (75 MHz, CDCl3) δ 164.0, 163.5, 148.5, 
141.9, 140.1, 138.3, 135.4, 132.0, 130.3, 130.1, 128.6, 125.8, 124.6, 124.2, 121.5, 120.4, 
119.1, 116.8, 53.3, 9.7. IR: 3100.0 (m), 3060.2 (m), 2957.2 (m), 2914.0 (m), 2834.3 (m), 
1724.6 (s), 1687.1 (s), 1677.9 (s), 1449.2 (m), 1342.4 (s), 1254.5 (s), 1198.4 (s), 1084.8 
(m), 1047.4 (m), 863.1 (m), 733.3 (s), 690.8 (s) cm
-1
.   HRMS (ESI) M/Z+ Calc. 





(Z)-Methyl 3-(furan-2-yl)-2-(3-methyl-1H-indole-1-carbonyl)acrylate (IV-35f): 
Methyl 3-(3-methyl-1H-indol-1-yl)-3-oxopropanoate (0.330 g, 1.44 mmol), furan-2-
carbaldehyde (0.173 g, 1.80 mmol), glacial acetic acid (0.40 mL, 0.576 mmol), piperidine 
(0.10 mL, 0.0144 mmol) and benzene (30 mL) were mixed according to general method 
A to yield IV-35f as a light brown solid (0.210 g, 47%) after 12 h. Rf 0.30-0.35 (20% 
EtOAc/Hex). [m.p. 142-144 °C] 
1
H NMR (300 MHz, CDCl3) δ 8.58 (d, J = 8.1 Hz, 1H), 
7.66 (s, 1H), 7.47 – 7.17 (m, 4H), 6.89 (s, 1H), 6.66 (d, J = 3.5 Hz, 1H), 6.30 (d, J = 1.7 
Hz, 1H), 3.71 (s, 3H), 2.13 (s, 3H). 
13
C NMR (75 MHz, CDCl3) δ 164.7, 164.2, 148.6, 
146.9, 135.5, 132.0, 128.8, 125.2, 123.9, 122.6, 122.2, 118.8, 118.7, 118.5, 116.8, 112.6, 
52.7, 9.6. IR: 3126.6 (w), 2947.2 (w), 3053.5 (w), 2910.7 (w), 1710.1 (s), 1688.1 (s), 
1629.7 (s), 1448.6 (s), 1433.8 (s), 1390.9 (s), 1376.5 (m), 1247.9 (s), 1227.1 (s), 1204.3 
(s), 1047.4 (m), 1017.5 (m), 877.6 (m), 731.1 (s), 700.9 (m), 590.1 (m) cm
-1
. HRMS 
(ESI) M/Z+ Calc. 309.1001, Obs. 309.0998. 
 
 
(Z)-Methyl 2-(3-methyl-1H-indole-1-carbonyl)-3-(thiophen-2-yl)acrylate (IV-35g):  
Methyl 3-(3-methyl-1H-indol-1-yl)-3-oxopropanoate (0.500 g, 2.16 mmol), thiophene-2-
carbaldehyde (0.303 g, 2.70 mmol), glacial acetic acid (0.0520 g, 0.867 mmol), 
piperidine (0.184 g, 0.216 mmol) and benzene (30 mL)  were combined according to 
general method A to afford IV-35g as a white solid (0.371 g, 53%) after 12 h. Rf 0.30-
0.35 (20% EtOAc/Hex). [m.p. 128-130 °C]  
1
H NMR (300 MHz, CDCl3) δ 8.68 (d, J = 
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8.0 Hz, 1H), 8.10 (s, 1H), 7.56 – 7.31 (m, 5H), 7.03 – 6.95 (m, 2H), 3.81 (s, 3H), 2.20 (s, 
3H). 
13
C NMR (75 MHz, CDCl3) δ 164.7, 164.2, 135.8, 135.4, 134.3, 132.4, 132.1, 
128.0, 125.4, 124.2, 123.0, 122.2, 119.5, 118.8, 116.9, 52.7, 9.7. IR: 3103.3 (m), 3060.2 
(m), 2910.7 (w), 2850.9 (w), 1710.3 (s), 1677.8 (s), 1604.7 (s), 1450.8 (s), 1418.1 (s), 
1392.2 (s), 1345.9 (s), 1251.1 (s), 1200.1 (s), 1142.5 (m), 1044.6 (m), 964.6 (w), 880.2 
(m), 759.3 (s), 711.2 (s), 613.0 (m) cm
-1
. HRMS (ESI) M/Z+ Calc. 325.0773, Obs. 
325.0769. 
 
(Z)-Methyl 2-(3-methyl-1H-indole-1-carbonyl)-3-(pyridin-2-yl)acrylate (IV-35h): 
Methyl 3-(3-methyl-1H-indol-1-yl)-3-oxopropanoate (0.330 g, 1.44 mmol), 
picolinaldehyde (0.193 g,  1.80 mmol), glacial acetic acid (0.400 mL, 0.576 mmol), 
piperidine (0.100 mL, 0.144 mmol) and benzene (30 mL)  were combined according to 
general method A to afford IV-35h as a white solid (0.250 g, 54%) after 12 h. Rf 0.30-
0.35 (20% EtOAc/Hex). [m.p. 98-100 °C] 
1
H NMR (300 MHz, CDCl3) δ 8.55 (d, J = 8.0 
Hz, 1H), 8.20 – 8.15 (m, 1H), 7.80 (s, 1H), 7.62 – 7.49 (m, 1H), 7.44 – 7.10 (m, 4H), 7.07 
– 6.97 (m, 1H), 6.84 (s, 1H), 3.72 (s, 3H), 2.07 (s, 3H). 
13
C NMR (75 MHz, CDCl3) δ 
164.7, 164.6, 150.6, 150.1, 140.8, 136.6, 135.6, 131.8, 129.3, 126.2, 125.0, 124.4, 123.5, 
122.5, 118.6, 118.3, 116.7, 53.0, 9.7. IR: 3060.2 (w), 2940.6 (w), 2920.7 (w), 1721.8 (s), 
1690.9 (s), 1678.7 (s), 1450.7 (s), 1433.4 (s), 1332.8 (m), 1262.9 (s), 1202.3 (s), 1087.5 
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(m), 881.6 (m), 730.9 (s), 700.2 (s), 622.5 (m) cm
-1
. HRMS (ESI) M/Z+ Calc. 320.1161, 
Obs. 320.1162.  
 
(Z)-Methyl 2-(3-(2-(1,3-dioxoisoindolin-2-yl)ethyl)-1H-indole-1-carbonyl)-3-(4-
methoxyphenyl)acrylate (IV-35i): Methyl 3-(3-(2-(1,3-dioxoisoindolin-2-yl)ethyl)-1H-
indol-1-yl)-3-oxopropanoate (1.08 g, 2.77 mmol), 4-methoxybenzaldehyde (0.459 g, 3.37 
mmol), glacial acetic acid (0.0940 g, 1.57 mmol), piperidine (0.022 g, 0.253 mmol) and 
benzene (150 mL)  were mixed according to general method A to yield IV-35i as a light 
yellow solid (0.569 g, 40%) after 16 h. Rf 0.40 (40% EtOAc/Hex). [m.p. 147-149 °C]  
1
H 
NMR (300 MHz, CDCl3) δ 8.64 (d, J = 8.0 Hz, 1H), 7.92 (s, 1H), 7.78 – 7.72 (m, 2H), 
7.71 – 7.64 (m, 3H), 7.48 – 7.31 (m, 4H), 7.13 (s, 1H), 6.79 – 6.71 (m, 2H), 3.95 – 3.88 
(m, 2H), 3.77 (s, 3H), 3.74 (s, 3H), 3.05 – 2.96 (m, 2H). 
13
C NMR (75 MHz, CDCl3) δ 
168.1, 165.5, 164.9, 161.9, 143.3, 135.5, 133.9, 132.1, 131.9, 131.1, 125.6, 124.8, 124.4, 
123.2, 122.9, 119.7, 118.9, 117.0, 114.6, 55.3, 52.7, 37.1, 24.1. IR: 3120.0 (w), 3060.2 
(w), 2950.6 (w), 2844.3 (w), 1790.2 (s), 1691.8 (s), 1678.5 (s), 1652.9 (s), 1598.7 (s), 
1434.3 (m), 1390.0 (s), 1256.0 (s), 1203.9 (s), 1172.7 (s), 1121.3 (m), 1019.5 (m), 888.2 
(m), 750.6 (m), 718.5 (s), 529.5 (m) cm
-1






(IV-35j): Methyl 3-(3-(2-bromoethyl)-1H-indol-1-yl)-3-oxopropanoate (0.345 g, 1.06 
mmol), 4-methoxybenzaldehyde (0.244 g, 1.64 mmol), glacial acetic acid (0.0315 g, 
0.524 mmol), piperidine (0.0172 g, 0.202 mmol) and benzene (30 mL)  were combined 
according to general method A to afford IV-35j as a yellowish orange solid (0.384 g, 
82%) after 14 h. Rf 0.31 (20% EtOAc/Hex). [m.p. 90-92 °C]  
1
H NMR (300 MHz, 
CDCl3) δ 8.67 (d, J = 8.0 Hz, 1H), 7.94 (s, 1H), 7.55 – 7.42 (m, 2H), 7.42 – 7.34 (m, 3H), 
7.07 (s, 1H), 6.79 – 6.73 (m, 2H), 3.80 (s, 3H), 3.75 (s, 3H), 3.66 (t, J = 7.2 Hz, 1H), 3.52 
(t, J = 7.3 Hz, 1H), 3.16 (t, J = 7.3 Hz, 1H), 3.06 (t, J = 7.1 Hz, 1H). 
13
C NMR (101 
MHz, CDCl3) δ 165.5, 165.0, 162.0, 143.6, 135.5, 132.1, 130.6, 125.7, 124.7, 124.3, 
123.6, 123.4, 123.2, 120.3, 118.5, 117.2, 114.7, 77.2, 55.4, 52.8, 43.1, 31.0, 28.7, 28.5. 
IR: 3060.2 (w), 3007.0 (w), 2957.2 (w), 2834.3 (w), 1708.5 (m), 1691.0 (m), 1598.9 (s), 
1512.2 (m), 1450.9 (m), 1392.8 (m), 1256.3 (s), 1203.1 (s), 1172.6 (s), 1026.8 (m), 878.2 
(w), 830.6 (m), 730.4 (s), 700.6 (s), 539.5 (m) cm
-1






acrylate (IV-35k): Methyl 3-(3-(2-methoxy-2-oxoethyl)-1H-indol-1-yl)-3-
oxopropanoate (1.01 g, 3.50 mmol), 4-methoxybenzaldehyde (0.615 g, 4.52 mmol), 
glacial acetic acid (0.105 g, 1.75 mmol), piperidine (0.043 g, 0.506 mmol) and benzene 
(150 mL)  were combined according to general method A to afford IV-35k as a light 
yellow solid (0.568 g, 40%) after 16 h. Rf 0.26 (40% EtOAc/Hex). [m.p. 147-149 °C] 
1
H 
NMR (300 MHz, CDCl3) δ 8.66 (d, J = 8.1 Hz, 1H), 7.93 (s, 1H), 7.57 – 7.42 (m, 3H), 
7.42 – 7.33 (m, 2H), 7.20 (s, 1H), 6.80 – 6.74 (m, 2H), 3.80 (s, 3H), 3.74 (s, 3H), 3.65 (s, 
3H), 3.63 (s, 2H). 
13
C NMR (75 MHz, CDCl3) δ 170.8, 165.6, 164.9, 161.9, 143.5, 135.4, 
132.1, 130.8, 125.6, 124.7, 124.4, 124.2, 123.1, 119.0, 117.0, 115.8, 114.6, 55.3, 52.8, 
52.1, 30.7. IR: 3050.2 (w), 3003.7 (w), 2953.9 (w), 2841.0 (w), 1737.6 (m), 1722.3 (m), 
1710.6 (m), 1691.1 (m), 1598.9 (s), 1512.4 (m), 1450.7 (m), 1392.8 (m), 1256.2 (s), 
1202.3 (m), 1172.0 (s), 1045.5 (m), 1026.7 (m), 888.2 (w), 730.4 (s), 700.4 (s) cm
-1
. 
HRMS (ESI) M/Z+ Calc. 407.1369, Obs. 407.1389. 
 
(Z)-Methyl 2-(1H-indole-1-carbonyl)-3-(4-methoxyphenyl)acrylate (IV-35l): Methyl 
3-(1H-indol-1-yl)-3-oxopropanoate (0.194 g, 0.897 mmol), 4-methoxybenzaldehyde 
(0.159 g,  1.17 mmol), glacial acetic acid (0.0248 g, 0.413 mmol), piperidine (0.0766 g, 
0.897 mmol) and benzene (10 mL)  were combined according to general method A to 





H NMR (300 MHz, CDCl3) δ 8.70 (d, J = 8.8 Hz, 1H), 7.95 (s, 1H), 7.57 (d, J 
= 7.3 Hz, 1H), 7.50 – 7.29 (m, 4H), 7.21 (d, J = 3.8 Hz, 1H), 6.81 – 6.71 (m, 2H), 6.54 
(d, J = 3.7 Hz, 1H), 3.79 (s, 3H), 3.72 (s, 3H). 
 13
C NMR (75 MHz, CDCl3) δ 165.8, 
164.9, 161.9, 143.4, 135.1, 132.0, 131.0, 125.8, 125.2, 124.6, 124.4, 123.1, 120.9, 120.8 
(2), 116.8, 114.6, 109.9, 55.2, 52.7. IR: 3139.9 (w), 3046.9 (w), 2940.6 (w), 2834.3 (w), 
1708.5 (s), 1691.0 (s), 1597.9 (s), 1511.8 (s), 1449.3 (m), 1389.1 (m), 1253.7 (s), 1221.6 
(m), 1170.7 (m), 1113.3 (m), 1054.2 (m), 887.6 (m), 749.7 (s), 727.5 (s) cm
-1
. HRMS 
(ESI) M/Z+ Calc. 335.1158, Obs. 335.1155. 
 
(Z)-Methyl 2-(3-methyl-1H-indole-1-carbonyl)pent-2-enoate (IV-35m): Methyl 3-(3-
methyl-1H-indol-1-yl)-3-oxopropanoate (0.500 g, 2.16 mmol), propionaldehyde (0.155 
mL, 2.16 mmol), TiCl4•THF (1.44 g, 4.32 mmol), CCl4 (0.417 mL, 4.32 mmol), pyridine 
(0.700 mL, 8.65 mmol) and THF (35 mL) were combined according to general method B 
to yield IV-35m as a white solid (0.410 g, 66%) after 14 h. Rf 0.70 (20% EtOAc/Hex). 
[m.p. 104-106 °C] 
1
H NMR (300 MHz, CDCl3) δ 8.56 (d, J = 7.5 Hz, 1H), 7.51 (d, J = 
8.2 Hz, 1H), 7.45 – 7.30 (m, 2H), 7.26 – 7.17 (m, 1H), 6.94 (s, 1H), 3.75 (s, 3H), 2.31 – 
2.15 (m, 5H), 1.08 (t, J = 7.5 Hz, 3H). 
13
C NMR (75 MHz, CDCl3) δ 164.0, 150.5, 135.5, 
131.9, 129.4, 125.3, 124.0, 122.4, 122.1, 119.1, 118.8, 116.7, 52.5, 23.3, 12.5, 9.6. IR: 
3053.5 (w), 2967.2 (w), 2953.9 (w), 2870.9 (w), 1725.2 (s), 1690.6 (s), 1652.6 (s), 1643.2 
(m), 1450.9 (s), 1392.0 (s), 1330.1 (s), 1264.5 (m), 1212.6 (s), 1149.9 (m), 1047.8 (m), 
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874.0 (m), 745.4 (s), 701.4 (m), 625.4 (w) cm
-1
.  HRMS (ESI) M/Z+ Calc. 271.1208, 
Obs. 271.1214.    
 
(Z)-Methyl 2-(3-methyl-1H-indole-1-carbonyl)hex-2-enoate (IV-35n): Methyl 3-(3-
methyl-1H-indol-1-yl)-3-oxopropanoate (0.500 g, 2.16 mmol), butyraldehyde (0.194 mL, 
2.16 mmol), TiCl4•THF (1.44 g, 4.32 mmol), CCl4 (0.417 mL, 4.32 mmol), pyridine 
(0.700 mL, 8.65 mmol) and THF (35 mL) were mixed according to general method B to 
afford IV-35n as yellow oil (0.442 g, 68%) after 14 h. Rf 0.70 (20% EtOAc/Hex). 
1
H 
NMR (300 MHz, CDCl3) δ 8.56 (d, J = 7.9 Hz, 1H), 7.51 (d, J = 8.2 Hz, 1H), 7.45 – 7.18 
(m, 3H), 6.93 (s, 1H), 3.75 (s, 3H), 2.25 (s, 3H), 2.18 (q, J = 15.0, 7.5 Hz, 2H), 1.58 – 
1.43 (m, 2H), 0.90 (t, J = 7.4 Hz, 3H). 
13
C NMR (75 MHz, CDCl3) δ 164.0, 149.3, 135.5, 
131.9, 130.0, 125.2, 124.0, 122.5, 119.0, 118.8, 116.8, 52.5, 31.8, 21.4, 13.7, 9.6. IR: 
3056.8 (w), 2963.8 (m), 2930.6 (w), 2867.5 (w), 1725.2 (s), 1691.0 (s), 1679.0 (s), 
1450.9 (s), 1392.6 (s), 1340.6 (m), 1329.1 (w), 1248.9 (s), 1212.4 (s), 1078.7 (m), 1039.4 
(w), 951.3 (w), 732.6 (s), 701.4 (s) cm
-1





Methyl 2-(3-methyl-1H-indole-1-carbonyl)acrylate (IV-35o): Using conditions 
established by Yiotakis:
24
 A round bottom flask was charged with acetic acid (12 mL), 
methyl 3-(3-methyl-1H-indol-1-yl)-3-oxopropanoate (0.602 g, 2.60 mmol), formaldehyde 
(0.0708 g, 2.359 mmol), and Cu(OAc)2 (0.0416 g, 0.229 mmol) and the mixture was 
heated at reflux for 3 h. The solvent was removed in vacuo and diethyl ether was added. 
The mixture was filtered and the filtrate was washed successively with 1 M HCl, dilute 
NaHCO3, 1 M HCl, and brine. The organics were dried with Na2SO4 and concentrated 
under reduced pressure. The residue was purified using silica gel flash chromatography to 
yield IV-35o as a brown oil (0.470 g, 74%). Rf 0.37 (20% EtOAc/Hex). 
1
H NMR (300 
MHz, CDCl3) δ 8.44 (d, J = 7.3 Hz, 1H), 7.56 – 7.49 (m, 1H), 7.44 – 7.30 (m, 2H), 6.99 
(s, 1H), 6.79 (d, J = 0.4 Hz, 1H), 6.15 (s, 1H), 3.81 (d, J = 0.8 Hz, 3H), 2.27 – 2.25 (m, 
3H).  
13
C NMR (75 MHz, CDCl3) δ 163.8, 163.6, 137.3, 135.7, 132.0, 131.7, 125.4, 
124.1, 122.7, 119.2, 119.0, 116.6, 52.8, 9.7. IR: 3119.9 (w), 3060.2 (w), 2960.5 (w), 
2914.0 (w), 1736.9 (s), 1728.1 (s), 1690.8 (s), 1678.3 (s), 1449.6 (s), 1387.6 (m), 1343.5 
(m), 1235.7 (m), 1170.7 (m), 1151.2 (m), 1061.6 (m), 931.4 (w), 881.6 (m), 735.1 (s), 
701.4 (m) cm
-1






35p): Methyl 3-(3-methyl-1H-indol-1-yl)-3-oxopropanoate (0.201 g, 0.868 mmol), 
cinnamaldehyde (0.158 g, 1.19 mmol), glacial acetic acid (0.0525 g, 0.873 mmol), 
piperidine (0.0259 g, 0.304 mmol) and benzene (15 mL)  were combined according to 
general method A to yield IV-35p as a red solid (0.280 g, 93%) after 12 h. Rf 0.40 (20% 
EtOAc/Hex). [m.p. 108-110 °C] 
1
H NMR (300 MHz, CDCl3) δ 8.65 (s, 1H), 7.76 (d, J = 
11.8 Hz, 1H), 7.58 – 7.52 (m, 1H), 7.49 – 7.27 (m, 7H), 7.12 (d, J = 15.3 Hz, 1H), 6.97 
(s, 1H), 6.89 – 6.76 (m, 1H), 3.79 (s, 3H), 2.25 (s, 3H). 
13
C NMR (75 MHz, CDCl3) 
(Isomers!) δ 164.6, 145.0, 144.2, 135.6, 135.1, 132.1, 130.0, 128.8, 127.8, 126.7, 125.3, 
124.1, 122.8, 122.2, 119.2, 119.0,116.8, 52.6, 34.5, 31.5, 25.1, 22.5, 14.1, 9.7. IR: 3123.3 
(w), 3036.9 (w), 2953.9 (w), 2841.0 (w), 1710.8 (s), 1720.8 (s), 1678.1 (s), 1611.5 (s), 
1589.9 (s), 1434.0 (s), 1392.4 (m), 1340.6 (m), 1236.3 (s), 1210.4 (s), 1154.0 (m), 1080.2 
(m), 1047.9 (m), 974.9 (w), 888.2 (w), 746.8 (s), 689.0 (s) cm
-1
. HRMS (ESI) M/Z+ 
Calc. 345.1365, Obs. 345.1367.  
 
Methyl 3-ethyl-2-(3-methyl-1H-indole-1-carbonyl)pent-2-enoate (IV-35q): Methyl 3-
(3-methyl-1H-indol-1-yl)-3-oxopropanoate (0.800 g, 3.46 mmol), pentan-3-one  (0.372 
mL, 3.46 mmol), TiCl4•THF (2.31 g, 6.92 mmol), CCl4 (0.669 mL, 6.92 mmol), pyridine 
(1.12 mL, 13.8 mmol) and THF (20 mL) were combined according to general method B 
to yield IV-35q as a white solid (0.642 g, 62%) after 12 h. Rf 0.50 (15% EtOAc/Hex). 
[m.p. 109-111 °C] 
1
H NMR (300 MHz, CDCl3) δ 8.56 (s, 1H), 7.52 (d, J = 7.6 Hz, 1H), 
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7.43 – 7.29 (m, 2H), 6.98 (s, 1H), 3.66 (s, 3H), 2.78 (q, J = 7.5 Hz, 2H), 2.26 (d, J = 1.3 
Hz, 3H), 2.18 (q, J = 7.5 Hz, 2H), 1.24 (t, J = 7.3 Hz, 3H), 1.06 (t, J = 7.5 Hz, 3H). 
13
C 
NMR (75 MHz, CDCl3) δ 166.9, 163.9, 135.6, 131.9, 125.1, 124.6, 123.8, 122.6, 118.9, 
118.6, 116.7, 52.0, 28.7, 25.1, 12.8, 12.2, 9.7. IR: 2970.5 (w), 2943.9 (w), 2867.5 (w), 
1723.0 (s), 1678.6 (s), 1632.1 (m), 1451.9 (m), 1367.6 (m), 1347.1 (m), 1213.8 (s), 
1124.0 (w), 838.4 (m), 767.3 (s), 753.5 (s), 672.3 (s) cm
-1
.  HRMS (ESI) M/Z+ Calc. 
299.1521, Obs. 299.1522. 
 
(Z)-Methyl 4-methyl-2-(3-methyl-1H-indole-1-carbonyl)pent-2-enoate (IV-35r): 
Methyl 3-(3-methyl-1H-indol-1-yl)-3-oxopropanoate (1.06 g, 4.58 mmol), 
isobutyraldehyde (0.429 g,  5.95 mmol), glacial acetic acid (0.126 g, 2.10 mmol), 
piperidine (0.389 g, 4.58 mmol) and benzene (25 mL)  were combined according to 
general method A to afford IV-35r as a white solid (1.24 g, 95%) after 12 h. Rf 0.4 (15% 
EtOAc/Hex). [m.p. 128-130 °C] 
1
H NMR (300 MHz, CDCl3) δ 8.58 (d, J = 8.0 Hz, 1H), 
7.55 – 7.49 (m, 1H), 7.45 – 7.30 (m, 2H), 7.11 – 6.92 (m, 2H), 3.75 (s, 3H), 2.71 – 2.40 
(m, 1H), 2.27 (s, 3H), 1.07 (d, J = 6.7 Hz, 6H). 
13
C NMR (75 MHz, CDCl3) δ 164.1, 
163.9, 154.7, 135.5, 131.8, 127.6, 125.2, 124.0, 122.5, 118.9, 118.8, 116.6, 52.4, 29.6, 
21.4, 9.5. IR: 3113.3 (w), 2953.9 (m), 2930.6 (w), 2874.2 (w), 1725.2 (s), 1690.7 (s), 
1679.8 (s), 1652.6 (m), 1449.8 (s), 1392.6 (s), 1340.7 (s), 1331.4 (m), 1243.5 (s), 1227.9 
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(s), 1190.9 (m), 1153.6 (m), 1043.5 (m), 888.2 (m), 759.2 (s), 747.4 (s) cm
-1
. HRMS 
(ESI) M/Z+ Calc. 285.1365, Obs. 285.1361. 
 
(E)-1-(3-methyl-1H-indol-1-yl)-3-phenylprop-2-en-1-one (IV-35s): Sodium hydride 
(0.186 g, 4.64 mmol) was suspended in THF (20 mL) and cooled to 0 
°
C.  In a separate 
flask, 3-methyl-1H-indole (0.487 g, 3.72 mmol) was dissolved in THF (5 mL) and 
syringed into the basic solution. After 30 min, cinnamoyl chloride (3.37 mmol) in THF (5 
mL) was slowly added. The reaction was stirred for 12 h at room temperature then 
quenched with water. The organic layer was separated and the aqueous layer was 
extracted three times with EtOAc.  The combined organic layers were washed with brine, 
dried with Na2SO4, filtered, and concentrated under reduced pressure.  The residue was 
purified by silica gel flash chromatography to afford IV-35s as a yellow-orange oil (0.617 
g, 70%).  (15% EtOAc/Hex, Rf 0.50) 
1
H NMR (300 MHz, CDCl3) δ 8.61 (d, J = 7.7 Hz, 
1H), 7.98 (d, J = 15.5 Hz, 1H), 7.68 – 7.58 (m, 2H), 7.57 – 7.51 (m, 1H), 7.46 – 7.31 (m, 
6H), 7.20 (d, J = 15.4 Hz, 1H), 2.32 (dd, J = 1.3, 0.6 Hz, 3H). 
13
C NMR (75 MHz, 
CDCl3) δ 163.6, 145.7, 136.0, 134.3, 131.4, 130.4, 128.8, 128.1, 124.9, 123.4, 121.4, 
118.7, 118.2, 117.3, 116.7, 9.6. IR: 3060.2 (w), 3023.6 (w), 2920.7 (w), 1677.4 (s), 
1665.9 (s), 1619.7 (s), 1613.2 (s), 1575.7 (m), 1445.8 (s), 1387.1 (s), 1372.2 (s), 1346.9 
(s), 1298.6 (s), 1229.5 (s), 1199.5 (s), 1119.3 (m), 1066.2 (s), 963.0 (m), 848.3 (m), 755.8 
(s), 731.0 (s), 698.6 (s), 678.5 (s) cm
-1




Preparation of (Z)-Methyl 3-(4-methoxyphenyl)-2-(1H-pyrrole-1-carbonyl)acrylate 
(IV-38): 
 
Methyl 3-oxo-3-(1H-pyrrol-1-yl)propanoate (19): Following a modification of Evans' 
reported procedure:
25
 n-BuLi (10M in hexanes, 36 mmol) was added to a solution of 
diisopropylamine (3.13 mL, 22.16 mmol) in THF (40 mL) at -78°C. After 30 min, methyl 
acetate (2.9 mL, 36.5 mmol) was added slowly and the mixture was stirred for another 30 
min. A solution of di(1H-pyrrol-1-yl)methanone
26
 (3.55 g, 22.16 mmol) in THF (10 mL) 
was added to the reaction vessel. After 1 h, the reaction was quenched with AcOH and 
washed with saturated NaHCO3. The organic layer was separated, and the aqueous layer 
was washed with Et2O. The combined organic layers were dried over Na2SO4, filtered, 
and concentrated. The crude product was dissolved in THF, and 1,8-
diazabicyclo[5.4.0]undec-7-ene (500 µL, 3.34 mmol) was added. After 1 h, EtOAc was 
added to the reaction flask. The mixture was washed with 0.5M CuSO4, washed with 
brine, dried over Na2SO4, filtered, concentrated, and purified to afford 19 as a brown oil 
(2.92g, 79%). Rf 0.28 (20% EtOAc/Hex). 
1
H NMR (300 MHz, CDCl3) δ 7.23 (s, 2H), 
6.31 – 6.22 (m, 2H), 3.83 (s, 2H), 3.70 (s, 3H).
13
C NMR (75 MHz, CDCl3) δ 166.2, 
163.1, 119.1, 113.7, 52.6, 41.8. IR: 3143.2 (w), 3000.4 (w), 2950.6 (w), 1742.1 (s), 
1709.9 (s), 1469.4 (m), 1343.4 (s), 1249.2 (s), 1208.0 (m), 1160.0 (m), 1115.1 (s), 1076.0 
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(m), 994.5 (m), 917.8 (s), 738.5 (s), 675.7 (m), 610.0 (m), 597.7 (m), 519.6 (m) cm
-1
. 
HRMS (ESI) M/Z+ Calc. 167.0582, Obs. 167.0596. 
 
(Z)-Methyl 3-(4-methoxyphenyl)-2-(1H-pyrrole-1-carbonyl)acrylate (IV-38): Methyl 
3-oxo-3-(1H-pyrrol-1-yl)propanoate (0.500 g, 2.99 mmol), 4-methoxybenzaldehyde 
(0.560 g,  4.11 mmol), glacial acetic acid (0.105 g, 1.75 mmol), piperidine (0.0431 g, 
0.506 mmol) and benzene (25 mL)  were combined according to general method A to 
afford IV-38 as a brown solid (0.780 g, 91%) after 12 h. Rf 0.25 (20% EtOAc/Hex). 
[m.p. 79-81 °C] 
 1
H NMR (300 MHz, CDCl3) δ 7.91 (s, 1H), 7.37 – 7.29 (m, 3H), 6.85 – 
6.78 (m, 3H), 6.27 (s, 2H), 3.80 (s, 3H), 3.78 (s, 3H). 
13
C NMR (75 MHz, CDCl3) δ 
165.2, 164.7, 162.0, 144.0, 132.0, 124.6, 122.3, 114.6, 114.1, 55.3, 52.8. IR: 3143.2 (w), 
3073.4 (w), 2960.5 (w), 2837.6 (w), 1709.6 (s), 1678.6 (s), 1598.3 (s), 1512.6 (s), 1451.8 
(m), 1288.9 (m), 1253.2 (m), 1202.3 (m), 1173.4 (s), 1126.4 (m), 1069.3 (m), 1017.7 (m), 
884.9 (m), 825.1 (m), 730.3 (s), 700.5 (s) cm
-1







4.5.3. In(OTf)3-Catalyzed Cyclizations IV36a-r, IV-37, and IV-39 
General Procedure: To a mixture of In(OTf)3 (0.10 equiv) in DCE or toluene 
heated to a reflux, a solution of acrylates IV-35 (1.0 equiv) in solvent was syringed into 
the reaction vessel. The reaction was monitored by TLC and quenched with water. The 
phases were separated, and the product was extracted from the aqueous phase with DCM. 
The combined organic layers were washed with brine, dried over MgSO4, filtered, and 
concentrated for column chromatography using silica gel.  
 Rationale for cis-trans assigment: The major diastereomer is trans in spatial 
orientation based on a correlation between the calculated dihedral angle  between Ha and 
Hb for both the cis- and trans-isomers and the expected Karplus coupling constant. This 
value was then compared to the experimental value using 
1
H NMR (Table 4.5).  
Diastereomeric ratios are reported where applicable, and the integral value for each signal 








carboxylate (IV-36a): (Z)-Methyl 3-(4-methoxyphenyl)-2-(3-methyl-1H-indole-1-
carbonyl)acrylate (0.070 g, 0.200 mmol), In(OTf)3 (0.0112 g, 0.0200 mmol) and 1,2-
DCE (5 mL) were combined according to the general procedure to afford IV-36a as an 
orange oil (0.0666 g, 95%)  after 2 h. Rf 0.40 (20% EtOAc/Hex). Diastereomeric ratio: 
(15:1). 
1
H NMR (300 MHz, CDCl3) δ 8.10 – 8.01 (m, 1.13), 7.50 – 7.42 (m, 1.22), 7.38 – 
7.30 (m, 2.22), 7.22 – 7.15 (m, 2.02), 6.92 – 6.85 (m, 2.08), 5.01 (d, J = 4.7 Hz, 1.04), 
4.46 (d, J = 9.8 Hz, 0.05), 4.00 (d, J = 5.3 Hz, 0.93), 3.86 (s, 3.00), 3.81 (s, 4.28), 3.26 (s, 
0.16), 1.93 (s, 3.14). 
13
C NMR (75 MHz, CDCl3) δ 168.2, 164.5, 159.1, 138.8, 136.4, 
131.3, 130.2, 128.5, 124.4, 124.0, 122.2, 118.9, 114.5, 113.9, 110.8, 63.0, 55.3, 53.2, 
42.0, 8.1. IR: 3000.4 (w), 2950.6 (w), 2920.7 (w), 2834.3 (w), 1737.3 (s), 1726.3 (s), 
1512.5 (m), 1453.7 (m), 1396.6 (m), 1311.3 (m), 1247.6 (s), 1176.7 (m), 1127.3 (w), 
1031.6 (m), 828.4 (m), 749.4 (m) cm
-1






(IV-36b): (Z)-Methyl 2-(3-methyl-1H-indole-1-carbonyl)-3-phenylacrylate (0.0750 g, 
0.225 mmol), In(OTf)3 (0.0126 g, 0.0224 mmol) and 1,2-DCE (5 mL) were mixed 
according to the general procedure to yield IV-36b as a pale yellow solid (0.0726 g, 
97%)  after 1 h. Rf 0.50 (15% EtOAc/Hex). Diastereomeric ratio: (16:1). [m.p. 95-97 °C] 
1
H NMR (300 MHz, CDCl3) δ 8.10 – 8.03 (m, 1.10), 7.49 – 7.44 (m, 1.27), 7.42 – 7.30 
(m, 5.93), 7.28 – 7.23 (m, 3.14), 5.05 (d, J = 5.2 Hz, 1.12), 4.50 (d, J = 9.8 Hz, 0.06), 
4.03 (d, J = 5.3 Hz, 0.97), 3.88 – 3.84 (m, 3.51), 3.20 (s, 0.22), 1.98 – 1.91 (m, 3.37). 
13
C 
NMR (75 MHz, CDCl3) δ 168.1, 164.4, 139.4, 138.5, 136.4, 130.4, 129.2, 127.9, 127.5, 
124.4, 124.1, 122.1, 119.0, 113.9, 111.0, 62.8, 53.3, 42.6, 8.2. IR: 3063.5 (w), 3026.9 
(w), 2950.6 (w), 2917.3 (w), 2874.2 (w), 1737.2 (s), 1725.6 (s), 1635.4 (m), 1452.1 (s), 
1396.0 (m), 1310.8 (w), 1161.8 (s), 954.6 (w), 771.9 (s), 747.3 (s), 699.3 (s) cm
-1
. HRMS 
(ESI) M/Z+ Calc. 319.1208, Obs. 319.1210. 
 
Methyl 1-(4-bromophenyl)-9-methyl-3-oxo-2,3-dihydro-1H-pyrrolo[1,2-a]indole-2-
carboxylate (IV-36c): (Z)-Methyl 3-(4-bromophenyl)-2-(3-methyl-1H-indole-1-
carbonyl)acrylate (0.075 g, 0.188 mmol), In(OTf)3 (0.0106 g, 0.0188 mmol) and 1,2-
DCE (4 mL) were combined according to the general procedure to afford IV-36c as a 
colorless oil (0.0696 g, 93%)  after 14 h. Rf 0.40 (20% EtOAc/Hex). Diastereomeric 
ratio: (16:1). 
1
H NMR (300 MHz, CDCl3) δ 8.14 – 8.02 (m, 1.12), 7.54 – 7.43 (m, 3.42), 
7.39 – 7.30 (m, 2.17), 7.19 – 7.07 (m, 2.09), 5.06 – 4.93 (m, 1.08), 4.48 (d, J = 9.9 Hz, 
247 
 
0.07), 3.98 (d, J = 5.4 Hz, 1.00), 3.87 (s, 3.12), 3.27 (s, 0.18), 1.94 (d, J = 1.3 Hz, 3.29). 
13
C NMR (75 MHz, CDCl3) δ 167.8, 164.0, 138.3, 137.7, 136.3, 132.3, 131.7, 130.2, 
129.2, 124.5, 124.2, 121.8, 119.0, 113.9, 111.2, 62.5, 53.3, 42.0, 8.2. IR: 3056.8 (w), 
2957.2 (w), 2910.7 (w), 2850.9 (w), 1736.9 (s), 1725.9 (s), 1635.4 (m), 1452.7 (m), 
1435.1 (m), 1378.8 (m), 1251.1 (m), 1163.3 (m), 1132.5 (w), 1009.4 (m), 961.3 (w), 
820.9 (w), 768.3 (m), 734.5 (m) cm
-1




a]indole-2-carboxylate (IV-36d): (Z)-Methyl 2-(3-methyl-1H-indole-1-carbonyl)-3-(4-
(trifluoromethyl)phenyl)acrylate (0.075 g, 0.194 mmol), In(OTf)3 (0.0109 g, 0.0194 
mmol) and 1,2-DCE (4 mL) were combined according to the general procedure to afford 
IV-36d as a white solid (0.0686 g, 92%)  after 14 h. Rf 0.40 (20% EtOAc/Hex). [m.p. 
129-131 °C] Diastereomeric ratio: (20:1). 
1
H NMR (300 MHz, CDCl3) δ 8.11 – 8.04 (m, 
1.05), 7.64 (d, J = 8.1 Hz, 2.19), 7.53 – 7.31 (m, 5.55), 5.14 (d, J = 5.3 Hz, 1.05), 4.53 (d, 
J = 9.9 Hz, 0.05), 4.00 (d, J = 5.4 Hz, 1.01), 3.88 (s, 3.12), 3.22 (s, 0.15), 1.94 (d, J = 1.4 
Hz, 3.26). 
13
C NMR (75 MHz, CDCl3) δ 167.7, 163.8, 143.4, 137.3, 136.2, 130.3, 127.9, 
126.2, 126.2, 124.6, 124.4, 119.1, 114.0, 111.4, 62.4, 53.4, 42.2, 8.3. IR: 3056.8 (w), 
2947.2 (w), 2920.7 (w), 2860.9 (w), 1737.2 (s), 1726.6 (s), 1615.5 (w), 1453.6 (m), 
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1396.9 (m), 1322.1 (s), 1251.4 (m), 1163.1 (s), 1123.0 (s), 1111.5 (s), 1067.4 (m), 1018.6 
(m), 964.6 (w), 858.3 (m), 748.5 (m) cm
-1




carboxylate (IV-36e): 2-(3-Methyl-1H-indole-1-carbonyl)-3-(4-nitrophenyl)acrylate 
(0.100 g, 0.264 mmol), In(OTf)3 (0.0148 g, 0.0264 mmol) and 1,2-DCE (6 mL) were 
combined according to the general procedure to afford IV-36e as a pale orange solid 
(0.0838 g, 84%)  after 2.5 h. Rf 0.50 (15% EtOAc/Hex). [m.p. 141-143 °C] 
Diastereomeric ratio: (19:1). 
1
H NMR (300 MHz, CDCl3) δ 8.26 – 8.19 (m, 2.29), 8.08 – 
8.03 (m, 1.09), 7.53 – 7.41 (m, 3.57), 7.41 – 7.33 (m, 2.34), 5.19 (d, J = 5.4 Hz, 1.15), 
4.56 (d, J = 10.0 Hz, 0.05), 4.00 (d, J = 5.4 Hz, 1.00), 3.89 (s, 3.21), 3.26 (s, 0.19), 1.94 
(d, J = 1.4 Hz, 3.41). 
13
C NMR (75 MHz, CDCl3) δ 167.5, 163.4, 147.5, 146.6, 136.7, 
136.1, 130.3, 129.8, 128.5, 124.7, 124.5, 124.5, 123.6, 119.2, 113.9, 111.6, 62.1, 53.5, 
42.0, 8.3. IR: 3063.5 (w), 2947.2 (w), 2914.0 (w), 2857.6 (w), 1737.1 (s), 1726.0 (s), 
1598.9 (m), 1514.3 (m), 1453.2 (m), 1396.4 (m), 1344.2 (s), 1311.0 (m), 1250.1 (m), 
1164.1 (m), 1132.7 (m), 1104.1 (m), 1021.0 (w), 971.2 (w), 856.6 (m), 732.7 (s), 697.8 
(s) cm
-1





carboxylate (IV-36f): ((Z)-Methyl 3-(furan-2-yl)-2-(3-methyl-1H-indole-1-
carbonyl)acrylate (0.075 g, 0.242 mmol), In(OTf)3 (0.0136 g, 0.0242 mmol) and 1,2-
DCE (4 mL) were combined according to the general procedure to afford IV-36f as a 
pale yellow oil (0.0726 g, 97%)  after 2 h. Rf 0.40 (20% EtOAc/Hex). Diastereomeric 
ratio: (18:1). 
1
H NMR (300 MHz, CDCl3) δ 8.08 – 8.01 (m, 1.12), 7.51 – 7.43 (m, 1.18), 
7.41 – 7.38 (m, 1.12), 7.37 – 7.29 (m, 2.32), 6.37 – 6.31 (m, 1.10), 6.27 – 6.21 (m, 1.11), 
5.17 (d, J = 4.9 Hz, 1.08), 4.45 (d, J = 9.5 Hz, 0.05), 4.24 (d, J = 4.9 Hz, 1.00), 3.88 (s, 
3.32), 3.48 (s, 0.15), 2.09 (d, J = 1.3 Hz, 3.40). 
13
C NMR (75 MHz, CDCl3) δ 167.8, 
163.9, 150.9, 142.8, 136.3, 135.8, 130.2, 124.4, 124.2, 119.0, 113.9, 111.3, 110.4, 107.4, 
59.2, 53.3, 36.0, 8.1. IR: 3079.0 (w), 2953.9 (w), 2910.7 (w), 2841.0 (w), 1737.4 (s), 
1725.9 (s), 1711.3 (s), 1598.9 (w), 1453.4 (m), 1379.8 (m), 1310.4 (w), 1263.0 (m), 
1124.9 (w), 1074.2 (w), 1010.4 (m), 795.2 (m), 731.6 (s), 700.9 (s) cm
-1
. HRMS (ESI) 





carboxylate (IV-36g): (Z)-Methyl 2-(3-methyl-1H-indole-1-carbonyl)-3-(thiophen-2-
yl)acrylate (0.075 g, 0.230 mmol), In(OTf)3 (0.0129 g, 0.0230 mmol) and 1,2-DCE (4 
mL) were combined according to the general procedure to afford IV-36g as a pale yellow 
solid (0.0737 g, 98%)  after 2 h. Rf 0.40 (20% EtOAc/Hex). [m.p. 132-134 °C] 
Diastereomeric ratio: (24:1). 
1
H NMR (300 MHz, CDCl3) δ 8.08 – 8.03 (m, 1.11), 7.51 – 
7.45 (m, 1.27), 7.39 – 7.31 (m, 2.40), 7.28 – 7.24 (m, 1.12), 7.03 – 6.96 (m, 2.18), 5.38 
(d, J = 5.2 Hz, 1.03), 4.47 (d, J = 9.6 Hz, 0.04), 4.11 (d, J = 5.3 Hz, 1.00), 3.88 (s, 3.22), 
3.39 (s, 0.14), 2.05 (d, J = 1.3 Hz, 3.38). 
13
C NMR (75 MHz, CDCl3) δ 167.7, 163.7, 
142.1, 137.7, 136.3, 130.1, 127.1, 125.8, 125.3, 124.4, 124.3, 119.1, 113.9, 111.5, 63.2, 
53.3, 37.7, 8.4. IR: 3055.8 (w), 2953.1 (w), 2920.2 (w), 2859.2 (w), 1729.1 (s), 1631.9 
(m), 1455.2 (s), 1396.5 (m), 1379.1 (m), 1312.2 (m), 1252.2 (m), 1161.1 (m), 1132.7 (m), 
1062.9 (w), 961.5 (w), 845.0 (w), 748.5 (s), 701.7 (s) cm
-1
.  HRMS (ESI) M/Z+ Calc. 
325.0773, Obs. 325.0781. 
 
Methyl 9-(2-(1,3-dioxoisoindolin-2-yl)ethyl)-1-(4-methoxyphenyl)-3-oxo-2,3-dihydro-
1H-pyrrolo[1,2-a]indole-2-carboxylate (IV-36i): (Z)-Methyl 2-(3-(2-(1,3-
dioxoisoindolin-2-yl)ethyl)-1H-indole-1-carbonyl)-3-(4-methoxyphenyl)acrylate (0.075 
g, 0.147 mmol), In(OTf)3 (0.00828 g, 0.0147 mmol) and 1,2-DCE (5 mL) were combined 
according to the general procedure to afford IV-36i as a light yellow solid (0.0721 g, 
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96%)  after 4 h. Rf 0.30 (20% EtOAc/Hex). [m.p. 142-144 °C] Diastereomeric ratio: 
(14:1).  
1
H NMR (300 MHz, CDCl3) δ 8.12 – 8.01 (m, 1.06), 7.81 – 7.72 (m, 2.13), 7.72 
– 7.56 (m, 3.28), 7.34 – 7.16 (m, 4.43), 6.92 – 6.83 (m, 2.12), 5.09 – 4.97 (m, 1.05), 4.46 
(d, J = 9.8 Hz, 0.07), 4.03 (d, J = 5.2 Hz, 1.00), 3.86 – 3.76 (m, 6.11), 3.76 – 3.57 (m, 
2.36), 3.27 (s, 0.21), 2.88 – 2.75 (m, 1.13), 2.70 – 2.56 (m, 1.08). 
13
C NMR (75 MHz, 
CDCl3) δ 167.9, 167.9, 164.7, 159.3, 140.7, 135.4, 133.9, 132.0, 131.1, 130.2, 128.6, 
124.6, 124.2, 123.1, 119.1, 114.7, 114.0, 111.2, 62.7, 55.3, 53.2, 42.1, 36.9, 22.7. IR: 
3050.2 (w), 2970.5 (w), 2841.0 (w), 1728.0 (s), 1709.5 (s), 1513.0 (m), 1456.8 (m), 
1435.4 (m), 1391.0 (s), 1247.7 (s), 1178.0 (s), 1021.0 (s), 831.7 (m), 775.3 (m), 718.1 (s) 
cm
-1
.  HRMS (ESI) M/Z+ Calc. 508.1634, Obs. 508.1631.  
 
Methyl 9-(2-bromoethyl)-1-(4-methoxyphenyl)-3-oxo-2,3-dihydro-1H-pyrrolo[1,2-
a]indole-2-carboxylate (IV-36j): (Z)-Methyl 2-(3-(2-bromoethyl)-1H-indole-1-
carbonyl)-3-(4-methoxyphenyl)acrylate (0.061 g, 0.138 mmol), In(OTf)3 (0.0081 g, 0.014 
mmol) and 1,2-DCE (7 mL) were combined according to the general procedure to afford 
IV-36j as a brown oil (0.0418 g, 69%)  after 12 h. Rf 0.24 (30% EtOAc/Hex). 
Diastereomeric ratio: (25:1). 
1
H NMR (300 MHz, CDCl3) δ 8.20 – 8.14 (m, 0.17), 8.12 – 
8.06 (m, 0.95), 7.71 (s, 0.07), 7.52 – 7.44 (m, 1.30), 7.42 – 7.29 (m, 2.54), 7.21 – 7.14 (m, 
2.08), 7.10 – 7.14  (m, 0.31), 6.93 – 6.80 (m, 2.44), 5.06 (d, J = 4.9 Hz, 1.00), 4.52 – 4.45 
(m, 0.04), 4.06 – 4.01 (m, 0.98), 3.90 – 3.77 (m, 6.82), 3.56 – 3.21 (m, 3.42H), 3.12 – 
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2.64 (m, 3.54). 
13
C NMR (75 MHz, CDCl3) δ 167.8, 164.7, 159.4, 141.1, 140.9, 135.2, 
135.0, 131.5, 131.1, 131.0, 130.2, 130.0, 128.3, 124.6, 124.3, 118.8, 114.7, 114.4, 114.2, 
113.9, 112.2, 111.3, 62.6, 55.3, 53.3, 43.2, 42.3, 31.1, 27.3, 27.2. IR: 3017.0 (w), 2953.9 
(w), 2927.3 (w), 2831.0 (w), 1737.2 (s), 1726.3 (s), 1712.0 (s), 1610.9 (m), 1452.8 (s), 
1392.3 (m), 1365.0 (m), 1317.0 (m), 1245.5 (s), 1173.6 (s), 1028.3 (m), 931.4 (w), 831.0 
(m), 747.6 (s) cm
-1
. HRMS (ESI) M/Z+ Calc. 441.0576, Obs. 441.0575. 
 
Methyl 9-(2-methoxy-2-oxoethyl)-1-(4-methoxyphenyl)-3-oxo-2,3-dihydro-1H-
pyrrolo[1,2-a]indole-2-carboxylate (IV-36k): (Z)-Methyl 2-(3-(2-methoxy-2-oxoethyl)-
1H-indole-1-carbonyl)-3-(4-methoxyphenyl)acrylate (0.075 g, 0.184 mmol), In(OTf)3 
(0.0103 g, 0.0184 mmol) and 1,2-DCE (5 mL) were combined according to the general 
procedure to afford IV-36k as a white solid (0.0698 g, 93%)  after 3 h. Rf 0.40 (20% 
EtOAc/Hex). [m.p. 159-161 °C] Diastereomeric ratio: (13:1).  
1
H NMR (300 MHz, 
CDCl3) δ 8.12 – 8.05 (m, 1.07), 7.52 – 7.45 (m, 1.14), 7.39 – 7.29 (m, 2.27), 7.22 – 7.09 
(m, 2.29), 6.92 – 6.80 (m, 2.25), 5.07 (d, J = 5.6 Hz, 1.10), 4.47 (d, J = 9.8 Hz, 0.08), 
4.02 (d, J = 5.4 Hz, 1.00), 3.88 – 3.84 (m, 3.13), 3.81 – 3.77 (m, 3.40), 3.60 – 3.56 (m, 
3.37), 3.47 – 3.38 (m, 1.11), 3.30 – 3.20 (m, 1.39). 
13
C NMR (75 MHz, CDCl3) δ 170.7, 
167.7, 164.7, 159.3, 141.1, 135.1, 130.5, 130.1, 128.7, 124.7, 124.3, 119.1, 114.5, 114.0, 
107.7, 62.6, 55.3, 53.2, 52.0, 42.2, 29.2. IR: 3046.9 (w), 3003.7 (w), 2957.2 (m), 2917.3 
(w), 2824.4 (w), 1737.3 (s), 1725.9 (s), 1712.1 (s), 1608.9 (m), 1515.9 (m), 1453.0 (m), 
253 
 
1349.8 (m), 1247.6 (m), 1158.9 (s), 1092.5 (m), 1031.8 (s), 951.3 (m), 835.4 (s), 753.9 (s) 
cm
-1
. HRMS (ESI) M/Z+ Calc. 407.1369, Obs. 407.1361.  
 
Methyl 1-(4-methoxyphenyl)-3-oxo-2,3-dihydro-1H-pyrrolo[1,2-a]indole-2-
carboxylate (IV-36l): (Z)-Methyl 2-(1H-indole-1-carbonyl)-3-(4-
methoxyphenyl)acrylate (0.100 g, 0.298 mmol), In(OTf)3 (0.0168 g, 0.0299 mmol) and 
DCE (5 mL) were combined according to the general procedure to afford IV-36l as a 
yellow solid (0.983 g, 98%) after 1 h. Rf 0.45 (30% EtOAc/Hex). Diastereomeric ratio: 
(10:1). [m.p. 113-115 °C] 
1
H NMR (300 MHz, CDCl3) δ 8.12 – 8.05 (m, 0.95), 7.55 – 
7.48 (m, 1.07), 7.38 – 7.27 (m, 2.24), 7.24 – 7.16 (m, 2.26), 6.92 – 6.81 (m, 2.24), 6.33 
(dd, J = 1.7, 0.7 Hz, 0.10), 6.29 (dd, J = 1.7, 0.7 Hz, 0.96), 5.05 (dd, J = 5.6, 1.7 Hz, 
1.09), 4.46 (d, J = 9.6 Hz, 0.10), 4.03 (d, J = 5.7 Hz, 0.98), 3.87 (s, 3.02), 3.81 (s, 3.00), 
3.80 (s, 0.35), 3.26 (s, 0.27). 
13
C NMR (75 MHz, CDCl3) δ 168.0, 164.9, 159.3, 144.2, 
135.3, 131.4, 130.5, 128.6, 124.7, 124.0, 121.0, 114.5, 114.0, 102.1, 77.2, 62.4, 55.3, 
53.2, 42.5. IR: 3001.4 (w), 2927.7 (w), 2838.0 (w), 1730.2 (s), 1610.9 (m), 1589.6 (m), 
1512.2 (m), 1474.9 (s), 1384.8 (m), 1322.0 (m), 1245.6 (s), 1162.0 (s), 1029.8 (m), 937.8 
(w), 807.0 (s), 749.5 (s) cm
-1





(IV-36m): (Z)-Methyl 2-(3-methyl-1H-indole-1-carbonyl)pent-2-enoate (0.075 g, 0.276 
mmol), In(OTf)3 (0.0233 g, 0.0415 mmol) and toluene (4 mL) were combined according 
to the general procedure to afford IV-36m as a colorless oil (0.0665 g, 89%)  after 14 h. 
Rf 0.50 (15% EtOAc/Hex). 
1
H NMR (300 MHz, CDCl3) δ 8.04 – 7.95 (m, 1H), 7.47 – 
7.39 (m, 1H), 7.33 – 7.22 (m, 2H), 3.83 – 3.72 (m, 5H), 2.22 (s, 3H), 2.11 – 1.95 (m, 1H), 
1.84 – 1.66 (m, 1H), 0.99 (t, J = 7.4 Hz, 3H). 
13
C NMR (75 MHz, CDCl3) δ 168.9, 165.2, 
139.6, 136.5, 130.0, 124.2, 123.7, 118.7, 113.8, 109.7, 58.6, 53.0, 38.7, 26.5, 10.8, 8.5. 
IR: 3056.8 (w), 2963.8 (w), 2920.7 (w), 2867.5 (w), 1737.1 (s), 1725.2 (s), 1711.9 (s), 
1635.4 (m), 1453.3 (m), 1396.6 (m), 1307.5 (m), 1250.9 (m), 1188.2 (w), 1027.4 (w), 
948.0 (m), 745.4 (s) cm
-1
. HRMS (ESI) M/Z+ Calc. 271.1208, Obs. 271.1207. 
 
Methyl 9-methyl-3-oxo-1-propyl-2,3-dihydro-1H-pyrrolo[1,2-a]indole-2-carboxylate 
(IV-36n): (Z)-Methyl 2-(3-methyl-1H-indole-1-carbonyl)hex-2-enoate (0.075 g, 0.263 
mmol), In(OTf)3 (0.0221 g, 0.03945 mmol) and toluene (4 mL) were combined according 
to the general procedure to afford IV-36n as a colorless oil (0.0628 g, 84%)  after 14 h 
(contaminated with ≤5% starting material as determined by 
1





H NMR (300 MHz, CDCl3) δ 8.05 – 7.97 (m, 1H), 7.47 – 7.43 (m, 1H), 
7.34 – 7.28 (m, 2H), 3.82 (s, 3H), 3.81 – 3.74 (m, 2H), 2.25 (d, J = 1.1 Hz, 3H), 2.04 – 
1.90 (m, 1H), 1.77 – 1.65 (m, 1H), 1.43 (q, J = 15.4, 7.4 Hz, 2H), 0.99 (t, J = 7.3 Hz, 3H). 
13
C NMR (75 MHz, CDCl3) δ 169.0, 165.3, 140.0, 136.5, 130.1, 124.2, 123.7, 122.2, 
118.7, 113.8, 109.6, 59.2, 53.1, 37.4, 36.0, 20.0, 13.9, 8.5. IR: 3073.4 (w), 2960.5 (m), 
2924.0 (m), 2864.2 (m), 1737.0 (s), 1725.8 (s), 1712.5 (s), 1691.7 (s), 1630.3 (w), 1453.0 
(s), 1435.7 (m), 1418.6 (m), 1396.0 (m), 1248.6 (m), 1212.6 (m), 1162.1 (m), 1059.1 (w), 
1026.2 (w), 951.3 (w), 746.2 cm
-1
. HRMS (ESI) M/Z+ Calc. 285.1365, Obs. 285.1366.  
 
Methyl 9-methyl-3-oxo-2,3-dihydro-1H-pyrrolo[1,2-a]indole-2-carboxylate(IV-36o): 
Methyl 2-(3-methyl-1H-indole-1-carbonyl)acrylate (0.100 g, 0.411 mmol), In(OTf)3 
(0.0355 g, 0.0632 mmol) and toluene (5 mL) were combined according to the general 
procedure to afford IV-36o as a pale yellow solid (0.0471 g, 47%)  after 1 h. Rf 0.34 
(20% EtOAc/Hex). [m.p. 95-97 °C] 
1
H NMR (300 MHz, CDCl3) δ 8.04 – 7.97 (m, 1H), 
7.49 – 7.41 (m, 1H), 7.35 – 7.27 (m, 2H), 4.15 (dd, J = 9.3, 4.9 Hz, 1H), 3.84 (s, 3H), 
3.54 – 3.44 (m, 1H), 3.33 (ddd, J = 17.2, 9.3, 1.3 Hz, 1H), 2.20 (t, J = 1.3 Hz, 3H). 
13
C 
NMR (75 MHz, CDCl3) δ 168.8, 165.5, 136.4, 136.3, 130.4, 124.3, 123.6, 118.7, 113.8, 





carboxylate (IV-36p): (2Z,4E)-Methyl 2-(3-methyl-1H-indole-1-carbonyl)-5-
phenylpenta-2,4-dienoate (0.0750 g, 0.209 mmol), In(OTf)3 (0.0117 g, 0.0208 mmol) and 
1,2-DCE (5 mL) were combined according to the general procedure to afford IV-36p as a 
pale yellow oil (0.0533 g, 71%)  after 1 h. Rf 0.50 (15% EtOAc/Hex). Diastereomeric 
ratio: (8:1). 
1
H NMR (300 MHz, CDCl3) δ 8.11 – 8.01 (m, 1.14), 7.52 – 7.43 (m, 1.38), 
7.42 – 7.26 (m, 8.52), 6.71 (d, J = 15.7 Hz, 1.14), 6.33 – 6.15 (m, 1.14), 4.64 (dd, J = 8.4, 
5.1 Hz, 1.00), 4.55 (t, J = 9.2 Hz, 0.14), 4.39 (d, J = 9.5 Hz, 0.11), 3.97 (d, J = 5.0 Hz, 
0.93), 3.87 (s, 3.03), 3.67 (s, 0.40), 2.20 (d, J = 1.3 Hz, 2.80), 2.18 (d, J = 1.2 Hz, 0.45). 
13
C NMR (75 MHz, CDCl3) δ 168.1, 164.4, 137.3, 136.4, 136.0, 133.2, 130.3, 128.7, 
128.1, 126.5, 126.0, 124.4, 124.1, 119.0, 113.9, 111.5, 60.1, 53.2, 40.6, 8.2. IR: 3056.8 
(w), 3033.6 (w), 2957.2 (w), 2917.3 (w), 2850.9 (w), 1738.4 (s), 1718.5 (s), 1715.1 (s), 
1588.9 (w), 1446.1 (s), 1393.0 (s), 1363.1 (m), 1246.9 (s), 1160.5 (m), 964.6 (m), 745.4 
(s), 692.2 (s) cm
-1
. HRMS (ESI) M/Z+ Calc. 345.1365, Obs. 345.1363.                                                                                                          
 
Methyl 1,1-diethyl-9-methyl-3-oxo-2,3-dihydro-1H-pyrrolo[1,2-a]indole-2-
carboxylate (IV-36q):  Methyl 3-ethyl-2-(3-methyl-1H-indole-1-carbonyl)pent-2-enoate 
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(0.0800 g, 0.267mmol), In(OTf)3 (0.0225 g, 0.0400 mmol) and toluene (4 mL) were 
combined according to the general procedure to afford IV-36q as a colorless oil (0.0784 
g, 98%)  after 12 h. Rf 0.40 (15% EtOAc/Hex). 
1
H NMR (300 MHz, CDCl3) δ 8.02 – 
7.93 (m, 1H), 7.42 – 7.33 (m, 1H), 7.26 – 7.18 (m, 2H), 3.90 (s, 1H), 3.72 (s, 3H), 2.17 
(d, J = 1.1 Hz, 3H), 2.06 – 1.64 (m, 4H), 0.90 – 0.73 (m, 6H). 
13
C NMR (75 MHz, 
CDCl3) δ 168.0, 165.7, 140.8, 136.1, 129.9, 124.1, 123.8, 118.6, 113.9, 109.8, 104.9, 
60.2, 52.4, 48.1, 29.9, 29.7, 9.1, 8.9. IR: 3036.9 (w), 2963.8 (m), 2934.0 (m), 2870.9 (m), 
1748.3 (s), 1737.7 (s), 1725.2 (s), 1615.5 (w), 1453.6 (s), 1396.7 (s), 1303.3 (m), 1263.5 
(m), 1158.6 (s), 1017.7 (m), 954.6 (w), 732.5 (s), 695.6 (s) cm
-1
. HRMS (ESI) M/Z+ 
Calc. 299.1521, Obs. 299.1521.  
 
Methyl 1-isopropyl-9-methyl-3-oxo-2,3-dihydro-1H-pyrrolo[1,2-a]indole-2-
carboxylate (IV-36r): (Z)-Methyl 4-methyl-2-(3-methyl-1H-indole-1-carbonyl)pent-2-
enoate (0.075 g, 0.263 mmol), In(OTf)3 (0.0148 g, 0.0263 mmol) and toluene (4 mL) 
were combined according to the general procedure to afford IV-36r as a white solid 
(0.063 g, 84%)  after 12 h. Rf 0.40 (15% EtOAc/Hex). [m.p. 68-70 °C] 
1
H NMR (300 
MHz, CDCl3) δ 8.06 – 7.95 (m, 1H), 7.49 – 7.43 (m, 1H), 7.35 – 7.28 (m, 2H), 3.85 (d, J 
= 3.8 Hz, 1H), 3.82 – 3.77 (m, 4H), 2.39 (m, 1H), 2.25 (d, J = 1.0 Hz, 3H), 1.04 (d, J = 
6.8 Hz, 3H), 0.85 (d, J = 6.8 Hz, 3H). 
13
C NMR (75 MHz, CDCl3) δ 169.3, 165.5, 139.3, 
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136.5, 130.1, 124.2, 123.7, 118.7, 113.8, 110.1, 55.0, 53.1, 43.8, 30.7, 20.2, 17.4, 8.8. IR: 
3056.8 (w), 2947.2 (w), 2917.3 (w), 2864.2 (w), 1737.2 (s), 1725.3 (s), 1625.5 (w), 
1453.2 (m), 1396.2 (m), 1307.9 (m), 1255.3 (m), 1161.6 (m), 1094.4 (m), 1031.0 (m), 
954.6 (m), 805.2 (w), 745.7 (s) cm
-1
.  HRMS (ESI) M/Z+ Calc. 285.1365, Obs. 
285.1364.  
Methyl 9,9,10-trimethyl-6-oxo-6,7,8,9-tetrahydropyrido[1,2-a]indole-7-carboxylate 
(IV-37): Compound IV-37 was afforded (0.00450 g, 6%) as a light brown oil (≥95% 
Purity!). 
1
H NMR (300 MHz, CDCl3) δ 8.48 – 8.42 (m, 1H), 7.47 – 7.41 (m, 1H), 7.35 – 
7.28 (m, 2H), 3.94 – 3.83 (m, 4H), 2.59 – 2.45 (m, 1H), 2.34 (s, 3H), 1.98 (dd, J = 13.5, 
4.9 Hz, 1H), 1.62 (s, 3H), 1.42 (s, 3H). 
13
C NMR (101 MHz, CDCl3) δ 170.0, 165.3, 
138.8, 134.1, 131.8, 124.9, 124.1, 117.7, 116.6, 113.2, 52.7, 48.1, 40.1, 32.0, 29.2, 26.8, 
9.8. IR: 2955.7 (w), 2926.0 (w), 2870.0 (w), 1745.6 (s), 1696.5 (s), 1457.1 (s), 1394.6 
(s), 1288.9 (w), 1196.6 (m), 1164.9 (m), 1123.2 (m), 1090.3 (m), 957.3 (w), 749.6 (s) cm
-
1
. HRMS (ESI) M/Z+ Calc. 285.1365, Obs. 285.1369.  
 
Methyl 1-(4-methoxyphenyl)-3-oxo-2,3-dihydro-1H-pyrrolizine-2-carboxylate (IV-
39): (Z)-Methyl 3-(4-methoxyphenyl)-2-(1H-pyrrole-1-carbonyl)acrylate (0.152 g, 0.531 
mmol), In(OTf)3 (0.0308 g, 0.055 mmol) and 1,2-DCE (13 mL) were combined 
according to the general procedure to afford IV-39 as a red oil (0.0817 g, 54%)  after 12 
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h. Rf 0.35 (20% EtOAc/Hex). 
1
H NMR (400 MHz, CDCl3) δ 7.20 – 7.06 (m, 3.27), 6.91 
– 6.78 (m, 2.20), 6.53 (t, J = 3.1 Hz, 0.10), 6.36 – 6.29 (m, 0.96), 6.02 – 6.00 (m, 0.08), 
5.99 – 5.94 (m, 0.95), 4.87 (d, J = 3.9 Hz, 1.01), 4.40 (d, J = 9.1 Hz, 0.07), 3.92 (d, J = 
5.1 Hz, 0.91), 3.85 (s, 2.96), 3.80 (s, 3.00), 3.79 (s, 0.67), 3.24 (s, 0.26). 
13
C NMR (75 
MHz, CDCl3) δ 167.8, 165.5, 159.2, 140.5, 131.9, 128.4, 120.0, 114.4, 113.6, 111.7, 
106.2, 105.0, 62.5, 55.3, 53.2, 42.4. IR: 3143.2 (w), 3106.6 (w), 3000.4 (w), 2957.2 (w), 
2910.7 (w), 2837.6 (w), 1754.8 (s), 1737.3 (s), 1727.2 (s), 1608.9 (w), 1512.0 (m), 
1401.6 (m), 1291.3 (m), 1242.7 (m), 1161.7 (m), 1080.8 (m), 974.5 (w), 901.5 (w), 833.4 
(w), 719.4 (s) cm
-1
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INDIUM(III)- CATALYZED INTRAMOLECULAR FRIEDEL-







5.1. IMPORTANCE OF PYRROLO[3,2,1-ij]QUINOLINES 
Heterocyclic compounds, especially nitrogen-containing heterocycles, are a 
prominent class of compounds in the pharmaceutical and agrochemical industries, 
with heterocycles constituting around 60% of all drug substances. Among 
heterocyclic compounds, tetrahydroquinoline (THQ) V-1 is a common structural 
motif found in numerous biologically active natural products and pharmacologically 
relevant therapeutic agents.
1
 Within the THQ class of compounds, the pyrrolo[3,2,1-
ij]quinolines derivatives have garnered considerable attention in the area of drug 
discovery and agrochemistry due to its structural diversity (Figure 5.1).  
                                                 
††
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The pyrrolo[3,2,1-ij]quinolines are primarily characterized by two isomeric 
structures (4H-pyrrolo[3,2,1-ij]quinoline  V-3, and the 6H-pyrrolo[3,2,1-ij]quinoline V-4) 
or by the reduced and oxidized forms V-2, and V-5 to V-9. From among them, 
compounds containing a 4H-pyrrolo[3,2,1-ij]quinoline core have been found to exhibit 
interesting physiological and therapeutic properties (Figure 5.2). For example, the 
compound V-10 acts as an antagonist for the human MT1 and MT2 melatonin receptor 
subtypes expressed in NIH 3T3 cells.
2
 Derivative V-11 possesses good anticonvulsant 
properties;
3
 the compound V-12 was identified as acetylcholinesterase inhibitor for the 
treatment of voiding dysfunction.
4
 Quinoline derivative V-13 were shown to have high 
activity towards Mycobacterium tuberculosis H37Rv (ATCC 27294) strain.
5
 Compounds 
V-14 act as  an inhibitor of the enzyme farnesyl protein transferase (FPT).
6
 The 
pyrroloquinoline derivative V-15, was identified as an inhibitor of aldosterone synthase 
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(CYP11 B2), a lead candidate for the treatment of hyperaldosteronism, congestive heart 
failure, and myocardial fibrosis.
7
 Another compound, V-16, shows potent antagonistic 
property at 5-HT2A in the potential treatment of psychosis.
8
 PHA-529311 (V-17) shows 
inhibitory activity against herpesvirus DNA polymerases,
9
 and derivative V-18 acts as a 
potential SIRT1 activator (sirtuin 1) for the treatment of type II diabetes and other 
metabolic disorders.
10
 KC11404 (V-19), has been identified as a lead candidate for the 
potential treatment of asthma, demonstrated potent histamine and platelet activating 
factor (PAF) antagonism and 5-lipoxygenase inhibitory properties.
11
  Another 
pyrrolo[3,2,1-ij]quinoline derivative V-20 have been reported to be highly potent agonists 
at 5-HT2c (5-hydroxytryptamine) with selectivity over 5-HT2a isoform for the 
prophylactic management of epilepsy and obesity.
12
 Recently, Turov et al. showed that 
the V-21 derivative has high diuretic activity. The pyrrrolo[3,2,1-ij]quinoline derivatives 
were also found to be key intermediates towards the synthesis of other bioactive 
compounds.
13
 Finally, the 1,2,5,6-tetrahydro-4H-pyrrrolo[3,2,1-ij]quinoline system is 
present at the core of the lilolidine (V-7) alkaloids,
14
 which have been explored as 
therapeutics, fungicides (i.e., lilolidone V-8)
15
 and as red-light-emitting dopants in 








5.2. PREVIOUS METHODS FOR PYRROLO[3,2,1-ij] QUINOLINE SYNTHESIS  
While a number of methods have been reported for the synthesis of pyrrolo[3,2,1-
ij]quinoline (PQ) derivatives V-2, a majority of these strategies can be classified for 
clarity into two major categories: the construction of (i) six-membered ring using an 
indole template B or (ii) five-membered ring using a suitably substituted 1,2,3,4-
tetrahydroquinoline A (Figure 5.3). The traditional, simple, and very popular synthetic 
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methods of PQs involve either Fischer indolization,
12,8,3,11
 Friedel-Crafts-type substitution 
of the aromatic ring
7, 17
 or transition-metal catalyzed annulations.
10, 18
 Other less popular 
















 the Wittig reaction,
26
 and the 
Michael–type annulation.
6, 15
 In this section, the major synthetic methodology for the 





5.2.1. ROUTES FOR THE CONSTRUCTION OF FIVE MEMBERED RINGS 
5.2.1.1. FISCHER INDOLIZATION REACTIONS 
In 1983, the Stanton group reported Fischer indolization of 1-
aminotetrahydroquinoline V-23 with cyclopentanone in the presence of hot glacial acid 






Jasserand and co-workers synthesized a series of compounds based on 
pyrrolo[3,2,1-ij]quinoline structures using the Fischer indole reaction.
11
 The reaction of 
1-amino-1,2,3,4-tetrahydroquinolines V-25 with ethyl levulinate in the presence of 
HCl/AcOH at 80 
o
C, afforded V-26 (Figure 5.5). These compounds were ultimately 
converted into V-27, which were tested for their pharmacological activities against three 
mediators associated with asthma-histamine, PAF, and leukotrienes.   
 
 
The Isaac group synthesized pyrrolo[3,2,1-ij]quinolines derivatives using a 
Fischer indole cyclization route while developing an agonist at the 5-HT2c receptor for 
the potential treatment of epilepsy and obesity.
12
 The 1-amino-1,2,3,4-
tetrahydroquinoline V-28 was reacted with 4-chlorobutanal in aqueous methanol at reflux 
to afford desired product V-29 in good yield. Resulting compound was transformed into 
N-methylated derivative V-30 using Boc2O followed by reduction with LAH (Figure 
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5.6). When tested, the compound V-30 was found to be very potent at the 5-HT2c (5-





5.2.1.2. TRANSITION METAL-CATALYZED REACTIONS 
In 2009, the Pal group developed a copper catalyzed C-N bond forming reaction 
towards the synthesis of 2-substituted pyrrolo[3,2,1-ij]quinolines.
18h
 When 8-iodo-6-
bromo-1,2,3,4-tetrahydroquinoline V-31 was reacted with requisite alkynes in the 
presence of 10 mol% of Pd/C, furnished 8-alkynyl-1,2,3,4-tetrahydroquinolines V-32. 
Subsequent cyclization upon subjecting to 10 mol% CuI in DMF at 100 
o
C afforded 
pyrroloquinoline derivatives V-33. The reaction worked well for aryl and alkyl 
substituted alkynes, providing products in moderate to good yields. Pal also demonstrated 
the scope of this reaction by performing further structural elaboration via Pd-catalyzed 




In continuation of the above studies, Pal and co-workers disclosed a two step, 
transition metal-catalyzed synthesis of 5-subsituted pyrrolo[3,2,1-ij]quinolines V-36.
10
 
The reaction sequence involved Sonogashira coupling of 6-substituted 8-iodo-2,3-
dihydroquinolin-4(1H)-one V-34 with requisite alkynes to generate 8-alkynyl-2,3-
dihydroquinolin-4(1H)-one V-35 followed by an intramolecular C-N bond formation 
reaction with 5 mol % PdCl2 (Figure 5.8). Pal was also able to screen other substrates 
having EDG/EWG aryl, cyano, alkyl alcohol, alkyl halide, and alkyl substituents on the 
alkynes. The reactions proceeded smoothly in all cases with yields ranging from 
moderate to good. Further in their studies, easy derivatization of the resulting products 
was demonstrated by converting into chloro aldehydes and oxime derivatives. Finally, all 
the products were tested for potential SIRT1 activator towards the treatment of type II 
diabetes and other metabolic disorders. 
 
 
Gunther et al. developed a novel Pd(II)-catalyzed intramolecular hetero-
cyclization method for the synthesis of fused tricyclic quinolines V-38 (Figure 5.9).
18i
 
The reaction involves PdCl2-catalyzed heteroannulation of 6-bromo-8-(3,5-
dimethylphenyl)ethynyl-1,2,3,4-tetrahydroquinolines V-37. Heteroannulation was 
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achieved in good yields. The reaction tolerates bromide, cyanide, and esters substituents 
on the THQ.  
 
Recently, Liu and co-workers reported palladium-catalyzed oxidative 
aryltrifluoromethylation of activated alkenes.
18c
 In one representative example, alkene V-
39 reacted with TMSCF3/CsF in the presence of Pd(OAc)2/Yb(OTf)3 as a catalyst to 
generate pyrroloquinolines V-40 (Figure 5.10). The reaction utilizes TMSCF3/CsF as 




Wipf and group disclosed titanocene(III)-catalyzed reductive cyclization of an 
epoxide tethered to substituted anilines and aminopyridines to form indoles and 
azaindolines.
18f
 For example, N-tetrahydroquinoline substituted epoxide V-41 
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titanocene(III) chloride-catalyzed ring-opening of epoxide followed by arene annulation 




In 2010, the Zhu group developed Pd(II)-catalyzed carbo-heterofunctionalization 
of activated alkenes for the synthesis of oxindoles and spirooxindoles.
18e
 In one example, 
N-tetrahydroquinoline substituted alkene V-43 successfully cyclized in the presence of 
Pd(OAc)2/PhI(OAc)2 at 100 
o
C in acetic acid to generate iodo-substituted 
pyrroloquinoline product V-44 (Figure 5.12). Along this line, Zhu also reported iodo-










5.2.1.3. SIGMATROPIC REARRANGEMENT REACTIONS 
In 1989, the Majumdar group developed a straight-forward one-pot reaction for 
the synthesis of substituted pyrrolo[3,2,1-ij]quinolines.
20a
 Treatment of 1-aryloxy-4-
tetrahydro-l-quinoylbut-2-ynes V-45 with mCPBA at room temperature for 12 h, 
facilitated a spontaneous [2,3]-followed by [3,3]-sigmatropic rearrangement to provide 
unstable aminol intermediate V-46. Addition of a stronger nucleophile such as KCN, 




In an analogous fashion to amine oxides above, the [2,3]-sigmatropic 
rearrangement reaction of azasulphenium ylides has also been used in the construction of 
pyrrolo[3,2,1-ij]quinoline ring systems (Figure 5.14). In 1984, the Gassman group 
reported one-step synthesis of pyrrolo[3,2,1-ij]quinolines.
20b
 When 1,2,3,4-
tetrahydroquinoline V-48 was reacted with chlorosulfonium chloride B followed by 
treatment with Et3N, product V-49 was furnished in 53% yield. Furthermore, reaction of 





5.2.1.4. BASE MEDIATED CYCLIZATION REACTIONS 
Guiotto and co-workers used a base mediated cyclization strategy to synthesize 
pyrrolo[3,2,1-ij]quinolines.
24
 The reaction of 8-(dibromopropyl)quinoline-2-one 
derivatives V-51 with 5% aq. KOH in ethanol at reflux, unexpectedly afforded only 




5.2.1.5. PUMMERER CYCLIZATION REACTION  
Proctor and co-workers disclosed a fluorous-phase Pummerer cyclative-capture 
strategy for the synthesis of pyrroloquinolines.
21a
 The addition of thiols to glyoxamides 
V-53 in the presence of trifluoroacetic anhydride formed hemithioacetals, which upon 
subsequent activation by BF3.Et2O underwent Pummerer cyclization to afford product V-





5.2.1.6. C-H ACTIVATION REACTIONS 
Recently, the Yang group developed a silver-catalyzed intramolecular cyclization 
via C-H activation to generate 1-alkylidene substituted pyrroloquinoline.
23a
 The reaction 
of diazoamide V-55 in the presence of 5 mol% AgOTf as the catalyst in dioxane at 
100
o
C, furnished with 61% of the desired quinoline derivatives V-56 (Figure 5.17). 
 
 
5.2.2. ROUTES FOR THE CONSTRUCTION OF SIX MEMBERED RINGS 
5.2.2.1. FRIEDEL-CRAFTS CYCLIZATION REACTION 
In 2011, the Hartmann group reported the synthesis of heteroaryl substituted 
1,2,5,6-tetrahydropyrrolo[3,2,1-ij]quinolin-4-one derivatives.
7
 Indoline V-57 was first 
converted into amide followed by a FC-cyclization to afford pyrrolo[3,2,1-ij]quinolines 
V-58. These fused heterocycles were then regioselectively brominated by treating with 
NBS in DMF at 0 
o
C. Finally, arylbromide were subjected to Suzuki coupling with an N-
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heterocyclic boronic acid to provide heteroaryl substituted products V-59 (Figure 5.18). 
Furthermore, these derivatives were tested for inhibition of aldosterone synthase (CYP11 
B2), a promising target for the treatment of hyperaldosteronism, congestive heart failure, 
and myocardial fibrosis. Interestingly, derivatives of V-59 were found to be more potent 






5.2.2.2. MICHAEL-TYPE CYCLIZATION REACTION 
In the works of Angibaud and co-workers,
6
 pyrrolo[3,2,1-ij]quinoline 
intermediate V-60 was generated by acylation of indoline V-57 with 3-chlorocinnamoyl 
chloride followed by PPA-catalyzed F-C acylation. The resulting tetrahydroquinolines 
were ultimately used in the preparation of V-61 (Figure 5.19). Further studies showed 
that compound V-61 has inhibitory activity for the enzyme farnesyl protein transferase 
(FPT). Inhibition of FPT would prevent a key step in the post-translational processing of 
Ras and the subsequent propagation of cell growth promoting signals. This would have 






5.2.2.3. SIGMATROPIC REARRANGEMENT REACTION 
Lingam et al. reported a simple and novel synthesis of pyrrolo[3,2,1-ij]quinoline 
derivatives V-63 by the polyphosphoric acid (PPA)-catalyzed aza-Cope rearrangement 
reaction of 3-arylprop-2-en-1-yl amines V-62 (Figure 5.20).
20c
   
 
 
5.2.2.4. TRANSITION METAL-CATALYZED REACTIONS 
Chen and co-workers developed a chemoselective asymmetric N-allylic alkylation 
of indoles with Morita-Baylis-Hillman carbonates to deliver chiral indole derivatives V-
64.
18a
  Further in their studies, these precursors were subjected to intramolecular radical 
cyclization or Heck coupling to afford pyrrolo[3,2,1-ij]quinoline derivatives V-65 in 





The palladium-mediated 6-endo-trig intramolecular Heck cyclization of N-
acryloyl-7-bromoindolines V-66 was developed by Dankwardt and co-workers in 1995 to 
generate tricyclic fused quinolines V-67 in 88-99% yields (Figure 5.22).
18d
 The reaction 
was proposed to go through a 6-endo pathway presumably due to strain involved in the 
approach of the palladium species to the α-position of the double bond of these 




The palladium(II)-catalyzed cyclization of N-allyl-7-bromoindoles V-68 to 








In 2007 Alper et al. reported Rh(I)-catalyzed hydroaminomethylation strategy for 
the synthesis of quinolines. The 2-isopropenylindolines V-70 was reacted with 5.0 mol% 
Rh(I) at 120 
o







5.2.2.5. INTRAMOLECULAR WITTIG REACTION 
In 2006, Adib and co-workers reported a one-pot synthesis of 4H-pyrrolo[3,2,1-
ij]quinolines using an intramolecular Wittig reaction.
26
 When acetylenic esters V-72 were 
reacted with indole-7-carboxaldehyde V-73 in the presence of triphenylphosphine 






5.2.2.6. FREE RADICAL CYCLIZATION/PHOTOCYCLIZATION  
The Padwa group has employed radical cyclization for the synthesis of the 
octahydropyrrolo[3,2,1-ij]quinoline ring system.
19c
 The reaction of N-allyl-7-bromo-3a-
methylhexahydroindolinone V-75 with n-Bu3SnH/AIBN in benzene at reflux provided 




West and co-workers reported intramolecular radical cyclization reaction 
involving ipso-substitution using sulfone substituted indoles. When 7-sulfone substituted 
indolines V-77 reacted in the presence of Bu3SnH/AIBN in toluene at reflux 







5.2.2.7. C-H ACTIVATION REACTIONS  
In 2005, Yi and co-workers generated pyrroloquinolines using ruthenium-
catalyzed regioselective hydroamination and C-H bond activation reaction.
23b
 As shown 
in Figure 6.28, substituted indolines V-79 on treatment with large excess of alkynes in the 
presence of Ru3(CO)3/NH4PF6 (1:3) in benzene at reflux for 12-26 h cleanly produced 
tricyclic quinoline products V-80 in 42-99 % yields. The alkyl, aryl, halogen and 
alkylether groups are well tolerated in the reaction. The reaction is postulated to proceed 
via ruthenium-mediated ortho- C-H bond insertion of an alkyne to form the ortho-
vinylated amine, the hydroamination of the second alkyne, and the subsequent 







5.2.2.8. BENZOTRIAZOLE METHODOLOGIES 
In 2001, Abonia and co-workers disclosed benzotriazole methodology towards the 
synthesis of pyrroloquinolines.
25b
 Under acidic conditions (p-TsOH), the benzotriazolyl-
derivatives of indolines V-81 were transformed to products V-82 in good yields on 
reaction with terminal alkenes (Figure 5.29). Abonia also demonstrated that 1-vinyl-2-
pyrrolidinone, dihydrofuran, dihydropyran, alkyl vinyl ethers, and styrenes can act as a 
suitable alkene partners. 
 
5.2.2.9. KNOEVENAGEL REACTION 
In 2004, Zhu and co-workers reported the synthesis of 1,7-annulated indoles 
during their study directed towards the development of cyclin kinase dependent 
inhibitors.
22
 The 7-formylindole was N-alkylated with 3-bromopropionate, which 
subsequently underwent Knoevenagel condensation in the presence of cesium carbonate 




5.2.2.10. MISCELLANEOUS APPROACHES 
Kouznetsov et al. employed a H2SO4-induced FC-alkylation reaction to generate 
4H-spiro[pyrrolo-[3,2,1-ij]quinolines. Upon heating the N-allyl substituted amine V-84 at 
90
o
C with 85% H2SO4, afforded desired product V-85 via N-allyl spiroquinoline 










ones reacted with a tethered styrene V-86 under photoreaction conditions in the presence 
of oxygen to afford products V-87 in 50-56% yield (Figure 5.32). It was observed that 
EDG-groups on styrene retarded the photoreaction where as EWG-group accelerated the 





Katritzky  and co-workers reported TsOH-catalyzed Friedel-Crafts-type ring 
closure of 5,6,7,8-tetrahydroindolizine derivative V-89 to generate pyrrolo[3,2,1-
ij]quinolines V-90 in 65% yield.
25a
 The required precursors were fashioned from 
tetrahydroindolizines V-88 upon subjection to lithiation followed by a reaction with 
trans-chalcone (Figure 5.33).  
 
 
Aniline V-91, bearing both N-crotonyl and N-allyl groups was transformed to N-
crotonyl indoline V-92 through radical cyclization, which was subsequently subjected to 
silicon/iodine exchange reaction with ICl. The resulting iodide intermediate was reacted 







All of these methods have some good advantages but also have several 
drawbacks, such as long reaction times, tedious workup procedures, and occurrence of 
several side reaction products, lower yields, lack of generality of the reaction, use of 
harsh conditions, poor selectivity, and the use of expensive transition metals. Therefore, 
the search continues for a better and convenient method for the synthesis of 
pyrrolo[3,2,1-ij]quinolines derivatives in terms of operational simplicity, economic 



















5.3. INDIUM(III)-CATALYZED INTRAMOLECULAR FRIEDEL-CRAFTS 
CYCLIZATION TO THE SYNTHESIS OF PYRROLO[3,2,1-
ij]QUINOLINES 
  Previous work done in the France lab has demonstrated that In(OTf)3 catalyzes 
intramolecular F-C alkylation of methyl 2-(1H-indole-1-carbonyl)acrylates V-94 (Figure 
5.35).
28
 This method provided an efficient and diastereoselective route to the synthesis of 
functionalized 1H-pyrrolo[1,2-a]-indole derivatives V-95. In an extension of this 
methodology, the France lab envisioned that a similar intramolecular F-C reaction should 
occur by employing a substrate with the indole 2-position blocked, as in the methyl 2-(2-
methyl-1H-indolecarbonyl) acrylate. With the 2-position unavailable, the only site for 
electrophilic attack would be the indole 7-position. Thus, cyclization would provide rapid 
access to pyrrolo[3,2,1-ij]quinolines compounds V-96. In recognizing the utility of this 
transformation, the France group sought to develop an annulation of N-substituted indolyl 









5.3.1. SUBSTRATE SYNTHESIS 
To test this concept, the synthesis of the requisite acrylates was carried out as 
previously described.
28
 The synthesis involved two-step reaction protocol, starting from 
commercially available indoles. First, treatment of indoles with methyl malonyl chloride 
afforded β-amidoesters. The required benzylidene malonate precursors V-94 were then 
prepared from the corresponding aldehydes and β-amidoesters under Knoevenagel 
condensation conditions.  
 
5.3.2. PROOF OF CONCEPT  
The acrylate V-94a (derived from 2-methyl indole and p-anisaldehyde) was 
chosen for preliminary investigation, the decision was influenced from previous work of 
France and co-workers on the pyrrolo[1,2-a]-indoles V-95.
28
 Initial efforts in the France 
group involved the examination of Lewis acids to achieve the desired F-C alkylation. We 
began by subjecting acrylate V-94a to 15 mol% In(OTf)3 in toluene at reflux, a 
previously optimized condition used for the synthesis of  pyrrolo[1,2-a]indoles V-95. As 
anticipated, V-94a readily cyclized to generate the desired pyrrolo[3,2,1-ij]quinoline 





5.3.3. REACTION SCOPE STUDIES  
With preliminary results in hand, subsequent studies sought to examine the scope 
and limitations of the In(III)-catalyzed intramolecular Friedel-Crafts alkylation of methyl 
2-(2-methyl-1H-indole-1-carbonyl)acrylates. Early reaction development was carried out 
using acrylates V-94 bearing substituted aryl group on alkene. Acrylate bearing an 
electron donating o-methoxy substituted phenyl V-94b readily cyclized to give its 
product V-96b in 87% yield (Table 5.1, entry 2), a reduced dr was observed (3.7:1). We 
primarily attribute this observation to a steric influence on the post-equilibrium 
protonation of the In(OTf)3-coordinated enolate.  Another plausible reason involves a 
weak association between the o-methoxy group and the indium-coordinated enolate, 
which hinders β-face protonation and generates more of the cis-product. Next, the 
electronic effect of electron-withdrawing aryl substituents on the product outcome was 
examined. When the 4-nitro, 3-nitro, and 4-cyano substituted aryl groups were employed 
(Table 5.1, entries 3-5), the corresponding quinoline products V-96c-e were formed in 
good yields (78%, 86%, and 78%, respectively). However, lower diastereoselectivity was 
observed in all cases (~2:1 dr).  Thus, a strong electronic influence on the reaction is 
observed when the aryl substituent is changed to a strong electron-withdrawing group. It 
is believed that the observed electronic effect may arise from epimerization at the 
benzylic C-6 position which erodes the ratio of thermodynamic trans-isomer. Given that 
C-6 is equivalent to a dibenzylic center, its hydrogen should have a pKa of ~30. When a 
strong electron-withdrawing group (NO2 or CN) is placed in the para- or meta-position 
of the phenyl ring, the pKa of that hydrogen would drop to ~16-20. Therefore, it was 






In contrast, when a strong electron donating group is present, the pKa of the 
hydrogen would be too high for epimerization (i.e., high dr for p-OMe). Competing 
epimerizations at C-5 and C-6, could account for the observed reduced 
diastereoselectivities. When the p-fluoro and m-bromo substituted aryl groups were used 
(Table 5.1, entries 6 and 7), both gave their respective products V-96f and V-96g in 94% 
and 61% yield.  However, while the m-bromide gave an 8:1 dr, the p-fluoride only gave a 
2.6:1 dr.  Given fluorine’s high electronegativity, a similar electronic effect may be 
occurring as was observed with the nitro and cyano groups.   
While pleased with the results of the aromatic substrates, the reaction scope to 
include heteroaromatic, and nonaromatic substrates was examined.  Heteroaryl 
substituents on the acrylate are also tolerated.  In a representative example, the 2-thienyl 
derivative V-94h underwent cyclization furnishing V-96h as a single observable 
diastereomer in 51% yield (Table 5.2, entry 1). In nonaromatic substrates, the France lab 
was particularly interested in examining acrylates derived from alkyl aldehydes and 
cinnamaldehyde.  When the propyl-substituted acrylate V-94i was subjected to the 
optimal reaction conditions, no conversion to the desired pyrrolo[3,2,1-ij]quinolines was 
observed even after 24 h. Thus, indicating that the nature of the alkene substituent has a 
significance influence on the reaction outcome.  After some optimization, it was found 
that the cyclization could be achieved efficiently at an elevated catalyst loading in toluene 
at reflux. Under these new conditions, the cyclized product V-96i was obtained in 84% 
yield with 25:1 dr (Table 5.2, entry 2). Subjecting the cinnamaldehyde-derived acrylate 






 Next, variation about the indole ring was examined (Table 5.3).  When the 2-
phenyl indolyl acrylate V-94k (derived from 2-phenyl indole and p-anisaldehyde) was 
subjected to the reaction conditions (Table 5.3, entry 1), pyrrolo[3,2,1-ij]quinolin-4-
one V-96k was obtained in 97% yield with 17:1 dr. 2,3-Disubstituted indoles also 
performed competently in the cyclization.  For example, the 2,3-dimethyl indolyl 
acrylate V-94l afforded its corresponding product V-96l in 80% yield with 50:1 dr 







 Similarly, the tetrahydrocyclopenta[b]indole based acrylate V-94m provided 
the tetracyclic product V-96m in 82% yield as a single observable diastereomer 
(Table 5.3, entry 3). Installing substituents on the benzenoid portion of indole was 
also tolerated and had no deleterious effect on the reaction outcome (Table 5.3, entries 
4 and 5). For example, the 5-fluoro- and 5-chloro-2-methyl indole derivatives V-94n 
and V-94o fashioned corresponding pyrrolo[3,2,1-ij]-quinoline derivatives in high 
yields (80% and 82%) and high diastereoselectivities (50:1 dr for V-96n  and >99:1 
dr for V-96o), respectively. 
 As previously mentioned, the tricyclic skeletons of the 1,2,5,6-tetrahydro-4H-
pyrrolo[3,2,1-ij]quinolines (lilolidines, V-7) have been shown to have very interesting 
applications. Toward this end, the reactivity of the indoline-derived substrate was 
investigated to determine its compatibility in the intramolecular F-C annulation 
(Figure 5.37).  Subjecting V-97a to the reaction conditions provided the lilolidine 
derivative V-98 in 81% yield as only one observable diastereomer in a mixture with 
its decarboxylated product.
 
Due to the success of indoline, we also employed the 
substrate V-97b  (derived from tetrahydroquinoline) in the cyclization (Figure 5.37).  
The resulting product will contain the 2,3,6,7-tetrahydro-1H,5H-benzo[ij]quinolizine 
core (also referred in the literature as 1,2,3,5,6,7-hexahydropyrido[3,2,1-ij]quinoline, 
which is present in the julolidine class of alkaloids. Thus, when V-97a  subjected to 
the reaction conditions, it readily cyclized to give the tricyclic product V-99 in 83% 
yield as the trans-diastereomer. This result is noteworthy since julolidine and its 
derivatives has been used as an key intermediate to synthesize various labeling 




























 In conclusion, this study has documented a general annulation route for the 
efficient assembly of a variety of densely functionalized 5,6-dihydro-4H-
pyrrolo[3,2,1-ij]quinolin-4-ones.  This transformation involves an In(OTf)3-induced 
diastereoselective Friedel-Crafts (F-C) alkylation of methyl 2-(2-methyl-1H-indole-
carbonyl)acrylates. The products are formed in good to high yields with 
diastereoselectivities up to >99% dr.  Further investigations into the observed 
stereoelectronic effects are currently underway.  Investigations involving the use of 
chiral Lewis acid complexes will be reported in due course. Finally, the scope of this 



































5.5.1. General Methods 
 All reactions were carried out in pre-dried glassware from the oven and any 
additional moisture was removed by flame-drying the reaction vessel.  Each reaction 
proceeded under a nitrogen atmosphere with anhydrous solvents, unless stated otherwise. 
Tetrahydrofuran and diethyl ether were distilled from a sodium/benzophenone ketyl 
under nitrogen and stored in a Schlenk flask. Benzene, toluene, 1,2-dichloroethane and 
dichloromethane were purified by distillation from calcium hydride. All other reagents 
were purchased from Acros, Sigma-Aldrich, Fluka, VWR, Merck, Alfa Aesar, TCI and 
Strem (for metal catalysts) and used without further purification.  Compounds V-100 
were synthesized according to our reported protocol.
32
 
 Chromatographic purification was performed as flash chromatography with 
Silicycle silica gel (40-65µm). For quantitative flash chromatography, technical grades 
solvents were utilized. Analytical thin-layer chromatography (TLC) was performed on 
EMD silica gel 60 F254 TLC glass plates. Visualization was accomplished with UV light, 
aqueous basic potassium permanganate (KMnO4) solution, iodine, aqueous acidic 
dinitrophenylhydrazine (DNP) solution, aqueous acidic p-anisaldehyde (PAA) solution, 
and an ethanol solution of phosphomolybdic acid (PMA) followed by heating.  Each 
yield refers to an isolated, analytically-pure material.  
Infrared (IR) spectra were obtained using a Nicolet 4700 FTIR with an ATR 
attachment from SmartOrbit Thermoelectronic Corp. The IR bands are characterized as 
weak (w), medium (m), and strong (s). Proton and carbon nuclear magnetic resonance 
spectra (
1
H NMR and 
13
C NMR) were recorded on a Varian Mercury Vx 300 MHz 
297 
 
spectrometer, Varian Mercury Vx 400 MHz spectrometer or Bruker 400 MHz 
spectrometer with solvent resonances as the internal standard (
1
H NMR: CDCl3 at 7.26 
ppm; 
13
C NMR: CDCl3 at 77.0 ppm). 
1
H NMR data are reported as follows: chemical 
shift (ppm), multiplicity (s = singlet, d = doublet, dd = doublet of doublets, dt = doublet 
of triplets, ddd = doublet of doublet of doublets, t = triplet, m = multiplet, br = broad), 
coupling constants (Hz), and integration. Mass spectra were obtained using a VG-70SE 
instrument. 
 Diastereomeric ratios for cyclized products V-96 (or V-98/V-99) were 
determined by 
1
H NMR based on comparing the signal ratios of the benzylic protons 
(~4.0-5.0 ppm) for the two diastereomeric protons. The first signal represents the trans 
isomer and the second signal represents the cis isomer. These assignments are based on 
the coupling constants.  
 
5.5.2. Experimental Procedures 
5.5.2.1. Synthesis of β-amide esters 
Sodium hydride (1.2 equiv.) was suspended in THF and cooled to 0 °C. In a 
separate flask, the desired N-heterocycle (1.0 equiv.) was dissolved in THF and syringed 
into the reaction vessel. After 30 min, methyl-3-chloro-3-oxopropanoate (1.25 equiv.) 
was added quickly. The reaction was stirred for 14 h at room temperature. The reaction 
mixture was quenched with water. The organic layer was separated, and the aqueous 
layer was extracted three times with EtOAc. The combined organic layers were washed 
with brine, dried with anhydrous Na2SO4, filtered, and concentrated under reduced 
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pressure. The residue was purified by silica gel flash chromatography for product 
isolation. 
 
Methyl 3-(2-methyl-1H-indol-1-yl)-3-oxopropanoate (V-100a): The general procedure 
was followed using sodium hydride (1.91 g, 47.7 mmol), 2-methyl-1H-indole (5.00 g, 
38.2 mmol), methyl-3-chloro-3-oxopropanoate (4.91 mL, 45.7 mmol), and THF (125 
mL). After 14 h, the reaction was quenched, and column chromatography afforded V-
100a as a brick red solid (6.05 g, 69%). (Rf 0.40, 30% EtOAc/Hex) [m.p. 74-76 °C]  
1
H 
NMR (400 MHz, CDCl3) δ ppm 7.87 - 7.92 (m, 1H), 7.43 - 7.48 (m, 1H), 7.21 - 7.28 (m, 
2H), 6.39 (s, 1H), 4.07 (s, 2H), 3.81 (s, 3H), 2.61 (d, J = 1.12 Hz, 3H). 
13
C NMR (101 
MHz, CDCl3) δ ppm 166.9, 165.9, 137.0, 136.3, 129.8, 123.9, 123.6, 120.0, 114.9, 110.6, 
52.7, 45.6, 17.3. IR: 3022.4 (w), 2953.1 (w), 1733.8 (s), 1700.1 (s), 1684.4 (s), 1606.3 
(m), 1588.1 (m), 1526.9 (m), 1450.5 (m), 1374.4 (m), 1300.3 (m), 1235.7 (s), 1162.5 (m), 
1085.2 (w), 758.3 (s), 668.5 (w), 649.4 (w) cm
-1
. HRMS (ESI) M/Z+ Calc. 231.0895, 
Obs. 231.0894. 
 
Methyl 3-oxo-3-(2-phenyl-1H-indol-1-yl)propanoate (V-100b): The general procedure 
was followed using sodium hydride (0.414 g, 17.3 mmol), 2-phenyl-1H-indole (3.00 g, 
15.5 mmol), methyl-3-chloro-3-oxopropanoate (2.0 mL, 18.7 mmol), and THF (140 mL). 
After 5 h, the reaction was quenched, and column chromatography afforded V-100b as an 
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orange oil (1.28 g, 28%). (Rf 0.48, 30% EtOAc/Hex) 
1
H NMR (400 MHz, CDCl3) δ ppm 
8.40 (qd, J = 0.84, 8.28 Hz, 1H), 7.55 - 7.59 (m, 1H), 7.44 - 7.49 (m, 5H), 7.36 - 7.41 (m, 
1H), 7.29 - 7.34 (m, 1H), 6.64 (d, J = 0.69 Hz, 1H), 3.63 (s, 3H), 3.39 (s, 2H).
 13
C NMR 
(101 MHz, CDCl3) δ ppm 166.8, 166.7, 139.0, 137.9, 133.3, 129.1, 129.0, 129.0, 125.5, 
124.2, 120.5, 120.4, 116.3, 112.5, 52.4, 45.9. IR: 3029.5 (w), 2958.2 (s), 2925.4 (s), 
2852.3 (s), 1745.4 (s), 1715.4 (s), 1604.8 (w), 1470.7 (m), 1451.8 (w), 1406.9 (m), 
1359.4 (m), 1341.8 (w), 1301.7 (m), 1253.6 (w), 1205.1 (m), 1155.5 (m), 1117.3 (w), 
1076.5 (m), 1056.7 (w), 1020.7 (w), 970.1 (m), 919.4 (w), 821.1 (w), 747.8 (m), 700.7 
(w) cm
-1
. HRMS (ESI) M/Z+ Calc. 293.1052, Obs. 293.1053. 
 
 
Methyl 3-(2,3-dimethyl-1H-indol-1-yl)-3-oxopropanoate (V-100c): The general 
procedure was followed using sodium hydride (0.330 g, 8.26 mmol), 2,3-dimethyl-1H-
indole (1.00 g, 6.89 mmol), methyl-3-chloro-3-oxopropanoate (0.921 mL, 8.61 mmol), 
and THF (35 mL). After 14 h, the reaction was quenched, and column chromatography 
afforded V-100c as a pale yellow solid (1.05 g, 62%). (Rf 0.26, 20% EtOAc/Hex) [m.p. 
75-77 °C] 
1
H NMR (300 MHz, CDCl3) δ 7.77-7.84 (m, 1H), 7.26-7.32 (m, 1H), 7.17 (m, 
2H), 3.88 (s, 2H), 3.72 (s, 3H), 2.34 (s, 3H), 2.03 (s, 3H). 
13
C NMR (75 MHz, CDCl3) δ 
ppm 8.2, 13.5, 45.2, 52.1, 114.5, 115.8, 117.7, 122.9, 123.6, 130.8, 131.6, 135.0, 165.3, 
166.7. IR: 2989.2 (w), 2959.3 (w), 2925.6 (w), 1741.6 (s), 1681.3 (s), 1615.5 (w), 1449.6 
(m), 1433.5 (m), 1361.6 (s), 1329.6 (m), 1259.5 (s), 1229.0 (w), 1162.2 (s), 1127.1 (m), 
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1100.2 (w), 1069.9 (w), 1019.5 (s), 928.9 (m), 833.2 (w), 759.5 (s), 691.3 (m), 613.1 (m) 
cm
-1
. HRMS (ESI) M/Z+ Calc. 245.1052, Obs. 245.1053. 
 
Methyl 3-(2,3-dihydrocyclopenta[b]indol-4(1H)-yl)-3-oxopropanoate (V-100d): The 
general procedure was followed using sodium hydride (0.764 g, 19.1 mmol), 1,2,3,4-
tetrahydrocyclopenta[b]indole (2.5 g, 15.9 mmol), methyl-3-chloro-3-oxopropanoate (2.1 
mL, 19.1 mmol), and THF (45 mL). After 16 h, the reaction was quenched, and column 
chromatography afforded V-100d as a brick red solid (3.47 g, 85%). (Rf 0.30, 25% 
EtOAc/Hex) [m.p. 120-122 °C] 
1
H NMR (300 MHz, CDCl3) δ ppm 8.41 (d, J = 5.46 Hz, 
1H), 7.31 - 7.37 (m, 1H), 7.21 - 7.30 (m, 2H), 3.86 (s, 2H), 3.79 (s, 3H), 2.92 - 3.00 (m, 
2H), 2.70 - 2.78 (m, 2H), 2.45 - 2.57 (m, 2H). 
13
C NMR (75 MHz, CDCl3) δ ppm 167.0, 
164.3, 140.9, 128.3, 126.9, 124.7, 124.2, 123.9, 118.5, 117.3, 52.7, 43.8, 29.5, 27.6, 23.6. 
IR: 3116.2 (w), 2988.6 (w), 2947.9 (w), 2928.3 (w), 2869.6 (w), 1752.8 (s), 1693.5 (s), 
1608.7 (m), 1447.9 (m), 1434.9 (s), 1379.7 (m), 1346.6 (w), 1325.2 (w), 1260.4 (s), 
1161.9 (m), 1122.1 (m), 1074.0 (m), 1029.6 (m), 768.6 (s), 749.6 (m), 686.1 (m) cm
-1
. 
HRMS (ESI) M/Z+ Calc. 257.1052, Obs. 257.1045. 
 
Methyl 3-(5-fluoro-2-methyl-1H-indol-1-yl)-3-oxopropanoate (V-100e): The general 
procedure was followed using potassium hydride (0.711 g, 17.7 mmol), 5-fluoro-2-
methyl-1H-indole (2.03 g, 13.6 mmol), methyl-3-chloro-3-oxopropanoate (1.9 mL, 17.7 
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mmol), and THF (18 mL). After 14 h, the reaction was quenched, and column 
chromatography afforded V-100e as a red solid (0.805 g, 24%). (Rf 0.20, 20% 
EtOAc/Hex)  [m.p. 80-82 °C] 
1
H NMR (300 MHz, CDCl3) δ ppm 7.96 (dd, J = 4.45, 
9.11 Hz, 1H), 7.08 (dd, J = 2.60, 8.54 Hz, 1H), 6.95 (dt, J = 2.64, 9.09 Hz, 1H), 6.35 (s, 
1H), 4.03 (s, 2H), 3.80 (s, 3H), 2.59 (s, 3H). 
13
C NMR (75 MHz, CDCl3) δ ppm 166.8, 
165.6, 161.2, 158.0, 138.1, 133.0, 130.9, 130.8, 116.5 and 116.4 (doublet), 111.6, 111.3, 
110.6 and 110.5 (doublet), 105.8, 105.4, 52.8, 45.4, 17.3. IR: 3013.0 (w), 2956.9 (w), 
1752.2 (s), 1682.4 (s), 1603.6 (m), 1476.2 (m), 1438.8 (m), 1376.3 (m), 1301.9 (w), 
1259.5 (w), 1187.8 (m), 1157.8 (s), 1129.8 (m), 1000.5 (m), 958.5 (m), 870.7 (m), 797.1 
(m), 780.4 (m), 668.4 (m) cm
-1
. HRMS (ESI) M/Z+ Calc. 249.0801, Obs. 249.0809. 
 
Methyl 3-(5-chloro-2-methyl-1H-indol-1-yl)-3-oxopropanoate (V-100f): The general 
procedure was followed using sodium hydride (0.2908 g, 7.27 mmol), 5-chloro-2-methyl-
1H-indole (1.00 g, 6.06 mmol), methyl-3-chloro-3-oxopropanoate (0.811 mL, 7.57 
mmol), and THF (30 mL). After 16 h, the reaction was quenched, and column 
chromatography afforded V-100f as a reddish brown solid (0.114 g, 11%). (Rf 0.25, 20% 
EtOAc/Hex) [m.p. 46-48 °C] 
1
H NMR (300 MHz, CDCl3) δ ppm 7.88 (dd, J = 0.44, 8.90 
Hz, 1H), 7.35 (d, J = 2.05 Hz, 1H), 7.16 (dd, J = 2.09, 8.90 Hz, 1H), 6.27 (d, J = 0.62 Hz, 
1H), 3.99 (s, 2H), 3.79 (s, 3H), 2.55 (s, 3H).
 13
C NMR (75 MHz, CDCl3) δ ppm 166.6, 
165.6, 137.8, 134.9, 130.9, 129.1, 123.9, 119.4, 116.3, 109.9, 52.7, 45.3, 17.2. IR: 2993.0 
(w), 2953.8 (w), 1746.0 (s), 1697.9 (s), 1594.7 (m), 1446.3 (s), 1362.6 (s), 1334.8 (m), 
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1309.2 (m), 1254.0 (s), 1159.8 (s), 1075.0 (w), 1041.4 (w), 1000.9 (w), 919.6 (w), 807.6 
(w), 723.6 (w) cm
-1
. HRMS (ESI) M/Z+ Calc. 265.0501, Obs. 265.0499. 
 
Methyl 3-(3,4-dihydroquinolin-1(2H)-yl)-3-oxopropanoate (V-100g): A mixture of 
potassium carbonate (6.23 g, 44.0 mmol) and 1,2,3,4-tetrahydroquinoline (3.0 g, 22.5 
mmol), methyl-3-chloro-3-oxopropanoate (2.7 mL, 24.8 mmol) and acetonitrile (60 mL) 
were heated to reflux. After 14 h, the reaction mixture was cooled, filtered and dried in 
vacuo. The residue was dissolved in EtOAc/Hex (1:2.5). The organic layer was separated, 
and the aqueous layer was extracted three times with EtOAc. The combined organic 
layers were dried with anhydrous sodium sulfate, filtered, and concentrated. Column 
chromatography afforded V-100g as a reddish orange oil (3.76 g, 72%). (Rf 0.30, 25% 
EtOAc/Hex) 
1
H NMR (300 MHz, CDCl3) δ ppm 7.07 - 7.19 (m, 4H), 3.74 - 3.83 (m, 
2H), 3.65 (s, 3H), 3.58 (s, 2H), 2.69 (t, J=6.49 Hz, 2H), 1.94 (quin, J=6.65 Hz, 2H). 
13
C 
NMR (75 MHz, CDCl3) δ ppm 168.1, 165.5, 128.4, 126.3, 125.8, 123.9, 52.2, 42.7, 41.4, 
26.4, 23.7. IR: 3004.1 (w), 2951.0 (w), 2889.1 (w), 1739.3 (s), 1651.4 (s), 1603.6 (w), 
1580.9 (w), 1491.8 (s), 1435.5 (w), 1386.9 (m), 1326.1 (w), 1201.5 (m), 1155.7 (m), 
1074.0 (w), 1019.9 (m), 949.0 (w), 763.0 (s) cm
-1








5.5.2.2. Preparation of Acrylates 
General Method A:
33
 The β-ester-amide (1.0 equiv.), aldehyde (1.3 equiv.), 
glacial acetic acid (0.5 equiv.), and piperidine (0.1 equiv.) were heated to a reflux in 
benzene using a Dean-Stark trap for 14 h. After cooling the reaction mixture to room 
temperature, water was added to the reaction vessel, and the organic layer was collected. 
Subsequently, the aqueous phase was extracted with EtOAc three times. The combined 
organic layers were washed with 1M HCl and saturated sodium bicarbonate. The 
combined organic layers were dried with Na2SO4, filtered, concentrated, and purified by 
silica gel column chromatography (gradient EtOAc/Hex).  
General Method B:
34
 A round bottom flask was charged with the β-ester-amide 
(1.0 equiv.) and THF (25 mL). After cooling the solution to 0 °C, titanium(IV) chloride 
tetrahydrofuran complex (2.0 equiv.) and CCl4 (2.0 equiv.) were added to the reaction 
vessel. After 1 h at 0 °C, the aldehyde (1.0 equiv.) was added slowly, and the reaction 
was stirred for an hour. Then, pyridine (4.0 equiv.) was added to the solution drop-wise. 
The reaction mixture was warmed to room temperature and allowed to stir for 14 h. The 
reaction was quenched with water and the organic layer was collected. The aqueous layer 
was extracted with ether, and the combined organic layers were washed with saturated 
NaHCO3 and brine. The organic layer was dried with Mg2SO4, filtered, concentrated, and 






94a): Methyl 3-(2-methyl-1H-indol-1-yl)-3-oxopropanoate (1.80 g, 7.78 mmol), 4-
methoxybenzaldehyde (1.2 mL, 10.1 mmol), glacial acetic acid (0.262 g, 4.37 mmol), 
piperidine (80 µL , 0.810 mmol) and benzene (120 mL) were mixed according to general 
method A to afford V-94a as an orange oil (2.50 g, 92%) after 18 h (Rf 0.24, 20% 
EtOAc/Hex) (Diastereomer!) 
1
H NMR (300 MHz, CDCl3) δ ppm 8.43 (br. s., 0.81), 7.87 
(s, 1.13), 7.72 (s, 0.15), 7.33 - 7.47 (m, 3.50), 7.21 - 7.30 (m, 2.08), 6.89 (d, J = 8.79 Hz, 
0.27), 6.75 (d, J = 8.76 Hz, 2.10), 6.35 (s, 1.00), 3.87 (d, J = 0.70 Hz, 0.25), 3.83 (s, 
0.26), 3.81 (s, 0.31), 3.77 (s, 2.63), 3.72 (s, 2.94), 2.48 (br. s., 2.87).  
13
C NMR (75 MHz, 
CDCl3) δ ppm 166.3, 165.1, 161.8, 142.9, 142.5, 131.9, 131.4, 129.8, 125.6, 124.7, 119.6, 
114.5, 114.3, 55.2, 52.7, 16.7. IR: 3065.3 (w), 2951.7 (w), 2939.1 (w), 1720.6 (s), 1682.4 
(s), 1600.9 (s), 1511.8 (s), 1452.5 (s), 1385.8 (m), 1321.3 (m), 1290.4 (m), 1258.9 (s), 
1203.7 (m), 1172.3 (s), 1123.0 (m), 1056.1 (w), 1027.6 (m), 917.2 (w), 831.4 (m), 763.9 
(s), 751.0 (s), 700.6 (m) cm
-1
.  HRMS (ESI) M/Z+ Calc. 349.1314, Obs. 349.1319. 
 
(Z)-Methyl 3-(2-methoxyphenyl)-2-(2-methyl-1H-indole-1-carbonyl)acrylate (V-
94b): Methyl 3-(2-methyl-1H-indol-1-yl)-3-oxopropanoate (0.200 g, 0.865 mmol), 2-
methoxybenzaldehyde (0.153 g, 1.12 mmol), glacial acetic acid (0.026 g, 0.433 mmol), 
piperidine (0.0147 g, 0.173 mmol) and benzene (20 mL) were mixed according to general 
method A to afford V-94b as a yellow solid (0.231 g, 75%) after 18 h (Rf 0.69, 30% 
EtOAc/Hex) [m.p. 102-104 °C] (Temperature for the 
1
H NMR and 
13




H NMR (400 MHz, CDCl3) δ ppm 8.30 (s, 1H), 8.22 (d, J = 7.28 Hz, 1H), 7.43 - 7.48 
(m, 1H), 7.36 - 7.42 (m, 1H), 7.28 - 7.34 (m, 1H), 7.22 - 7.28 (m, 2H), 6.87 (d, J = 8.34 
Hz, 1H), 6.82 (t, J = 7.84 Hz, 1H), 6.36 (s, 1H), 3.83 (s, 3H), 3.74 (s, 3H), 2.60 (d, J = 
0.94 Hz, 3H). 
13
C NMR (101 MHz, CDCl3) δ ppm 165.9, 165.2, 158.3, 139.7, 137.1, 
132.2, 130.2, 129.9, 129.2, 123.8, 123.5, 122.2, 120.9, 119.6, 115.6, 111.2, 110.0, 55.3, 
52.4, 16.5. IR: 3051.9 (w), 3003.8 (w), 2951.9 (m), 2840.2 (m), 1713.4 (s), 1680.3 (s), 
1618.7 (m), 1596.8 (s), 1574.7 (m), 1487.0 (m), 1455.4 (s), 1435.7 (s), 1383.5 (s), 1307.0 
(s), 1261.0 (s), 1240.3 (s), 1194.9 (s), 1164.3 (m), 1116.8 (m), 1083.5 (m), 1050.6 (w), 
1024.7 (m), 993.0 (w), 840.3 (w), 804.0 (w), 749.2 (s), 730.4 (s), 648.0 (w) cm
-1
. HRMS 
(ESI) M/Z+ Calc. 349.1314, Obs. 349.1315. 
 
(Z)-Methyl 2-(2-methyl-1H-indole-1-carbonyl)-3-(4-nitrophenyl)acrylate (V-94c): 
Methyl 3-(2-methyl-1H-indol-1-yl)-3-oxopropanoate (0.300 g, 1.30 mmol), 4-
nitrobenzaldehyde (0.255 g, 1.69 mmol), glacial acetic acid (0.0357 g, 0.596 mmol), 
piperidine (14.0 µL, 0.130 mmol) and benzene (25 mL) were mixed according to general 
method A to afford V-94c as a orange solid (0.300 g, 64%) after 18 h (Rf 0.45, 20% 
EtOAc/Hex) [m.p. 109-111 °C] (Temperature for the 
1
H NMR and 
13
C NMR = 70 °C).  
1
H NMR (400 MHz, CDCl3) δ ppm 8.03 - 8.09 (m, 3H), 7.94 (s, 1H), 7.49 - 7.54 (m, 
2H), 7.38 - 7.42 (m, 1H), 7.20 - 7.25 (m, 2H), 6.34 (d, J = 0.94 Hz, 1H), 3.85 (s, 3H), 
2.51 (s, 3H). 
13
C NMR (101 MHz, CDCl3) δ ppm 164.4, 164.0, 148.8, 139.9, 138.5, 
136.7, 132.8, 130.0, 129.9, 124.3, 124.1, 123.9, 120.0, 115.0, 111.2, 52.9, 16.4. IR: 
306 
 
3108.3 (w), 2953.4 (w), 2929.6 (w), 1726.0 (s), 1678.5 (s), 1596.9 (m), 1521.3 (s), 
1456.1 (s), 1436.1 (m), 1384.8 (s), 1291.1 (s), 1256.0 (s), 1200.9 (s), 1111.8 (w), 1083.9 
(w), 1027.5 (w), 992.3 (w), 852.1 (w), 825.8 (w), 749.1 (s), 691.0 (w) cm
-1
. HRMS (ESI) 
M/Z+ Calc. 364.1059, Obs. 364.1076. 
 
(Z)-Methyl 2-(2-methyl-1H-indole-1-carbonyl)-3-(3-nitrophenyl)acrylate (V-94d): 
Methyl 3-(2-methyl-1H-indol-1-yl)-3-oxopropanoate (0.350 g, 1.513 mmol), 3-
nitrobenzaldehyde (0.297 g, 1.97 mmol), glacial acetic acid (0.0417 g, 0.696 mmol), 
piperidine (15 µL , 0.151 mmol) and benzene (20 mL) were mixed according to general 
method A to afford V-94d as a pale yellow solid (0.220 g, 40 %) after 20 h. (Rf 0.40, 




C = 60 °C) 
1
H NMR 
(400 MHz, CDCl3) δ ppm 8.21 - 8.24 (m, 1H), 8.10 (ddd, J = 1.00, 2.16, 8.25 Hz, 1H), 
8.03 (br. s., 1H), 7.94 (s, 1H), 7.63 - 7.67 (m, 1H), 7.35 - 7.41 (m, 2H), 7.18 - 7.25 (m, 
2H), 6.33 (d, J = 0.88 Hz, 1H), 3.86 (s, 3H), 2.54 (s, 3H). 
13
C NMR (101 MHz, CDCl3) δ 
ppm 164.6, 164.2, 148.7, 139.9, 136.7, 134.4, 134.2, 132.1, 130.1, 130.0, 124.9, 124.3, 
124.2, 124.2, 120.0, 115.1, 111.3, 53.1, 16.7. IR: 3083.4 (w), 2954.9 (w), 2928.5 (w), 
1727.7 (s), 1678.7 (s), 1630.1 (w), 1597.5 (w), 1576.9 (w), 1532.1 (s), 1456.4 (s), 1437.6 
(m), 1386.4 (s), 1351.2 (s), 1308.8 (s), 1258.6 (s), 1203.4 (s), 1086.2 (w), 1027.7 (w), 
992.8 (w), 824.9 (w), 808.9 (w), 751.6 (m), 736.8 (m), 676.3 (w) cm
-1
. HRMS (ESI) 




(Z)-Methyl 3-(4-cyanophenyl)-2-(2-methyl-1H-indole-1-carbonyl)acrylate (V-94e): 
Methyl 3-(2-methyl-1H-indol-1-yl)-3-oxopropanoate (0.350 g, 1.51 mmol), 4-
cyanobenzaldehyde (0.258 g, 1.97 mmol), glacial acetic acid (0.0417 g, 0.696 mmol), 
piperidine (15 µL , 0.151 mmol) and benzene (20 mL) were mixed according to general 
method A to afford V-94e as a off-white solid (0.325 g, 62%) after 18 h. (Rf 0.35, 20% 
EtOAc/Hex) [m.p. 122-124 °C] 
1
H NMR (300 MHz, CDCl3) δ ppm 8.81 - 8.05 (br. s., 
1H), 7.38 - 7.53 (m, 6H), 7.20 - 7.28 (m, 2H), 6.35 (s, 1H), 3.82 (s, 3H), 2.46 (br. s., 3H).
 
13
C NMR (75 MHz, CDCl3) δ ppm 164.6, 164.0, 140.4, 136.4, 132.5, 131.5, 129.6, 
124.2, 119.9, 117.7, 113.8, 111.2, 53.1, 16.7. IR: 3056.6 (w), 2954.9 (w), 2928.2 (w), 
2229.5 (m), 1725.7 (s), 1677.7 (s), 1627.5 (m), 1596.9 (m), 1576.6 (m), 1504.2 (w), 
1456.0 (s), 1435.5 (m), 1384.3 (s), 1303.3 (s), 1256.1 (s), 1201.7 (s), 1152.5 (w), 1117.1 
(w), 1084.3 (m), 1027.4 (m), 992.3 (m), 936.0 (w), 830.2 (m), 750.5 (s) cm
-1
. HRMS 
(ESI) M/Z+ Calc. 344.1161, Obs. 344.1169. 
 
(Z)-Methyl 3-(4-fluorophenyl)-2-(2-methyl-1H-indole-1-carbonyl)acrylate (V-94f): 
Methyl 3-(2-methyl-1H-indol-1-yl)-3-oxopropanoate (0.350 g, 1.51 mmol), 4-
fluorobenzaldehyde (0.210 mL, 2.00 mmol), glacial acetic acid (0.0417 g, 0.695 mmol), 
piperidine (15 µL, 0.151 mmol) and benzene (25 mL) were mixed according to general 
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method A to afford V-94f as a yellow solid (0.293 g, 57%) after 18 h (Rf 0.40, 20% 




C = 60 °C)  
1
H NMR (300 
MHz, CDCl3) δ ppm 8.20 (br. s., 1H), 7.89 (s, 1H), 7.34 - 7.45 (m, 3H), 7.17 - 7.30 (m, 
2H), 6.92 (t, J = 8.59 Hz, 2H), 6.34 (s, 1H), 3.80 (s, 3H), 2.50 (s, 3H). 
13
C NMR (75 
MHz, CDCl3) δ ppm 165.7, 165.5, 164.7, 162.4, 141.8, 136.9, 131.9 and 131.7 (doublet), 
129.9, 124.2 and 124.0 (doublet), 119.8, 116.4, 116.1, 115.5, 110.9, 52.7, 16.6. IR: 
3076.2 (w), 2951.8 (w), 1724.8 (s), 1683.9 (s), 1627.8 (w), 1598.7 (s), 1508.9 (s), 1456.5 
(s), 1436.7 (m), 1386.76 (s), 1301.0 (m), 1260.4 (s), 1197.7 (s), 1162.4 (s), 834.7 (m), 
750.5 (s), 668.5 (m) cm
-1
. HRMS (ESI) M/Z+ Calc. 337.1114, Obs. 349.1107. 
 
 
(Z)-Methyl 3-(3-bromophenyl)-2-(2-methyl-1H-indole-1-carbonyl)acrylate (V-94g): 
Methyl 3-(2-methyl-1H-indol-1-yl)-3-oxopropanoate (0.350 g, 1.51 mmol), 3-
bromobenzaldehyde (0.230 mL, 1.97 mmol), glacial acetic acid (0.0417 g, 0.696 mmol), 
piperidine (15 µL , 0.151 mmol) and benzene (20 mL) were mixed according to general 
method A to afford V-94g as a pale gray solid (0.430 g, 72 %) after 18 h. (Rf 0.40, 20% 




C = 60 °C) 
1
H NMR 
(400 MHz, CDCl3) δ ppm 8.08 - 8.19 (m, 1H), 7.86 (s, 1H), 7.52 - 7.56 (m, 1H), 7.39 - 
7.44 (m, 2H), 7.27 - 7.33 (m, 1H), 7.21 - 7.27 (m, 2H), 7.05 - 7.11 (m, 1H), 6.35 (d, J = 
0.75 Hz, 1H), 3.85 (s, 3H), 2.54 (s, 3H). 
13
C NMR (101 MHz, CDCl3) δ ppm 165.0, 
164.4, 141.2, 136.8, 136.5, 134.5, 133.5, 132.5, 130.5, 130.3, 130.0, 127.5, 124.2, 124.0, 
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123.0, 119.8, 115.3, 111.0, 52.8, 16.6. IR: 2962.5 (w), 2926.4 (w), 1726.6 (s), 1681.3 (s), 
1625.7 (m), 1596.8 (w), 1561.3 (w), 1456.4 (s), 1435.7 (m), 1384.9 (s), 1311.0 (s), 
1258.9 (s), 1198.1 (s), 1076.9 (w), 1027.7 (w), 994.3 (w), 786.6 (w), 750.3 (s), 680.8 (w) 
cm
-1
. HRMS (ESI) M/Z+ Calc. 397.0314, Obs. 397.0316. 
 
 
(Z)-Methyl 2-(2-methyl-1H-indole-1-carbonyl)-3-(thiophen-2-yl)acrylate (V-94h): 
Methyl 3-(2-methyl-1H-indol-1-yl)-3-oxopropanoate (0.350 g, 1.51 mmol), thiophene-2-
carbaldehyde (0.220 g, 1.97 mmol), glacial acetic acid (0.0417 g, 0.696 mmol), 
piperidine (15 µL , 0.150 mmol) and benzene (20 mL) were mixed according to general 
method A to afford V-94h as a off-white solid (0.396 g, 81%) after 18 h. (Rf 0.45, 20% 
EtOAc/Hex) [m.p. 153-155 °C] 
1
H NMR (300 MHz, CDCl3) δ ppm 8.28 (br. s., 1H), 
8.04 (d, J = 0.37 Hz, 1H), 7.42 - 7.48 (m, 1H), 7.36 (d, J = 5.06 Hz, 1H), 7.29 - 7.33 (m, 
1H), 7.23 - 7.29 (m, 2H), 6.95 - 7.00 (m, 1H), 6.39 (s, 1H), 3.79 (s, 3H), 2.50 (s, 3H). 
13
C 
NMR (75 MHz, CDCl3) δ ppm 165.3, 164.9, 136.9, 135.7, 135.1, 134.6, 132.5, 129.9, 
128.0, 124.9, 124.2, 124.0, 119.7, 115.9, 111.0, 108.0, 52.8, 16.8. IR: 3104.8 (w), 2952.1 
(w), 2927.5 (w), 1719.0 (s), 1675.8 (s), 1611.7 (s), 1455.9 (s), 1385.9 (s), 1342.5 (m), 
1303.5 (s), 1253.5 (s), 1202.6 (s), 1086.3 (w), 1051.6 (w), 1027.9 (w), 992.9 (w), 858.1 
(w), 750.5 (s), 717.4 (m) cm
-1





(Z)-methyl 2-(2-methyl-1H-indole-1-carbonyl)pent-2-enoate (V-94i): Methyl 3-(2-
methyl-1H-indol-1-yl)-3-oxopropanoate (0.500 g, 2.16 mmol), propanaldehyde (0.155 
mL, 2.16 mmol), TiCl4•THF (1.44 g, 4.32 mmol), CCl4 (0.418 mL, 4.32 mmol), pyridine 
(0.699 mL, 8.65 mmol) and THF (35 mL) were combined according to general method B 
to yield V-94i as a clear oil (0.421 g, 72%) after 14 h. (Rf 0.55, 20% EtOAc/Hex). 
1
H 
NMR (300 MHz, CDCl3) δ ppm 8.13 (br. s., 1H), 7.50 - 7.58 (m, 1H), 7.27 - 7.36 (m, 
3H), 6.48 (d, J = 0.77 Hz, 1H), 3.82 (s, 3H), 2.60 (s, 3H), 2.28 (quin, J = 7.63 Hz, 2H), 
1.13 (t, J = 7.53 Hz, 3H). 
13
C NMR (75 MHz, CDCl3) δ ppm 165.1, 164.2, 150.7, 136.8, 
136.5, 131.5, 129.8, 123.8, 123.7, 119.8, 115.2, 110.4, 52.5, 23.1, 16.9, 12.3. IR: 2973.6 
(w), 2936.1 (w), 1726.6 (s), 1685.9 (s), 1643.0 (w), 1596.5 (w), 1575.5 (w), 1456.3 (s), 
1436.9 (m), 1384.1 (s), 1310.8 (s), 1289.7 (s), 1243.9 (s), 1205.4 (w), 1036.7 (w), 989.8 
(w), 783.4 (w), 750.3 (s) cm
-1
.  HRMS (ESI) M/Z+ Calc. 271.1208, Obs. 271.1218.  
 
 
(2Z, 4E)-Methyl 2-(2-methyl-1H-indole-1-carbonyl)-5-phenylpenta-2,4-dienoate (V-
94j): Methyl 3-(2-methyl-1H-indol-1-yl)-3-oxopropanoate (0.300 g, 1.30 mmol), 
cinnamaldehyde (0.21 mL, 1.69 mmol), glacial acetic acid (0.0357 g, 0.596 mmol), 
piperidine (13.97 µL, 0.1297 mmol) and benzene (25 mL) were mixed according to 
general method A to afford V-94j as a reddish orange oil (0.256 g, 57%) after 20 h. (Rf 
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0.48, 20% EtOAc/Hex) 
1
H NMR (300 MHz, CDCl3) δ ppm 8.10 - 8.18 (m, 1H), 7.76 (d, 
J = 11.73 Hz, 1H), 7.45 - 7.51 (m, 1H), 7.34 - 7.42 (m, 2H), 7.23 - 7.34 (m, 5H), 7.12 (d, 
J = 15.39 Hz, 1H), 6.82 - 6.95 (m, 1H), 6.42 (s, 1H), 3.74 (s, 3H), 2.54 (d, J = 0.99 Hz, 
3H). 
13
C NMR (75 MHz, CDCl3) δ ppm 165.1, 164.8, 145.4, 145.0, 136.7, 136.6, 135.1, 
130.0, 129.7, 129.7, 129.0, 128.8, 128.5, 127.8, 123.9, 123.7, 122.2, 119.8, 115.3, 110.4, 
52.6, 16.7. IR: 3030.0 (w), 2949.9 (w), 1721.0 (s), 1682.4 (s), 1614.7 (m), 1590.8 (m), 
1456.2 (s), 1435.3 (m), 1384.9 (s), 1308.3 (s), 1278.6 (s), 1237.6 (s), 1202.0 (w), 1077.2 
(w), 993.8 (w), 836.1 (w), 750.7 (s), 691.5 (w) cm
-1




94k): Methyl 3-oxo-3-(2-phenyl-1H-indol-1-yl)propanoate (1.28 g, 4.36 mmol), 4-
methoxybenzaldehyde (0.70 mL, 5.75 mmol), glacial acetic acid (0.131 g, 2.18 mmol), 
piperidine (50 µL, 0.506 mmol) and benzene (120 mL) were mixed according to general 
method A to afford V-94k as a dark brown solid (0.456 g, 25%) after 18 h. (Rf 0.37, 20% 
EtOAc/Hex) [m.p. 105-107 °C] 
1
H NMR (300 MHz, CDCl3) δ ppm 8.63 (d, J = 8.17 Hz, 
1H), 7.40 - 7.51 (m, 2H), 7.29 - 7.38 (m, 2H), 7.19 - 7.27 (m, 2H), 7.16 (s, 1H), 7.00 - 
7.13 (m, 4H), 6.54 - 6.61 (m, 2H), 6.34 (s, 1H), 3.73 (s, 3H), 3.71 (s, 3H). 
13
C NMR (75 
MHz, CDCl3) δ ppm 166.8, 164.4, 161.5, 143.1, 139.8, 138.2, 133.4, 131.6, 129.6, 128.6, 
127.8, 125.4, 125.2, 125.0, 124.3, 120.2, 116.6, 114.0, 111.9, 55.3, 52.3. IR: 3065.3 (w), 
2951.7 (w), 2939.1 (w), 1720.6 (s), 1682.4 (s), 1600.9 (s), 1511.8 (s), 1452.5 (s), 1385.8 
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(m), 1321.3 (m), 1290.4 (m), 1258.9 (s), 1203.7 (m), 1172.3 (s), 1123.0 (m), 1056.1 (w), 
1027.6 (m), 917.2 (w), 831.4 (m), 763.9 (s), 751.0 (s), 700.6 (m) cm
-1
. HRMS (ESI) 




94l): Methyl 3-(2,3-dimethyl-1H-indol-1-yl)-3-oxopropanoate (1.00 g, 4.08 mmol), 4-
methoxybenzaldehyde (0.617 mL, 5.10 mmol), glacial acetic acid (0.112 g, 1.88 mmol), 
piperidine (0.0340 g, 0.407 mmol) and benzene (35 mL) were mixed according to general 
method A to afford V-94l as a yellow solid (1.080 g, 73%) after 18 h. (Rf 0.25, 20% 
EtOAc/Hex) [m.p. 94-96 °C] 
1
H NMR (300 MHz, CDCl3) δ ppm 8.63 (br. s, 1H), 7.87 
(br. s., 1H), 7.33 - 7.48 (m, 3H), 7.28 (br. s., 2H), 6.73 (d, J = 8.50 Hz, 2H), 3.77 (s, 3H), 
3.67 (d, J = 1.21 Hz, 3H), 2.25 - 2.53 (m, 3H), 2.15 (s, 3H).
 13
C NMR (75 MHz, CDCl3) 
δ ppm 165.9, 165.2, 161.9, 142.5, 136.1, 131.8, 131.5, 126.6, 125.3, 124.3, 123.6, 117.9, 
116.5, 114.6, 55.2, 52.4, 13.4, 8.6. IR: 3008.4 (w), 2933.3 (w), 2839.7 (w), 1721.5 (s), 
1675.4 (s), 1601.6 (s), 1513.5 (s), 1458.5 (s), 1396.3 (m), 1306.8 (s), 1258.4 (s), 1203.4 
(m), 1174.8 (s), 1133.5 (w), 1028.0 (w), 907.9 (w), 832.0 (w), 750.0 (s) cm
-1
. HRMS 





carbonyl)acrylate (V-94m): Methyl 3-(2,3-dihydrocyclopenta[b]indol-4(1H)-yl)-3-
oxopropanoate (0.175 g, 0.681 mmol), 4-methoxybenzaldehyde (0.107 mL, 0.885 mmol), 
glacial acetic acid (0.0187 g, 0.313 mmol), piperidine (6.8 µL, 0.0680 mmol) and 
benzene (15 mL) were mixed according to general method A to afford V-94m as a white 
solid (0.0520 g, 20%) after 18 h. (Rf 0.40, 20% EtOAc/Hex) [m.p. 156-158 °C] 
1
H NMR 
(300 MHz, CDCl3) δ ppm 8.64 - 8.72 (m, 1H), 7.82 (s, 1H), 7.24 - 7.44 (m, 5H), 6.75 - 
6.82 (m, 2H), 3.80 (s, 3H), 3.75 (s, 3H), 2.60 - 2.80 (m, 4H), 2.25 - 2.50 (m, 2H). 
13
C 
NMR (75 MHz, CDCl3) δ ppm 165.5, 165.3, 161.8, 142.9, 141.7, 140.9, 132.0, 128.1, 
127.4, 124.9, 124.5, 124.3, 124.2, 118.5, 117.7, 114.7, 55.3, 52.7, 28.9, 27.5, 23.8. IR: 
2950.7 (w), 2857.5 (w), 1720.8 (m), 1681.7 (s), 1602.0 (s), 1513.5 (s), 1450.13 (m), 
1392.8 (m), 1258.2 (s), 1173.02 (s), 1120.5 (w), 1103.5 (w), 1043.3 (w), 983.9 (w), 831.7 
(w), 751.0 (m) cm
-1
. HRMS (ESI) M/Z+ Calc. 375.1448, Obs. 375.1474. 
 
(Z)-Methyl 2-(5-fluoro-2-methyl-1H-indole-1-carbonyl)-3-(4-methoxyphenyl) 
acrylate (V-94n): Methyl 3-(5-fluoro-2-methyl-1H-indol-1-yl)-3-oxopropanoate (0.301 
g, 1.21 mmol), 4-methoxybenzaldehyde (0.180 mL, 1.48 mmol), glacial acetic acid 
(0.0520 g, 0.873 mmol), piperidine (25 µL , 0.253 mmol) and benzene (30 mL) were 
mixed according to general method A to afford V-94n as a pale brick solid (0.382 g, 




C = 60 °C)  
1
H NMR (300 MHz, CDCl3) δ ppm 8.25 (br s, 1H), 7.85 (s, 1H), 7.28 - 
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7.39 (m, 2H), 7.05 (dd, J = 2.57, 8.61 Hz, 1H), 6.95 (dt, J = 2.58, 9.12 Hz, 1H), 6.70 - 
6.79 (m, 2H), 6.27 (s, 1H), 3.78 (s, 3H), 3.71 (s, 3H), 2.46 (s, 3H). 
13
C NMR (75 MHz, 
CDCl3) δ ppm 166.0, 165.0, 162.1, 161.5, 158.3, 143.0, 133.3, 131.8, 131.1 and 131.0 
(doublet), 125.8, 124.9, 116.9, 114.6, 111.5, 111.2, 110.3, 105.5, 105.2, 55.2, 52.5, 16.5. 
IR: 2948.8 (w), 2903.6 (w), 1720.7 (m), 1685.4 (m), 1602.5 (s), 1513.7 (s), 1472.7 (m), 
1448.5 (m), 1389.2 (m), 1301.5 (m), 1274.6 (s), 1260.5 (s), 1176.5 (s), 995.0 (w), 957.3 
(w), 832.8 (w), 764.3 (s), 750.0 (s) cm
-1




acrylate (V-94o): Methyl 3-(5-chloro-2-methyl-1H-indol-1-yl)-3-oxopropanoate (0.565 
g, 2.14 mmol), 4-methoxybenzaldehyde (0.337 mL, 2.77 mmol), glacial acetic acid 
(0.0589 g, 0.982 mmol), piperidine (21 µL, 0.214 mmol) and benzene (30 mL) were 
mixed according to general method A to afford V-94o as a off-white solid (0.300 g, 37%) 




C = 60 °C)  
1
H NMR (300 MHz, CDCl3) δ ppm 8.20 (d, J = 8.54 Hz, 1H), 7.86 (s, 1H), 
7.30 - 7.40 (m, 3H), 7.20 (dd, J = 2.11, 8.85 Hz, 1H), 6.72 - 6.79 (m, 2H), 6.26 (s, 1H), 
3.78 (s, 3H), 3.70 - 3.75 (m, 3H), 2.47 (s, 3H). 
13
C NMR (75 MHz, CDCl3) δ ppm 166.1, 
164.9, 162.1, 143.2, 138.0, 135.4, 131.8, 131.2, 129.5, 125.8, 124.9, 124.1, 119.3, 116.7, 
114.7, 109.8, 55.2, 52.5, 16.5. IR: 2952.3 (w), 2839.8 (w), 2360.1 (m), 2342.4 (m), 
1718.7 (s), 1683.4 (s), 1597.9 (s), 1512.5 (s), 1442.9 (s), 1385.6 (s), 1345.9 (w), 1294.5 
315 
 
(m), 1255.6 (s), 1201.3 (m), 1171.5 (s), 1124.2 (w), 1072.5 (w), 1021.4 (w), 995.1 (w), 




HRMS (ESI) M/Z+ Calc. 
383.0924, Obs. 383.0922. 
 
Methyl 2-(indoline-1-carbonyl)-3-(4-methoxyphenyl)acrylate (V-97a): Methyl 3-
(indolin-1-yl)-3-oxopropanoate (0.350 g, 1.60 mmol), 4-methoxybenzaldehyde (0.252 
mL, 2.08 mmol), glacial acetic acid (0.0440 g, 0.734 mmol), piperidine (16 µL, 0.160 
mmol) and benzene (30 mL) were mixed according to general method A to afford V-97a 
as an orange oil (0.390 g, 72%) after 20 h. (Rf 0.35, 20% EtOAc/Hex) (Diastereomers!) 
1
H NMR (300 MHz, CDCl3) δ ppm 8.41 (d, J = 8.03 Hz, 1.00), 7.82 (s, 0.20), 7.70 (s, 
1.14), 7.43 - 7.54 (m, 2.47), 7.28 - 7.33 (m, 0.81), 7.16 - 7.22 (m, 1.27), 7.01 - 7.13 (m, 
1.44), 6.80 - 6.88 (m, 2.53), 4.36 - 4.50 (m, 0.18), 4.18 - 4.31 (m, 0.20), 3.94 (br.s., 1.16), 
3.83 (s, 3.16), 3.61 - 3.80 (m, 3.87), 3.71 - 3.76 (m, 1.78), 2.92 - 3.22 (m, 2.49).
 13
C 
NMR (101 MHz, CDCl3) δ ppm 165.4, 165.0, 161.9, 142.6, 142.4, 140.6, 132.0, 131.8, 
127.7, 126.0, 125.8, 124.6, 124.4, 117.5, 114.8, 114.5, 55.3, 52.4, 48.4, 28.0.  IR: 3004.8 
(w), 2951.7 (w), 2839.7 (w), 1716.9 (s), 1645.7 (s), 1598.9 (s), 1512.6 (s), 1482.3 (s), 
1413.3 (m), 1255.3 (s), 1174.5 (s), 1126.4 (m), 1057.9 (m), 1027.4 (m), 832.3 (m), 755.8 
(s), 668.5 (m) cm
-1






(V-97b): Methyl 3-(3,4-dihydroquinolin-1(2H)-yl)-3-oxopropanoate (0.3500 g, 1.5010 
mmol), 4-methoxybenzaldehyde (0.2370 mL, 1.9510 mmol), glacial acetic acid (0.0414 
g, 0.6900 mmol), piperidine (14.80 µL, 0.1501 mmol) and benzene (30 mL) were mixed 
according to general method A to afford V-97b as a orange oil (0.4230 g, Crude = 80.19 
%) after 15 h. Rf 0.35 (20% EtOAc/Hex). HRMS (ESI) M/Z+ Calc. 351.1471, Obs. 
351.1499. 
 
5.5.2.3. In(OTf)3-Catalyzed Cyclizations  
General Procedure: To a mixture of In(OTf)3 (0.10-0.15 equiv.) in 1,2-DCE (or 
toluene) heated to a reflux, dissolved V-94 (or V-97) (1.0 equiv.) was syringed into the 
reaction vessel. The reaction was monitored by TLC and quenched with water. The 
phases were separated, and the product was extracted from the aqueous phase with DCM. 
The combined organic layers were washed with brine, dried over Mg2SO4, filtered, and 






quinoline-5-carboxylate (V-96a): (Z)-Methyl 3-(4-methoxyphenyl)-2-(2-methyl-1H-
indole-1-carbonyl)acrylate (0.258 g, 0.739 mmol), In(OTf)3 (0.0428 g, 0.0760 mmol) and 
1,2-DCE (13 mL) were combined according to the  general procedure to afford V-96a as 
a brown solid (0.161 g, 63%) after 3 h. (Rf 0.35, 20% EtOAc/Hex) [m.p. 122-124 °C] 
Diastereomeric ratio: (50:1).  
1
H NMR (300 MHz, CDCl3) δ ppm 7.31 - 7.37 (m, 1H), 
7.14 - 7.20 (m, 2H), 7.08 - 7.13 (m, 1H), 6.84 - 6.92 (m, 2H), 6.71 (d, J = 7.48 Hz, 1H), 
6.41 (d, J = 1.25 Hz, 1H), 4.96 (d, J = 10.85 Hz, 1H), 4.19 (d, J = 10.88 Hz, 1H), 3.81 (s, 
3H), 3.68 (s, 3H), 2.71 (d, J = 1.03 Hz, 3H). 
13
C NMR (75 MHz, CDCl3) δ ppm 169.0, 
164.0, 159.0, 137.2, 134.9, 130.9, 129.6, 127.4, 124.0, 122.7, 121.0, 118.4, 114.3, 109.4, 
58.8, 55.2, 52.6, 45.3, 15.2. IR: 2954.7 (w), 2922.5 (w), 2850.5 (w), 1749.6 (s), 1709.3 
(s), 1611.6 (w), 1513.5 (s), 1443.5 (s), 1381.8 (s), 1340.9 (s), 1252.6 (s), 1178.9 (w), 
1153.2 (m), 1032.8 (m), 818.6 (m), 764.7 (m), 749.1 (s) cm
-1
. HRMS (ESI) M/Z+ Calc. 
349.1314, Obs. 349.1310. 
 
Methyl 6-(2-methoxyphenyl)-2-methyl-4-oxo-5,6-dihydro-4H-pyrrolo[3,2,1-ij] 
quinoline-5-carboxylate (V-96b): (Z)-Methyl 3-(2-methoxyphenyl)-2-(2-methyl-1H-
indole-1-carbonyl)acrylate (0.060 g, 0.172 mmol), In(OTf)3 (0.0145 g, 0.0250 mmol) and 
toluene (4 mL) were combined according to the general procedure to afford V-96b as a 
clear oil (0.0522 g, 87%) after 3 h. (Rf 0.35, 20% EtOAc/Hex) Diastereomeric ratio: 
(3.7:1). (Trans diastereomer chemical shifts reported)  
1
H NMR (400 MHz, CDCl3) δ 
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ppm 7.33 (d, J = 7.72 Hz, 1H), 7.23 - 7.29 (m, 1H), 7.11 (t, J = 7.62 Hz, 1H), 6.83 - 6.94 
(m, 3H), 6.76 (d, J = 7.47 Hz, 1H), 6.40 (d, J = 1.13 Hz, 1H), 5.26 (d, J = 7.72 Hz, 1H), 
4.41 (d, J = 7.65 Hz, 1H), 3.75 (s, 3H), 3.67 (s, 3H), 2.72 (d, J = 0.94 Hz, 3H). 
13
C NMR 
(101 MHz, CDCl3) δ ppm 169.4, 164.4, 157.3, 137.2, 135.1, 129.7, 129.0, 127.7, 127.4, 
124.0, 121.8, 120.9, 120.6, 118.1, 111.2, 109.2, 56.2, 55.4, 52.7, 41.8, 15.2. IR: 3065.0 
(w), 3032.3 (w), 3003.1 (m), 2954.0 (m), 2839.0 (m), 1745.7 (s), 1707.2 (s), 1627.5 (w), 
1600.6 (w), 1586.6 (w), 1573.3 (w), 1493.3 (m), 1443.7 (m), 1380.9 (m), 1338.7 (m), 
1287.0 (m), 1210.6 (s), 1154.0 (m), 1119.0 (m), 1047.7 (w), 1026.1 (m), 967.6 (m), 911.8 
(m), 820.2 (w), 748.8 (m), 732.9 (m) cm
-1




ij]quinoline-5-carboxylate (V-96c): (Z)-Methyl 2-(2-methyl-1H-indole-1-carbonyl)-3-
(4-nitrophenyl)acrylate (0.070 g, 0.1922 mmol), In(OTf)3 (0.0162 g, 0.0288 mmol) and 
toluene (4 mL) were combined according to the  general procedure to afford V-96c as an 
orange oil (0.0548 g, 78.34) after 14 h. (Rf 0.40, 20% EtOAc/Hex). Diastereomeric ratio: 
(2.4:1) (Trans diastereomer chemical shifts reported) 
1
H NMR (300 MHz, CDCl3) δ ppm 
8.19 - 8.28 (m, 2H), 7.42 - 7.50 (m, 2H), 7.39 (d, J = 7.77 Hz, 1H), 7.15 (t, J = 7.64 Hz, 
1H), 6.64 (d, J = 7.48 Hz, 1H), 6.45 (d, J = 1.21 Hz, 1H), 5.16 (d, J = 10.44 Hz, 1H), 4.21 
(d, J = 10.44 Hz, 1H), 3.69 (s, 3H), 2.71 (d, J = 1.17 Hz, 3H).
 13
C NMR (75 MHz, 
CDCl3) δ ppm 168.4, 163.0, 147.6, 146.8, 137.6, 129.6, 127.8, 124.3, 124.2, 120.8, 120.6, 
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119.2, 109.6, 58.0, 53.0, 45.8, 15.2. IR: 3066.3 (w), 2955.2 (w), 2923.9 (w), 2850.9 (w), 
1746.1 (s), 1709.3 (s), 1606.7 (w), 1519.4 (s), 1444.4 (s), 1381.0 (s), 1345.7 (s), 1285.8 
(m), 1268.1 (m), 1211.2 (w), 1154.5 (s), 1109.6 (w), 1048.0 (w), 1008.1(w), 967.4 (w), 
863.3 (m), 819.5 (m), 748.9 (s), 735.0 (s), 706.7 (m), 611.3 (w) cm
-1
. HRMS (ESI) M/Z+ 
Calc. 364.1059, Obs. 364.1048. 
 
Methyl 2-methyl-6-(3-nitrophenyl)-4-oxo-5,6-dihydro-4H-pyrrolo[3,2,1-ij]quinoline-
5-carboxylate (V-96d): (Z)-Methyl 2-(2-methyl-1H-indole-1-carbonyl)-3-(3-
nitrophenyl)acrylate (0.100 g, 0.275 mmol), In(OTf)3 (0.0231 g, 0.0411 mmol) and 1,2-
DCE (4 mL) were combined according to the  general procedure to afford V-96d as a off-
white solid (0.0861 g, 86%) after 13 h. (Rf 0.35, 20% EtOAc/Hex) [m.p. 106-108 °C] 
Diastereomeric ratio: (2.2:1). (Trans diastereomer chemical shifts reported)   
1
H NMR 
(300 MHz, CDCl3) δ ppm 8.19 - 8.28 (m, 2H), 7.42 - 7.50 (m, 2H), 7.39 (d, J = 7.77 Hz, 
1H), 7.15 (t, J = 7.64 Hz, 1H), 6.64 (d, J = 7.48 Hz, 1H), 6.43 - 6.46 (m, 1H), 5.16 (d, J = 
10.44 Hz, 1H), 4.21 (d, J = 10.44 Hz, 1H), 3.69 (s, 3H), 2.71 (d, J = 1.17 Hz, 3H). 
13
C 
NMR (75 MHz, CDCl3) δ ppm 168.4, 163.0, 147.6, 146.8, 137.6, 129.6, 127.8, 125.0, 
124.3, 124.2, 120.8, 120.6, 119.2, 109.6, 58.0, 53.0, 45.8, 15.2. IR: 3066.6 (w), 2955.3 
(w), 2923.4 (w), 1746.0 (s), 1708.6 (s), 1530.3 (s), 1444.0 (s), 1380.6 (s), 1346.0 (s), 
1286.5 (m), 1267.1 (m), 1154.2 (s), 1052.1 (w), 1003.0 (w), 966.4 (w), 904.1 (w), 817.3 
(m), 738.9 (s), 709.5 (m), 613.4 (m) cm
-1






quinoline-5-carboxylate (V-96e): (Z)-Methyl 3-(4-cyanophenyl)-2-(2-methyl-1H-
indole-1-carbonyl)acrylate (0.0900 g, 0.263 mmol), In(OTf)3 (0.0220 g, 0.0392 mmol) 
and 1,2-DCE (4 mL) were combined according to the  general procedure to afford V-96e 
as a pale orange solid (0.0704 g, 78%) after 14 h. (Rf 0.35, 20% EtOAc/Hex). [m.p. 155-
157 °C] Diastereomeric ratio: (1.85:1). (Trans diastereomer chemical shifts reported)  
1
H 
NMR (300 MHz, CDCl3) δ ppm 7.66 (d, J = 8.25 Hz, 2H), 7.38 (d, J = 7.88 Hz, 3H), 
7.14 (t, J = 7.62 Hz, 1H), 6.64 (d, J = 7.44 Hz, 1H), 6.44 (d, J = 0.92 Hz, 1H), 5.09 (d, J 
= 10.30 Hz, 1H), 4.18 (d, J = 10.30 Hz, 1H), 3.69 (s, 3H), 2.71 (s, 3H). 
13
C NMR (75 
MHz, CDCl3) δ ppm 168.4, 163.1, 144.8, 137.5, 132.8, 129.4, 127.7, 124.3, 120.8, 120.6, 
119.1, 118.4, 112.0, 109.6, 58.0, 52.9, 46.0, 15.2. IR: 2955.3 (w), 2922.9 (w), 2229.2 
(w), 1748.4 (s), 1712.4 (s), 1532.6 (w), 1445.2 (s), 1383.0 (s), 1344.2 (m), 1275.0 (s), 
1262.2 (s), 1156.3 (m), 819.0 (w), 749.7 (s) cm
-1




quinoline-5-carboxylate (V-96f): (Z)-Methyl 3-(4-fluorophenyl)-2-(2-methyl-1H-
indole-1-carbonyl)acrylate (0.0760 g, 0.225 mmol), In(OTf)3 (0.0188 g, 0.0330 mmol) 
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and 1,2-DCE (8 mL) were combined according to the  general procedure to afford V-96f 
as a yellow solid (0.0716 g, 94%) after 1 h. (Rf 0.68, 30% EtOAc/Hex) [m.p. 153-155 
°C] Diastereomeric ratio: (2.6:1) (Trans diastereomer chemical shifts reported)  
1
H 
NMR (300 MHz, CDCl3) δ ppm 7.36 (d, J = 7.77 Hz, 1H), 7.19 - 7.25 (m, 2H), 7.13 (t, J 
= 7.62 Hz, 1H), 7.00 - 7.09 (m, 2H), 6.68 (d, J = 7.44 Hz, 1H), 6.42 (d, J = 1.17 Hz, 1H), 
5.01 (d, J = 10.85 Hz, 1H), 4.18 (d, J = 10.85 Hz, 1H), 3.68 (s, 3H), 2.71 (s, 3H). 
13
C 
NMR (75 MHz, CDCl3) δ ppm 168.8, 163.7, 137.3, 134.8, 130.2 and 130.1 (doublet), 
127.5, 124.2, 122.1, 120.9, 118.7, 116.1, 115.8, 109.5, 77.2, 58.7, 52.7, 45.4, 15.2. IR: 
3058.4 (w), 2954.5 (w), 2923.0 (w), 1746.8 (s), 1708.7 (s), 1605.3 (w), 1509.8 (s), 1443.8 
(s), 1380.9 (s), 1340.0 (s), 1267.9 (m), 1224.3 (s), 1159.1 (s), 1097.6 (w), 1051.5 (w), 
1010.0 (w), 967.1 (w), 818.5 (m), 748.7 (s) cm
-1




quinoline-5-carboxylate (V-96g): (Z)-Methyl 3-(3-bromophenyl)-2-(2-methyl-1H-
indole-1-carbonyl)acrylate (0.100 g, 0.252 mmol), In(OTf)3 (0.0213 g, 0.0377 mmol) and 
1,2-DCE (4 mL) were combined according to the  general procedure to afford V-96g as a 
pale yellow solid (0.0614 g, 61%) after 14 h. (Rf 0.40, 20% EtOAc/Hex) [m.p. 123-125 
°C] Diastereomeric ratio: (8.3:1). (Trans diastereomer chemical shifts reported) 
1
H 
NMR (300 MHz, CDCl3) δ ppm 7.41 - 7.49 (m, 2H), 7.33 - 7.39 (m, 1H), 7.10 - 7.27 (m, 
3H), 6.69 (d, J = 7.48 Hz, 1H), 6.43 (d, J = 0.92 Hz, 1H), 4.98 (d, J = 10.59 Hz, 1H), 4.19 
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(d, J = 10.63 Hz, 1H), 3.70 (s, 3H), 2.71 (s, 3H). 
13
C NMR (75 MHz, CDCl3) δ ppm 
168.7, 163.4, 141.6, 137.3, 134.8, 131.5, 131.1, 130.5, 127.5, 127.2, 124.2, 122.9, 121.4, 
120.9, 118.8, 109.5, 58.3, 52.8, 45.7, 15.2. IR: 2961.7 (w), 2921.4 (w), 1750.2 (s), 1711.7 
(s), 1570.7 (w), 1474.8 (w), 1444.8 (s), 1381.9 (s), 1341.5 (s), 1275.8 (s), 1261.6 (m), 
1155.6 (m), 764.3 (s), 749.7 (s) cm
-1




quinoline-5-carboxylate (V-96h): (Z)-Methyl 2-(2-methyl-1H-indole-1-carbonyl)-3-
(thiophen-2-yl)acrylate (0.0900 g, 0.277 mmol), In(OTf)3 (0.0233 g, 0.0415 mmol) and 
1,2-DCE (4 mL) were combined according to the  general procedure to afford V-96h as a 
off-white solid (0.0459 g, 51%) after 14 h. (Rf 0.40, 20% EtOAc/Hex) [m.p. 153-155 °C] 
(Single Diastereomer)  
1
H NMR (300 MHz, CDCl3) δ ppm 7.37 (d, J = 7.70 Hz, 1H), 
7.23 - 7.28 (m, 1H), 7.17 (t, J = 7.62 Hz, 1H), 6.91 - 6.99 (m, 3H), 6.42 (s, 1H), 5.32 (d, J 
= 9.45 Hz, 1H), 4.25 (d, J = 9.45 Hz, 1H), 3.72 (s, 3H), 2.70 (s, 3H). 
13
C NMR (75 MHz, 
CDCl3) δ ppm 169.0, 163.8, 142.6, 137.8, 134.8, 128.0, 127.4, 127.0, 125.7, 124.6, 122.2, 
121.3, 119.4, 109.9, 59.7, 53.3, 41.7, 15.6. IR: 2961.2 (w), 2927.0 (w), 1751.0 (s), 1712.1 
(s), 1445.7 (s), 1382.5 (s), 1341.1 (s), 1275.5 (s), 1267.3 (m), 1156.4 (m), 1042.5 (w), 
1004.0 (w), 748.9 (s), 702.5 (w) cm
-1






carboxylate (V-96i): (Z)-Methyl 2-(2-methyl-1H-indole-1-carbonyl)pent-2-enoate 
(0.090 g, 0.332 mmol), In(OTf)3 (0.0559 g, 0.0995 mmol) and toluene (5 mL) were 
combined according to the  general procedure to afford V-96i as a clear oil (0.0754 g, 
84%) after 12 h. (Rf 0.40, 20% EtOAc/Hex)  [m.p. 108-110 °C] Diastereomeric ratio: 
(25:1). (Trans diastereomer chemical shifts reported) 
1
H NMR (300 MHz, CDCl3) δ ppm 
7.33 (d, J = 7.48 Hz, 1H), 7.18 (t, J = 7.55 Hz, 1H), 7.06 (d, J = 6.00 Hz, 1H), 6.35 - 6.39 
(m, 1H), 3.86 (d, J = 4.69 Hz, 1H), 3.61 - 3.71 (m, 4H), 2.66 - 2.73 (m, 3H), 1.78 - 1.95 
(m, 1H), 1.61 - 1.77 (m, 1H), 0.95 (t, J = 7.40 Hz, 3H). 
13
C NMR (75 MHz, CDCl3) δ 
ppm 169.6, 164.3, 136.9, 134.6, 127.5, 123.7, 121.7, 120.6, 118.1, 109.2, 55.8, 52.8, 
41.5, 27.2, 15.1, 10.6. IR: 2963.1 (w), 2927.6 (w) 1743.0 (w), 1715.0 (s), 1629.2 
(s),1573.2 (w), 1447.6 (w), 1381.4 (s), 1328.6 (m), 1274.9 (m), 1259.8 (m), 1194.6 (w), 








carboxylate (V-96j): (2Z, 4E)-Methyl 2-(2-methyl-1H-indole-1-carbonyl)-5-
phenylpenta-2,4-dienoate (0.0700 g, 0.203 mmol), In(OTf)3 (0.0341 g, 0.0608 mmol) and 
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toluene (4 mL) were combined according to the  general procedure to afford V-96j as a 
pale yellow solid (0.0457 g, 65%) after 14 h. (Rf 0.35, 20% EtOAc/Hex) [m.p. 98-100 
°C] Diastereomeric ratio: (20:1). (Trans diastereomer chemical shifts reported)  
1
H 
NMR (300 MHz, CDCl3) δ ppm 7.26 - 7.43 (m, 6H), 7.21 (t, J = 7.57 Hz, 1H), 7.08 (d, J 
= 7.40 Hz, 1H), 6.63 (d, J = 15.68 Hz, 1H), 6.40 (d, J = 1.14 Hz, 1H), 6.24 (dd, J = 8.65, 
15.68 Hz, 1H), 4.58 (t, J = 9.44 Hz, 1H), 4.00 (d, J = 10.22 Hz, 1H), 3.78 (s, 3H), 2.70 (d, 
J = 1.10 Hz, 3H). 
13
C NMR (75 MHz, CDCl3) δ ppm 169.0, 164.0, 137.2, 136.2, 134.6, 
134.5, 128.6, 128.0, 127.6, 126.5, 126.4, 124.1, 121.0, 120.5, 118.8, 109.3, 56.7, 52.8, 
43.9, 15.2. IR: 3026.9 (w), 2952.8 (w), 2922.4 (w), 1749.6 (s), 1709.8 (s), 1444.3 (s), 
1380.9 (s), 1340.2 (m), 1276.0 (m), 1260.8 (m), 1200.1 (w), 1151.3 (m), 968.1 (w), 813.1 
(w), 749.0 (s), 695.0 (m)cm
-1
. HRMS (ESI) M/Z+ Calc. 345.1365, Obs. 345.1360. 
 
Methyl 6-(4-methoxyphenyl)-4-oxo-2-phenyl-5,6-dihydro-4H-pyrrolo[3,2,1-ij] 
quinoline-5-carboxylate (V-96k): (Z)-Methyl 3-(4-methoxyphenyl)-2-(2-phenyl-1H-
indole-1-carbonyl)acrylate (0.160 g, 0.390 mmol), In(OTf)3 (0.0223 g, 0.0400 mmol) and 
1,2-DCE (13 mL) were combined according to the  general procedure to afford V-96k as 
a reddish orange solid (0.155 g, 97%) after 3 h. (Rf 0.33, 20% EtOAc/Hex) [m.p. 108-
110 °C] Diastereomeric ratio: (17.3:1). (Trans diastereomer chemical shifts reported) 
1
H 
NMR (300 MHz, CDCl3) δ ppm 8.16 - 8.22 (m, 1H), 7.71 - 7.76 (m, 1H), 7.16 - 7.45 (m, 
7H), 7.02 - 7.09 (m, 2H), 6.71 - 6.77 (m, 2H), 5.19 (d, J = 4.40 Hz, 1H), 4.05 (d, J = 4.43 
Hz, 1H), 3.86 (s, 3H), 3.73 (s, 3H). 
13
C NMR (75 MHz, CDCl3) δ ppm 168.0, 164.9, 
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158.9, 139.4, 134.4, 132.0, 131.7, 130.5, 128.4, 128.4, 128.4, 127.0, 124.9, 124.5, 120.2, 
116.7, 114.3, 114.1, 63.0, 55.2, 53.3, 42.7. IR: 3056.9 (w), 2953.2 (w), 2837.9 (w), 
1730.5 (s), 1610.2 (s), 1511.9 (s), 1454.6 (s), 1392.4 (s), 1345.1 (m), 1305.2 (m), 1246.7 
(s), 1145.4 (s), 1103.0 (w), 1029.6 (s), 830.8 (m), 748.6 (s), 699.8 (s), 628.6 (m) cm
-1
. 
HRMS (ESI) M/Z+ Calc. 411.1471, Obs. 411.1470. 
 
Methyl 6-(4-methoxyphenyl)-1,2-dimethyl-4-oxo-5,6-dihydro-4H-pyrrolo[3,2,1-ij] 
quinoline-5-carboxylate (V-96l): (Z)-Methyl 2-(2,3-dimethyl-1H-indole-1-carbonyl)-3-
(4-methoxyphenyl)acrylate (0.0900 g, 0.2476 mmol), In(OTf)3 (0.0208 g, 0.0371 mmol) 
and DCE (5 mL) were combined according to the  general procedure to afford V-96l as a 
clear oil (0.7740 g, 86%) after 4 h. Rf 0.40 (20% EtOAc/Hex). Diastereomeric ratio: 
(50:1). (Trans diastereomer chemical shifts reported) 
1
H NMR (400 MHz, CDCl3) δ ppm 
7.31 (d, J = 7.72 Hz, 1H), 7.12 - 7.19 (m, 3H), 6.85 - 6.89 (m, 2H), 6.72 (d, J = 7.47 Hz, 
1H), 4.94 (d, J = 10.60 Hz, 1H), 4.17 (d, J = 10.60 Hz, 1H), 3.81 (s, 3H), 3.68 (s, 3H), 
2.64 (d, J = 0.82 Hz, 3H), 2.22 (d, J = 0.88 Hz, 3H). 
13
C NMR (101 MHz, CDCl3) δ ppm 
169.2, 163.6, 159.0, 134.0, 132.3, 131.2, 129.5, 129.1, 123.9, 122.5, 121.1, 116.9, 116.7, 
114.3, 58.9, 55.2, 52.6, 45.2, 12.4, 8.6.  IR: 3035.9 (w), 2999.5 (w), 2953.5 (m), 2924.2 
(m), 2837.8 (m), 1747.0 (s), 1700.9 (s), 1627.9 (w), 1610.8 (m), 1585.2 (w), 1512.4 (s), 
1452.4 (s), 1378.4 (s), 1353.9 (s), 1338.2 (s), 1286.7 (m), 1250.0 (s), 1211.6 (m), 1178.1 
(m), 1155.5 (s), 1136.1 (w), 1112.2 (w), 1030.9 (m), 980.7 (w), 912.6 (w), 850.7 (w), 
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822.5 (w), 792.4 (w), 768.1 (w), 746.4 (m), 731.9 (m), 610.7 (w) cm
-1
. HRMS (ESI) 




pyrrolo[3,2,1-ij]quinoline-5-carboxylate (V-96m): (Z)-Methyl 3-(4-methoxyphenyl)-2-
(1,2,3,4-tetrahydrocyclopenta[b]indole-4-carbonyl)acrylate (0.0450 g, 0.120 mmol), 
In(OTf)3 (0.0101 g, 0.0178 mmol) and toluene (3 mL) were combined according to the  
general procedure to afford V-96m as a white solid (0.0369 g, 82%) after 12 h. (Rf 0.40, 
20% EtOAc/Hex) [m.p. 140-142 °C] (Single Diastereomer observed) 
1
H NMR (300 
MHz, CDCl3) δ ppm 7.39 - 7.47 (m, 2H), 7.13 - 7.29 (m, 2H), 7.03 - 7.09 (m, 1H), 6.76 - 
6.82 (m, 2H), 3.91 (s, 1H), 3.89 (d, J = 0.40 Hz, 3H), 3.75 (s, 3H), 3.74 (s, 1H), 2.49 (td, 
J = 5.46, 13.07 Hz, 1H), 2.29 - 2.41 (m, 1H), 2.03 - 2.27 (m, 2H), 1.75 - 1.87 (m, 2H). 
13
C NMR (75 MHz, CHLOROFORM-d) δ ppm 170.4, 169.2, 160.6, 147.1, 141.0, 140.0, 
133.9, 128.1, 126.3, 125.9, 123.3, 117.4, 114.6, 109.6, 91.5, 67.9, 59.9, 55.5, 53.0, 51.7, 
37.7, 36.3, 26.3. IR: 3059.4 (w), 2953.0 (w), 2867.2 (w), 1737.7 (s), 1708.1 (s), 1601.1 
(m), 1579.5 (w), 1487.4 (m), 1474.2 (m), 1480.2 (m), 1352.9 (m), 1331.6 (m), 1304.1 
(m), 1272.9 (s), 1227.6 (s), 1174.0 (m), 1156.2 (m), 1111.4 (w), 1096.0 (w), 1029.9 (s), 
863.2 (w), 844.6 (w), 821.6 (w), 752.2 (s), 734.8 (s), 712.7 (m) cm
-1
. HRMS (ESI) M/Z+ 





[3,2,1-ij]quinoline-5-carboxylate (V-96n): (Z)-Methyl 2-(5-fluoro-2-methyl-1H-indole-
1-carbonyl)-3-(4-methoxyphenyl)acrylate (0.0750 g, 0.204 mmol), In(OTf)3 (0.0180 g, 
0.0320 mmol) and 1,2-DCE (7 mL) were combined according to the  general procedure 
to afford V-96n as a yellow solid (0.660 g, 88%) after 12 h. (Rf 0.40, 20% EtOAc/Hex) 
[m.p. 106-108 °C] (Single Diastereomer Observed) 
1
H NMR (400 MHz, CDCl3) δ ppm 
7.13 - 7.18 (m, 2H), 7.01 (ddd, J = 0.63, 2.21, 8.96 Hz, 1H), 6.86 - 6.91 (m, 2H), 6.43 - 
6.48 (m, 1H), 6.37 - 6.39 (m, 1H), 4.92 (d, J = 10.79 Hz, 1H), 4.17 (d, J = 10.85 Hz, 1H), 
3.81 (s, 3H), 3.68 (s, 3H), 2.70 (d, J = 1.19 Hz, 3H). 
13
C NMR (101 MHz, CDCl3) δ ppm 
168.8, 163.7, 161.7, 159.3, 159.2, 138.7, 131.1, 130.3, 129.5, 128.1 and 128.0 (d), 124.0 
and 123.9 (d), 114.4, 109.2, 109.2, 109.1, 108.9, 104.7, 104.4, 58.5, 55.2, 52.7, 45.3, 
15.2. IR: 3001.9 (w), 2954.8 (w), 2838.9 (w), 1747.3 (s), 1709.5 (s), 1632.7 (m), 1610.7 
(m), 1513.3 (s), 1479.6 (s), 1435.4 (s), 1381.4 (s), 1327.8 (m), 1254.6 (s), 1210.5 (s), 










ij]quinoline-5-carboxylate (V-96o): (Z)-Methyl 2-(5-chloro-2-methyl-1H-indole-1-
carbonyl)-3-(4-methoxyphenyl)acrylate (0.0100 g, 0.261 mmol), In(OTf)3 (0.0220 g, 
0.0391 mmol) and toluene (5 mL) were combined according to the  general procedure to 
afford V-96o as a white solid (0.0900 g, 90%) after 4 h. (Rf 0.45, 20% EtOAc/Hex) [m.p. 
132-134 °C] Diastereomeric ratio: (100:1) (Trans diastereomer chemical shifts reported) 
1
H NMR (300 MHz, CDCl3) δ ppm 7.29 - 7.33 (m, 1H), 7.11 - 7.18 (m, 2H), 6.85 - 6.93 
(m, 2H), 6.68 (d, J = 1.10 Hz, 1H), 6.35 (d, J = 1.14 Hz, 1H), 4.91 (d, J = 10.74 Hz, 1H), 
4.16 (d, J = 10.77 Hz, 1H), 3.81 (s, 3H), 3.67 (s, 3H), 2.69 (s, 3H).
 13
C NMR (75 MHz, 
CDCl3) δ ppm 168.6, 163.7, 159.2, 138.5, 133.2, 130.1, 129.7, 129.5, 128.4, 123.9, 121.1, 
118.3, 114.4, 108.6, 58.5, 55.2, 52.7, 45.2, 15.2. IR 2954.9 (w), 2838.0 (w), 1747.7 (s), 
1710.5 (s), 1611.3 (m), 1513.0 (s) 1462.4 (m), 1427.7 (m), 1371.8 (s), 1251.1 (s), 1210.2 
(m), 1178.1 (m), 1152.2 (s), 1031.1 (m), 886.2 (m), 858.6 (m), 829.4 (m), 763.7 (w), 
737.9 (s), 701.6 (m) cm
-1
. HRMS (ESI) M/Z+ Calc. 383.0924, Obs. 383.0923.  
 
Methyl 6-(4-methoxyphenyl)-4-oxo-2,4,5,6-tetrahydro-1H-pyrrolo[3,2,1-ij]quinoline-
5-carboxylate (V-98): (Z)-Methyl 2-(indoline-1-carbonyl)-3-(4-methoxyphenyl)acrylate 
(0.0750 g, 0.222 mmol), In(OTf)3 (0.0187 g, 0.0333 mmol) and toluene (5 mL) were 
combined according to the  general procedure to afford V-98 as a off-white solid (0.0606 
g, 81%) after 42 h. (Rf 0.40, 20% EtOAc/Hex) [m.p. 69-71 °C] (Mixture of Single 
Diastereomer and Decarboxylated product) 
1
H NMR (300 MHz, CDCl3) δ ppm 7.06 - 
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7.17 (m, 7.16), 6.84 - 6.93 (m, 7.14), 6.64 - 6.75 (m, 2.38), 4.66 (d, J = 10.77 Hz, 1.00), 
4.27 (dd, J = 7.05, 9.69 Hz, 1.36), 4.02 - 4.22 (m, 5.13), 3.77 - 3.87 (m, 8.16), 3.65 (s, 
3.16), 3.17 - 3.33 (m, 5.05), 2.77 - 2.98 (m, 2.87).  
13
C NMR (75 MHz, CDCl3) δ ppm 
169.7, 166.9, 162.9, 158.9, 158.6, 141.0, 140.1, 133.7, 131.2, 129.3, 128.9, 128.8, 125.6, 
125.4, 124.0, 123.9, 123.6, 123.5, 122.6, 114.3, 114.2, 57.0, 55.2, 55.2, 52.5, 45.5, 45.2, 
45.0, 41.4, 40.2, 27.9. IR: 3035.8 (w), 2951.3 (w), 2837.7 (w), 1745.8 (m), 1668.2 (s), 
1595.3 (m), 1512.9 (s), 1480.9(s), 1468.7 (m), 1396.6 (m), 1353.3 (w), 1250.1 (s), 1178.6 
(w), 1153.9 (w), 1031.8 (w), 834.7 (w), 764.9 (m), 747.5 (m) cm
-1
. HRMS (ESI) M/Z+ 
Calc. 337.1314, Obs. 337.1313. 
 
trans-Methyl 4-(4-methoxyphenyl)-3-oxo-1,2,3,5,6,7-hexahydropyrido[3,2,1-ij] 
quinoline-2-carboxylate (V-99): (Z)-Methyl 3-(4-methoxyphenyl)-2-(1,2,3,4-
tetrahydroquinoline-1-carbonyl)acrylate (0.075 g, 0.213 mmol), In(OTf)3 (0.0179 g, 
0.0320 mmol) and toluene (5 mL) were combined according to the  general procedure to 
afford V-99 as a colorless oil (0.0622 g, 83%) after 42 h. (Rf 0.40, 20% EtOAc/Hex) 
(Single Diastereomer observed) 
1
H NMR (400 MHz, CDCl3) δ ppm 7.07 - 7.12 (m, 2H), 
7.02 - 7.06 (m, 1H), 6.83 - 6.91 (m, 3H), 6.65 - 6.69 (m, 1H), 4.53 (d, J = 10.04 Hz, 1H), 
3.96 - 4.04 (m, 1H), 3.82 - 3.91 (m, 2H), 3.79 (s, 3H), 3.62 (s, 3H), 2.85 (t, J = 6.27 Hz, 
2H), 1.93 - 2.03 (m, 2H). 
13
C NMR (101 MHz, CDCl3) δ ppm 169.3, 165.0, 158.8, 134.9, 
131.0, 129.3, 128.5, 127.1, 126.4, 125.4, 123.0, 114.3, 55.2, 55.0, 52.5, 43.9, 41.3, 27.3, 
21.3. IR: 3003.2 (w), 2950.0 (w), 2886.7 (w), 1746.6 (s), 1666.8 (s), 1612.8 (w), 1592.4 
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(w), 1513.7 (s), 1469.9 (m), 1460.9 (w), 1383.3 (m), 1274.9 (m), 1251.2 (m), 1179.0 (w), 
1154.0 (w), 1031.7 (w), 764.4 (s), 749.9 (s) cm
-1
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 and the structurally-related tacaman
2
 families of indole 
alkaloids occupy a central place in natural product chemistry due to their wide range of 
complex structural variation. It also represents a large group of biologically-active, 
naturally-occurring indole alkaloids that are isolated from several plants of the 
Apocyanaceae and Tabernaemontana genera. These biogenetically related vinca-eburnan 
and tacaman families is characterized by a common pentacyclic framework (VI-1) that 
contains either a cis- or trans-fused D/E ring system (Figure 6.1).
3
 The eburnan skeleton 
has an ethyl group at C(20), while the tacaman skeleton has the ethyl group at C(14) 
instead,
4
 and include eburnamine VI-2, eburnamonine VI-3, vincamine VI-4, vinpocetine 
VI-5, deethyleburnamonine VI-6, vindeburnol VI-8, criocerine VI-9, strempeliopine VI-
10, tacamonine VI-11, tacamine VI-12, and avotacamine VI-13 among their prototypical 
members. While the vast majority of compounds belonging to these families have a cis-
fused D/E ring system, several important biologically-active derivatives, such as 
vindeburnol VI-8, possess a trans-fused junction.  
                                                 
‡‡
This work was performed in collaboration with Marchello A. Cavitt, a fellow graduate student in the 




Many of these compounds exhibit a variety of pharmacological activities, ranging 
from antitumor activity to muscle-stimulating activity.
5
 Over the past 10 years, numerous 
efforts to fully understand the compounds’ modulatory effects on brain circulation and 
neuronal homeostasis have been reported.
6
 For example, vincamine VI-4 has been shown 
to have neuroprotective effects resulting from the blockage of voltage-gated sodium ion 
channels.
7
 Similarly, vinpocetine (VI-5), the most extensively studied cogener of the 
eburnan class, is currently prescribed in Europe (tradename: Cavinton) for the treatment 
of disorders arising from cerebrovascular and cerebral neurodegenerative diseases.
8
 This 







6.2. SYNTHETIC STUDIES ON (±)-DEETHYLEBURNAMONINE  
Several synthetic strategies have been reported for the assembly of the pentacyclic 
core present in the natural products and their analogues. The most common approach is to 
establish the [ABCD]-type octahydroindolo[2,3-a]-quinolizine ring skeleton starting from 
suitable indole precursor and subsequent formation of the E-ring as desired in the final 
target.   The ABCD ring system is most often prepared by one of the following methods: 
(1) a Pictet-Spengler/Bischler-Napieralski cyclization;
10
 (2) a Michael-type annulation;
11
 
or (3) annulation reactions of dihydro-β-carboline derivatives.
12
 In 2008, Padwa and co-
workers published an alternate route to the eburna-vinca and tacaman alkaloids that 
involves a Rh(II)-catalyzed intramolecular dipolar cycloaddition of an α-diazo 
indoloamide, followed by reductive ring-opening and base-induced keto-amide ring 
contraction to build the full ABCDE skeleton.
13
 The remaining part of this section will 
provide a brief synopsis of approaches towards the synthesis of (±)-
deethyleburnamonine. 
 
6.2.1. POTIER’S APPROACH 
The Potier group disclosed the first synthesis of (±)-deethyleburnamonine in 1973 
using a reductive cyclization of a pyridinium salt in the presence of hydrogen.
14
 The 
pyridinium salt VI-13 obtained from tryptophyl bromide and methyl nicotinate. The 
hydrogenation of an ethanolic solution of VI-13 over PtO2 at room temperature yielded 




6.2.2. LOUNASMAA’S APPROACH 
In 1988, Lounasmaa reported the total synthesis of (±)-deethyleburnamonine 
utilizing the modified Potier-Polonovski reaction and Pictet-Spengler-type cyclization.
15
  
The pyridinium salt VI-13 was efficiently transformed into N-Boc protected 
tryptophylpiperidine VI-16 through a sequence that involved a catalytic hydrogenation 
over PtO2 followed by protection of indole with t-butyloxycarbonyl anhydride (Figure 
6.3). N-Boc-tryptophylpiperidine VI-16 was converted into corresponding N-oxide, 
which was then submitted to the modified Polonovski condition, followed by cyanide 
trapping to furnish key intermediate α-aminonitrile VI-17. The AgBF4-induced Pictet-
Spengler-type cyclization of α-aminonitrile followed by a spontaneous lactamization 




In continuation of their studies directed towards the synthesis of vincamine-
eburnamonine derivatives, Lounasmaa and co-workers developed an efficient 
stereoselective acid-catalyzed epimerization of 1-substituted indolo[2,3-a]quinolizidines 
to generate cis- and trans-deethyleburnamonine starting common intermediate VI-19 
(Figure 6.4).
16
 The key ester precursor VI-19 was synthesized in three steps from 
tryptophyl bromide and methyl nicotinate involving Pd-catalyzed hydrogenation followed 
by an acid-induced cyclization. Reduction of VI-19 with LAH gave in its corresponding 
alcohol VI-20 in high yields, which was then rapidly transformed into its nitrile 
derivative VI-22 via tosylate VI-21.  Finally, mild acid treatment of VI-22 afforded 
desired product VI-6b in 55% over two steps. Treatment of ester derivative VI-19 with 
TFA under reflux furnished the other isomer, which was then converted to cis-





In 1999, Lounasmaa reported further modification in the synthesis of 
deethyleburnamonine by making use of base-catalyzed cyclization of nitrile derivative 
VI-22.
17
 Tetracyclic nitrile VI-22 was heated to reflux in methanolic solution of NaOMe, 
and the cycle was repeated until higher conversions to imine VI-23 were achieved. When 
imine VI-23 was heated to reflux in 25% HCl, (±)-deethyleburnamonine VI-6b was 








6.2.3. STOIT’S APPROACH 
In 1989, Stoit and Pandit disclosed the application of the substituted 5,10-
methylenetetrahydrofolate model towards the formal synthesis of deethyleburnamonine.
18
 
Stoit generated the required substituted 5,10-methylenetetrahydrofolate model VI-25 
using the addition of the dianion of dimethyl 2-methoxycarbonylglutarate VI-24 to 1,5,5-
trimethyl-3-tosyl-l-imidazolidinium iodide (Figure 6.6). Next, 7-carbon functionalized 
carbon fragment transfer on tryptamine was achieved using AcOH in refluxing 
acetonitrile to afford mixture of E/Z isomers VI-26. Without separation, this mixture was 
treated with acidic conditions to furnish VI-27 in 95% yield. The treatment of VI-27 with 
AcOH/Et3N mixture to generate diastereomeric pair of lactams VI-28 in 75% yields. The 
lactam VI-28b upon decarbomethoxylation followed by LAH reduction provided 




6.2.4. MASSIOT’S APPROACH 
Massiot et al. reported the Rh(III)-catalyzed isomerization-cyclization of indolyl-
tetrahydropiperidine approach for the synthesis of deethyleburnamonine.
19
 The 
pyridinium salts VI-13 was subjected to reduction using NaBH4 to generate 
tetrahydropyridine key precursor VI-30. When ester VI-30 was reacted in the presence of 
Rh(III)-salts underwent isomerization of alkene to generate enamine intermediate VI-
32a, which immediately cyclized through a tandem fashion to furnish the pentacyclic 






6.2.5. MANN’S APPROACH 
In 2011, Mann and co-workers reported an expeditious route to 
deethyleburnamonine, a direct precursor of vinderburnol via one-pot allylamine-enamine 
isomerization, followed by a rare Pictet-Spengler condensation.
20
 The 
tetrahydropiperidine precursor VI-30 was obtained in two steps described previously 
using tryptophyl bromide and ethylhomonicotinate. The allyl amine VI-30 was then 
subjected to DBU and irradiated using microwave irradiation at 160
o
C for 6 h, furnished 
deethyleburnamonine in 64% yield (Figure 6.8). This total synthesis represent the 
shortest synthesis with three steps, providing (±)-deethyleburnamonine product in 52% 




6.3. CYCLOPROPANE RING-OPENING/FRIEDEL-CRAFTS APPRAOCH TO 
(±)-DEETHYLEBURNAMONINE 
Previous work in our lab demonstrated that 30 mol % In(OTf)3 successfully 
catalyzes the cyclizations of alkenyl cyclopropyl ketones and cyclopropyl heteroaryl 
ketones to form the functionalized cyclohexyl rings.
21
 The use of the donor-acceptor 
cyclopropanes bearing a secondary electron acceptor (an ester group) is essential, as it 
permits effective catalysis under mild reaction conditions. In continuation of our studies 
focusing on utilizing donor-acceptor cyclopropanes to generate interesting carbo- and 
heterocycles, in 2011 we disclosed our report on In(OTf)3-catalyzed tandem ring-
opening/intramolecular Friedel-crafts cyclization of donor-acceptor cyclopropanes for the 
facile construction of hydropyrido[1,2-a]indole derivatives in good to excellent yields (up 
to >99%) (Figure 6.9).
22
 The methodology is highly modular, operationally simple and 
amenable to a diverse number of functional groups and substitution patterns. Success 
with this methodology, prompted us to investigate the possibility of using our 
methodology for the rapid construction of the pentacyclic framework of the eburnan and 
tacaman classes of alkaloids, both of which possess the 6,7,8,9-tetrahydropyrido[1,2-
a]indole ring system. More specifically, we determined to choose (±)-
deethyleburnamonine (VI-6) as an initial synthetic target because it represents the 
simplest example of both the alkaloid classes (no ethyl group present). Using our 
methodology, the ABDE rings could be rapidly accessed, in contrast to previous reports 






6.3.1. RETROSYNTHETIC ANALYSIS 
The France group envisioned that (±)-deethyleburnamonine would arise from the 
ABDE tetracycle VI-34 following N-deprotection, N-alkylation (C-ring formation), and 
decarbalkoxylation (Figure 6.10). Tetracycle VI-35 would then be generated from the N-
acylated indolyl cyclopropane VI-36 via an indium-catalyzed cyclization of D-A-A 
cyclopropane. The requisite cyclopropane is expected to arise from the N-acylation, diazo 





6.3.2. SYNTHESIS OF THE MODEL SUBSTRATE 
Our initial analysis of the target structure led us to focus on the construction of 
tetracyclic hydropyrido[1,2-a]indole core of the molecule via our tandem cyclopropane 
ring-opening/F-C alkylation sequence. To achieve this, it was decided to use cyclopropyl 
VI-41 derived from 3-methyl indole and Cbz-protected 3,4-dihyropyridine as our model 
substrate. The requisite model substrate was synthesized in three high yielding steps 
involving N-acylation, diazo transfer, and Rh-catalyzed cyclopropanation with Cbz-




With the model substrate in hand, it was subjected to our tandem cyclopropane 
ring-opening/F-C alkylation reaction conditions. It readily cyclized to provide the desired 
tetracyclic hydropyrido[1,2-a]indole product in 97% yield with a 7.5:1 dr (Figure 6.12).  
This result is noteworthy as the D/E rings of the product possesses only the 20,21-cis-ring 
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6.3.3. STRATEGY FOR THE SYNTHESIS OF (±)-DEETHYLEBURNAMONINE 
Success of the proposed route is predicated on facile access to cyclopropane VI-
36a, which was readily synthesized in three steps (Figure 6.13). Commercially available 
3-(2-bromoethyl)-1H-indole was treated with methyl malonyl chloride to provide the 
required β-ester amide VI-38 in 84% yield. Next, diazo transfer with tosyl azide provided 
the α-diazo ester VI-39 in 88% yield. The resulting diazo species VI-38 was treated with 
Rh2esp2 in the presence of the Cbz-protected 2,3-dihyropyridine afforded the requisite 
cyclopropane VI-36a in 81% yield. With a fully functionalized cyclopropyl precursor in 
hand, it was treated with 30 mol% In(OTf)3. As anticipated, the substrate VI-36a readily 
cyclized to form tetracycle VI-35a in 97% yield. The major product formed was the all-
cis diastereomer with 8:1 dr. With VI-35a in hand, we envisioned that C-ring formation 
(N-alkylation) should be facile upon Cbz-deprotection. Unfortunately, the desired product 





To alleviate this issue, a Boc-protected 2,3-dihydropyridine was employed as the 
alkene for cyclopropanation, which afforded cyclopropane VI-37b in 49% yield (Figure 
6.14). The lower yield observed for the Boc-protected enamine is most likely due to the 
increased steric interference in the transition state between the t-Bu group of the enamine 
and the multi-dentate esp ligand of the rhodium carbenoid during cyclopropanation. 
Cyclization of VI-37b similarly provided the all-cis diasteromer VI-36b (~3:1 dr) but 
with less efficiency than the Cbz case (97% vs 71%), which may also be a result of the 
steric influence of the Boc t-butyl group. Fortunately, when VI-36b was subjected to 
TFA, both deprotection and C-ring closure occurred, generating VI-35 in 87% yield. 
Finally, Krapcho decarbalkoxylation
23









In summary, a concise, diastereoselective total synthesis of (±)-
deethyleburnamonine is reported. The key steps of the synthesis involve: (a) a tandem 
ring-opening/Friedel-Crafts alkylation to assemble the tetracyclic ABDE ring system 
with a cis D/E fused ring junction; (b) a TFA-promoted N-Boc deprotection/N-alkylation 
to generate the C-ring; and (3) a Krapcho decarbalkoxylation to generate the target. Using 
this protocol, (±)-deethyleburnamonine was rapidly obtained in ~18-19% overall yield 








All reactions were carried out in pre-dried glassware from the oven where 
additional moisture was removed by flame drying the reaction vessel.  Each reaction 
proceeded under a nitrogen atmosphere, and dry solvents were used, unless stated 
otherwise.  Tetrahydrofuran and diethyl ether were distilled from a sodium/benzophenone 
ketyl under nitrogen and stored in a Schlenk flask.  Acetonitrile and dichloromethane 
were purified by distillation from CaH2 under N2 prior to use.  All other reagents were 
purchased from Acros, Sigma-Aldrich, Fluka, VWR, Merck, Alfa Aesar, TCI and Strem 
(for metal catalysts) and used without further purification.  Chromatographic purification 
was performed as flash chromatography with Dynamic Adsorbents silica gel (32-65 μm) 
and solvents indicated as eluent with 0.1-0.5 bar pressure.  For quantitative flash 
chromatography, technical grade solvents were utilized. Analytical thin-layer 
chromatography (TLC) was performed on EMD silica gel 60 F254 TLC glass plates.  
Visualization was accomplished with UV light, aqueous basic potassium permanganate 
(KMnO4) solution, iodine, aqueous acidic dinitrophenylhydrazine (DNP) solution, 
aqueous acidic p-anisaldehyde (PAA) solution, and ethanol solution of phosphomolybdic 
acid (PMA) followed by heating. Each yield refers to isolated analytically pure material.  
Infrared (IR) spectra were obtained using a Nicolet 4700 FTIR with an ATR attachment 
from SmartOrbit Thermoelectronic Corp. The IR bands are characterized as weak (w), 





C NMR) were recorded on a Varian Mercury Vx 300 spectrometer or a 
Varian Mercury Vx 400 spectrometer with solvent resonances as the internal standard (
1
H 
NMR: CDCl3 at 7.26 ppm; 
13
C NMR: CDCl3 at 77.0 ppm).  
1
H NMR data are reported as 
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follows: chemical shift (ppm), multiplicity (s = singlet, d = doublet, dd = doublet of 
doublets, dt = doublet of triplets, ddd = doublet of doublet of doublets, t = triplet, m = 
multiplet), coupling constants (Hz), and integration.  Mass spectra were obtained using a 
VG-70SE instrument. 
 
Preparation of N-Cbz-protected aminocyclopropane (VI-36a). In a round bottom 
flask charged with a magnetic stir bar, Rh2esp2 (1.4 mg, 1.87 μmol) was dissolved in 
CH2Cl2 (6 mL).  The reaction vessel was cooled to 0 ˚C and benzyl 3,4-dihydropyridine-
1(2H)-carboxylate (0.037 g, 0.187 mmol) was added. After 10 min, 3-(3-(2-bromoethyl)-
1H-indol-1-yl)-2-diazo-3-oxopropanoate VI-39 (0.085 g, 0.243 mmol) was dissolved in 
CH2Cl2 (2 mL) and syringed into the reaction mixture. After 10 min, the ice bath was 
removed and the reaction proceeded at room temperature. After 12 h, the solution was 
quenched with saturated thiourea and stirred for 30 min. The organic layer was separated 
and the aqueous layer was extracted three times with CH2Cl2. The combined organic 
layers were washed with brine, dried over Na2SO4, and concentrated under reduced 
pressure. The residue was purified by silica gel flash chromatography (30% EtOAc/Hex, 
Rf 0.25) to afford VI-36a as a light brown oil (0.081 g, 81%). (Rotamers!!!) 
1
H NMR 
(300 MHz, CDCl3) δ 8.47 (d, J = 8.2 Hz, 1H), 7.57 – 7.28 (m, 8H), 7.05 (d, J = 43.0 Hz, 
1H), 5.19 (d, J = 3.2 Hz, 2H), 4.74 (d, J = 21.7 Hz, 1H), 3.79 (d, J = 3.3 Hz, 3H), 3.71 – 
3.51 (m, 4H), 3.35 – 3.10 (m, 3H), 2.46 – 2.25 (m, 1H), 2.25 – 2.01 (m, 1H), 2.00 – 1.76 
(m, 2H). 
13
C NMR (75 MHz, CDCl3) δ 168.4, 168.3, 167.3, 167.2, 165.7, 165.7, 165.6, 
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165.5, 153.5, 152.9, 136.0, 135.9, 130.3, 130.1, 130.0, 128.5, 128.3, 128.2, 128.1, 128.0, 
127.9, 126.8, 126.5, 126.3, 125.9, 125.7, 124.3, 124.1, 123.3, 123.1, 122.9, 122.4, 122.2, 
120.4, 119.7, 119.2, 119.1, 118.6, 117.4, 117.1, 116.9, 116.7, 111.4, 111.3, 110.7, 110.6, 
67.8, 67.7, 58.0, 57.9, 57.7, 53.4, 52.9, 52.9, 52.8, 43.3, 42.1, 41.9, 38.8, 38.7, 31.3, 30.9, 
28.6, 28.4, 23.7, 23.2, 23.0, 22.9, 21.2, 19.3, 19.2.  IR: 2951.9 (w), 2928.1 (w), 2847.1 
(w), 1761.3 (s), 1703.26 (s), 1451.7 (s), 1370.7 (m), 1275.5 (m), 1218.3 (m), 1170.7 (m), 
742.1 (s) cm
-1
.  HRMS (ESI) M/Z
+
 Calc. 538.1103, Obs. 538.1094. 
 
Preparation of N-Cbz-protected ABDE tetracycle (VI-35a). 2-Benzyl 7-methyl 7-(3-
(2-bromoethyl)-1H-indole-1-carbonyl)-2-azabicyclo[4.1.0]heptane-2,7-dicarboxylate VI-
36a (0.045 g, 0.083 mmol) was added to a solution of In(OTf)3 (0.014 g, 0.025 mmol) in 
CH2Cl2 (3 mL) at room temperature. Upon completion as monitored by TLC, the reaction 
mixture was quenched with water and extracted three times with CH2Cl2. The combined 
organic layers were washed with brine, dried over Na2SO4 and concentrated under 
reduced pressure. The residue was purified by silica gel flash column chromatography 
(25% EtOAc/Hex, Rf 0.25) to afford VI-35a as a pale brown oil (0.098 g, 98%) after 2 h. 
Diastereomeric ratio: (8:1). 
1
H NMR (300 MHz, CDCl3) δ 8.41 (dd, J = 14.5, 6.9 Hz, 
1.07), 7.50 – 7.19 (m, 9.14), 5.93 (dd, J = 17.0, 4.6 Hz, 1), 5.30 – 5.06 (m, 2.54), 4.09 (d, 
J = 13.2 Hz, 1.16), 3.92 – 3.57 (m, 4.64), 3.56 – 2.76 (m, 5.17), 2.75 – 2.48 (m, 2.28), 
1.77 (d, J = 10.4 Hz, 1.25), 1.53 (s, 2.17), 1.43 – 1.26 (m, 1.08). 
13
C NMR (75 MHz, 
CDCl3) δ 168.1, 162.8, 155.1, 136.0, 134.7, 130.2, 130.0, 129.1, 129.0, 128.5, 128.2, 
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128.1, 125.6, 125.5, 124.4, 124.3, 117.9, 117.8, 117.0, 116.7, 116.5, 68.2, 68.1, 55.9, 
53.1, 52.5, 48.3, 42.5, 39.7, 37.7, 30.0, 27.2, 27.5, 26.6, 24.6. IR: 2950.4 (w), 2910.7 (w), 
2880.6 (w), 1755.7 (s), 1719.2 (s), 1442.8 (m), 1275.6 (m), 758.2 (s) cm
-1
. HRMS (ESI) 
M/Z
+
 Calc. 538.1103, Obs. 538.1105. 
 
Preparation of N-Boc-protected aminocyclopropane (VI-37b). In a round bottom flask 
charged with a magnetic stir bar, Rh2esp2 (1.0 mg, 1.319 μmol) was dissolved in CH2Cl2 
(15 mL). The reaction vessel was cooled to 0 ˚C and tert-butyl 3,4-dihydropyridine-
1(2H)-carboxylate (0.201 g, 1.098 mmol) was added. After 10 min, methyl 3-(3-(2-
bromoethyl)-1H-indol-1-yl)-2-diazo-3-oxopropanoate VI-38 (0.500 g, 1.422 mmol) was 
dissolved in CH2Cl2 (5 mL) and syringed into the reaction mixture. After 10 min, the ice 
bath was removed and the reaction proceeded at room temperature. After 12 h, the 
solution was quenched with saturated aqueous thiourea and stirred for 30 min. The 
organic layer was separated and the aqueous layer was extracted three times with CH2Cl2. 
The combined organic layers were washed with brine, dried with Na2SO4, and 
concentrated under reduced pressure. The residue was purified by silica gel flash 
chromatography (30% EtOAc/Hex, Rf 0.25) afforded VI-37b as a colorless oil (0.271 g, 
49%). 
1
H NMR (300 MHz, CDCl3) δ 8.47 (d, J = 8.1 Hz, 1H), 7.56 – 7.45 (m, 1H), 7.43 
– 7.28 (m, 2H), 6.98 (d, J = 66.6 Hz, 1H), 4.74 (d, J = 9.4 Hz, 1H), 3.79 (d, J = 3.8 Hz, 
3H), 3.70 – 3.35 (m, 4H), 3.27 (t, J = 6.9 Hz, 2H), 3.17 (t, J = 6.8 Hz, 1H), 2.45 – 2.04 
(m, 2H), 1.93 – 1.76 (m, 2H), 1.47 (d, J = 7.5 Hz, 9H). 
13
C NMR (75 MHz, CDCl3) δ 
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168.6, 165.8, 152.6, 151.8, 136.1, 129.9, 129.8, 127.9, 126.9, 126.7, 125.8, 124.1, 122.2, 
121.9, 120.3, 119.6, 118.4, 117.1, 110.1, 109.3, 81.2, 81.1, 58.2, 52.9, 43.3, 42.2, 41.1, 
34.6, 31.6, 31.2, 28.5, 28.4, 28.2, 25.3, 23.7, 23.0, 22.6, 21.4, 14.1. IR: 2998 (w), 2942.3 





 Calc. 504.1300, Obs. 504.1251. 
 
Preparation of N-Boc-protected ABDE tetracycle (VI-36b). 2-tert-Butyl 7-methyl 7-
(3-(2-bromoethyl)-1H-indole-1-carbonyl)-2-azabicyclo[4.1.0]heptane-2,7-dicarboxylate 
VI-37b (0.075 g, 0.148 mmol) was added to a solution of In(OTf)3 (0.030 g, 0.053 mmol) 
in CH2Cl2 (10 mL) at room temperature. Upon completion as determined by TLC, the 
reaction mixture was quenched with water and extracted three times with CH2Cl2. The 
combined organic layers were washed with brine, dried over Na2SO4 and concentrated 
under reduced pressure. The residue was purified by silica gel flash column 
chromatography (25% EtOAc/Hex, Rf 0.30) to afford VI-36b as a colorless oil (0.053 g, 
71%) after 3 h. Diastereomeric ratio: (3.2:1). 
1
H NMR (300 MHz, CDCl3) δ 8.55 – 8.43 
(m, 1.11H), 7.57 – 7.49 (m, 1.16), 7.42 – 7.30 (m, 2.5), 5.97 (s, 1), 4.05 (t, J = 11.6 Hz, 
090), 3.84 (s, 1), 3.76 (d, J = 3.9 Hz, 2.87), 3.73 – 3.63 (m, 1.17), 3.52 (dt, J = 20.5, 12.0 
Hz, 2.33), 3.33 – 3.05 (m, 2.64), 2.65 (d, J = 12.1 Hz, 2.39), 2.29 (d, J = 10.6 Hz, 0.22), 
1.86 (d, J = 13.0 Hz, 1), 1.69 – 1.49 (m, 13.63). 
13
C NMR (75 MHz, CDCl3) 168.2, 
167.5, 163.0, 154.6, 154.3, 134.7, 134.5, 130.3, 130.1, 130.0, 129.7, 129.5, 125.4, 124.4, 
124.2, 118.0, 117.9, 117.8, 116.7, 116.5, 81.1, 81.1, 56.0, 53.6, 53.1, 52.5, 50.2, 42.5, 
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40.3, 39.9, 37.6, 29.9, 28.4, 28.3, 27.5, 26.8, 24.7, 24.4, 22.8. IR: 2997.9 (w), 2961.3 (w), 
1766.3 (m), 1726.7 (s), 1469.1 (s), 1186.1 (m), 760.3 (s), 663.1 (m) cm
-1
. HRMS (ESI) 
M/Z
+
 Calc. 504.1300, Obs. 504.1255. 
 
Preparation of N-Boc-protected pentacycle (VI-35). Tetracycle VI-36b (0.030 g, 0.059 
mmol) was dissolved in trifluoroacetic acid (2 mL) and stirred for 2 h.  Saturated aqueous 
NaHCO3 was slowly added to quench the reaction. The resulting mixture was extracted 
three times with CH2Cl2, washed with brine, dried over MgSO4, and concentrated under 
reduced pressure. The residue was purified by silica gel flash chromatography (1.5% 
MeOH/CH2Cl2, Rf 0.40) to afford VI-35 as a colorless oil (0.0168 g, 87% yield). 
Diastereomeric ratio: (5:1). 
1
H NMR (300 MHz, CDCl3) δ 8.41 – 8.30 (m, 1.11), 7.46 – 
7.40 (m, 1.27), 7.36 – 7.25 (m, 2.45), 4.46 – 4.34 (m, 1.11), 3.84 (s, 0.60), 3.75 (d, J = 3.8 
Hz, 3.24), 3.68 – 3.59 (m, 9.42), 3.36 – 3.28 (m, 2.61), 2.98 – 2.74 (m, 3.24), 2.68 – 2.33 
(m, 4.88), 1.65 (ddd, J = 10.6, 9.2, 7.6 Hz, 4.01). 
13
C NMR (75 MHz, CDCl3) δ 168.6, 
167.4, 164.0, 160.9, 135.3, 135.0, 128.4, 128.3, 127.7, 127.5, 126.9, 126.4, 124.8, 124.0, 
122.1, 120.9, 120.3, 118.8, 117.2, 116.7, 112.6, 104.9, 77.4, 77.0, 76.6, 70.3, 55.3, 53.6, 
53.1, 49.5, 48.4, 44.2, 35.8, 33.8, 32.4, 29.6, 27.0, 24.8, 16.1, 14.6. HRMS (ESI) M/Z
+
 





Preparation of (±)-Deethyleburnamonine (VI-6a). To a 10 mL round bottom flask 
equipped with a stir bar, -amide ester VI-35 (0.050 g, 0.154 mmol), NaCl (9.46 mg, 
0.161 mmol), water (5.55 µL, 0.308 mmol) and DMSO (3 mL) were added at room 
temperature. The flask was fitted with a reflux condenser and heated to 150 ˚C with 
vigorous stirring. After heating for 16 h, TLC analysis indicated consumption of starting 
material. The reaction was cooled and diluted with 7:3 Hexanes/Et2O (25 mL) and 
washed three times with water. The organic layer was dried over MgSO4 and 
concentrated under reduced pressure. The residue was purified by silica gel flash 
chromatography (1.5% MeOH/CH2Cl2, Rf 0.40) to afford VI-6a as a white solid (0.0349 
g, 85% yield). 
1
H NMR (300 MHz, CDCl3) δ 7.46 – 7.41 (m, 1H), 7.36 – 7.27 (m, 2H), 
4.40 – 4.30 (m, 1H), 3.39 – 3.29 (m, 2H), 3.02 – 2.83 (m, 2H), 2.72 – 2.57 (m, 3H), 2.46 
(qdd, J = 10.9, 5.3, 3.1 Hz, 3H), 1.69 – 1.55 (m, 3H), 1.00 – 0.81 (m, 1H). 
13
C NMR (75 
MHz, CDCl3) δ 167.3, 134.3, 131.3, 129.8, 124.3, 123.8, 118.0, 116.2, 112.7, 53.4, 50.4, 
44.5, 39.7, 34.3, 25.3, 24.7, 16.3. The physical characterization of the product matches 
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The results obtained from the projects in this thesis have often been unexpected and 
interesting, and thus prompt further investigation that was not able to be completed 
during the time frame of theses project. 
1. Interrupted Homo-Nazarov Cyclization: A Trapping of the Oxy-Allyl Cationic 
Intermediate with a Suitable Nucleophile  
As detailed in Chapter 2, alkenyl cyclopropyl ketones such as II-33 undergo a 
homo-Nazarov cyclization reaction in the presence of catalytic amounts of In(OTf)3 to 
furnish cyclohexenone and methylene cyclohexenol derivatives. This reaction proceeds 
via an oxyallyl cationic intermediate Int-d. Although mechanistically distinct, this 
reaction is homologous to the Nazarov cyclization, as it proceeds via a similar cyclic 
oxyallyl cationic intermediate. While the interrupted Nazarov cyclization reaction has 
been studied in great detail, much less is known about the homologous homo-Nazarov 
cyclization reaction. The interruption with a suitable nucleophile such as amines, 
alcohols, or allyl silanes could lead to a wide range of new and interesting α-substituted 






2. Novel Pyrido[1,2-a]indole-based Fluorescent Probes with Varying Emission 
Colors for Imaging in Living Cells 
While the majority of the research described in Chapter 3 showed that 
hydropyrido[1,2-a]indole-6(7H)-ones derivatives were efficiently obtained using our 
tandem cyclopropane ring-opening/Friedel-Crafts reaction sequence, additional work to 
generate pyrido[1,2-a]indole-based fluorescent compounds with varying emission colors 
for imaging living cells would be of interest. Some initial reactions mentioned within this 
thesis had limited success, yet these analogues might be accessible in high yields through 
optimization of the reaction conditions. Alternative reaction pathways based on the use of 
In(III)-catalyzed cycloisomerization of either N-indolyl cyclopropen-3,3-dicarbonyl 
compounds  or N-indolyl cyclopropanes substituted with acylic ethers could be highly 






3. Experimental and Theoretical Studies on the In(III)-Catalyzed Rearrangement 
and Cyclization of N-Indolyl Cyclopropanes and N-Indolyl Alkylidene 
Malonate Monoamides 
As was reported in Chapter 3, N-indolyl cyclopropanes undergo a tandem 
cyclopropane ring-opening/Friedel-Crafts alkylation reaction in the presence of 30 mol% 
of In(OTf)3. However, vicinally disubstituted cyclopropane III-50 (derived β-methyl 
styrene) afforded hydropyrido[1,2-a]indole product III-51, none of the anticipated 
product III-52 was observed. The formation of this product could be explained if the 
cyclopropane undergoes a ring-opening via anchimeric assistance from phenyl donor 
group A to form phenonium intermediate species B, which subsequently reorganizes via 
1,2-methide shift to generate  N-indolyl alkylidene malonate monoamide precursor C. An 
In(III)-catalyzed activation of monoamide then gives rise to carbocationic intermediate D 
which then undergoes a further 1,2-hydride shift to form carbocation E. An 
intramolecular Friedel-Crafts reaction generates the observed product III-51. Further 
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mechanistic examination of this cationic rearrangement pathway is currently underway in 
the France lab.   
Along these lines, a detailed mechanistic investigation into the divergent reaction 
pathway of a cationic intermediate B generated when monoamide IV-35r (derived from 
isobutyraldehyde) was subjected to cyclization conditions would be of significant interest 
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